US20030220365A1 - Cell adhesion-inhibiting antiinflammatory compounds - Google Patents

Cell adhesion-inhibiting antiinflammatory compounds Download PDF

Info

Publication number
US20030220365A1
US20030220365A1 US10/387,317 US38731703A US2003220365A1 US 20030220365 A1 US20030220365 A1 US 20030220365A1 US 38731703 A US38731703 A US 38731703A US 2003220365 A1 US2003220365 A1 US 2003220365A1
Authority
US
United States
Prior art keywords
thieno
pyridine
carboxamide
chlorophenoxy
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/387,317
Inventor
Andrew Stewart
Steven Boyd
David Arendsen
Pramila Bhatia
Kevin Condroski
Jennifer Freeman
Indrani Gunawardana
Gui-Dong Zhu
Kraig Lartey
Catherine McCarty
Nicholas Mort
Meena Patel
Michael Staeger
David Stout
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/387,317 priority Critical patent/US20030220365A1/en
Publication of US20030220365A1 publication Critical patent/US20030220365A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to compounds that are useful for treating inflammatory diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation in a mammal.
  • Inflammation results from a cascade of events that includes vasodilation accompanied by increased vascular permeability and exudation of fluid and plasma proteins. This disruption of vascular integrity precedes or coincides with an infiltration of inflammatory cells.
  • Inflammatory mediators generated at the site of the initial lesion serve to recruit inflammatory cells to the site of injury. These mediators (chemokines such as IL-8, MCP-1, MIP-1, and RANTES, complement fragments and lipid mediators) have chemotactic activity for leukocytes and attract the inflammatory cells to the inflamed lesion.
  • chemokines such as IL-8, MCP-1, MIP-1, and RANTES, complement fragments and lipid mediators
  • These chemotactic mediators which cause circulating leukocytes to localize at the site of inflammation require the cells to cross the vascular endothelium at a precise location. This leukocyte recruitment is accomplished by a process called cell adhesion.
  • the first step consists of leukocyte rolling along the vascular endothelial cell lining in the region of inflammation.
  • the rolling step is mediated by an interaction between leukocyte surface oligosaccharides (such as Sialylated Lewis-X antigen (Slex)) and a selectin molecule expressed on the surface of the endothelial cell in the region of inflammation.
  • leukocyte surface oligosaccharides such as Sialylated Lewis-X antigen (Slex)
  • the selectin molecule is not normally expressed on the surface of endothelial cells but rather is induced by the action of inflammatory mediators such as TNF- ⁇ and interleukin-1. Rolling decreases the velocity of the circulating leukocyte in the region of inflammation and allows the cells to more firmly adhere to the endothelial cell. The firm adhesion is accomplished by the interaction of integrin molecules that are present on the surface of the rolling leukocytes and their counter-receptors-the Ig superfamily molecule-on the surface of the endothelial cell.
  • the Ig superfamily molecules or CAMs Cell Adhesion Molecules
  • Cell Adhesion Molecules are either not expressed or are expressed at low levels on normal vascular endothelial cells.
  • the CAM's are induced by the action of inflammatory mediators like TNF-alpha and IL-1.
  • the final event in the adhesion process is the extravasation of the leukocyte through the endothelial cell barrier and the migration of the leukocyte along the chemotactic gradient to the site of inflammation. This transmigration is mediated by the conversion of the leukocyte integrin from a low avidity state to a high avidity state.
  • the adhesion process relies on the induced expression of selectins and CAM's on the surface of vascular endothelial cells to mediate the rolling and firm adhesion of leukocytes to the vascular endothelium.
  • NFkB transcription factor
  • IkB inhibitor molecule
  • IkB Vermaa, I. M., Stevenson, J. K., Schwarz, E. M., Antwerp, D. V., and Miyamoto, S, 1995, Rel/NFlB/IkB Family: Intimate Tales of Association and Dissociation, Genes Dev. 9: 2723-2735; and Baldwin, A. S.
  • NFkB is found in the cytoplasm complexed with IkB. Activation of NFkB occurs in response to inflammatory mediators such as TNF- ⁇ , IL-1, and lipopolysaccharide. Activation of NFkB requires phosphorylation of IkB followed by ubiquitinylation of the IkB molecule and subsequent degradation by proteosomes. Release of NFkB from association with IkB results in translocation of the dimer to the nucleus where it can associate with specific DNA sequences.
  • the e-selectin gene and CAM's contain NFkB-recognition sequences upstream from their coding regions.
  • the DNA-bound NFkB acting with other proteins in the transcription complex directs the expression of the e-selectin and CAM genes among others controlled by this transcription factor.
  • the present invention discloses compounds that inhibit the expression of e-selectin and ICAM-1 relative to VCAM-1. These compounds are useful for the treatment or prophylaxis of diseases caused by expression of adhesion molecules. These diseases include those in which leukocyte trafficking plays a role, notably acute and chronic inflammatory diseases, autoimmune diseases, tumor metastasis, allograft rejection, and reperfusion injury.
  • E, F, and G are independently selected from
  • E, F or G is nitrogen or N + —O ⁇ , and further provided that at least one of E, F or G is carbon;
  • Y and Z are independently selected from
  • L A is selected from
  • X A is selected from
  • alkyl of one to six carbons optionally substituted with
  • L B is selected from
  • X B is selected from
  • R 1 , R 2 , R 3 , R 4 , and R 5 are absent or independently selected from
  • compositions containing compounds of Formula I are disclosed.
  • alkanoyl refers to an alkyl group attached to the parent molecular group through a carbonyl group.
  • alkenyl refers to a monovalent straight or branched chain group of 2-12 carbon atoms containing at least one carbon-carbon double bond derived from an alkene by the removal of one hydrogen atom.
  • alkenylene refers to a divalent straight or branched chain group of 2-10 carbon atoms containing a carbon-carbon double bond derived from an alkene by the removal of two hydrogen atoms.
  • alkoxy refers to an alkyl group attached to the parent molecular group through an oxygen atom.
  • alkoxyalkoxy refers to an alkoxy group attached to the parent molecular group through another alkoxy group.
  • alkoxycarbonyloxy refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyloxy group, as defined herein.
  • alkoxycarbonyloxymethylene refers to an alkoxycarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein.
  • alkyl refers to a saturated straight or branched chain group of 1-20 carbon atoms derived from an alkane by the removal of one hydrogen atom.
  • alkylcarbonyl refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group.
  • alkylcarbonyloxy refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyloxy group, as defined herein.
  • alkylcarbonyloxymethylene refers to an alkylcarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein.
  • alkylene denotes a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms.
  • Representative examples of alkylene include, but are not limited to, —CH 2 —, —CH 2 CH 2 —, —CH 2 CH 2 CH 2 —, —CH 2 CH 2 CH 2 CH 2 —, —CH 2 CH(CH 3 )CH 2 —, and the like.
  • amino refers to a —NR 80 R 81 group, where R 80 and R 81 are independently selected from hydrogen and alkyl.
  • aminocarbonyl refers to an amino group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • aminocarbonyloxy refers to an aminocarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
  • aminocarbonyloxymethylene refers to an aminocarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein.
  • aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings.
  • the aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane or cyclopentene ring.
  • the aryl groups of this invention can be optionally substituted.
  • carbonyl refers to a —C(O)— group.
  • carbonyloxy refers to a carbonyl group as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein.
  • cycloalkyl refers to a monovalent saturated cyclic hydrocarbon group of 3-12 carbons derived from a cycloalkane by the removal of a single hydrogen atom.
  • ethylenedioxy refers to a —O(CH 2 ) 2 O— group wherein the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety through one carbon atom forming a 5 membered ring or the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety through two adjacent carbon atoms forming a six membered ring.
  • halo or halogen as used herein refers to F, Cl, Br, or I.
  • heterocycle represents a represents a 4-, 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur.
  • the 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds.
  • heterocycle also includes bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring.
  • Heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, oxadiazolyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazol
  • Heterocyclics also include bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group such as
  • Heterocyclics also include compounds of the formula
  • X* is selected from —CH 2 —, —CH 2 O— and —O—
  • Y* is selected from —C(O)— and —(C(R′′) 2 ) v —, where R′′ is hydrogen or alkyl of one to four carbons, and v is 1-3.
  • These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, and the like.
  • the heterocycle groups of this invention can be optionally substituted.
  • methylene refers to a —CH 2 — group.
  • perfluoroalkyl refers to an alkyl group in which all of the hydrogen atoms have been replaced by fluoride atoms.
  • phenyl refers to a monocyclic carbocyclic ring system having one aromatic ring.
  • the aryl group can also be fused to a cyclohexane or cyclopentane ring.
  • the phenyl groups of this invention can be optionally substituted.
  • prodrugs as used herein represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • prodrug represents compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood.
  • a thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference.
  • spiroalkyl refers to an alkylene group wherein two carbon atoms of the alkylene group are attached to one carbon atom of the parent molecular group thereby forming a carbocyclic ring of three to eleven carbon atoms.
  • tautomer refers to a proton shift from one atom of a molecule to another atom of the same molecule wherein two or more structurally distinct compounds are in equilibrium with each other.
  • thioalkoxy refers to an alkyl group attached to the parent molecular group through a sulfur atom.
  • Compounds of the present invention can exist as stereoisomers wherein asymmetric or chiral centers are present. These compounds are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom.
  • the present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers are designated ( ⁇ )
  • Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art.
  • Geometric isomers can exist in the compounds of the present invention.
  • the present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring.
  • Substituents around a carbon-carbon double bond are designated as being in the Z or E configuration wherein the term “Z” represents substituents on the same side of the carbon-carbon double bond and the term “E” represents substituents on opposite sides of the carbon-carbon double bond.
  • Tautomers can also exist in the compounds of the present invention.
  • the present invention contemplates tautomers due to proton shifts from one atom to another atom of the same molecule generating two distinct compounds that are in equilibrium with each other.
  • Compounds of the present invention include, but are not limited to
  • N 2 -4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]carbonyl]-N 6 -[(nitroamino)iminomethyl]-L-lysine, methyl ester,
  • the compounds of the present invention act as antiinflammatory agents with potencies below 1 ⁇ M and are therefore useful for treating inflammatory diseases.
  • the present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers.
  • the pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray.
  • parenteral administration refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.
  • compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.
  • suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate.
  • Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants.
  • compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin.
  • adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of
  • Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • biodegradable polymers such as polylactide-polyglycolide.
  • Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues.
  • the injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol
  • compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner.
  • embedding compositions which can be used include polymeric substances and waxes.
  • the active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • Suspensions in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used.
  • the present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like.
  • the preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic.
  • the compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids.
  • pharmaceutically acceptable salt is meant those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 et seq.
  • the salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid.
  • Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained.
  • lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides
  • dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates
  • long chain halides such as decyl
  • Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine.
  • Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like.
  • Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like.
  • Preferred salts of the compounds of the invention include phosphate, tris and acetate.
  • Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants.
  • the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required.
  • Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
  • compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration.
  • the selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
  • dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient.
  • the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses-per day.
  • Scheme 1 shows the preparation of thieno[2,3-d]pyrimidines from esters of general formula 1 by published procedures. 4-Chlorothieno[2,3-d]pyrimidines of general formula 3 were substituted with thiols to provide 4-thioethers of general formula 4 or substituted with amines to provide 4-aminothieno[2,3-d]pyrimidines of general formula 5.
  • Scheme 2 shows the preparation of 2-carboxy-substituted thieno[2,3-d]pyrimidines.
  • Pyrimidinones of general formula 1 weres reacted with phosphoryl chloride to produce 4-chloro pyrimidines of general formula 6, which were then substituted with thiols to provide thioethers of general formula 7.
  • Scheme 3 shows the preparation of thieno[3,2-d]pyrimidines derived from chloropyrimidines of general formula 8. Substitution of the chlorides with thiols provided thioethers of general formula 9, and substitution of the chlorides with amines provided aminopyrimidines of general formula 10.
  • Scheme 5 shows the preparation of 6-alkyl substituted thieno[2,3-d]pyrimidines with alkylthio groups at the 4-position.
  • 2-aminothiophene 13 was acylated to provide amide 14 which was cyclized to provide thienopyrimidinone 15.
  • the pyrimidinone was converted to chloride 16 and further to thioether 17 by standard procedures.
  • aicds 21 may be converted to amides 22 or 23 by other coupling methods, such as carbodiimide (for example, N-ethyl-N′-(3-dimethylamino)propyl carbodiimide hydrochloride (EDC)), mixed anhydrides (derived from pivaloyl chloride or isobutyl chloroformate treatment), and active esters (for example, derived from N-hydroxysuccinimide, p-nitrophenol).
  • carbodiimide for example, N-ethyl-N′-(3-dimethylamino)propyl carbodiimide hydrochloride (EDC)
  • EDC N-ethyl-N′-(3-dimethylamino)propyl carbodiimide hydrochloride
  • mixed anhydrides derived from pivaloyl chloride or isobutyl chloroformate treatment
  • active esters for example, derived from N-hydroxysuccinimide, p-
  • Scheme 7 illustrates the analogous preparation of 4-ether-substituted thienopyridines of general formula 30.
  • esters of general formula 25 may be reacted with mono or disubstituted amines in polar solvents such as dimethylformamide or methanol.
  • Esters of general formula 25 were hydrolyzed to carboxylic acids of general formula 28 by basic hydrolysis with sodium or lithium hydroxide in aqueous methanol or tetrahydrofuran. The acids were then converted to amides of general formula 30 by reaction of the corresponding acid chlorides of general formula 29 with amines.
  • the acids 30 were coupled to amines by standard peptide-coupling conditions as described in Scheme 6 for, amides 22 or 23.
  • Esters of general formula 33 were converted to amides of general formula 34 by the procedures described for 26, 27 or 30 in Scheme 7.
  • Scheme 9 shows the conversion of acids of general formula 21 to aldehyde or ketone-derived compounds.
  • aldehydes of general formula 36 were produced by reduction of the N-methyl-N-methoxylamides of general formula 35.
  • the amides of general formula 35 were also reacted with Grignard reagents to produce unsymmetrical ketones of general formula 39.
  • Aldehydes of general formula 36 and Ketones of general formula 39 were utilized for the production of oximes of general formula 37 or 40 by reaction with hydroxylamine derivatives.
  • Aldehyde of general formula 36 were reacted with phosphoranes (or phosphonoacetate salts) to produce 2-alkenyl substituted derivatives of general formula 38.
  • Ketones of general formula 39 were reduced to the corresponding alkanes of general formula 41 by treatment with hydrazine and strong base, such as potassium hydroxide.
  • Analogous 2-position derivatives of thienopyridine ethers of general formula 28 in Scheme 7 would follow similar synthetic routes as described in Scheme 9. Thuds, acids 28 may be converted to aldehydes, ketones, oximes, alkenes, or alkanes substitutions at the 2-position.
  • Amides of general formula 34 may be converted to the corresponding thionoamides of general formula 42 by treatment with Lawesson's reagent as shown in Scheme 10.
  • Scheme 13 illustrates an alternative method for the preparation of 2-carbeoxaldehydes of general formula 36 or 47.
  • the alcohols were then oxidized to the aldehydes using Swern conditions.
  • the aldehydes were then reacted with Wittig reagents (for example phosphoranes to produce the acrylate derivatives of general formula 48 (Jung, M. E. and Kiankarami, M. J. Org. Chem. 1998, 63, 2968-2974).
  • thienopyridines of general formula 27 or 30 were alkylated on the pyridine nitrogen using alkyl iodides (or alkyl bromides or triflates) to produce the pyridinium salts of general formula 49.
  • R may be alkylcarbonyloxymethylene, aminocarbonyloxyymethylene, alkoxycarbonyloxymethylene, or alkyl.
  • Such derivatives may serve as prodrug forms of the thienopyridine amides 27 or 30.
  • 50 may be reacted with alkyl or arylmagnesium halides, or alkyl lithium salts, to provide amides of general formula 53.
  • Isocyanate 50 was hydrolyzed under aqueous conditions to produce 2-amino derivatives of general formula 54.
  • Amines of general formula 54 were reacted with appropriate electrophiles to further derivatize this position.
  • Scheme 19 shows the use of boronic acid derivatives to functionalize the 4-position of the thieno[2,3-c]pyridines.
  • the chemistry depicted may be applied to a broad range of aryl olefins analogous to bromostyrene 62.
  • bromostyrene 62 was converted to the boronic acid 63 under standard conditions, and the boronic acid was coupled to 4-bromothienopyridine 32 under Suzuki conditions, affording the styryl analog 64.
  • the ester 64 was converted to the amide 65 by the previously described method (Miyara, N and Suzuki, A. Chem. Rev. 1995, 95, 2457-2463).
  • the olefinic group may then be converted to the epoxide 66, which can undergo reactions with nucleophilic reagents at the less-hindered position of the epoxide to producing analogs of general formula 67.
  • styryl derivative 65 may be converted to the diol 68 by standard methods.
  • Scheme 21 depicts the preparation of 5-halo thienopyridine derivatives, as exemplified by the preparation of the 5-chloro analog 75.
  • Formylation of lithiated 2,3,5-trichloropyridine with methyl formate gave aldehyde 72.
  • Displacement of the 3 and 5 chlorines with excess 4-bromophenol and reaction with methylthioglycolate gave the 5-chlorothienopyridine 74 in low yield, together with the major product 73.
  • the 5-chloro isomer was treated with ammonia in methanol in a pressure tube to generate the amide 75. It should be noted that this chemistry may be applied using a range of phenols or hydroxy heterocyclic compounds in place of 4-bromophenol.
  • Scheme 23 illustrates the preparation of 4-acyl derivatives: of thieno[2,3-c]pyridines.
  • Carboxylic acid 85 was converted to amide 86 via the acid chloride, then the hydroxyamide 86 underwent thionyl chloride-mediated cyclization to the oxazoline 87 (Meyers, A. I.; Stoianova, D. J. Org. Chem. 1997, 62, 5219-5221).
  • Palladium mediated alkoxycarbonylation of 87 yielded ester 88 (Heck, R. F.; et al. J. Org. Chem. 1974, 39, 3318).
  • Ester 88 may be converted to the Weinreb amide 89 by standard methods.
  • Scheme 24 depicts a proposed method for the formation of 4-hydroxy substituted thieno[2,3-c]pyridine.
  • Reaction of phenol 92 with dihydropyran under acidic conditions yields tetrahydropyranyl ether 93 (Grant, H. N., et al. Helv. Chim. Acta. 1963, 46, 41).
  • Lithiation of 93 and subsequent quench with methyl formate gives aldehyde 94.
  • Displacement of the halide with methyl thioglycolate and subsequent cyclization with cesium carbonate yields the ester 95.
  • Removal of the tetrahydropyranyl ether with aqueous HCl gives hydroxypyridine 96, which may be converted to the amide as described previously.
  • Scheme 25 proposes the use of the 4-hydroxy group for introduction of functionality to the 4-position of the thieno[2,3-c]pyridines.
  • the 2-carboxylic acid group is first protected as the oxazoline 99 (through the intermediate amide 98), then the hydroxy group is converted to the aryl triflate 100 by standard conditions.
  • Triflate 100 may then be converted to the N-methyl-N-methoxy amide 89 under conditions similar to that for bromide 87.
  • 4-triflate 100 may serve as a coupling partner in a variety of transition-metal mediated couplings with appropriate nucleophilic partners (for example, boronic acids, boranes, alkyl or aryl-zinc reagents).
  • Scheme 27 illustrates additional derivatives which can be derived from amino esters of general formula 108 or amino amides of general formula 109.
  • amino amides of general formula 109 may be treated with 1,1′-carbonyldiimidazole to produce cyclic imides of general formula 110.
  • the 3-amino group was acylated (for example, with acid chlorides and weak base, or by coupling with acids using carbodiimides) to give the diamides of general formula 111.
  • the 3-amino group may be alkylated under reductive conditions using aldehydes and a reducing agent (such as triacetoxyborohydride), to provide alkylated amines of general formula 112.
  • Scheme 28 shows the preparation of compounds bearing alkyl substituents at the 3-position of the thieno[2,3-c]pyridines.
  • 3,5-dichloropyridine was deprotonated with strong base (for example, lithium diisopropylamide), and then reacted with an acylating reagent (ester, N-methyl-N-methoxyamide, acyl pyrazole, or others) to provide ketone 113.
  • the anion can be reacted with an aldehyde (for example, acetaldehyde) and then subsequently the product may be oxidized (for example, with tetrapropylammonium perruthenate) to provide ketone 113.
  • an aldehyde for example, acetaldehyde
  • the product may be oxidized (for example, with tetrapropylammonium perruthenate) to provide ketone 113.
  • the dichloroketone was reacted sequentially with phenols and then with methyl thioglycolate to provide cyclic products of general formula 114.
  • the ester of general formula 114 may be converted to various derivatives as outlined previously.
  • Scheme 29 describes a similar strategy used to obtain derivatives with alkoxy groups at the 3-position of thieno[2,3-c]pyridines.
  • Ester 116 was substituted and cyclized to provide 3-hydroxy analogs of general formula 117.
  • the hydroxy group may be left unsubstituted, leading to amides of general formula 118 (or other derivatives).
  • hydroxy esters of general formula 117 may be alkylated by standard procedures to produce 3-alkoxy derivates of general formula 119, followed by amide formation to provide compounds of general formula 120.
  • Scheme 30 shows the procedure used for the transformation of a commercially available furo[2,3-b]pyridine 121 into an amide 122.
  • Scheme 31 proposes the preparation of thienopyridine derivatives containing an amide group at the 3-position.
  • Thienopyridines of general formula 44 are halogenated using electophilic halide sources (for example, N-bromosuccinimide, I 2 ), to produce 3-halothienopyridines of general formula 123.
  • Metal-halogen exchange, followed by trapping with carbon dioxide, provides acids of general formula 124.
  • the acids are converted into amides of general formula 125 by standard procedures, or may be homologated to esters of general formula 126 (for example, by the Arndt-Eisert procedure). Esters of general formula 126 may then be converted to amides or other functionality by the methods described above.
  • Scheme 32 describes the methods used for the preparation of a variety of thieno[2,3-b]pyridines starting from the known 4-chloro-5-ester 127. Displacement of the chlorine of 127 proceeded with thiols in the presence of potassium carbonate to provide 4-thioethers of general formula 128. Ester 127 was also hydrolyzed to the acid 129, which was converted to amides of general formula 130 by standard coupling conditions.
  • Scheme 33 shows the conversion of thioethers of general formula 128 to 2,4-disubstituted analogs.
  • the corresponding acids of general formula 131 may be thermally decarboxylated to provide the 5-unsubstituted analogs of general formula 132.
  • Compounds of general formula 132 were treated with strong base (for example, n-butyllithium), and reacted with carbon dioxide to provide the 2-carboxylic acids of general formula 133.
  • the acids were then transformed into amides of general formula 134 by previously described procedures.
  • Scheme 34 illustrates the preparation of thieno[3,2-b]pyridines. Chloride 135 was transformed by a similar set of conditions to that described in Scheme 33 to produce acids of general formula 139 and amides of general formula 140.
  • Scheme 35 depicts the preparation of thieno[3,2-c]pyridines.
  • thienopyridone 141 4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-nitrile 144 was prepared according to literature methods (Eloy, F.; Deryckere, A. Bul. Soc. Chim. Belg. 1970, 79, 301; Troxler, F.; Wiskott. E. U.S. Pat. No. 3,998,835).
  • Treatment of thienopyridone 144 with phosphoryl chloride at 130° C. provided chloride 145, which upon exposure to thiols under basic conditions afforded thioethers of general formula 146.
  • Hydrolysis of the nitrile group with polyphosphoric acid gave the corresponding amides of general formula 147.
  • Scheme 37 shows the preparation of intermediates of general formula 151 useful for the preparation of alternative 2-derivatives.
  • Scheme 38 depicts an example of the preparation of a related class of inhibitors based on an oxazolopyridine structure.
  • Commercially available 3-chloropyridine is oxidized to the N-oxide 152 with peracetic acid, which is then nitrated in a mixture of concentrated nitric, concentrated sulfuric, and fuming sulfuric acids to give the 4-nitro derivative 153.
  • the chlorine in 153 is then displaced with the sodium salt of p-cresol, and the resulting biaryl ether 154 is hydrogenated (Raney nickel catalysis) to reduce both the nitro functional group and the N-oxide to give 155.
  • the amino group of 155 is protected with an N-trimethylacetyl group, and the 5-hydroxyl group is introduced according the procedure of Chu-Moyer and Berger (J. Org. Chem. 1995, 60, 5721) by formation of the dianion of 156, quenching with trimethyl borate, and oxidation of the intermediate boronate ester followed by hydrolysis with basic hydrogen peroxide to give hydroxypyridine 157.
  • the amide is hydrolyzed with hydrochloric acid to give 158, which is condensed with methyl oxalyl chloride to give the oxazolopyridine 158.
  • the methyl ester in 159 was then converted to the primary amide by treatment with ammonia in methanol to give the target compound 160.
  • Scheme 39 illustrates an example of the preparation of an analogous thiazolopyridine-based inhibitor.
  • the scheme illustrates the use of para-cresol substituted pyridine as starting material, but the synthesis may be generalized to other aryl, heterocyclic, or alkyl ethers.
  • the dianion of 4-N-trimethylacetyl)-amino-3-(4-methylphenoxy)-pyridine is quenched with tetramethylthiuram disulfide to introduce the 5-mercapto group into the substituted pyridine ring as dithiocarbamate 161.
  • a related imidazopyridine class of compounds may be prepared from intermediates shown in Scheme 40.
  • 5-Hydroxypyridine 157 may be converted to the corresponding aniline 166 by heating in ammonium hydroxide saturated with sulfur dioxide in a pressure vessel (Newman and Galt, J. Org. Chem. 1960, 25, 214).
  • the resulting diaminopyridine 167 may be condensed with methyl oxalyl chloride to give the imidazopyridine 168.
  • the ester functionality may then be converted to amide 169 by treatment with ammonia in methanol, as described previously.
  • Scheme 41 is an illustration of the preparation of thienopyridazine-containing inhibitors.
  • the protected thiophene acid 170 was deprotonated with strong base (e.g. n-butyllithium), and reacted with a formylating reagent.
  • strong base e.g. n-butyllithium
  • the resultant oxazoline aldehyde 171 was hydrolyzed and cyclized with hydrazine to provide the hydroxy thienopyridazine 172.
  • the hydroxy group was converted to the chloride 173 by the action of phosphorous oxychloride and subsequent substitution by alkoxides produced the ethers 174.
  • the amide group is introduced in a manner analogous to that described above for the thienopyridines, providing amide 176.
  • Scheme 43 outlines the preparation of 4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide using a modification of the route described in Scheme 7.
  • a two step sequence was adopted for assembling the thienopyridine core in the synthesis of 182.
  • Treatment of the dichloropyridine aldehyde with one equivalent of N-BOC-protected 4-hydroxyaniline afforded compound 179, which was cyclized to give ester 180. Transformation to the amide 181 followed the previously described procedure, and the Boc-group was removed by treatment with trifluoroacetic acid.
  • aniline 182 also serves as starting material for Sandmeyer reactions via the diazonium salt, in which the amino group may be converted to a variety of functional groups, including halo, hydroxy, cyano, among other standard Sandmeyer products.
  • Scheme 44 exemplifies a general method for the preparation of 4-substituted aminophenoxythieno[2,3-c]pyridines using methodology described by Buchwald, et al. (Wolfe, John; Buchwald, Stephen L. J. Org. Chem. 1997, 62, 6066).
  • Iodide 183 prepared by the previously described methods, was coupled with disubstituted amines (such as morpholine in the above example) in the presence of bis(dibenzylideneacetone)dipalladium and BINAP to provide the substituted aniline 184.
  • Scheme 45 describes the preparation of 4-(4-hydroxymethylphenyl)thieno[2,3-c]pyridine 188, utilizing a modification of the route shown in Scheme 7. Starting with mono-tritylated 4-hydroxybenzyl alcohol, condensation with dichloroaldehyde 18, followed by cyclization with methyl thioglycolate, provided protected benzyl alcohol 188. Standard transformations provided alcohol 188.
  • Scheme 46 describes the preparation of a protected benzyl alcohol 190, starting from mono-tetrahydropyran-protected hydroxybenzyl alcohol 189. Standard acid-catalyzed hydrolysis of the THP group can also yield the benzyl alcohol analog 188.
  • benzyl alcohol 188 may be further derivatized to esters, using standard coupling procedures, for example by carbodiimide conditions shown above, or by use of acid chloride.
  • the alcohol may be converted to carbamates (R ⁇ NH 2 , mono or disubstituted amino) by treatment with isocyanates or carbamoyl chlorides.
  • Glycosides of benzyl alcohol 187 may be produced using the procedure outlined in Scheme 48. Treatment of the alcohol 187 and tri-O-acetyl-D-glucal with stoichiometric scandium triflate afforded stereo-specifically protected glycoside 192, which was deprotected with methyl amine to give the free glycoside 193.
  • Scheme 51 exemplifies the preparation of 4-heterocyclephenoxythienopyridines.
  • Cyano derivative 202 was transformed into imidazoline 205 under the conditions described above. Incorporation of other heterocycles was accomplished using known Stille, Suzuki, or Heck conditions as exemplified by the Stille coupling of iodo compound 194 and tributylstannylthiophene to provide compound 205A.
  • the aryl coupling reactions described above may be applied to compounds with a variety of substituents at C-2 of the thienopyridine, in addition to the methyl amides exemplified in Scheme 51.
  • Cyclopropylcarbinyl alcohol derivatives of the 4-phenyl ethers may be prepared according to the procedure described in Schemes 52 and 53.
  • Commercially available phenylcyclopropane carboxylic acid is converted to the corresponding alcohol 206 by LAH reduction, then demethylation and selective protection of the hydroxymethyl group affords phenol 207.
  • phenol 207 was condensed with dichloroaldehyde 18 and then methyl thioglycolate, to produce thienopyridine 208. Standard transformations led to the desired compounds 209 and 210.
  • alcohol 206 was alkylated to produce the polyether phenol 211 which was converted into cyclopropylcarbinyl polyether 212 using similar procedures described in Scheme 52.
  • alkylation chemistry may be broadly applied by replacement of the diether tosylate shown with other alkyl halides or sulfonate esters.
  • difluoroacetic acid derivative 213 was synthesized by a copper mediated coupling between iodide 194 and ethyl iododifluoroacetate in the presence of phenol, which was found to remarkably inhibit side reactions. Reduction of the ester 213 gave difluoroethyl alcohol 214. Alkylation of alcohol 214 with ethoxyethyl tosylate in the presence of sodium hydride and 15-crown-5 afforded polyether 215.
  • Esters 218 were then converted to other active derivatives such as amides using previously described procedures. Benzyl ether 218 was hydrogenolyzed to phenol 219, which was converted to the corresponding amide 220 by standard procedures. Phenol 219 also serves as a partner in Mitsunobu reactions with a variety of primary or secondary alcohols, to provide alkyl ethers of general formula 221 (Huang, F., et al. J. Med. Chem. 1998, 41, 4216-4223). Esters of general formula 221 were converted to amides of general formula 222 by treatment under the standard conditions of reflux with methanolic amine solutions.
  • Thienopyridine analogs bearing a 4-carbonyl group may be prepared by the procedures described in Scheme 56.
  • Dichloropyridine aldehyde 18 was treated with methyl thioglycolate under previously described conditions to produce the 4-chlorothienopyridine ester 223.
  • Ester exchange was accomplished by base catalyzed hydrolysis to acid 224, and tert-butyl esterification to 225 was accomplished with O-t-butyl trichloroacetimidate under Lewis acid catalysis. Palladium-catalyzed carbethoxylation proceeded under previously described conditions to give diester 226.
  • ester 228 may be transformed to various 2-substituted thienopyridine analogs directly, or oxidized to the corresponding 4-keto derivative 230. Standard transformation of ester 230 to amide 231 completes the synthesis.
  • ester 226 may be selectively converted to amide derivatives by initial alkaline hydroysis of the ethyl ester, coupling to an amine, then acidic hydrolysis of the tert-butyl ester, and finally coupling to another amine to produce 308.
  • Scheme 58 illustrates the conversion of aldehyde 233 to the acrylate 236, which was accomplished by Homer-Emmons condensation with trimethyl phosphonoacetate (Jung, M. E. and Kiankarami, M. J. Org. Chem. 1998, 63, 2968-2974).
  • the described methods may be extended to analogs bearing a wide variety of C-4 substituents, including aryloxy, alkoxy, arylamino, aryl, alkyl.
  • the derived ester 236 was then subjected to hydrolysis to provide acid 237.
  • Carboxylic acid 237 was subjected to standard coupling conditions to produce amide 238.
  • the derived acrylates of general formula 239 may be oxidized to the corresponding diols of general formula 240 with catalytic osmium tetroxide in the presence of 4-methylmorpholine-N-oxide.
  • the strategy outlined is generally applicable to analogs with a variety of L A X A substituents.
  • Aldehydes of general formula 233 were also reacted with organomagnesium (or organolithium) reagents to produce secondary alcohols which were oxidized to the corresponding ketones of general formula 242.
  • Oxidation is preferably accomplished by standard Swern conditions (DMSO and oxalyl chloride in CH 2 Cl 2 solution at low temperature, followed by treatment with tertiary amines such as ethyldiisopropyl amine), but other conditions (tetra-n-propyl perruthenate, manganese dioxide) may be employed.
  • DMSO and oxalyl chloride in CH 2 Cl 2 solution at low temperature followed by treatment with tertiary amines such as ethyldiisopropyl amine), but other conditions (tetra-n-propyl perruthenate, manganese dioxide) may be employed.
  • tertiary amines such as ethyldiisopropyl amine
  • manganese dioxide tetra-n-propyl perruthenate, manganese dioxide
  • Nitriles of general formula 244 were also converted to cyanoamidines of general formula 248 when subjected to excess cyanamide in THF with DBU as the base.
  • the 3-amino-1,2,4-oxadiazoles of general formula 249 were then generated by treatment of cyanoamidines of general formula 248 with hydroxylamine hydrochloride and triethyamine in methanol.
  • Scheme 61 depicts the preparation of 2-arylcarbonylthienopyridines.
  • Thienopyridines of general formula 44 were deprotonated with alkyllithium base and condensed with nitrobenzaldehdyes to produce the benzyl alcohols of general formula 250.
  • Tin(II)-induced reduction of the nitrophenyls to the anilines of general formula 251 were followed by selective alcohol oxidation with pyridinium chlorochromate.
  • the nitro benzyl alcohols of general formula 250 were also converted to the corresponding ketones of general formula 253 under Swern conditions (for example, oxalyl chloride/DMSO/CH 2 Cl 2 at low temperature, followed by treatment with amine bases).
  • Scheme 62 depicts the preparation of 2-carbamatethienopyridines and 2-ureathienopyridines.
  • Alcohols of general formula 232 were converted to the amines of general formula 254 by Mitsunobu reaction with phthalimide, followed by deprotection with hydrazine.
  • the amines of general formula 254 were converted to the corresponding ureas of general formula 255 by reaction with potassium isocyanate under acidic conditions.
  • the alcohols of general formula 232 were converted to the corresponding carbamates of general formula 256.
  • This chemistry is generally applicable to the use of substituted isocyanates or carbamoyl chlorides, leading to mono or disubstituted carbamates or ureas.
  • Scheme 63 illustrates the preparation of 2-thioureathienopyridines, starting from 2-aminothienpyridines of general formula 54. Reaction of 54 with substituted isothiocyanates in pyridine at reflux provided the thioureas of general formula 257.
  • Scheme 64 exemplifies the synthesis of sulfonamides at the 2-position of the thienopyridines.
  • An improved procedure for decarboxylation of thienopyridine-2-carboxylic acids is shown, wherein acids of general formula 21 were heated in diphenylether at 210° C. to provide thienopyridines of general formula 44 in high yield.
  • Compounds 44 were deprotonated with strong base, then treated with sulfur dioxide to produce intermediate sulfinic acids.
  • N-chlorosuccinimide produced sulfonyl chlorides of general formula 258, from which a variety of sulfonamides of general formula 259 were prepared by reaction with ammonia, primary or secondary amines in the presence of diisopropylethylamine in protic solvents such as methanol (Prugh, J. D., et al. J. Med. Chem. 1991, 34, 1805-1818; Davidsen, S. K., et al. J. Med. Chem. 1998, 41, 74-95).
  • protic solvents such as methanol
  • Scheme 65 provides the outline of the synthesis of additional 2-arylthienopyridines with amino or hydroxy groups on the aryl ring.
  • Suzuki coupling of boronic acids of general formula 79 with nitro-substituted aryl iodides produced biaryls of general formula 260.
  • Biaryls of general formula 260 were reduced to the aminophenyl derivatives of general formula 261 with tin(II) chloride.
  • Methyl ethers of general formula 262 were prepared from boronic acids 79 by coupling with methoxy iodobenzenes, and were converted to the hydroxy derivatives of general formula 263 through the use of boron tribromide to demethylate the methyl ethers.
  • Schemes 66-71 illustrate syntheses for additional 5-membered heterocycles at the 2-position of the thienopyridines.
  • Scheme 66 outlines a method for producing 1,3,4-oxadiazoles.
  • Hydrazides of general formula 264 were prepared by treating esters of general formula 20 or 25 with hydrazine in methylene chloride. The hydrazides were converted to 5-amino-1,3,4-oxadiazoles of general formula 265 by reaction with cyanogen bromide. Hydrazides of general formula 264 may be converted to 5-unsubstituted or 5-alkyl-substituted-1,3,4-oxadiazoles of general formula 266 by condensation with orthoesters under reflux conditions.
  • Scheme 67 indicates a method of preparing 1,3,4-triazoles from methyl esters of general formula 20 or 25. Condensation with aminoguanidine under basic conditions (for example sodium methoxide in methanol) produced the 2-amino-1,3,4-triazoles of general formula 267. Nonspecific methylation was performed on 1,3,4 triazoles of general formula 267 using sodium hydride and methyl iodide, which provided mono-methyl triazoles of general formula 268, dimethyl triazoles of general formula 269, and trimethyl triazoles of general formula 270, which were chromatographically separable.
  • aminoguanidine under basic conditions (for example sodium methoxide in methanol) produced the 2-amino-1,3,4-triazoles of general formula 267.
  • Nonspecific methylation was performed on 1,3,4 triazoles of general formula 267 using sodium hydride and methyl iodide, which provided mono-methyl triazoles of general formula 268, dimethyl triazoles of general formula 269,
  • Scheme 68 indicates a method for the preparation of 1,3,4-thiadiazoles of general formula 272.
  • the acid chlorides derived from acids of general formula 21 or 28 were reacted with thiosemicarbazide or substituted thiosemicarbazides to give intermediate
  • Schemes 66-71 illustrate syntheses for additional 5-membered heterocycles at the 2-position of the thienopyridines.
  • Scheme 66 outlines a method for producing 1,3,4-oxadiazoles.
  • Hydrazides of general formula 264 were prepared by treating esters of general formula 20 or 25 with hydrazine in methylene chloride. The hydrazides were converted to 5-amino-1,3,4-oxadiazoles of general formula 265 by reaction with cyanogen bromide. Hydrazides of general formula 264 may be converted to 5-unsubstituted or 5-alkyl-substituted-1,3,4-oxadiazoles of general formula 266 by condensation with orthoesters under reflux conditions.
  • Scheme 67 indicates a method of preparing 1,3,4-triazoles from methyl esters of general formula 20 or 25. Condensation with aminoguanidine under basic conditions (for example sodium methoxide in methanol) produced the 2-amino-1,3,4-triazoles of general formula 267. Nonspecific methylation was performed on 1,3,4 triazoles of general formula 267 using sodium hydride and methyl iodide, which provided mono-methyl triazoles of general formula 268, dimethyl triazoles of general formula 269, and trimethyl triazoles of general formula 270, which were chromatographically separable.
  • Scheme 68 indicates a method for the preparation of 1,3,4-thiadiazoles of general formula 272.
  • the acid chlorides derived from acids of general formula 21 or 28 were reacted with thiosemicarbazide or substituted thiosemicarbazides to give intermediate acylated thiosemicarbazides of general formula 271, which were cyclized under acid catalysis (for example methanesulfonic acid in refluxing toluene) to provide thiadiazoles of general formula 272.
  • Scheme 69 provides a method for the preparation of 1,3,4-oxadiazol-2-thiones and the derived alkylthio-substituted oxadiazoles of general formula 274.
  • Hydrazides of general formula 264 were treated with carbon disulfide in potassium hydroxide in aqueous ethanol solution to give the cyclic thiocarbamates of general formula 273.
  • the thiocarbonyl group was alkylated in low yield with alkyl halides to give the alkylthio 1,3,4-oxadiazoles of general formula 274.
  • Scheme 70 shows the preparation of tetrazoles at the 2-position of thienopyridines.
  • 2-Cyano derivatives of general formula 244 were converted to tetrazoles of general formula 275 using trimethylsilyl azide in the presence of catalytic dibutyltin oxide.
  • the tetrazoles were converted to the N-methyl derivatives of general formula 276 by use of a solution of diazomethane in methanol.
  • Scheme 71 illustrates the syntheses of 2-oxazole and 2-imidazole thienopyridines.
  • Chloroethyl amides of general formula 277 were prepared by chlorination of the corresponding hydroxyethyl amides and then cyclized to oxazolines of general formula 278 under basic catalysis (for example, diazabicycloundecane in dichloromethane).
  • the oxazolines of general formula 278 may be converted to the oxazoles of general formula 278 by dehydrogenation according to the procedure of Meyers (Meyers, A. I., et al. J. Amer. Chem. Soc. 1975, 97, 7383).
  • Aminoethyl amides of general formula 280 were cyclized to the imidazolines of general formula 281 by treatment with calcium oxide at high temperature in diphenyl ether.
  • Imidazolines of general formula 281 may be converted to imidazoles of general formula 282 by literature methods (Hughey, J. L., et al. Synthesis [SYNTBF]1980, (6), 489).
  • Scheme 73 provides a synthesis for 3-carboxythienopyridines.
  • 3,5-dichloropyridine was treated with strong base such as lithium diusopropylamide in anhydrous ethereal solvent at low temperature, followed by the addition of t-butyl chlorooxoacetate to provide the 4-tert-butyl-2-ketoester of 3,5-dichloropyridine 283.
  • the ester 283 was then reacted with 1.25 equivalents of preformed potassium phenoxides at ambient temperature, to give the monoaryloxy derivatives as the main product.
  • the monoaryloxy esters were treated with methyl thioglycolate and base such as potassium t-butoxide or cesium carbonate to provide the desired thienopyridine diesters of general formula 284.
  • the diesters of general formula 284 were then treated with methanolic amines to give the corresponding 3-tert-butyl ester amides of general formula 285.
  • the tert-butyl ester amides of general formula 285 were converted to the corresponding acid amides of general formula 287 by solvolysis with trifluoroacetic acid. Diesters of general formula 284 may also be converted to the acids of general formula 286 by a similar solvolysis reaction.
  • Scheme 74 describes the use of 4-bromothienopyridine 32 to prepare 4-amino substituted thienopyridine derivatives.
  • Ester 32 was converted to amides of general formula 288 by standard procedures, and then coupled to a variety of amines using palladium(0) catalysis, as described by Buchwald (J. Org. Chem. 1997, 62, 6066-6068), producing 4-amino derivatives general formula 289.
  • Scheme 75 outlines the preparation and reactions of 7-chloro and 7-bromothienopyridine derivatives.
  • the analogs are useful for preparing active derivatives as well as serving as synthetic intermediates for a variety of 7-substituted thienopyridines.
  • Esters of general formula 25 were oxidized to the pyridine-N-oxides of general formula 290 with meta-chloroperbenzoic acid.
  • the N-oxides were rearranged to the 7-halo derivatives of general formula 291 by warming in phosphorous oxychloride or phosphorous oxybromide.
  • the resultant 7-halides could be converted to the amide derivatives of general formula 292 by standard methods without reaction of the 7-chloro or 7-bromo moieties.
  • the chloro or bromo groups could be substituted with amines or alcohols to provide 7-amino derivatives of general formula 293 and 7-alkoxy derivatives of general formula 294 respectively.
  • Esters of general formula 294 were converted to amides of general formula 295 using standard methods.
  • 7-Hydroxy analogs of general formula 296 were prepared from 291 derivatives using acetic anhydride followed by hydrolysis with water.
  • the 7-halo derivatives 291, in particular the 7-bromo derivatives were effective educts in Suzuki reactions with aryl boronic acids, similar to those described in Scheme 19 and 65.
  • Scheme 76 describes the preparation of furopyridine analogs such as 299 (Example 327).
  • dichloropyridinecarboxaldehyde 18 was reacted sequentially with a potassium phenoxide, then with ethyl glycolate, followed by cyclization under basic conditions, affording furopyridine ester 298 in low yield.
  • Standard hydrolysis and coupling conditions afforded the amide 299.
  • the amide was converted to the thioamide 300 by treatment with Lawesson's reagent in hot toluene.
  • Scheme 77 illustrates the preparation N-alkyl 5-amino-1,3,4,-oxadiazoles.
  • the treatment of 265 in refluxing trimethylorthoformate followed by reduction of the eneamine intermediate with sodium borohydride in refluxing ethanol provides the N-alkylated 5-amino-1,3,4,-oxadiazoles of general formula 301.
  • Scheme 78 exemplifies the synthesis of substituted vinyl moieties at the 4-position of thienopyridines.
  • Treatment of aldehyde 227 with the appropriate diethylphosphonate in the presence of potassium bis(trimethylsilyl)amide provided 302.
  • Compound 302 was then treated with sulfuric acid in methanol to yield the methyl ester 303, followed by standard amide formation with ammonia and-methanol to produce 4-vinylsubstituted thienopyridines of general formula 304.
  • Installation of a substituted vinyl can also be accomplished by using Wittig phosphorane chemistry.
  • Scheme 79 demonstrates the preparation of 4-substituted alkyl thienopyridines.
  • Alcohol 228 was subjected to palladium on carbon in acetic acid to generate the methylene derivative 305.
  • Treatment of 305 with sulfuric acid in methanol yields 306.
  • Formation of the amide is accomplished by treatment of 306 with ammonia in methanol to yield 307
  • Scheme 80 illustrates the preparation of thiazole derivatives at the 2-position of thienopyridines.
  • Thioamides of general formula 309 were alkylated and cyclized with ethyl bromopyruvate, providing thiazole esters of general formula 310.
  • Standard amide formation led to amides of general formula 311.
  • Other amines may be used to produce a variety of substituted amides.
  • esters of general formula 310 may be converted to carbamates of general formula 312 through Curtius rearrangement of the intermediate acid.
  • the tert-butyl carbamates of general formula 312 were converted to the primary amines of general formula 313 by the action of trifluoroacetic acid.
  • Aldehyde 18 was reacted with the appropriate organomagnesium halide, to give an intermediate secondary alcohol, which was oxidized to the corresponding ketone 314.
  • the method of oxidation was the Swern procedure, although other standard oxidations of this type may be employed (e.g PCC, TPAP).
  • the procedure then follows that previously described for the 3-unsubstituted analogs, leading to ester 315. Ester 315 then served as starting material for the preparation of amides, or other heterocyclic derivatives at the 2-position of the thienopyridines.
  • Scheme 82 describes a method for producing cyclic derivatives between the 2- and 3-positions of thienopyridines.
  • 3-Methyl derivative 115 was treated with N-bromosuccinimide (or alternatively N-chlorosuccinimide) in carbon tetrachloride to give bromomethyl (or chloromethyl) compound 316 (X ⁇ Br, Cl).
  • Compound 316 can then be reacted with a primary amine, through alkylation and acylation, leading to the tricyclic lactam 317.
  • These esters in turn can be reacted with substituted amines to yield the corresponding amides 319.
  • Example 1A 35 g, 140 mmol and LiCl (6.5 g, 153 mmol) in DMSO (80 mL) and water (8 mL) was heated to 150° C. for 18 hours, cooled to room temperature, diluted with water, and extracted with ethyl acetate. The extract was dried (MgSO 4 ), filtered, and concentrated to provide the designated compound.
  • Example 1B (3.97 g, 22.0 mmol) in POCl 3 (22 mL) was heated to reflux for 2 hours, cooled, poured onto ice, diluted with water, made basic with concentrated ammonium hydroxide, and extracted with ethyl acetate. The extract was dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 10% ethyl acetate-hexane to provide the designated compound.
  • Example 1C (0.25 g, 1.26 mmol) in DMF (1.2 mL) was treated sequentially with methyl thioglycolate (0.134 g, 1.26 mmol) and potassium carbonate (0.174 g, 1.26 mmol), stirred at room temperature for 18 hours, cooled, poured into water, diluted with brine, and extracted with dichloromethane. The extract was washed with water and brine, dried (MgSO 4 ), filtered, and concentrated. The residue was triturated then washed with 10% ethyl acetate/hexanes to provide the title compound.
  • Example 1C was processed as in Example 1D but substituting thiocresol for methyl thioglycolate to provide the title compound.
  • Example 1C was processed as in Example 1D but substituting 2-mercaptopyridine for methyl thioglycolate to provide the title compound.
  • Example 1C was processed as in Example 1D but substituting isobutyl mercaptan for methyl thioglycolate to provide the title compound.
  • Example 1C was processed as in Example 1D but substituting benzyl mercaptan for methyl thioglycolate to provide the title compound.
  • Example 1C was processed as in Example 1D but substituting 5-methyl-1,3,4-thiadiazol-2-thiol for methyl thioglycolate to provide the title compound.
  • Example 1A was processed as in examples 1C and 2 and to provide the title compound.
  • Example 1C (0.27 g, 1.37 mmol) in isopropanol (1.5 mL) was treated with benzylamine (0.19 mL, 1.71 mmol) and sodium carbonate (0.24 g, 2.3 mmol), stirred at room temperature overnight, filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 25% ethyl acetate/hexanes to provide the title compound.
  • Example 1C A solution of Example 1C (0.20 g, 1.01 mmol) in isopropanol (2 mL) was treated with 2-amino-5-methyl-1,3,4-thiadiazole (0.15 g, 1.26 mmol) and sodium carbonate (0.18 g, 1.7 mmol), stirred at room temperature for 48. hours, treated with cesium carbonate (0.55 g, 1.7 mmol), stirred at reflux for 24 hours, concentrated, treated with water, and extracted with dichloromethane. The extract was dried (MgSO 4 ), filtered, and concentrated. The residue was recrystallized with ethanol/water to provide the title compound.
  • Example 10A was processed as in Bull. Soc. Chim. France 1975, p 815 to provide the designated compound.
  • Example 10B was stirred in dioxane/water in the presence of 10% Na 2 CO 3 to provide the designated compound.
  • Example 10C was processed as in Example 1C to provide the designated compound.
  • Example 10D and 5-amino-1,3,4-thiadiazole-2-thiol were processed as in Example 1D to provide the title compound.
  • Example 16A A suspension of Example 16A in dichloromethane (3.3 mL) was treated sequentially with oxalyl chloride (0.03 mL, 0.33 mmol) and DMF (1 drop), and concentrated after formation of the acid chloride. The residue was suspended in THF (10 mL), transferred to a vigorously stirred solution of 1:1 ammonium hydroxide/water (10 mL), and extracted with dichloromethane. The extract was dried (MgSO 4 ), filtered, and concentrated. The residue was recrystallized from ethyl acetate/hexanes to provide the title compound.
  • Example 17A (5.05 g, 28.7 mmol) in DMF (70 mL) was treated with p-thiocresol (3.56 g, 28.7 mmol) and potassium carbonate (4.36 g, 31.6 mmol), stirred for 0.5 hours at 0° C. then for 1 hour at room temperature, poured into water, diluted with brine, and extracted with dichloromethane. The extract was washed sequentially with water and brine, dried (MgSO 4 ), filtered, and concentrated to provide the designated compound.
  • Example 17B was processed as in Example 1D to provide the title compound.
  • Example 17C (2.0 g, 6.35 mmol) and LiOH.H 2 O (1.4 g, 32 mmol) in isopropanol (25 mL) and water (15 mL) was heated to 75° C. for 1 hour, cooled, treated with water, and washed with diethyl ether. The aqueous layer was cooled in an ice bath and adjusted to pH 2 with 10% HCl. The resulting solid was collected, washed with water, dried, and recrystallized from ethanol/water to provide the title compound.
  • Example 18 A suspension of Example 18 (0.535 g, 1.78 mmol) in dichloromethane (25 mL) at 0° C. was treated sequentially with oxalyl chloride (0.34 g, 2.67 mmol) and DMF (1 drop), stirred at room temperature for 0.5 hours, and concentrated. The residue was suspended in THF, treated with THF (60 mL), water (30 mL), and concentrated NH 4 OH (30 mL), and stirred for 0.5 hours. The THF layer was separated, washed with brine, partially dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 5% methanol/dichloromethane and recrystallized from 95% ethanol to provide the title compound.
  • Example 17A was processed as in Examples 17B, 17C, 18, and 19 but substituting 2-mercaptopyridine for p-thiocresol in Example 17B to provide the title compound.
  • Example 17A was processed as in Examples 17B, 17C, 18, and 19 but substituting 4-chlorothiophenol for p-thiocresol in Example 17B to provide the title compound.
  • Example 18 A solution of Example 18 (0.66 g, 2.2 mmol) in dichloromethane was treated sequentially with oxalyl chloride (0.29 mL, 3.3 mmol) and DMF (1 drop), stirred for 30 minutes, and concentrated. The residue was suspended in THF, transferred to a solution of N,O-dimethylhydroxylamine hydrochloride (0.32 g, 3.3 mmol) and triethylamine (0.92 mL, 6.6 mmol) in 1:1 THF water, and stirred for 5 minutes. The THF layer was separated, dried (MgSO 4 ), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 20% ethyl acetate/hexanes to provide the title compound.

Abstract

Compounds having Formula I
Figure US20030220365A1-20031127-C00001
are useful for treating inflammation. Also disclosed are pharmaceutical compositions comprising compounds of Formula I, and methods of inhibiting/treating inflammatory diseases in a mammal.

Description

  • This application is a continuation-in-part of U.S. provisional application serial No. 60/087,907, filed Jun. 4, 1998, incorporated herein by reference.[0001]
    • TECHNICAL FIELD
  • The present invention relates to compounds that are useful for treating inflammatory diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation in a mammal. [0002]
    • BACKGROUND OF THE INVENTION
  • Inflammation results from a cascade of events that includes vasodilation accompanied by increased vascular permeability and exudation of fluid and plasma proteins. This disruption of vascular integrity precedes or coincides with an infiltration of inflammatory cells. Inflammatory mediators generated at the site of the initial lesion serve to recruit inflammatory cells to the site of injury. These mediators (chemokines such as IL-8, MCP-1, MIP-1, and RANTES, complement fragments and lipid mediators) have chemotactic activity for leukocytes and attract the inflammatory cells to the inflamed lesion. These chemotactic mediators which cause circulating leukocytes to localize at the site of inflammation require the cells to cross the vascular endothelium at a precise location. This leukocyte recruitment is accomplished by a process called cell adhesion. [0003]
  • Cell adhesion occurs through a coordinately regulated series of steps that allow the leukocytes to first adhere to a specific region of the vascular endothelium and then cross the endothelial barrier to migrate to the inflamed tissue (Springer, T. A., 1994, Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm, Cell 76: 301-314; Lawrence, M. B., and Springer, T. A., 1991, Leukocytes' Roll on a Selectin at Physiologic Flow Rates: Distinction from and Prerequisite for Adhesion Through Integrins, Cell.65: 859-873; von Adrian, U., Chambers, J. D., McEnvoy, L. M., Bargatze, R. F., Arfos, K. E, and Butcher, E. C., 1991, Two-Step Model of Leukocyte-Endothelial Cell Interactions in Inflammation, Proc. Natl. Acad. Sci. USA 88: 7538-7542; and Ley, K., Gaehtgens, P., Fennie, C., Singer, M. S., Lasky, L. H. and Rosen, S. D.,1991, Lectin-Like Cell Adhesion Molecule 1 Mediates Rolling in Mesenteric Venules in vivo, Blood 77: 2553-2555). These steps are mediated by families of adhesion molecules such as integrin, Ig supergene family members, and selectins which are expressed on the surface of the circulating leukocytes and on the vascular endothelial cells. The first step consists of leukocyte rolling along the vascular endothelial cell lining in the region of inflammation. The rolling step is mediated by an interaction between leukocyte surface oligosaccharides (such as Sialylated Lewis-X antigen (Slex)) and a selectin molecule expressed on the surface of the endothelial cell in the region of inflammation.. The selectin molecule is not normally expressed on the surface of endothelial cells but rather is induced by the action of inflammatory mediators such as TNF-α and interleukin-1. Rolling decreases the velocity of the circulating leukocyte in the region of inflammation and allows the cells to more firmly adhere to the endothelial cell. The firm adhesion is accomplished by the interaction of integrin molecules that are present on the surface of the rolling leukocytes and their counter-receptors-the Ig superfamily molecule-on the surface of the endothelial cell. The Ig superfamily molecules or CAMs (Cell Adhesion Molecules) are either not expressed or are expressed at low levels on normal vascular endothelial cells. The CAM's, like the selecting, are induced by the action of inflammatory mediators like TNF-alpha and IL-1. The final event in the adhesion process is the extravasation of the leukocyte through the endothelial cell barrier and the migration of the leukocyte along the chemotactic gradient to the site of inflammation. This transmigration is mediated by the conversion of the leukocyte integrin from a low avidity state to a high avidity state. The adhesion process relies on the induced expression of selectins and CAM's on the surface of vascular endothelial cells to mediate the rolling and firm adhesion of leukocytes to the vascular endothelium. [0004]
  • The induced expression of e-selectin and CAM's is mediated by the transcription factor NFkB. NFkB is a family of dimeric transcription factors made from monomers containing the 300 amino acid Rel domain. These factors can bind to DNA, interact with each other and bind to an inhibitor molecule termed IkB (Vermaa, I. M., Stevenson, J. K., Schwarz, E. M., Antwerp, D. V., and Miyamoto, S, 1995, Rel/NFlB/IkB Family: Intimate Tales of Association and Dissociation, Genes Dev. 9: 2723-2735; and Baldwin, A. S. 1996, The NFkB and IkB proteins: New Discoveries and Insights, Annu. Rev. Immunol. 14: 649-681). NFkB is found in the cytoplasm complexed with IkB. Activation of NFkB occurs in response to inflammatory mediators such as TNF-α, IL-1, and lipopolysaccharide. Activation of NFkB requires phosphorylation of IkB followed by ubiquitinylation of the IkB molecule and subsequent degradation by proteosomes. Release of NFkB from association with IkB results in translocation of the dimer to the nucleus where it can associate with specific DNA sequences. The e-selectin gene and CAM's contain NFkB-recognition sequences upstream from their coding regions. The DNA-bound NFkB acting with other proteins in the transcription complex directs the expression of the e-selectin and CAM genes among others controlled by this transcription factor. [0005]
  • The present invention discloses compounds that inhibit the expression of e-selectin and ICAM-1 relative to VCAM-1. These compounds are useful for the treatment or prophylaxis of diseases caused by expression of adhesion molecules. These diseases include those in which leukocyte trafficking plays a role, notably acute and chronic inflammatory diseases, autoimmune diseases, tumor metastasis, allograft rejection, and reperfusion injury. [0006]
    • SUMMARY OF THE INVENTION
  • In one embodiment of the present invention are disclosed compounds represented by structural Formula I: [0007]
    Figure US20030220365A1-20031127-C00002
  • or a pharmaceutically acceptable salt or prodrug thereof, where the symbol [0008]
    Figure US20030220365A1-20031127-P00900
    represents a single bond or a double bond, provided that when one bond is a double bond, the adjacent bond is a single bond;
  • E, F, and G are independently selected from [0009]
  • (1) carbon, [0010]
  • (2) nitrogen, and [0011]
  • (3) N[0012] +—O−,
  • provided that at least one of E, F or G is nitrogen or N[0013] +—O−, and further provided that at least one of E, F or G is carbon;
  • Y and Z are independently selected from [0014]
  • (1) carbon, [0015]
  • (2) nitrogen, [0016]
  • (3) oxygen, and [0017]
  • (4) S(O)[0018] t where t is an integer 0-2,
  • provided that at least one of Y or Z is other than carbon; [0019]
  • L[0020] A is selected from
  • (1) a covalent bond, [0021]
  • (2) —O—, [0022]
  • (3) —S(O)[0023] t—,
  • (4) —NR[0024] 6— where R6 is selected from
  • (a) hydrogen, [0025]
  • (b) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from, [0026]
  • (i) aryl and [0027]
  • (ii) cycloalkyl of three to ten carbons, [0028]
  • (c) alkanoyl where the alkyl part is of one to ten carbons, and [0029]
  • (d) cycloalkyl of three to ten carbons, [0030]
  • (5) —C(W)— where W is selected from [0031]
  • (a) O and [0032]
  • (b) S, and [0033]
  • (6) alkenylene;. [0034]
  • X[0035] A is selected from
  • (1) halo, [0036]
  • (2) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from [0037]
  • (a) oxo, [0038]
  • (b) cycloalkyl of three to ten carbons, [0039]
  • (c) —CO[0040] 2R7 where R7 is selected from
  • (i) hydrogen and [0041]
  • (ii) alkyl of one to ten carbons optionally substituted with 1, or 2 substituents independently selected from [0042]
  • aryl and [0043]
  • cycloalkyl of three to ten carbons, [0044]
  • (d) —NR[0045] 8R9 where R8 and R9 are independently selected from
  • (i) hydrogen, [0046]
  • (ii) alkyl of one to six carbons optionally substituted with 1 or 2 substituents independently selected from [0047]
  • —OH, [0048]
  • aryl, [0049]
  • heterocycle [0050]
  • cycloalkyl of three to ten carbons, and [0051]
  • —NR[0052] ARB where RA and RB are independently selected from
  • hydrogen and [0053]
  • alkyl of one to six carbons optionally substituted with [0054]
  • 1 or 2 substituents selected from —OH, [0055]
  • (iii) alkanoyl where the alkyl part is of one to to ten carbons, [0056]
  • (iv) cycloalkyl of three to ten carbons, [0057]
  • (v) alkoxy, [0058]
  • (vi) heterocycle, and [0059]
  • (vii) aryl, [0060]
  • where (vi) and (vii) are substituted with 1 or 2 substituents independently selected from [0061]
  • alkyl of one to six carbons and [0062]
  • halo, [0063]
  • (e) —C(W)R[0064] 10 where W is previously defined and R10 is selected from
  • (i) hydrogen, [0065]
  • (ii) alkyl of one to ten carbons optionally substituted with 1, or 2 substituents independently selected from [0066]
  • aryl and [0067]
  • cycloalkyl of three to ten carbons, [0068]
  • (iii) —NR[0069] 8R9, and
  • (iv) —OR[0070] 7,
  • (f) —OH, [0071]
  • (g) aryl, and [0072]
  • (h) heterocycle, [0073]
  • where (g) and (h) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from [0074]
  • (i) alkyl of one to twenty carbons, [0075]
  • (ii) —NR[0076] 8R9,
  • (iii) alkoxy of one to ten carbons, [0077]
  • (iv) thioalkoxy of one to ten carbons, [0078]
  • (v) halo, [0079]
  • (vi) perfluoroalkyl of one to three carbons, [0080]
  • (vii) alkenyl of two to ten carbons, [0081]
  • (viii) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from [0082]
  • alkoxy of one to ten carbons and [0083]
  • —OH, [0084]
  • (ix) —CO[0085] 2R7,
  • (x) aryl, and [0086]
  • (xi) —CHO, [0087]
  • (3) cycloalkyl of three to ten carbons, [0088]
  • (4) aryl, [0089]
  • (5) heterocycle [0090]
  • where (4) and (5) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from [0091]
  • (a) alkyl of one to twenty carbons, [0092]
  • (b) alkyl of one to ten carbons substituted with 1, 2, or 3 substituents independently selected from [0093]
  • (i) —OR[0094] 11 where R11 is selected from
  • hydrogen, [0095]
  • —C(W)R[0096] 12 where R12 is selected from
  • alkyl of one to ten carbons, [0097]
  • cycloalkyl of three to ten carbons, [0098]
  • aryl, and [0099]
  • heterocycle, and [0100]
  • heterocycle optionally substituted with 1, 2, 3, or 4 substituents independently selected from [0101]
  • —OH and [0102]
  • alkyl of one to six carbons optionally substituted with [0103]
  • 1 or 2 substituents selected from —OH, [0104]
  • (ii) alkoxy of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from [0105]
  • alkoxy and, [0106]
  • alkoxyalkoxy, [0107]
  • (iii) spiroalkyl of three to ten carbons, and [0108]
  • (iv) halo, [0109]
  • (c) alkoxy of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from [0110]
  • (i) alkoxy, and [0111]
  • (ii) alkoxyalkoxy, [0112]
  • (d) thioalkoxy of one to ten carbons, [0113]
  • (e) halo, [0114]
  • (f) perfluoroalkyl of one to three carbons, [0115]
  • (g) alkenyl of two to ten carbons optionally substituted with 1 or 2 substituents independently selected from [0116]
  • (i) —C(W)R[0117] 10 and
  • (ii) —C(W)R[0118] 12,
  • (h) —CO[0119] 2R7,
  • (i) —NR[0120] 8R9,
  • (j) aryl, [0121]
  • (k) —C(W)R[0122] 12,
  • (l) —CHO, [0123]
  • (m) —C(O)NR[0124] 8R9,
  • (n) —CN, [0125]
  • (o) heterocycle optionally-substituted with 1 or 2 substituents independently selected from [0126]
  • (i) alkyl of one to ten carbons and [0127]
  • (ii) perfluoroalkyl of one to three carbons, [0128]
  • (p) —C(W)R[0129] 10,
  • (q) ethylenedioxy, and [0130]
  • (r) —OCF[0131] 3,
  • (6) —OR[0132] 7,
  • (7) hydrogen, and [0133]
  • (8) —NR[0134] 8R9;
  • L[0135] B is selected from
  • (1) a covalent bond, [0136]
  • (2) —O—, [0137]
  • (3) —S(O)[0138] t—,
  • (4) —NR[0139] 6—,
  • (5) —C(W)—, and [0140]
  • (6) —C(═NR[0141] 13)— where R13 is selected from
  • (a) hydrogen, [0142]
  • (b) —NO[0143] 2,
  • (c) —CN, and [0144]
  • (d) —OR[0145] 14 where R14 is selected from
  • (i) hydrogen, [0146]
  • (ii) aryl, and [0147]
  • (iii) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from [0148]
  • aryl and [0149]
  • —C(O)R[0150] 15 where R15 is selected from
  • hydrogen, [0151]
  • —OH, [0152]
  • alkoxy, and [0153]
  • NR[0154] ARB;
  • X[0155] B is selected from
  • (1) hydrogen, [0156]
  • (2) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from [0157]
  • (a) —CO[0158] 2R7,
  • (b) —NR[0159] 8R9,
  • (c) —C(W)NR[0160] 8R9,
  • (d) heterocycle, [0161]
  • (e) aryl optionally substituted with 1 or 2 substituents independently selected from [0162]
  • (i) alkyl of one to ten carbons, [0163]
  • (ii) —NO[0164] 2, and
  • (iii) —NR[0165] ARB,
  • (f) —OR[0166] 16 where R16 is selected from
  • (i) hydrogen and [0167]
  • (ii) —C(W)NR[0168] ARB, and
  • (g) —NR[0169] AC(W)NR8R9,
  • (3) alkenyl of two to six carbons optionally substituted with 1 or 2 substituents independently selected from [0170]
  • (a) —C(W)NR[0171] ARB,
  • (b) —CO[0172] 2R7, and
  • (c) heterocycle, [0173]
  • (4) —NR[0174] 17R18 where R17 and R18 are independently selected from
  • (a) hydrogen, [0175]
  • (b) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from [0176]
  • (i) —OH, [0177]
  • (ii) —C(W)R[0178] 10,
  • (iii) —NR[0179] AC(═NR13)NRBR19 where RA, RB, and R13 are previously defined and R19 is selected from
  • hydrogen, [0180]
  • alkyl of one to ten carbons, and [0181]
  • —NO[0182] 2,
  • (iv) heterocycle, [0183]
  • (v) aryl, [0184]
  • (vi) halo, and [0185]
  • (vii) —NR[0186] ARB,
  • (c) alkoxy, [0187]
  • (d) aryl optionally substituted with 1, 2, or 3 substituents independently selected from [0188]
  • (i) halo, [0189]
  • (ii) alkyl of one to ten carbons, [0190]
  • (iii) alkoxy of one to ten carbons, and [0191]
  • (iv) perfluoroalkyl of one to three carbons, [0192]
  • (e) heterocycle, [0193]
  • (f) —NR[0194] ARB,
  • (g) —C(O)R[0195] 20 where R20 is selected from
  • (i) hydrogen, [0196]
  • (ii) alkyl of one to ten carbons, [0197]
  • (iii) —OR[0198] 12, and
  • (iv) —NR[0199] ARB,
  • (h) cycloalkyl of three to ten carbons, and [0200]
  • (i) —OH, [0201]
  • (5) alkoxy, [0202]
  • (6) —OH, [0203]
  • (7) —NR[0204] AC(═NR13)NRBR19,
  • (8) —C(W)NR[0205] 8R9,
  • (9) aryl, [0206]
  • (10) heterocycle, [0207]
  • where (9) and (10) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from [0208]
  • (a) halo, [0209]
  • (b) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from [0210]
  • (i) halo, [0211]
  • (ii) alkoxy of one to ten carbons, [0212]
  • (iii) NR[0213] ARB,
  • (iv) —OH, [0214]
  • (v) —CO[0215] 2R7,
  • (vi) —C(W)NR[0216] ARB, and
  • (vii) aryl, [0217]
  • (c) —NR[0218] ARB,
  • (d) alkoxy of one top ten carbons, [0219]
  • (e) thioalkoxy of one to ten carbons, [0220]
  • (f) perfluoroalkyl of one to three carbons, [0221]
  • (g) —OH, [0222]
  • (h) —C(W)NR[0223] 8R9,
  • (i) —CO[0224] 2R7,
  • (j) —NR[0225] AC(W)OR21 where RA is previously defined and R21 is selected from
  • (i) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents selected from [0226]
  • aryl and [0227]
  • cycloalkyl of three to ten carbons, [0228]
  • (ii) aryl, and [0229]
  • (iii) cycloalkyl of three to ten carbons, [0230]
  • (k) alkenyl of two to ten carbons, [0231]
  • (l) heterocycle, [0232]
  • (m) aryl, and [0233]
  • (n) —NO[0234] 2,
  • (11) —CN, [0235]
  • (12) —CHO, [0236]
  • (13) halo, and [0237]
  • (14) —B(OR[0238] A)(ORB);
  • provided that when R[0239] 1, R2, R3, R4, and R5 are hydrogen or absent, -LA- is a covalent bond, and -LB- is a covalent bond, then one of XA or XB is other than hydrogen; and
  • R[0240] 1, R2, R3, R4, and R5 are absent or independently selected from
  • (1) hydrogen, [0241]
  • (2) alkyl of one to six carbons optionally substituted with 1 or 2 substituents independently selected from [0242]
  • (a) —OC(O)R[0243] 22, where R22 is selected from
  • (i) alkyl, [0244]
  • (ii) alkoxy, and [0245]
  • (iii) NR[0246] ARB,
  • (b) alkoxy, [0247]
  • (c) —OH, [0248]
  • (d) —NR[0249] ARB,
  • (e) heterocycle, and [0250]
  • (f) aryl, [0251]
  • (3) —CO[0252] 2R7,
  • (4) —C(O)NR[0253] ARB,
  • (5) —SR[0254] 23 where R23 is selected from
  • (a) hydrogen, [0255]
  • (b) alkyl of one to six carbons, [0256]
  • (c) aryl optionally substituted with 1 or 2 substituents selected from [0257]
  • (i) alkyl of one to six carbons and [0258]
  • (ii) halo, [0259]
  • (6) —NR[0260] ARB,
  • (7) halo, [0261]
  • (8) alkoxy, [0262]
  • (9) perfluoroalkyl of one to three carbons, [0263]
  • (10) —OH, and [0264]
  • (11) heterocycle, [0265]
  • provided that when E, F, and Y are carbon, G is nitrogen, Z is sulfur, -L[0266] A- is a covalent bond, and XA is halo, R1 is other than —CO2R7.
  • In another embodiment of the invention are disclosed methods of treating diseases comprising administering an effective amount of a compound having Formula I. [0267]
  • In yet another embodiment of the invention are disclosed pharmaceutical compositions containing compounds of Formula I. [0268]
    • DETAILED DESCRIPTION OF THE INVENTION Definition of Terms
  • The term “alkanoyl” as used herein refers to an alkyl group attached to the parent molecular group through a carbonyl group. [0269]
  • The term “alkenyl” as used herein refers to a monovalent straight or branched chain group of 2-12 carbon atoms containing at least one carbon-carbon double bond derived from an alkene by the removal of one hydrogen atom. [0270]
  • The term “alkenylene” as used herein refers to a divalent straight or branched chain group of 2-10 carbon atoms containing a carbon-carbon double bond derived from an alkene by the removal of two hydrogen atoms. [0271]
  • The term “alkoxy” as used herein refers to an alkyl group attached to the parent molecular group through an oxygen atom. [0272]
  • The term “alkoxyalkoxy” as used herein refers to an alkoxy group attached to the parent molecular group through another alkoxy group. [0273]
  • The term “alkoxycarbonyloxy,” as used herein, refers to an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyloxy group, as defined herein. [0274]
  • The term “alkoxycarbonyloxymethylene,” as used herein, refers to an alkoxycarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein. [0275]
  • The term “alkyl” as used herein refers to a saturated straight or branched chain group of 1-20 carbon atoms derived from an alkane by the removal of one hydrogen atom. [0276]
  • The term “alkylcarbonyl,” as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group. [0277]
  • The term “alkylcarbonyloxy,” as used herein, refers to an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyloxy group, as defined herein. [0278]
  • The term “alkylcarbonyloxymethylene,” as used herein, refers to an alkylcarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein. [0279]
  • The term “alkylene,” denotes a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms. Representative examples of alkylene include, but are not limited to, —CH[0280] 2—, —CH2CH2—, —CH2CH2CH2—, —CH2CH2CH2CH2—, —CH2CH(CH3)CH2—, and the like.
  • The term “amino,” as used herein, refers to a —NR[0281] 80R81 group, where R80 and R81 are independently selected from hydrogen and alkyl.
  • The term “aminocarbonyl,” as used herein, refers to an amino group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein. [0282]
  • The term “aminocarbonyloxy,” as used herein, refers to an aminocarbonyl group, as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. [0283]
  • The term “aminocarbonyloxymethylene,” as used herein, refers to an aminocarbonyloxy group, as defined herein, appended to the parent molecular moiety through a methylene group, as defined herein. [0284]
  • The term “aryl” refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings. The aryl group can also be fused to a cyclohexane, cyclohexene, cyclopentane or cyclopentene ring. The aryl groups of this invention can be optionally substituted. [0285]
  • The term “carbonyl,” as used herein, refers to a —C(O)— group. [0286]
  • The term “carbonyloxy,” as used herein, refers to a carbonyl group as defined herein, appended to the parent molecular moiety through an oxy group, as defined herein. [0287]
  • The term “cycloalkyl” as used herein refers to a monovalent saturated cyclic hydrocarbon group of 3-12 carbons derived from a cycloalkane by the removal of a single hydrogen atom. [0288]
  • The term “ethylenedioxy,” as used herein, refers to a —O(CH[0289] 2)2O— group wherein the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety through one carbon atom forming a 5 membered ring or the oxygen atoms of the ethylenedioxy group are attached to the parent molecular moiety through two adjacent carbon atoms forming a six membered ring.
  • The terms “halo” or “halogen” as used herein refers to F, Cl, Br, or I. [0290]
  • The term “heterocycle” represents a represents a 4-, 5-, 6- or 7-membered ring containing one, two or three heteroatoms independently selected from the group consisting of nitrogen, oxygen and sulfur. The 4- and 5-membered rings have zero to two double bonds and the 6- and 7-membered rings have zero to three double bonds. The term “heterocycle” also includes bicyclic, tricyclic and tetracyclic groups in which any of the above heterocyclic rings is fused to one or two rings independently selected from an aryl ring, a cyclohexane ring, a cyclohexene ring, a cyclopentane ring, a cyclopentene ring or another monocyclic heterocyclic ring. Heterocycles include acridinyl, benzimidazolyl, benzofuryl, benzothiazolyl, benzothienyl, benzoxazolyl, biotinyl, cinnolinyl, dihydrofuryl, dihydroindolyl, dihydropyranyl, dihydrothienyl, dithiazolyl, furyl, homopiperidinyl, imidazolidinyl, imidazolinyl, imidazolyl, indolyl, isoquinolyl, isothiazolidinyl, isothiazolyl, isoxazolidinyl, isoxazolyl, morpholinyl, oxadiazolyl, oxazolidinyl, oxazolyl, oxadiazolyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyridazinyl, pyridyl, pyrimidinyl, pyrimidyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinolinyl, quinoxaloyl, tetrahydrofuryl, tetrahydroisoquinolyl, tetrahydroquinolyl, tetrazolyl, thiadiazolyl, thiazolidinyl, thiazolyl, thienyl, thiomorpholinyl, triazolyl, and the like. [0291]
  • Heterocyclics also include bridged bicyclic groups where a monocyclic heterocyclic group is bridged by an alkylene group such as [0292]
    Figure US20030220365A1-20031127-C00003
  • and the like. [0293]
  • Heterocyclics also include compounds of the formula [0294]
    Figure US20030220365A1-20031127-C00004
  • where X* is selected from —CH[0295] 2—, —CH2O— and —O—, and Y* is selected from —C(O)— and —(C(R″)2)v—, where R″ is hydrogen or alkyl of one to four carbons, and v is 1-3. These heterocycles include 1,3-benzodioxolyl, 1,4-benzodioxanyl, and the like. The heterocycle groups of this invention can be optionally substituted.
  • The term “oxo,” as used herein, refers to ═O. [0296]
  • The term “oxy,” as used herein, refers to —O—. [0297]
  • The term “methylene,” as used herein, refers to a —CH[0298] 2— group.
  • The term “perfluoroalkyl” as used herein refers to an alkyl group in which all of the hydrogen atoms have been replaced by fluoride atoms. [0299]
  • The term “phenyl” as used herein refers to a monocyclic carbocyclic ring system having one aromatic ring. The aryl group can also be fused to a cyclohexane or cyclopentane ring. The phenyl groups of this invention can be optionally substituted. [0300]
  • The term “pharmaceutically acceptable prodrugs” as used herein represents those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. [0301]
  • The term “prodrug,” as used herein, represents compounds which are rapidly transformed in vivo to the parent compound of the above formula, for example, by hydrolysis in blood. A thorough discussion is provided in T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. Symposium Series, and in Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, both of which are incorporated herein by reference. [0302]
  • The term “spiroalkyl” as used herein refers to an alkylene group wherein two carbon atoms of the alkylene group are attached to one carbon atom of the parent molecular group thereby forming a carbocyclic ring of three to eleven carbon atoms. [0303]
  • The term “tautomer” as used herein refers to a proton shift from one atom of a molecule to another atom of the same molecule wherein two or more structurally distinct compounds are in equilibrium with each other. [0304]
  • The term “thioalkoxy” as used herein refers to an alkyl group attached to the parent molecular group through a sulfur atom. [0305]
  • Compounds of the present invention can exist as stereoisomers wherein asymmetric or chiral centers are present. These compounds are designated by the symbols “R” or “S,” depending on the configuration of substituents around the chiral carbon atom. The present invention contemplates various stereoisomers and mixtures thereof. Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers are designated (±) Individual stereoisomers of compounds of the present invention can be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary or (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns. [0306]
  • Geometric isomers can exist in the compounds of the present invention. The present invention contemplates the various geometric isomers and mixtures thereof resulting from the arrangement of substituents around a carbon-carbon double bond or arrangement of substituents around a carbocyclic ring. Substituents around a carbon-carbon double bond are designated as being in the Z or E configuration wherein the term “Z” represents substituents on the same side of the carbon-carbon double bond and the term “E” represents substituents on opposite sides of the carbon-carbon double bond. The arrangement of substituents around a carbocyclic ring are designated as cis or trans wherein the term “cis” represents substituents on the same side of the plane of the ring and the term “trans” represents substituents on opposite sides of the plane of the ring. Mixtures of compounds wherein the substituents are disposed on both the same and opposite sides of plane of the ring are designated cis/trans. [0307]
  • Tautomers can also exist in the compounds of the present invention. The present invention contemplates tautomers due to proton shifts from one atom to another atom of the same molecule generating two distinct compounds that are in equilibrium with each other. [0308]
  • Compounds of the present invention include, but are not limited to [0309]
  • methyl 2-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)thio]acetate, [0310]
  • 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine, [0311]
  • 6-ethyl-4-(2-pyridinylthio)thieno[2,3-d]pyrimidine, [0312]
  • 6-ethyl-4-[(2-methylethyl)thio]thieno[2,3-d]pyrimidine, [0313]
  • 6-ethyl-4-[(phenylmethyl)thio]thieno[2,3-d]pyrimidine, [0314]
  • 6-ethyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-d]pyrimidine, [0315]
  • ethyl 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine-6-carboxylate, [0316]
  • 6-ethyl-N-(phenylmethyl)thieno[2,3-d]pyrimidin-4-amine, [0317]
  • 6-ethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine, [0318]
  • 4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine, [0319]
  • 4-chloro-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine, [0320]
  • 4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine, [0321]
  • 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine, [0322]
  • 7-methyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[3,2-d]pyrimidine, [0323]
  • 7-methyl-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]thieno[3,2-d]pyrimidine, [0324]
  • 4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-7-methylthieno[3,2-d]pyrimidine, [0325]
  • 7-methyl-N-[(4-(methylthio)phenyl]thieno[3,2-d]pyrimidin-7-amine, [0326]
  • 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-6-carboxamide, [0327]
  • methyl 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylate, [0328]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid, [0329]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0330]
  • 4-(2-pyridinylthio)thieno[2,3-c]pyridine-2-carboxamide, [0331]
  • 4-[(4-chlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0332]
  • N-methoxy-N-methyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0333]
  • N-methoxy-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0334]
  • N-(4-chlorophenyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0335]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, [0336]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-methyloxime, [0337]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-(phenylmethyl)oxime, [0338]
  • 2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-ylmethylene]amino]oxy]acetic acid, [0339]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-phenyloxime, [0340]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, oxime, [0341]
  • 2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-ylmethylene]-amino]oxy]acetamide, [0342]
  • (E)-3-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]-2-propenamide, [0343]
  • 1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone, [0344]
  • 2-benzoyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine, [0345]
  • 2-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine, [0346]
  • 1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone, oxime, [0347]
  • N-(2,3-dihydroxypropyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0348]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid, hydrazide, [0349]
  • N[0350] 2-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]carbonyl]-N6-[(nitroamino)iminomethyl]-L-lysine, methyl ester,
  • N-(aminoiminomethyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0351]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carbothioamide, [0352]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine, [0353]
  • methyl 4-[(2-methoxy-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxylate, [0354]
  • 4-[(2-amino -2-oxoethyl) thio]thieno[2,3-c]pyridine-2-carboxamide, [0355]
  • 4-[(4-bromophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0356]
  • 4-(phenylthio)thieno[2,3-c]pyridine-2-carboxamide, [0357]
  • 4-[[4-(trifluoromethyl)phenyl]thio]thieno[2,3-c]pyridine-2-carboxamide, [0358]
  • 4-[(2-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0359]
  • 4-[(3-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0360]
  • 4-[(3,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0361]
  • 4-[(3,5-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0362]
  • 4-[(2,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0363]
  • 4-[(2-methyl-3-furanyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0364]
  • 4-[[(4-chlorophenyl)methyl]thio]thieno[2,3-c]pyridine-2-carboxamide, [0365]
  • 4-[(3,4-dichlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0366]
  • 4-[(4-methoxyphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, [0367]
  • 4-(cyclohexylthio)thieno[2,3-c]pyridine-2-carboxamide, [0368]
  • 4-[(4-methylphenyl)thio]-N-[3-(4-morpholinyl)propyl]thieno[2,3-c]pyridine-2-carboxamide, trifluoromethylacetate salt, [0369]
  • 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxamide, [0370]
  • methyl 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxylate, [0371]
  • 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0372]
  • methyl 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxylate, [0373]
  • 4-(4-chlorophenoxy)thieno[2,3,-c]pyridine-2-carboxamide, [0374]
  • methyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate, [0375]
  • 4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0376]
  • 4-(4-octylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0377]
  • 4-[4-(1-methylethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0378]
  • 4-(2-bromo-4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0379]
  • 4-(4-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0380]
  • 4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0381]
  • 4-[4-(1,2-dihydroxyethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0382]
  • 4-[2-(2-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0383]
  • 4-[2-(2,3-dihydroxypropyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0384]
  • 4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, 1-oxide, [0385]
  • 4-[3-(pentadecyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0386]
  • 4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0387]
  • 4-(3-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0388]
  • 4-(4-t-butylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0389]
  • 4-(4-chloro-3-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0390]
  • 4-(4-chloro-2-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0391]
  • 4-(4-methoxyphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0392]
  • ethyl 3-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate, [0393]
  • 4-phenoxythieno[2,3-c]pyridine-2-carboxamide, [0394]
  • 4-(3-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0395]
  • 4-(4-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0396]
  • 4-(3,5-dimethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0397]
  • 4-(3-chloro-4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0398]
  • 4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0399]
  • 4-(4-(methoxymethyl)phenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0400]
  • 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridinium, iodide, [0401]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, [0402]
  • N-(4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl)-O-(3-tetrahydrofuranyl)carbamate, [0403]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-methanol, [0404]
  • (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoic acid, [0405]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxaldehyde, [0406]
  • (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide, [0407]
  • 4-bromothieno[2,3-c]pyridine-2-carboxamide, [0408]
  • methyl 4-bromothieno[2,3-c]pyridine-2-carboxylate, [0409]
  • 4-chlorothieno[2,3-c]pyridine-2-carboxamide, [0410]
  • 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide, [0411]
  • methyl 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxylate, [0412]
  • N-methyl-4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide, [0413]
  • 4-phenylthieno[2,3-c]pyridine-2-carboxamide, [0414]
  • methyl 4-phenylthieno[2,3-c]pyridine-2-carboxylate, [0415]
  • 4-([1,1′-biphenyl]-4-ylthio)thieno[2,3-c]pyridine-2-carboxamide, [0416]
  • 4-(5-formyl-2-furanyl)thieno[2,3-c]pyridine-2-carboxamide, [0417]
  • ethyl 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate, [0418]
  • 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid, [0419]
  • 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide, [0420]
  • methyl 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxalate, [0421]
  • 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-methanol, [0422]
  • 4-(4-Chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0423]
  • 4-(4-chlorophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide, [0424]
  • 4-(4-chlorophenoxy)-N,N-diethylthieno[2,3-c]pyridine-2-carboxamide, [0425]
  • 4-(4-chlorophenoxy)-N-cyclopropylthieno[2,3-c]pyridine-2-carboxamide, [0426]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]pyrrolidine, [0427]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]piperidine, [0428]
  • 4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]morpholine, [0429]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-methylpiperazine, [0430]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-phenyllpiperazine, [0431]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(phenylmethyl)-piperazine, [0432]
  • 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(2-pyridinyl)-piperazine, [0433]
  • 4-(4-chlorophenoxy)-N-(2-hydroxyethyl)lthieno[2,3-c]pyridine-2-carboxamide, [0434]
  • 4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-N-(1-methylethyl)-1-piperazineacetamide, trifluoroacetate salt, [0435]
  • 4-(4-chlorophenoxy)-N-[1-(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide, [0436]
  • 4-(4-chlorophenoxy)-N-[1,1-bis(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide, [0437]
  • (D,L)-4-(4-chlorophenoxy)-N-(2-hydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide, [0438]
  • 4-(4-chlorophenoxy)-N-[2-(4-morpholinyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide, [0439]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide, [0440]
  • 4-[(4-methylphenyl)methyl]thieno[2,3-c]pyridine-2-carboxamide, [0441]
  • methyl 4-[(4-methylphenyl)methyl]thieno[2,3-c]pyridine-2-carboxylate, [0442]
  • 4-(4-morpholinyl)thieno[2,3-c]pyridine-2-carboxamide, [0443]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, N-oxide, [0444]
  • methyl (4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-oxide, [0445]
  • 4-(4-chlorophenoxy)-2-(2-methoxyphenyl)thieno[2,3-c]pyridine, [0446]
  • 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine, [0447]
  • 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, [0448]
  • Methyl 4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylate, [0449]
  • 4-(4-Chlorophenoxy)-3-hydroxythieno[2,3-c]pyridine-2-carboxamide, [0450]
  • methyl 4-(4-chlorophenoxy)-3-hydroxythieno[2,3-c]pyridine-2-carboxylate, [0451]
  • 4-(4-Chlorophenoxy)-3-(1-methylethoxy)thieno[2,3-c]pyridine-2-carboxamide, [0452]
  • 3-bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine, [0453]
  • 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylic acid, [0454]
  • 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-3-carboxamide, [0455]
  • 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0456]
  • methyl 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate, [0457]
  • 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, [0458]
  • 4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine, [0459]
  • 4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide, [0460]
  • 4-chloro-N-(4-chlorophenyl)thieno[2,3-b]pyridine-5-carboxamide, [0461]
  • ethyl 4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-b]pyridine-5-carboxylate, [0462]
  • 7-[(4-methylphenyl)thio]thieno[3,2-b]pyridine-2-carboxamide, [0463]
  • methyl 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxylate, [0464]
  • methyl 3-amino-6-chlorothieno[2,3-b]pyridine-2-carboxylate, [0465]
  • 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide, [0466]
  • 2-bromo-4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine, [0467]
  • 4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carboxamide, [0468]
  • 4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carbonitrile, [0469]
  • 4-(4-Methylphenoxy)thieno[3,2-c]pyridine-2-carboxamide, [0470]
  • 4-(4-Methylphenoxy)thieno[3,2-c]pyridine-2-carbonitrile, [0471]
  • 7-(4-methylphenoxy)oxazolo[5,4-c]pyridine-2-carboxamide, [0472]
  • methyl 7-(4-methylphenoxy)oxazolo[5,4-c]pyridine-2-carboxylate, [0473]
  • 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide, [0474]
  • methyl 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxylate, [0475]
  • 7-(4-methylphenoxy)-3H-imidazo[4,5-c]pyridine-2-carboxamide, [0476]
  • methyl 7-(4-methylphenoxy)-3H-imidazo[4,5-c]pyridine-2-carboxylate, [0477]
  • 4-(4-chlorophenoxy)thieno[2,3-d]pyridazine-2-carboxamide, [0478]
  • 4-(4-chlorophenoxy)thieno[2,3-d]pyridazine-2-carboxylic acid, [0479]
  • 7-(4-chlorophenoxy)thieno[3,2-c]pyridine-2-carbamide, [0480]
  • 7-(4-chlorophenoxy)thieno[3,2-c]pyridine-2-carboxylic acid, [0481]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbothioamide, [0482]
  • 4-(4-chlorophenoxy)-N-ethylthieno[2,3-c]pyridine-2-carboxamide, [0483]
  • 4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide, [0484]
  • 4-(4-bromophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide, [0485]
  • N-(2-chloroethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0486]
  • 4-(4-bromophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide, [0487]
  • 4-(2-bromo-4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide, [0488]
  • N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0489]
  • N-(2-aminoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0490]
  • 4-(4-chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide, [0491]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide, [0492]
  • 4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide, [0493]
  • 4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carbohydrazide, [0494]
  • 4-(4-chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide, [0495]
  • 2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid, [0496]
  • N-(2-amino-2-oxoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0497]
  • N-(2-amino-2-oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0498]
  • (2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid, [0499]
  • N-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0500]
  • (2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid, [0501]
  • (2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid, [0502]
  • 4-(4-chlorophenoxy)-N-[(1R)-1-ethyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide, [0503]
  • (2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid, [0504]
  • 4-(4-chlorophenoxy)-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide, [0505]
  • 4-(4-chlorophenoxy)-N-[(1R)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide, [0506]
  • 4-(4-chlorophenoxy)-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide, [0507]
  • 4-(3-pyridinyloxy)thieno[2,3-c]pyridine-2-carboxamide, [0508]
  • 4-(4-bromophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0509]
  • 4-(4-bromophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide, [0510]
  • N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0511]
  • 4-(4-chloro-3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0512]
  • 4-(4-chloro-3 fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0513]
  • 4-(4-chloro-3-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0514]
  • 4-(3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0515]
  • 4-(2,3-difluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0516]
  • 4-(2,3-difluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0517]
  • 4-(3-fluorophenoxy)-N-methylthieno [2,3-c]pyridine-2-carboxamide, [0518]
  • N-methyl-4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0519]
  • 4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0520]
  • N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0521]
  • 4-[3-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0522]
  • N,N-dimethyl-4-(4-vinylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0523]
  • 4-(4-cyanophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0524]
  • 4-(4-cyanophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0525]
  • 4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0526]
  • 4-[4-(acetylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0527]
  • N-methyl-4-[4-(4-morpholinyl)phenoxy]thieno [2,3-c]pyridine-2-carboxamide, [0528]
  • 4-[4-(hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0529]
  • 4-[4-(hydroxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0530]
  • 4-[4-(methoxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0531]
  • 4-{4-[(2-methoxyethoxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0532]
  • 4-{4-[(2-methoxyethoxy)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0533]
  • 4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0534]
  • 4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0535]
  • 4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0536]
  • N-methyl-4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0537]
  • 4-{[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy}benzyl 2-furoate, [0538]
  • 4-[4-({[(2R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0539]
  • 4-(4-acetylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0540]
  • 4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0541]
  • N-methyl-4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0542]
  • 4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0543]
  • N-methyl-4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0544]
  • 4-{4-[(E)-3-(4-morpholinyl)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0545]
  • 4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino }-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0546]
  • N-methyl-4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0547]
  • 4-(4-{(E)-3-[(2,3-dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0548]
  • 4-(4-{(E)-3-[(2,3-dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0549]
  • 4-[4-((E)-3-{[2-(1H-imidazol-4-yl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0550]
  • 4-{4-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0551]
  • 4-{4-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0552]
  • 4-[4-(1H-imidazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0553]
  • N-methyl-4-[4-(1H-pyrazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0554]
  • N-methyl-4-[4-(1H-1,2,4-triazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0555]
  • N-methyl-4-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide, [0556]
  • 4-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0557]
  • N-methyl-4-[4-(2-thienyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0558]
  • 4-([1,1′-biphenyl]-4-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0559]
  • N-methyl-4-[4-(1-methyl-1H-imidazol-5-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0560]
  • 4-{4-[1-(hydroxymethyl)cyclopropyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0561]
  • 4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0562]
  • N-methyl-4-[4-(trifluoromethoxy)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0563]
  • 5-{4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine, [0564]
  • 4-[4-(1,1-difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0565]
  • 4-(4-{2-[2-(2-ethoxyethoxy)ethoxy]-1,1-difluoroethyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0566]
  • 4-(4-chlorophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium, [0567]
  • 4-(4-bromophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium, [0568]
  • 2-(aminocarbonyl)-4-(4-chlorophenoxy)-6-{[(isopropoxycarbonyl)oxy]methyl}thieno[2,3-c]pyridin-6-ium, [0569]
  • 4-(benzyloxy)thieno[2,3-c]pyridine-2-carboxamide, [0570]
  • 4-[(4-chlorophenyl)(hydroxy)methyl]thieno[2,3-c]pyridine-2-carboxamide, [0571]
  • 4-(4-chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0572]
  • N[0573] 4-(4-chlorophenyl)thieno[2,3-c]pyridine-2,4-dicarboxamide,
  • [4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]methanol, [0574]
  • 4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde, [0575]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde oxime, [0576]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde O-methyloxime, [0577]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime, [0578]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime, [0579]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime, [0580]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime, [0581]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone, [0582]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone oxime, [0583]
  • 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methoxy-N-methyl-2-oxoacetamide, [0584]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbonitrile, [0585]
  • 4-(4-chlorophenoxy)-N′-hydroxythieno[2,3-c]pyridine-2-carboximidamide, [0586]
  • 4-(4-chlorophenoxy)-N′-cyanothieno[2,3-c]pyridine-2-carboximidamide, [0587]
  • [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](2-nitrophenyl)methanol, [0588]
  • [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](2-nitrophenyl)methanone, [0589]
  • (2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone, [0590]
  • (2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol, [0591]
  • [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](3-nitrophenyl)methanol, [0592]
  • (3-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone, [0593]
  • (3-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol, [0594]
  • 4-(4-bromophenoxy)-2-vinylthieno[2,3-c]pyridine, [0595]
  • 1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol, [0596]
  • 1-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol, [0597]
  • [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanamine, [0598]
  • [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl carbamate, [0599]
  • N-{[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl}urea, [0600]
  • (E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide, [0601]
  • (E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-2-propenamide, [0602]
  • 3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2,3-dihydroxy-N-methylpropanamide, [0603]
  • 3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2,3-dihydroxypropanamide, [0604]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylamine, [0605]
  • 4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylformamide, [0606]
  • N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]urea, [0607]
  • N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N′-methylthiourea, [0608]
  • 4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-sulfonamide, [0609]
  • 4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-sulfonamide, [0610]
  • 4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-sulfonamide, [0611]
  • 4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]phenol, [0612]
  • 3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline, [0613]
  • 4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline, [0614]
  • 4-(4-chlorophenoxy)-2-(5-nitro-2-pyridinyl)thieno[2,3-c]pyridine, [0615]
  • 6-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-pyridinamine, [0616]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-pyridinamine, [0617]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-amine, [0618]
  • 5-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-ylamine, [0619]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4H-1,2,4-triazol-3-amine, [0620]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-thiadiazol-2-amine, [0621]
  • 4-(4-chlorophenoxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine, [0622]
  • 5-{4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine, [0623]
  • 4-(4-chlorophenoxy)-2-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]thieno[2,3-c]pyridine, [0624]
  • 4-(4-chlorophenoxy)-2-(2-methyl-2H-1,2,3,4-tetraazol-5-yl)thieno[2,3-c]pyridine, [0625]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4-methyl-4H-1,2,4-triazol-3-amine, [0626]
  • 4-(4-chlorophenoxy)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]thieno[2,3-c]pyridine, [0627]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-3-amine, [0628]
  • 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-1,3,4-thiadiazol-2-amine, [0629]
  • 4-(4-chlorophenoxy)-2-( 1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine, [0630]
  • 2-(1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine, [0631]
  • 3-7[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-5-amine, [0632]
  • 2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine, [0633]
  • methyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxylate, [0634]
  • 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxamide, [0635]
  • tert-butyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-ylcarbamate, [0636]
  • 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-amine, [0637]
  • 4-(4-chlorophenoxy)-2-(1,3-oxazol-2-yl)thieno[2,3-c]pyridine, [0638]
  • 4-(4-chlorophenoxy)-2-(1H-imidazol-2-yl)thieno [2,3-c]pyridine, [0639]
  • 4-chloro-3-methylthieno[2,3-c]pyridine-2-carboxamide, [0640]
  • 3-amino-4-chlorothieno[2,3-c]pyridine-2-carboxamide, [0641]
  • 4-(4-chlorophenoxy)-N,3-dimethylthieno[2,3-c]pyridine-2-carboxamide, [0642]
  • 4-(4-bromophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, [0643]
  • 7-chloro-4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, [0644]
  • tert-butyl 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate, [0645]
  • N-methyl-4-(4-toluidino)thieno[2,3-c]pyridine-2-carboxamide, [0646]
  • 4-(4-chloroanilino)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0647]
  • N-methyl-4-(4-morpholinyl)thieno[2,3-c]pyridine-2-carboxamide, [0648]
  • 7-chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0649]
  • 7-chloro-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0650]
  • 7-chloro-4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide, [0651]
  • 7-bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, [0652]
  • 7-bromo-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0653]
  • 4-(4-bromophenoxy)-7-chlorothieno[2,3-c]pyridine-2-carboxamide, [0654]
  • 4-(4-bromophenoxy)-7-chloro-N-methylthieno[2,3-c]pyridine-2-carboxamide, [0655]
  • 7-chloro-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0656]
  • 7-chloro-N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0657]
  • 7-chloro-N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, [0658]
  • 4-(4-chlorophenoxy)-N,7-dimethylthieno[2,3-c]pyridine-2-carboxamide, [0659]
  • 4-(4-chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxamide, [0660]
  • 4-(4-chlorophenoxy)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxamide, [0661]
  • 4-(4-chlorophenoxy)-N-methyl-7-(methylamino)thieno[2,3-c]pyridine-2-carboxamide, [0662]
  • 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide, [0663]
  • N-methyl-7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide, [0664]
  • 4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carboxamide, [0665]
  • 4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carbothioamide, [0666]
  • 4-[(E)-2-phenylethenyl]thieno[2,3-c]pyridine-2-carboxamide, [0667]
  • 4-(4-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0668]
  • 4-[3-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide, [0669]
  • 4-(3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0670]
  • 4-(4-bromophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0671]
  • 4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0672]
  • 4-(3,5-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0673]
  • 4-(2,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0674]
  • 4-(3,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0675]
  • 4-(2,4-difluorophenyl)thieno[2,3-c]pyridine-2-carboxamide, [0676]
  • 4-(4-fluorophenyl)thieno[2,3-c]pyridine-2-carboxamide, and [0677]
  • 4-(4-bromophenoxy)-5-chlorothieno[2,3-c]pyridine-2-carboxamide. [0678]
    • Determination of Biological Activity
  • Pooled primary human umbilical vein endothelial cells (HUVEC's) (Clonetics) between passages 3 and 7 were plated in 96-well plates (Costar), 100 μL/well, 5×10[0679] 4 cells/mL in Clonetics EBM/2% FBS/EGF/Bovine brain extract/gentamicin in the absence of hydrocortisone. The following day, compounds of the invention were added in 10 μL/well medium, and the plates were incubated at 37°C. 24 hours after compound addition, TNF (Gibco/BRL) in 10 μL/well medium was added to a final concentration of 5 ng/mL, and the cells were incubated an additional 6 hours at 37°C. Then media was removed, and the plates were washed once with D-PBS (Gibco/BRL) and treated with primary antibodies (Becton Dickinson, City), 100 μL/well in D-PBS/2% PSA (Sigma)/0.01% azide. Primary antibodies at an initial concentration of 1 mg/mL were used at the following dilutions: anti-ELAM-1, 1:2000, anti-ICAM-1, 1:2000 and anti-VCAM-1, 1:3000. Plates were stored overnight at 4° C., washed 3 times with D-PBS, and treated with secondary antibody (Jackson Labs), 100 μL/well 1:8000 dilution HRP-conjugated donkey anti-mouse IgG(H+L) in D-PBS/2% BSA. Plates were incubated a minimum of 1 hour at room temperature, washed 3 times with D-PBS and treated with 100 μL of ortho-phenylene diamine-2 HCl reagent per well. Plates were developed approximately 15 minutes and neutralized with 100 μL/well 1N sulfuric acid. Absorbance was read at 490 nm. Inhibitory potencies for representative compounds of the invention are shown in Table 1.
    TABLE 1
    CAM ELISA
    % Inhibition at 1 μM
    Example E-Selectin ICAM-1 VCAM-1
     2 28 35 4
     3 37 32 19
     16 35 32 19
     17 29 30 14
     19 79 67 41
     20 55 46 26
     21 63 55 23
     22 64 64 33
     32 75 63 41
     33 69 60 28
     53 70 67 48
     54 74 59 33
     60 74 71 42
     61 82 74 50
     79 66 63 38
     89 62 64 50
     90 47 51 27
     95 85 71 61
    102 78 68 53
    104 78 72 53
    110 44 48 39
    119 59 61 36
    120 72 72 49
    135 29 22 34
    123 39 31 12
    124 18 29 26
    125 72 69 44
    142
    151 69 73 44
    158 61 65 26
    159 30 45 13
    161 51 58 51
    170 66 67 53
    171 67 72 50
    183 63 69 48
    184 52 56 30
    187 78 72 54
    190C 70 65 37
    202 80 68 49
    210 64 58 42
    217 64 63 42
    218 66 64 51
    219 62 68 50
    220 60 51 32
    222 40 42 44
    223 34 36 36
    224 61 55 41
    225 75 78 60
    226 77 74 56
    227 61 62 44
    228 70 68 54
    228 67 64 52
    229 54 55 46
    230 56 53 45
    233 74 79 62
    236 59 59 33
    237I 71 77 54
    238 46 47 17
    249 75 69 61
    254 24 28 24
    255 67 65 19
    259 63 59 57
    261 20 16 0
    274 65 71 44
    275 73 72 64
    276 66 61 52
    279 30 40 24
    280 73 77 69
    281 18 25 20
    282A 8 15 5
    283 39 57 52
    284 56 68 45
    285 56 65 50
    286 54 64 46
    287 49 49 27
    289 64 62 52
    290 42 53 48
    294 46 45 24
    295 59 56 44
    301 44 48 34
    303 65 66 33
    311 72 77 36
    312 64 76 42
    313 57 68 39
    316 76 68 42
    320 64 67 55
    325 76 68 42
    329 72 62 64
    340 18 33 20
  • Thus the compounds of the present invention act as antiinflammatory agents with potencies below 1 μM and are therefore useful for treating inflammatory diseases. [0680]
    • Pharmaceutical Compositions and Methods of Treatment
  • The present invention also provides pharmaceutical compositions which comprise compounds of the present invention formulated together with one or more non-toxic pharmaceutically acceptable carriers. The pharmaceutical compositions may be specially formulated for oral administration in solid or liquid form, for parenteral injection, or for rectal administration. [0681]
  • The pharmaceutical compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, or as an oral or nasal spray. The term “parenteral” administration as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion. [0682]
  • Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, and the like), and suitable mixtures thereof, vegetable oils (such as olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of coating materials such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. [0683]
  • These compositions may also contain adjuvants such as preservative, wetting agents, emulsifying agents, and dispersing agents. Prevention of the action of microorganisms may be ensured by the inclusion of various antibacterial and antifungal agents, for example, paraben, chlorobutanol, phenol sorbic acid, and the like. It may also be desirable to include isotonic agents such as sugars, sodium chloride, and the like, Prolonged absorption of the injectable pharmaceutical form may be brought about by the inclusion of agents which delay absorption such as aluminum monostearate and gelatin. [0684]
  • In some cases, in order to prolong the effect of the drug, it is desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution which, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle. [0685]
  • Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides) Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions which are compatible with body tissues. [0686]
  • The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium just prior to use. [0687]
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents. [0688]
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. [0689]
  • The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. [0690]
  • Examples of embedding compositions which can be used include polymeric substances and waxes. [0691]
  • The active compounds can also be in micro-encapsulated form, if appropriate, with one or more of the above-mentioned excipients. [0692]
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethyl formamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. [0693]
  • Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. [0694]
  • Suspensions, in addition to the active compounds, may contain suspending agents as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof. [0695]
  • Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at room temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound. [0696]
  • Compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono- or multi-lamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable and metabolizable lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to a compound of the present invention, stabilizers, preservatives, excipients, and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. [0697]
  • Methods to form liposomes are known in the art. See, for example, Prescott, Ed., [0698] Methods in Cell Biology, Volume XIV, Academic Press, New York, N.Y. (1976), p. 33 et seq.
  • The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic acids. By “pharmaceutically acceptable salt” is meant those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well-known in the art. For example, S. M. Berge, et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1 et seq. The salts may be prepared in situ during the final isolation and purification of the compounds of the invention or separately by reacting a free base function with a suitable acid. Representative acid addition salts include, but are not limited to acetate, adipate, alginate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, digluconate, glycerophosphate, hemisulfate, heptanoate, hexanoate, fumarate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethansulfonate (isethionate), lactate, maleate, methanesulfonate, nicotinate, 2-naphthalenesulfonate, oxalate, pamoate, pectinate, persulfate, 3-phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, phosphate, glutamate, bicarbonate, p-toluenesulfonate and undecanoate. Also, the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides such as methyl, ethyl, propyl, and butyl chlorides, bromides and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl and diamyl sulfates; long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides; arylalkyl halides like benzyl and phenethyl bromides and others. Water or oil-soluble or dispersible products are thereby obtained. Examples of acids which may be employed to form pharmaceutically acceptable acid addition salts include such inorganic acids as hydrochloric acid, hydrobromic acid, sulphuric acid and phosphoric acid and such organic acids as oxalic acid, maleic acid, succinic acid and citric acid. [0699]
  • Basic addition salts can be prepared in situ during the final isolation and purification of compounds of this invention by reacting a carboxylic acid-containing moiety with a suitable base such as the hydroxide, carbonate or bicarbonate of a pharmaceutically acceptable metal cation or with ammonia or an organic primary, secondary or tertiary amine. Pharmaceutically acceptable salts include, but are not limited to, cations based on alkali metals or alkaline earth metals such as lithium, sodium, potassium, calcium, magnesium and aluminum salts and the like and nontoxic quaternary ammonia and amine cations including ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, diethylamine, ethylamine and the like. Other representative organic amines useful for the formation of base addition salts include ethylenediamine, ethanolamine, diethanolamine, piperidine, piperazine and the like. Preferred salts of the compounds of the invention include phosphate, tris and acetate. [0700]
  • Dosage forms for topical administration of a compound of this invention include powders, sprays, ointments and inhalants. The active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives, buffers, or propellants which may be required. Opthalmic formulations, eye ointments, powders and solutions are also contemplated as being within the scope of this invention. [0701]
  • Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration. The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required for to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. [0702]
  • Generally dosage levels of about 1 to about 50, more preferably of about 5 to about 20 mg of active compound per kilogram of body weight per day are administered orally to a mammalian patient. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g. two to four separate doses-per day. [0703]
    • Preparation of Compounds of this Invention Abbreviations
  • Abbreviations which have been used in the descriptions of the schemes and the examples that follow are: BH[0704] 3 for borane, BH3.DMS for borane dimethylsulfide complex, BINAP for 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, BF3OEt2 for boron trifluoride diethyl ether complex, n-BuLi for n-butyl lithium, CCl4 for carbon tetrachloride, Cs2CO3 for cesium carbonate, DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene, DMA for N,N-dimethylacetamide, DIBAL for diisobutylaluminum hydride, DME for dimethoxyethlane, DMF for N,N-dimethylformamide, DMSO for dimethylsulfoxide, DIPEA for diisopropylethylamine, DPPA for diphenylphosphoryl azide, EDCI or EDC for 1-ethyl-3-[3-(dimethylamino)propyl]-carbodiimide hydrochloride, Et3N for triethylamine, Et2O for diethyl ether, EtOAc for ethyl acetate, EtOH for ethanol, K2CO3 for potassium carbonate, LiAlH4 for lithium aluminum hydride, LDA for lithium diusopropylamide, MeOH for methanol, NaOMe for sodium methoxide, NaOH for sodium hydroxide, HCl for hydrochloric acid, NMP for 1-methyl-2-pyrrolidinone, H2/Pd for hydrogen and a palladium catalyst, iPrOH for isopropyl alcohol, PPh3 for triphenylphosphine, THF for tetrahydrofuran, THP for tetrahydropyran, TFA for trifluoroacetic acid, and pyBOP for benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate.
    • Synthetic Methods
  • The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes which illustrate the methods by which the compounds of the invention can be prepared. Further, all citations herein are incorporated by reference. [0705]
    Figure US20030220365A1-20031127-C00005
  • Scheme 1 shows the preparation of thieno[2,3-d]pyrimidines from esters of general formula 1 by published procedures. 4-Chlorothieno[2,3-d]pyrimidines of general formula 3 were substituted with thiols to provide 4-thioethers of general formula 4 or substituted with amines to provide 4-aminothieno[2,3-d]pyrimidines of general formula 5. [0706]
    Figure US20030220365A1-20031127-C00006
  • Scheme 2 shows the preparation of 2-carboxy-substituted thieno[2,3-d]pyrimidines. Pyrimidinones of general formula 1 weres reacted with phosphoryl chloride to produce 4-chloro pyrimidines of general formula 6, which were then substituted with thiols to provide thioethers of general formula 7. [0707]
    Figure US20030220365A1-20031127-C00007
  • Scheme 3 shows the preparation of thieno[3,2-d]pyrimidines derived from chloropyrimidines of general formula 8. Substitution of the chlorides with thiols provided thioethers of general formula 9, and substitution of the chlorides with amines provided aminopyrimidines of general formula 10. [0708]
    Figure US20030220365A1-20031127-C00008
  • Analogs having 2-carboxamide groups on the thieno[3,2-d]pyrimidine were prepared as shown in Scheme 4. The thiophene-2-position was deprotonated with a strong base such as lithium diisopropylamide, and the corresponding carbanion was treated with carbon dioxide to provide acids of general formula 11. The acids were converted to the corresponding amides of general formula 12 through the intermediate acid chlorides. [0709]
    Figure US20030220365A1-20031127-C00009
  • Scheme 5 shows the preparation of 6-alkyl substituted thieno[2,3-d]pyrimidines with alkylthio groups at the 4-position. Using known procedures, 2-aminothiophene 13 was acylated to provide amide 14 which was cyclized to provide thienopyrimidinone 15. The pyrimidinone was converted to chloride 16 and further to thioether 17 by standard procedures. [0710]
    Figure US20030220365A1-20031127-C00010
    Figure US20030220365A1-20031127-C00011
  • The general process for preparing 2,4-disubstituted thieno[2,3-c]pyridines is shown in Scheme 6. Commercially available 3,5-dichlorpyridine was treated with strong base such as lithium diisopropylamide in an anhydrous solvent at low temperature followed by reaction with methyl formate (or alternatively, dimethylformamide) to provide the known pyridine-4-carboxaldehyde 18. Aldehyde 18 was then substituted with one equivalent of thiol (R[0711] 1=substituted or unsubstituted aryl, alkyl, or heterocyclic) to produce chloroaldehyde of general formula 19. Treatment of 19 with methyl thioglycolate and a base such as cesium carbonate or potassium carbonate provided the 4-thioether [2,3-c]-thienopyridine esters of general formula 20. The esters were converted to the corresponding acids of general formula 21 by basic hydrolysis, for example using lithium, sodium, or potassium hydroxide in a mixture of water and alcohol or tetrahydrofuran. Acids of general formula 21 may also be converted to amides of general formula 22 or 23 through the intermediate acid chlorides by treatment first with oxalyl chloride or thionyl chloride, then with the amine of choice (R2, R3 can be substituted or unsubstituted alkyl, aryl, heterocyclic). Alternatively, aicds 21 may be converted to amides 22 or 23 by other coupling methods, such as carbodiimide (for example, N-ethyl-N′-(3-dimethylamino)propyl carbodiimide hydrochloride (EDC)), mixed anhydrides (derived from pivaloyl chloride or isobutyl chloroformate treatment), and active esters (for example, derived from N-hydroxysuccinimide, p-nitrophenol).
    Figure US20030220365A1-20031127-C00012
    Figure US20030220365A1-20031127-C00013
  • Scheme 7 illustrates the analogous preparation of 4-ether-substituted thienopyridines of general formula 30. Aldehyde 18 was substituted with alcohols (R[0712] 1=substituted or unsubstituted aryl, heterocyclic) under basic conditions (for example, potassium tert-butoxide or cesium carbonate in anhydrous tetrahydrofuran or dimethylformamide) to give pyridine-ethers of general formula 24, and then further reacted with methyl thioglycolate to provide the thieno[2,3-c]pyridine esters of general formula 25. These esters may be converted to the corresponding primary amides of general formula 26 by heating in methanolic ammonia solution. Alternatively, esters of general formula 25 may be reacted with mono or disubstituted amines in polar solvents such as dimethylformamide or methanol. Esters of general formula 25 were hydrolyzed to carboxylic acids of general formula 28 by basic hydrolysis with sodium or lithium hydroxide in aqueous methanol or tetrahydrofuran. The acids were then converted to amides of general formula 30 by reaction of the corresponding acid chlorides of general formula 29 with amines. Alternatively, the acids 30 were coupled to amines by standard peptide-coupling conditions as described in Scheme 6 for, amides 22 or 23.
    Figure US20030220365A1-20031127-C00014
  • Similar methods may be utilized for the preparation of 4-bromothieno[2,3-c]pyridine 32, as shown in Scheme 8. 3,5-Dibromopyridine was converted to aldehyde 31 by the procedure described for preparation of compound 18 in Scheme 6. Reaction of 31 with methyl thioglycolate, for example in the presence of cesium carbonate in DMF, produced 4-bromothieno[2,3-c]pyridine ester 32. Bromide 32 served as starting material for the preparation of 4-aryl, heterocyclic, alkyl, or alkenyl derivatives of general formula 33, using Suzuki coupling methodology as shown. Bromide 32 may also be coupled with terminal alkynes to provide alkynyl derivatives (R[0713] 1=alkynyl) following Sonogashira methodology (Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett. 1975, 4467-70). Esters of general formula 33 were converted to amides of general formula 34 by the procedures described for 26, 27 or 30 in Scheme 7.
    Figure US20030220365A1-20031127-C00015
    Figure US20030220365A1-20031127-C00016
  • Scheme 9 shows the conversion of acids of general formula 21 to aldehyde or ketone-derived compounds. For example, aldehydes of general formula 36 were produced by reduction of the N-methyl-N-methoxylamides of general formula 35. The amides of general formula 35 were also reacted with Grignard reagents to produce unsymmetrical ketones of general formula 39. Aldehydes of general formula 36 and Ketones of general formula 39 were utilized for the production of oximes of general formula 37 or 40 by reaction with hydroxylamine derivatives. Aldehyde of general formula 36 were reacted with phosphoranes (or phosphonoacetate salts) to produce 2-alkenyl substituted derivatives of general formula 38. Ketones of general formula 39 were reduced to the corresponding alkanes of general formula 41 by treatment with hydrazine and strong base, such as potassium hydroxide. Analogous 2-position derivatives of thienopyridine ethers of general formula 28 in Scheme 7 would follow similar synthetic routes as described in Scheme 9. Thuds, acids 28 may be converted to aldehydes, ketones, oximes, alkenes, or alkanes substitutions at the 2-position. [0714]
    Figure US20030220365A1-20031127-C00017
  • Amides of general formula 34 (or 26, 27 or 30), may be converted to the corresponding thionoamides of general formula 42 by treatment with Lawesson's reagent as shown in Scheme 10. [0715]
    Figure US20030220365A1-20031127-C00018
  • As shown in Scheme 11, 4-sulfoxides of general formula 43 were produced by reaction of thioethers of general formula 20 with an oxidant such as m-chloroperoxybenzoic acid under controlled conditions. [0716]
    Figure US20030220365A1-20031127-C00019
  • Alternative functionality was introduced at the 2-position of thienopyridines of general formula 44 by metallation of the 2-position, followed by reaction with appropriate electrophiles, as shown in Scheme 12. Acids of general formula 21 (L[0717] AXA=thioalkoxy, alkoxy, alkyl, alkenyl, aryl, heterocyclic) were decarboxylated at elevated temperatures (optionally in the presence of copper powder) to afford 2-unsubstituted derivatives of general formula 44. Compounds of general formula 44 were deprotonated with strong organic bases such as n-butyllithium, and then reacted with electrophiles such as borates, cyanoformates, aldehydes, or trialkyltin chlorides according to standard procedures (Masakatsu, N.; Kazuhiro, N.; Ichiro, M.; Iwao; W. Chem. Lett. 1983, 6, 905-908).
    Figure US20030220365A1-20031127-C00020
  • Scheme 13 illustrates an alternative method for the preparation of 2-carbeoxaldehydes of general formula 36 or 47. Esters of general formula 20 or 25 (R[0718] 1=thioalkoxy, alkoxy, alkyl, alkenyl, aryl, heterocyclic) were reduced to the corresponding alcohols of general formula 46 using calcium borohydride. The alcohols were then oxidized to the aldehydes using Swern conditions. The aldehydes were then reacted with Wittig reagents (for example phosphoranes to produce the acrylate derivatives of general formula 48 (Jung, M. E. and Kiankarami, M. J. Org. Chem. 1998, 63, 2968-2974).
    Figure US20030220365A1-20031127-C00021
  • As shown in Scheme 14, thienopyridines of general formula 27 or 30 were alkylated on the pyridine nitrogen using alkyl iodides (or alkyl bromides or triflates) to produce the pyridinium salts of general formula 49. For example, R may be alkylcarbonyloxymethylene, aminocarbonyloxyymethylene, alkoxycarbonyloxymethylene, or alkyl. Such derivatives may serve as prodrug forms of the thienopyridine amides 27 or 30. [0719]
    Figure US20030220365A1-20031127-C00022
  • A variety of 2-aminothieno[2,3-c]pyridine derivatives were available starting from the 2-carboxylic acids of general formula 21 or 28, as shown in Scheme 15, wherein R[0720] 1 may be thioalkoxy, alkoxy, alkyl, alkenyl, aryl, heterocyclic. Curtius rearrangement led to isocyanates of general formula 50, which were reacted with alcohols (alkyl, aryl, heterocyclic, or dialkylaminoalkyl) to provide carbamates of general formula 51. Isocyanates 50 may be reacted with amines (ammonia, primary alkyl or secondary alkyl) to provide ureas of general formula 52. Also, 50 may be reacted with alkyl or arylmagnesium halides, or alkyl lithium salts, to provide amides of general formula 53. Isocyanate 50 was hydrolyzed under aqueous conditions to produce 2-amino derivatives of general formula 54.
    Figure US20030220365A1-20031127-C00023
  • Amines of general formula 54 were reacted with appropriate electrophiles to further derivatize this position. Thus reaction of 54 with aryl or alkylsulfonyl chlorides (R[0721] 2=alkyl, aryl, heterocyclic) or sulfamoyl chlorides, (R2=NH2, mono- or di-alkylamino) to give sulfonamides of general formula 55. Amino derivative 54 was also reacted with acyl chlorides (R2=alkyl, heterocyclic, or aryl) to produce amides of general formula 53 as shown in Scheme 16.
    Figure US20030220365A1-20031127-C00024
  • Functionality present on the aryl rings attached at the 4-position of the thieno[2,3-c]pyridines may be further reacted to advantage, as illustrated in Scheme 17. For example, styryl derivative 56 was converted to the 1,2-diol 57 by treatment with osmium tetroxide under standard conditions. The 4-(4-bromophenoxy) derivative 58 underwent fascile substitution with aryl boronic acids under palladium catalysis under Suzuki conditions to provide biaryl derivatives of general formula 59. Alternatively, alkoxycarbonylation under palladium catalysis efficiently provides esters of general formula 61. [0722]
    Figure US20030220365A1-20031127-C00025
    Figure US20030220365A1-20031127-C00026
  • Scheme 19 shows the use of boronic acid derivatives to functionalize the 4-position of the thieno[2,3-c]pyridines. The chemistry depicted may be applied to a broad range of aryl olefins analogous to bromostyrene 62. In the case shown, bromostyrene 62 was converted to the boronic acid 63 under standard conditions, and the boronic acid was coupled to 4-bromothienopyridine 32 under Suzuki conditions, affording the styryl analog 64. The ester 64 was converted to the amide 65 by the previously described method (Miyara, N and Suzuki, A. Chem. Rev. 1995, 95, 2457-2463). The olefinic group may then be converted to the epoxide 66, which can undergo reactions with nucleophilic reagents at the less-hindered position of the epoxide to producing analogs of general formula 67. Alternatively, styryl derivative 65 may be converted to the diol 68 by standard methods. [0723]
    Figure US20030220365A1-20031127-C00027
  • Another method for introduction of substituents at the 4-position of the thieno[2,3-c]pyridines is shown in Scheme 20. Bromide 32 may be converted to the corresponding cuprate through the intermediate zinc bromide reagent, which then may be reacted with appropriate electrophiles (acid chlorides, alkyl halides, aldehydes, ketones) to afford the substituted compounds of general formula 69 (Zhu, L.; Wehmeyer, R. M.; Rieke, R. D. J. Org. Chem. 1991, 56, 1445-1453). [0724]
    Figure US20030220365A1-20031127-C00028
  • Scheme 21 depicts the preparation of 5-halo thienopyridine derivatives, as exemplified by the preparation of the 5-chloro analog 75. Formylation of lithiated 2,3,5-trichloropyridine with methyl formate gave aldehyde 72. Displacement of the 3 and 5 chlorines with excess 4-bromophenol and reaction with methylthioglycolate gave the 5-chlorothienopyridine 74 in low yield, together with the major product 73. The 5-chloro isomer was treated with ammonia in methanol in a pressure tube to generate the amide 75. It should be noted that this chemistry may be applied using a range of phenols or hydroxy heterocyclic compounds in place of 4-bromophenol. [0725]
    Figure US20030220365A1-20031127-C00029
  • The 2-position of thienopyridines was substituted with aryl, vinyl, acetylenic or alkyl groups using the procedure shown in Scheme 22. Boronic acids of general formula 79 prepared according to Scheme 12, was coupled to aryl halides under palladium catalysis to produce 2-aryl derivatives of general formula 80. [0726]
    Figure US20030220365A1-20031127-C00030
  • Scheme 23 illustrates the preparation of 4-acyl derivatives: of thieno[2,3-c]pyridines. Carboxylic acid 85 was converted to amide 86 via the acid chloride, then the hydroxyamide 86 underwent thionyl chloride-mediated cyclization to the oxazoline 87 (Meyers, A. I.; Stoianova, D. J. Org. Chem. 1997, 62, 5219-5221). Palladium mediated alkoxycarbonylation of 87 yielded ester 88 (Heck, R. F.; et al. J. Org. Chem. 1974, 39, 3318). Ester 88 may be converted to the Weinreb amide 89 by standard methods. Amide 89 was reacted with the appropriate Grignard reagents to provide the desired 4-acyl products of general formula 90. Hydrolysis of the oxazoline and conversion of the resultant carboxylic acid to the amide yields the desired products of general formula 91. [0727]
    Figure US20030220365A1-20031127-C00031
  • Scheme 24 depicts a proposed method for the formation of 4-hydroxy substituted thieno[2,3-c]pyridine. Reaction of phenol 92 with dihydropyran under acidic conditions yields tetrahydropyranyl ether 93 (Grant, H. N., et al. Helv. Chim. Acta. 1963, 46, 41). Lithiation of 93 and subsequent quench with methyl formate gives aldehyde 94. Displacement of the halide with methyl thioglycolate and subsequent cyclization with cesium carbonate yields the ester 95. Removal of the tetrahydropyranyl ether with aqueous HCl gives hydroxypyridine 96, which may be converted to the amide as described previously. [0728]
    Figure US20030220365A1-20031127-C00032
  • Scheme 25 proposes the use of the 4-hydroxy group for introduction of functionality to the 4-position of the thieno[2,3-c]pyridines. The 2-carboxylic acid group is first protected as the oxazoline 99 (through the intermediate amide 98), then the hydroxy group is converted to the aryl triflate 100 by standard conditions. Triflate 100 may then be converted to the N-methyl-N-methoxy amide 89 under conditions similar to that for bromide 87. It should be noted that 4-triflate 100 may serve as a coupling partner in a variety of transition-metal mediated couplings with appropriate nucleophilic partners (for example, boronic acids, boranes, alkyl or aryl-zinc reagents). [0729]
    Figure US20030220365A1-20031127-C00033
  • Compounds with amino substitutions at the 3-position of the thieno[2,3-c]pyridines were prepared according to the procedures outlined in Scheme 26. Aldehyde 18 was converted to the cyanopyridine 107 by treatment with hydroxylamine under dehydrating conditions. In a manner similar to the reactions involving aldehyde 18, cyanopyridine 107 was sequentially substituted with phenols and methyl thioglycolate to provide the 3-amino thieno[2,3-c]pyridines of general formula 108. Esters of general formula 108 were then converted to amides of general formula 109 by standard procedures. [0730]
    Figure US20030220365A1-20031127-C00034
  • Scheme 27 illustrates additional derivatives which can be derived from amino esters of general formula 108 or amino amides of general formula 109. For example, amino amides of general formula 109 may be treated with 1,1′-carbonyldiimidazole to produce cyclic imides of general formula 110. The 3-amino group was acylated (for example, with acid chlorides and weak base, or by coupling with acids using carbodiimides) to give the diamides of general formula 111. The 3-amino group may be alkylated under reductive conditions using aldehydes and a reducing agent (such as triacetoxyborohydride), to provide alkylated amines of general formula 112. [0731]
    Figure US20030220365A1-20031127-C00035
  • Scheme 28 shows the preparation of compounds bearing alkyl substituents at the 3-position of the thieno[2,3-c]pyridines. Using similar chemistry to that described for compound 30, 3,5-dichloropyridine was deprotonated with strong base (for example, lithium diisopropylamide), and then reacted with an acylating reagent (ester, N-methyl-N-methoxyamide, acyl pyrazole, or others) to provide ketone 113. Alternatively, the anion can be reacted with an aldehyde (for example, acetaldehyde) and then subsequently the product may be oxidized (for example, with tetrapropylammonium perruthenate) to provide ketone 113. Following the protocol outlined for example 30, the dichloroketone was reacted sequentially with phenols and then with methyl thioglycolate to provide cyclic products of general formula 114. The ester of general formula 114 may be converted to various derivatives as outlined previously. [0732]
    Figure US20030220365A1-20031127-C00036
  • Scheme 29 describes a similar strategy used to obtain derivatives with alkoxy groups at the 3-position of thieno[2,3-c]pyridines. Ester 116 was substituted and cyclized to provide 3-hydroxy analogs of general formula 117. The hydroxy group may be left unsubstituted, leading to amides of general formula 118 (or other derivatives). Alternatively, hydroxy esters of general formula 117 may be alkylated by standard procedures to produce 3-alkoxy derivates of general formula 119, followed by amide formation to provide compounds of general formula 120. [0733]
    Figure US20030220365A1-20031127-C00037
  • Scheme 30 shows the procedure used for the transformation of a commercially available furo[2,3-b]pyridine 121 into an amide 122. [0734]
    Figure US20030220365A1-20031127-C00038
  • Scheme 31 proposes the preparation of thienopyridine derivatives containing an amide group at the 3-position. Thienopyridines of general formula 44 are halogenated using electophilic halide sources (for example, N-bromosuccinimide, I[0735] 2), to produce 3-halothienopyridines of general formula 123. Metal-halogen exchange, followed by trapping with carbon dioxide, provides acids of general formula 124. The acids are converted into amides of general formula 125 by standard procedures, or may be homologated to esters of general formula 126 (for example, by the Arndt-Eisert procedure). Esters of general formula 126 may then be converted to amides or other functionality by the methods described above.
    Figure US20030220365A1-20031127-C00039
  • Scheme 32 describes the methods used for the preparation of a variety of thieno[2,3-b]pyridines starting from the known 4-chloro-5-ester 127. Displacement of the chlorine of 127 proceeded with thiols in the presence of potassium carbonate to provide 4-thioethers of general formula 128. Ester 127 was also hydrolyzed to the acid 129, which was converted to amides of general formula 130 by standard coupling conditions. [0736]
    Figure US20030220365A1-20031127-C00040
  • Scheme 33 shows the conversion of thioethers of general formula 128 to 2,4-disubstituted analogs. The corresponding acids of general formula 131 may be thermally decarboxylated to provide the 5-unsubstituted analogs of general formula 132. Compounds of general formula 132 were treated with strong base (for example, n-butyllithium), and reacted with carbon dioxide to provide the 2-carboxylic acids of general formula 133. The acids were then transformed into amides of general formula 134 by previously described procedures. [0737]
    Figure US20030220365A1-20031127-C00041
  • Scheme 34 illustrates the preparation of thieno[3,2-b]pyridines. Chloride 135 was transformed by a similar set of conditions to that described in Scheme 33 to produce acids of general formula 139 and amides of general formula 140. [0738]
    Figure US20030220365A1-20031127-C00042
  • Scheme 35 depicts the preparation of thieno[3,2-c]pyridines. Starting with thienopyridone 141, 4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-nitrile 144 was prepared according to literature methods (Eloy, F.; Deryckere, A. Bul. Soc. Chim. Belg. 1970, 79, 301; Troxler, F.; Wiskott. E. U.S. Pat. No. 3,998,835). Treatment of thienopyridone 144 with phosphoryl chloride at 130° C. provided chloride 145, which upon exposure to thiols under basic conditions afforded thioethers of general formula 146. Hydrolysis of the nitrile group with polyphosphoric acid gave the corresponding amides of general formula 147. [0739]
    Figure US20030220365A1-20031127-C00043
  • Scheme 36 show that ethers of general formula 149 were prepared in an analogous fashion as previously described in Scheme 35. [0740]
    Figure US20030220365A1-20031127-C00044
  • Scheme 37 shows the preparation of intermediates of general formula 151 useful for the preparation of alternative 2-derivatives. Treatment of the known 2-bromo-4-chlorothieno[3,2-c]pyridine 150 with 1 equivalent of a thiol afforded 2-bromothieno[3,2-c]pyridines of general formula 151. [0741]
    Figure US20030220365A1-20031127-C00045
    Figure US20030220365A1-20031127-C00046
  • Scheme 38 depicts an example of the preparation of a related class of inhibitors based on an oxazolopyridine structure. Commercially available 3-chloropyridine is oxidized to the N-oxide 152 with peracetic acid, which is then nitrated in a mixture of concentrated nitric, concentrated sulfuric, and fuming sulfuric acids to give the 4-nitro derivative 153. The chlorine in 153 is then displaced with the sodium salt of p-cresol, and the resulting biaryl ether 154 is hydrogenated (Raney nickel catalysis) to reduce both the nitro functional group and the N-oxide to give 155. The amino group of 155 is protected with an N-trimethylacetyl group, and the 5-hydroxyl group is introduced according the procedure of Chu-Moyer and Berger (J. Org. Chem. 1995, 60, 5721) by formation of the dianion of 156, quenching with trimethyl borate, and oxidation of the intermediate boronate ester followed by hydrolysis with basic hydrogen peroxide to give hydroxypyridine 157. The amide is hydrolyzed with hydrochloric acid to give 158, which is condensed with methyl oxalyl chloride to give the oxazolopyridine 158. The methyl ester in 159 was then converted to the primary amide by treatment with ammonia in methanol to give the target compound 160. [0742]
    Figure US20030220365A1-20031127-C00047
  • Scheme 39 illustrates an example of the preparation of an analogous thiazolopyridine-based inhibitor. The scheme illustrates the use of para-cresol substituted pyridine as starting material, but the synthesis may be generalized to other aryl, heterocyclic, or alkyl ethers. The dianion of 4-N-trimethylacetyl)-amino-3-(4-methylphenoxy)-pyridine is quenched with tetramethylthiuram disulfide to introduce the 5-mercapto group into the substituted pyridine ring as dithiocarbamate 161. Subsequent deprotection of the amine under acidic conditions is followed by acylation of the free aniline 162 with methyl oxalyl chloride to afford the oxalamide 163. The thiazolopyridine bicyclic core 164 is then prepared by treatment with mild acid (for example formic acid at reflux). The ester functionality was converted to the corresponding amide 165 with a solution of an amine in methanol with warming. [0743]
    Figure US20030220365A1-20031127-C00048
  • A related imidazopyridine class of compounds may be prepared from intermediates shown in Scheme 40. 5-Hydroxypyridine 157 may be converted to the corresponding aniline 166 by heating in ammonium hydroxide saturated with sulfur dioxide in a pressure vessel (Newman and Galt, J. Org. Chem. 1960, 25, 214). After removal of the pivaloyl group of 166 with hydrochloric acid, the resulting diaminopyridine 167 may be condensed with methyl oxalyl chloride to give the imidazopyridine 168. The ester functionality may then be converted to amide 169 by treatment with ammonia in methanol, as described previously. [0744]
    Figure US20030220365A1-20031127-C00049
  • Scheme 41 is an illustration of the preparation of thienopyridazine-containing inhibitors. The protected thiophene acid 170 was deprotonated with strong base (e.g. n-butyllithium), and reacted with a formylating reagent. The resultant oxazoline aldehyde 171 was hydrolyzed and cyclized with hydrazine to provide the hydroxy thienopyridazine 172. The hydroxy group was converted to the chloride 173 by the action of phosphorous oxychloride and subsequent substitution by alkoxides produced the ethers 174. The amide group is introduced in a manner analogous to that described above for the thienopyridines, providing amide 176. [0745]
    Figure US20030220365A1-20031127-C00050
  • The syntheses of water-soluble glycosyl amide derivatives of general formula 178 are shown in Scheme 42. Tributylphosphine-mediated coupling of thienopyridine carboxylic acids of general formula 21 or 28 with 2,3,4,6-tetra-O-acetyl-D-glucopyranosyl azide with assistance of PyBOP smoothly furnished the protected β-glycosyl amides of general formula 177. No other isomers were detected in the reaction. Cleavage of the acetyl groups with methyl amine provided compounds of general formula 178. [0746]
    Figure US20030220365A1-20031127-C00051
  • Scheme 43 outlines the preparation of 4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide using a modification of the route described in Scheme 7. A two step sequence was adopted for assembling the thienopyridine core in the synthesis of 182. Treatment of the dichloropyridine aldehyde with one equivalent of N-BOC-protected 4-hydroxyaniline afforded compound 179, which was cyclized to give ester 180. Transformation to the amide 181 followed the previously described procedure, and the Boc-group was removed by treatment with trifluoroacetic acid. It should be noted that aniline 182 also serves as starting material for Sandmeyer reactions via the diazonium salt, in which the amino group may be converted to a variety of functional groups, including halo, hydroxy, cyano, among other standard Sandmeyer products. [0747]
    Figure US20030220365A1-20031127-C00052
  • Scheme 44 exemplifies a general method for the preparation of 4-substituted aminophenoxythieno[2,3-c]pyridines using methodology described by Buchwald, et al. (Wolfe, John; Buchwald, Stephen L. J. Org. Chem. 1997, 62, 6066). Iodide 183, prepared by the previously described methods, was coupled with disubstituted amines (such as morpholine in the above example) in the presence of bis(dibenzylideneacetone)dipalladium and BINAP to provide the substituted aniline 184. [0748]
    Figure US20030220365A1-20031127-C00053
  • Scheme 45 describes the preparation of 4-(4-hydroxymethylphenyl)thieno[2,3-c]pyridine 188, utilizing a modification of the route shown in Scheme 7. Starting with mono-tritylated 4-hydroxybenzyl alcohol, condensation with dichloroaldehyde 18, followed by cyclization with methyl thioglycolate, provided protected benzyl alcohol 188. Standard transformations provided alcohol 188. [0749]
    Figure US20030220365A1-20031127-C00054
  • Scheme 46 describes the preparation of a protected benzyl alcohol 190, starting from mono-tetrahydropyran-protected hydroxybenzyl alcohol 189. Standard acid-catalyzed hydrolysis of the THP group can also yield the benzyl alcohol analog 188. [0750]
    Figure US20030220365A1-20031127-C00055
  • As shown in Scheme 47, benzyl alcohol 188 may be further derivatized to esters, using standard coupling procedures, for example by carbodiimide conditions shown above, or by use of acid chloride. In addition, the alcohol may be converted to carbamates (R═NH[0751] 2, mono or disubstituted amino) by treatment with isocyanates or carbamoyl chlorides.
    Figure US20030220365A1-20031127-C00056
  • Glycosides of benzyl alcohol 187 may be produced using the procedure outlined in Scheme 48. Treatment of the alcohol 187 and tri-O-acetyl-D-glucal with stoichiometric scandium triflate afforded stereo-specifically protected glycoside 192, which was deprotected with methyl amine to give the free glycoside 193. [0752]
    Figure US20030220365A1-20031127-C00057
  • Stille coupling of iodophenyl derivative 194 (or the corresponding bromophenyl analogs) with tributylethoxyvinyltin allows for the introduction of an acetyl group onto the 4-position of the phenyl ether as shown in Scheme 49. The intermediate vinyl ether is hydrolyzed during the work up conditions, thus providing acetophenone derivative 195. Addition of methylmagnesium bromide to ketone 195 at −50°C. did not give the expected addition product, but rather aldol adduct 196 was isolated in 40% yield. The palladium catalyzed carbonylation of bromophenoxy methyl ester 197 in aqueous media afforded the acid 198 in modest yield. PyBOP- or EDC-mediated coupling with amines (illustrated above with morpholine), followed by amination of the 2-methyl ester, provided the diamides 199. [0753]
    Figure US20030220365A1-20031127-C00058
  • In Scheme 50 the preparation of cinnamide ethers is described. Heck reaction of the bromophenoxy methyl ester 197 with t-butyl acrylate using tritolylphosphine as ligand furnished cinnamate 200 in good yield. Hydrolysis of the t-butyl ester with trifluoroacetic acid, followed by PyBOP or EDC-mediated coupling with an amine, and then amination of the methyl ester, provided diamide 201. [0754]
    Figure US20030220365A1-20031127-C00059
    Figure US20030220365A1-20031127-C00060
  • Scheme 51 exemplifies the preparation of 4-heterocyclephenoxythienopyridines. Treatment of para-cyanophenyl derivative 202 with hydroxyamine in a mixture of DMF and ethanol smoothly gave hydroxyimidamide 203, which was heated with trifluoroacetic anhydride in pyridine to provide the oxadiazole 204. Cyano derivative 202 was transformed into imidazoline 205 under the conditions described above. Incorporation of other heterocycles was accomplished using known Stille, Suzuki, or Heck conditions as exemplified by the Stille coupling of iodo compound 194 and tributylstannylthiophene to provide compound 205A. The aryl coupling reactions described above may be applied to compounds with a variety of substituents at C-2 of the thienopyridine, in addition to the methyl amides exemplified in Scheme 51. [0755]
    Figure US20030220365A1-20031127-C00061
  • Cyclopropylcarbinyl alcohol derivatives of the 4-phenyl ethers may be prepared according to the procedure described in Schemes 52 and 53. Commercially available phenylcyclopropane carboxylic acid is converted to the corresponding alcohol 206 by LAH reduction, then demethylation and selective protection of the hydroxymethyl group affords phenol 207. Using the procedure of Scheme 7, phenol 207 was condensed with dichloroaldehyde 18 and then methyl thioglycolate, to produce thienopyridine 208. Standard transformations led to the desired compounds 209 and 210. [0756]
    Figure US20030220365A1-20031127-C00062
  • As shown in Scheme 53, alcohol 206 was alkylated to produce the polyether phenol 211 which was converted into cyclopropylcarbinyl polyether 212 using similar procedures described in Scheme 52. Such alkylation chemistry may be broadly applied by replacement of the diether tosylate shown with other alkyl halides or sulfonate esters. [0757]
    Figure US20030220365A1-20031127-C00063
  • In Scheme 54, difluoroacetic acid derivative 213 was synthesized by a copper mediated coupling between iodide 194 and ethyl iododifluoroacetate in the presence of phenol, which was found to remarkably inhibit side reactions. Reduction of the ester 213 gave difluoroethyl alcohol 214. Alkylation of alcohol 214 with ethoxyethyl tosylate in the presence of sodium hydride and 15-crown-5 afforded polyether 215. [0758]
    Figure US20030220365A1-20031127-C00064
  • An alternative synthesis of 4-alkoxythieno[2,3-c]pyridines through a phenolic alkylation strategy is outlined in Scheme 55. Mitsunobu alkylation of 5-chloro-3-hydroxypyridine provided benzyl ether 216, which was deprotonated with alkyllithium base and the resulting anion was treated with methyl formate to produce the pyridine carboxaldehyde 217. Construction of the thienopyridine core is accomplished by condensation with methyl thioglycolate under previously described conditions, leading to ester 218. This method may be applied to other alkyl ethers analogous to 216 to provide a variety of 4-alkoxy derivatives related to 218. Esters 218 were then converted to other active derivatives such as amides using previously described procedures. Benzyl ether 218 was hydrogenolyzed to phenol 219, which was converted to the corresponding amide 220 by standard procedures. Phenol 219 also serves as a partner in Mitsunobu reactions with a variety of primary or secondary alcohols, to provide alkyl ethers of general formula 221 (Huang, F., et al. J. Med. Chem. 1998, 41, 4216-4223). Esters of general formula 221 were converted to amides of general formula 222 by treatment under the standard conditions of reflux with methanolic amine solutions. [0759]
    Figure US20030220365A1-20031127-C00065
    Figure US20030220365A1-20031127-C00066
    Figure US20030220365A1-20031127-C00067
  • Thienopyridine analogs bearing a 4-carbonyl group may be prepared by the procedures described in Scheme 56. Dichloropyridine aldehyde 18 was treated with methyl thioglycolate under previously described conditions to produce the 4-chlorothienopyridine ester 223. Ester exchange was accomplished by base catalyzed hydrolysis to acid 224, and tert-butyl esterification to 225 was accomplished with O-t-butyl trichloroacetimidate under Lewis acid catalysis. Palladium-catalyzed carbethoxylation proceeded under previously described conditions to give diester 226. Reduction/oxidation reactions led to the aldehyde 227, which was then condensed with arylmagnesium halide reagents (exemplified above with 4-chlorophenyl magnesium chloride) to produce alcohol 228. The ester 228 may be transformed to various 2-substituted thienopyridine analogs directly, or oxidized to the corresponding 4-keto derivative 230. Standard transformation of ester 230 to amide 231 completes the synthesis. It should be noted that ester 226 may be selectively converted to amide derivatives by initial alkaline hydroysis of the ethyl ester, coupling to an amine, then acidic hydrolysis of the tert-butyl ester, and finally coupling to another amine to produce 308. [0760]
    Figure US20030220365A1-20031127-C00068
  • A variety of 2-substituted thieno[2,3-c]pyridines are accessible from 2-esters of general formula 20 and 25. Scheme 57 exemplifies products which may be obtained from hydroxymethyl derivatives of general formula 232. Calcium borohydride reduction of esters of general formula 20 or 25 provided alcohols of general formula 232. Swern oxidation cleanly provided aldehydes of general formula 233. This versatile intermediate may be converted to olefins by standard Wittig conditions, as exemplified by the preparation of 2-vinylthienopyridines of general formula 234 (Hibino, S. J. Org. Chem. 1984, 49, 5006-5008). Additional modification to dihydroxyethyl compound 235 was accomplished through the use of catalytic osmium tetroxide with 4-methylmorpholine N-oxide as stoichiometric oxidant. [0761]
    Figure US20030220365A1-20031127-C00069
    Figure US20030220365A1-20031127-C00070
  • Scheme 58 illustrates the conversion of aldehyde 233 to the acrylate 236, which was accomplished by Homer-Emmons condensation with trimethyl phosphonoacetate (Jung, M. E. and Kiankarami, M. J. Org. Chem. 1998, 63, 2968-2974). The described methods may be extended to analogs bearing a wide variety of C-4 substituents, including aryloxy, alkoxy, arylamino, aryl, alkyl. The derived ester 236 was then subjected to hydrolysis to provide acid 237. Carboxylic acid 237 was subjected to standard coupling conditions to produce amide 238. The derived acrylates of general formula 239 may be oxidized to the corresponding diols of general formula 240 with catalytic osmium tetroxide in the presence of 4-methylmorpholine-N-oxide. [0762]
    Figure US20030220365A1-20031127-C00071
  • Scheme 59 illustrates the use of aldehyde 233, with L[0763] AXA=aryloxy, as starting material for the preparation of oxime derivatives of general formula 241. The strategy outlined is generally applicable to analogs with a variety of LAXA substituents. Aldehydes of general formula 233 were also reacted with organomagnesium (or organolithium) reagents to produce secondary alcohols which were oxidized to the corresponding ketones of general formula 242. Oxidation is preferably accomplished by standard Swern conditions (DMSO and oxalyl chloride in CH2Cl2 solution at low temperature, followed by treatment with tertiary amines such as ethyldiisopropyl amine), but other conditions (tetra-n-propyl perruthenate, manganese dioxide) may be employed. The ketones were then converted to oximes of general formula 243 by previously described methods.
    Figure US20030220365A1-20031127-C00072
  • The preparation of 2-heterocyclic thienopyridines of general formula 249 is illustrated in Scheme 60. Primary amides of general formula 26 were treated with excess trifluoroacetic anhydride in pyridine to smoothly produce nitriles of general formula 244, which serves as a convenient intermediate for the preparation of amidine and azole derivatives. Thus, nitriles of general formula 244 were converted to the amidoximes of general formula 245 by treatment with hydroxylamine hydrochloride and triethylamine. Reaction of amidoximes of general formula 245 with acetyl chloride, trifluoroacetic anhydride, triethylorthoformate or trichloroacetyl chloride in pyridine produced the oxadiazoles of general formula 246 with variations in X dictated by the choice of acylating/dehydrating reagent. The trichloromethyl oxadiazoles of general formula 246 (X═CCl[0764] 3) were converted to the 5-amino-1,2,4-oxadiazoles of general formula 247 by heating with ammonia in a sealed tube. Nitriles of general formula 244 were also converted to cyanoamidines of general formula 248 when subjected to excess cyanamide in THF with DBU as the base. The 3-amino-1,2,4-oxadiazoles of general formula 249 were then generated by treatment of cyanoamidines of general formula 248 with hydroxylamine hydrochloride and triethyamine in methanol.
    Figure US20030220365A1-20031127-C00073
  • Scheme 61 depicts the preparation of 2-arylcarbonylthienopyridines. Thienopyridines of general formula 44 were deprotonated with alkyllithium base and condensed with nitrobenzaldehdyes to produce the benzyl alcohols of general formula 250. Tin(II)-induced reduction of the nitrophenyls to the anilines of general formula 251 were followed by selective alcohol oxidation with pyridinium chlorochromate. The nitro benzyl alcohols of general formula 250 were also converted to the corresponding ketones of general formula 253 under Swern conditions (for example, oxalyl chloride/DMSO/CH[0765] 2Cl2 at low temperature, followed by treatment with amine bases).
    Figure US20030220365A1-20031127-C00074
  • Scheme 62 depicts the preparation of 2-carbamatethienopyridines and 2-ureathienopyridines. Alcohols of general formula 232 were converted to the amines of general formula 254 by Mitsunobu reaction with phthalimide, followed by deprotection with hydrazine. The amines of general formula 254 were converted to the corresponding ureas of general formula 255 by reaction with potassium isocyanate under acidic conditions. Similarly, the alcohols of general formula 232 were converted to the corresponding carbamates of general formula 256. This chemistry is generally applicable to the use of substituted isocyanates or carbamoyl chlorides, leading to mono or disubstituted carbamates or ureas. [0766]
    Figure US20030220365A1-20031127-C00075
  • Scheme 63 illustrates the preparation of 2-thioureathienopyridines, starting from 2-aminothienpyridines of general formula 54. Reaction of 54 with substituted isothiocyanates in pyridine at reflux provided the thioureas of general formula 257. [0767]
    Figure US20030220365A1-20031127-C00076
  • Scheme 64 exemplifies the synthesis of sulfonamides at the 2-position of the thienopyridines. An improved procedure for decarboxylation of thienopyridine-2-carboxylic acids is shown, wherein acids of general formula 21 were heated in diphenylether at 210° C. to provide thienopyridines of general formula 44 in high yield. Compounds 44 were deprotonated with strong base, then treated with sulfur dioxide to produce intermediate sulfinic acids. Addition of N-chlorosuccinimide produced sulfonyl chlorides of general formula 258, from which a variety of sulfonamides of general formula 259 were prepared by reaction with ammonia, primary or secondary amines in the presence of diisopropylethylamine in protic solvents such as methanol (Prugh, J. D., et al. J. Med. Chem. 1991, 34, 1805-1818; Davidsen, S. K., et al. J. Med. Chem. 1998, 41, 74-95). [0768]
    Figure US20030220365A1-20031127-C00077
  • Scheme 65 provides the outline of the synthesis of additional 2-arylthienopyridines with amino or hydroxy groups on the aryl ring. Using the method of Scheme 24, Suzuki coupling of boronic acids of general formula 79 with nitro-substituted aryl iodides produced biaryls of general formula 260. Biaryls of general formula 260 were reduced to the aminophenyl derivatives of general formula 261 with tin(II) chloride. Methyl ethers of general formula 262 were prepared from boronic acids 79 by coupling with methoxy iodobenzenes, and were converted to the hydroxy derivatives of general formula 263 through the use of boron tribromide to demethylate the methyl ethers. [0769]
    Figure US20030220365A1-20031127-C00078
  • Schemes 66-71 illustrate syntheses for additional 5-membered heterocycles at the 2-position of the thienopyridines. Scheme 66 outlines a method for producing 1,3,4-oxadiazoles. Hydrazides of general formula 264 were prepared by treating esters of general formula 20 or 25 with hydrazine in methylene chloride. The hydrazides were converted to 5-amino-1,3,4-oxadiazoles of general formula 265 by reaction with cyanogen bromide. Hydrazides of general formula 264 may be converted to 5-unsubstituted or 5-alkyl-substituted-1,3,4-oxadiazoles of general formula 266 by condensation with orthoesters under reflux conditions. [0770]
    Figure US20030220365A1-20031127-C00079
  • Scheme 67 indicates a method of preparing 1,3,4-triazoles from methyl esters of general formula 20 or 25. Condensation with aminoguanidine under basic conditions (for example sodium methoxide in methanol) produced the 2-amino-1,3,4-triazoles of general formula 267. Nonspecific methylation was performed on 1,3,4 triazoles of general formula 267 using sodium hydride and methyl iodide, which provided mono-methyl triazoles of general formula 268, dimethyl triazoles of general formula 269, and trimethyl triazoles of general formula 270, which were chromatographically separable. [0771]
    Figure US20030220365A1-20031127-C00080
  • Scheme 68 indicates a method for the preparation of 1,3,4-thiadiazoles of general formula 272. The acid chlorides derived from acids of general formula 21 or 28 were reacted with thiosemicarbazide or substituted thiosemicarbazides to give intermediate [0772]
    Figure US20030220365A1-20031127-C00081
  • Schemes 66-71 illustrate syntheses for additional 5-membered heterocycles at the 2-position of the thienopyridines. Scheme 66 outlines a method for producing 1,3,4-oxadiazoles. Hydrazides of general formula 264 were prepared by treating esters of general formula 20 or 25 with hydrazine in methylene chloride. The hydrazides were converted to 5-amino-1,3,4-oxadiazoles of general formula 265 by reaction with cyanogen bromide. Hydrazides of general formula 264 may be converted to 5-unsubstituted or 5-alkyl-substituted-1,3,4-oxadiazoles of general formula 266 by condensation with orthoesters under reflux conditions. [0773]
    Figure US20030220365A1-20031127-C00082
  • Scheme 67 indicates a method of preparing 1,3,4-triazoles from methyl esters of general formula 20 or 25. Condensation with aminoguanidine under basic conditions (for example sodium methoxide in methanol) produced the 2-amino-1,3,4-triazoles of general formula 267. Nonspecific methylation was performed on 1,3,4 triazoles of general formula 267 using sodium hydride and methyl iodide, which provided mono-methyl triazoles of general formula 268, dimethyl triazoles of general formula 269, and trimethyl triazoles of general formula 270, which were chromatographically separable. [0774]
    Figure US20030220365A1-20031127-C00083
  • Scheme 68 indicates a method for the preparation of 1,3,4-thiadiazoles of general formula 272. The acid chlorides derived from acids of general formula 21 or 28 were reacted with thiosemicarbazide or substituted thiosemicarbazides to give intermediate acylated thiosemicarbazides of general formula 271, which were cyclized under acid catalysis (for example methanesulfonic acid in refluxing toluene) to provide thiadiazoles of general formula 272. [0775]
    Figure US20030220365A1-20031127-C00084
  • Scheme 69 provides a method for the preparation of 1,3,4-oxadiazol-2-thiones and the derived alkylthio-substituted oxadiazoles of general formula 274. Hydrazides of general formula 264 were treated with carbon disulfide in potassium hydroxide in aqueous ethanol solution to give the cyclic thiocarbamates of general formula 273. The thiocarbonyl group was alkylated in low yield with alkyl halides to give the alkylthio 1,3,4-oxadiazoles of general formula 274. [0776]
    Figure US20030220365A1-20031127-C00085
  • Scheme 70 shows the preparation of tetrazoles at the 2-position of thienopyridines. 2-Cyano derivatives of general formula 244 were converted to tetrazoles of general formula 275 using trimethylsilyl azide in the presence of catalytic dibutyltin oxide. The tetrazoles were converted to the N-methyl derivatives of general formula 276 by use of a solution of diazomethane in methanol. [0777]
    Figure US20030220365A1-20031127-C00086
  • Scheme 71 illustrates the syntheses of 2-oxazole and 2-imidazole thienopyridines. Chloroethyl amides of general formula 277 were prepared by chlorination of the corresponding hydroxyethyl amides and then cyclized to oxazolines of general formula 278 under basic catalysis (for example, diazabicycloundecane in dichloromethane). The oxazolines of general formula 278 may be converted to the oxazoles of general formula 278 by dehydrogenation according to the procedure of Meyers (Meyers, A. I., et al. J. Amer. Chem. Soc. 1975, 97, 7383). Aminoethyl amides of general formula 280 were cyclized to the imidazolines of general formula 281 by treatment with calcium oxide at high temperature in diphenyl ether. Imidazolines of general formula 281 may be converted to imidazoles of general formula 282 by literature methods (Hughey, J. L., et al. Synthesis [SYNTBF]1980, (6), 489). [0778]
    Figure US20030220365A1-20031127-C00087
  • In Scheme 72, an improved preparation of 3-alkyl-substituted thienopyridines of general formula 115 is disclosed. Aldehyde 18 was condensed with preformed potassium phenoxides to produce a mixture of mono- and disubstituted aryloxyaldehydes. This mixture was then reacted with the desired Grignard reagent, followed by a Swern oxidation of the resultant mixture of secondary alcohols to give the desired aryloxy ketone compounds. The mixture of aryloxy ketones were further reacted with methyl thioglycolate in the presence of cesium carbonate to provide the 2,3,4-trisubstituted thieno[2,3-c]pyridine esters of general formula 114. These esters were converted to the corresponding acids by hydrolysis with lithium hydroxide, and then the acids were coupled with various amines, for example by carbodiimides, to give the desired amides of general formula 115. [0779]
    Figure US20030220365A1-20031127-C00088
  • Scheme 73 provides a synthesis for 3-carboxythienopyridines. Using methodology analogous to that described for the preparation of 20 or 25, 3,5-dichloropyridine was treated with strong base such as lithium diusopropylamide in anhydrous ethereal solvent at low temperature, followed by the addition of t-butyl chlorooxoacetate to provide the 4-tert-butyl-2-ketoester of 3,5-dichloropyridine 283. The ester 283 was then reacted with 1.25 equivalents of preformed potassium phenoxides at ambient temperature, to give the monoaryloxy derivatives as the main product. Without purification, the monoaryloxy esters were treated with methyl thioglycolate and base such as potassium t-butoxide or cesium carbonate to provide the desired thienopyridine diesters of general formula 284. The diesters of general formula 284 were then treated with methanolic amines to give the corresponding 3-tert-butyl ester amides of general formula 285. The tert-butyl ester amides of general formula 285 were converted to the corresponding acid amides of general formula 287 by solvolysis with trifluoroacetic acid. Diesters of general formula 284 may also be converted to the acids of general formula 286 by a similar solvolysis reaction. [0780]
    Figure US20030220365A1-20031127-C00089
  • Scheme 74 describes the use of 4-bromothienopyridine 32 to prepare 4-amino substituted thienopyridine derivatives. Ester 32 was converted to amides of general formula 288 by standard procedures, and then coupled to a variety of amines using palladium(0) catalysis, as described by Buchwald (J. Org. Chem. 1997, 62, 6066-6068), producing 4-amino derivatives general formula 289. [0781]
    Figure US20030220365A1-20031127-C00090
    Figure US20030220365A1-20031127-C00091
  • Scheme 75 outlines the preparation and reactions of 7-chloro and 7-bromothienopyridine derivatives. The analogs are useful for preparing active derivatives as well as serving as synthetic intermediates for a variety of 7-substituted thienopyridines. Esters of general formula 25 were oxidized to the pyridine-N-oxides of general formula 290 with meta-chloroperbenzoic acid. The N-oxides were rearranged to the 7-halo derivatives of general formula 291 by warming in phosphorous oxychloride or phosphorous oxybromide. The resultant 7-halides could be converted to the amide derivatives of general formula 292 by standard methods without reaction of the 7-chloro or 7-bromo moieties. However, under more forcing conditions, the chloro or bromo groups could be substituted with amines or alcohols to provide 7-amino derivatives of general formula 293 and 7-alkoxy derivatives of general formula 294 respectively. Esters of general formula 294 were converted to amides of general formula 295 using standard methods. 7-Hydroxy analogs of general formula 296 were prepared from 291 derivatives using acetic anhydride followed by hydrolysis with water. In addition, the 7-halo derivatives 291, in particular the 7-bromo derivatives, were effective educts in Suzuki reactions with aryl boronic acids, similar to those described in Scheme 19 and 65. [0782]
    Figure US20030220365A1-20031127-C00092
  • Scheme 76 describes the preparation of furopyridine analogs such as 299 (Example 327). By a procedure analogous to that of the preparation of 20 or 25, dichloropyridinecarboxaldehyde 18 was reacted sequentially with a potassium phenoxide, then with ethyl glycolate, followed by cyclization under basic conditions, affording furopyridine ester 298 in low yield. Standard hydrolysis and coupling conditions afforded the amide 299. The amide was converted to the thioamide 300 by treatment with Lawesson's reagent in hot toluene. [0783]
    Figure US20030220365A1-20031127-C00093
  • Scheme 77 illustrates the preparation N-alkyl 5-amino-1,3,4,-oxadiazoles. The treatment of 265 in refluxing trimethylorthoformate followed by reduction of the eneamine intermediate with sodium borohydride in refluxing ethanol provides the N-alkylated 5-amino-1,3,4,-oxadiazoles of general formula 301. [0784]
    Figure US20030220365A1-20031127-C00094
  • Scheme 78 exemplifies the synthesis of substituted vinyl moieties at the 4-position of thienopyridines. Treatment of aldehyde 227 with the appropriate diethylphosphonate in the presence of potassium bis(trimethylsilyl)amide provided 302. Compound 302 was then treated with sulfuric acid in methanol to yield the methyl ester 303, followed by standard amide formation with ammonia and-methanol to produce 4-vinylsubstituted thienopyridines of general formula 304. Installation of a substituted vinyl can also be accomplished by using Wittig phosphorane chemistry. [0785]
    Figure US20030220365A1-20031127-C00095
  • Scheme 79 demonstrates the preparation of 4-substituted alkyl thienopyridines. Alcohol 228 was subjected to palladium on carbon in acetic acid to generate the methylene derivative 305. Treatment of 305 with sulfuric acid in methanol yields 306. Formation of the amide is accomplished by treatment of 306 with ammonia in methanol to yield 307 [0786]
    Figure US20030220365A1-20031127-C00096
  • Scheme 80 illustrates the preparation of thiazole derivatives at the 2-position of thienopyridines. Thioamides of general formula 309 were alkylated and cyclized with ethyl bromopyruvate, providing thiazole esters of general formula 310. Standard amide formation led to amides of general formula 311. Other amines may be used to produce a variety of substituted amides. In addition, esters of general formula 310 may be converted to carbamates of general formula 312 through Curtius rearrangement of the intermediate acid. The tert-butyl carbamates of general formula 312 were converted to the primary amines of general formula 313 by the action of trifluoroacetic acid. [0787]
    Figure US20030220365A1-20031127-C00097
  • Scheme 81 outlines an alternative method for preparing 3-substituted thienopyridines, wherein Ar=unsubstituted or substituted aryl, or heterocycle, and R=alkyl, alkoxy, substituted alkyl, aryl, arylalkyl. Aldehyde 18 was reacted with the appropriate organomagnesium halide, to give an intermediate secondary alcohol, which was oxidized to the corresponding ketone 314. The method of oxidation was the Swern procedure, although other standard oxidations of this type may be employed (e.g PCC, TPAP). The procedure then follows that previously described for the 3-unsubstituted analogs, leading to ester 315. Ester 315 then served as starting material for the preparation of amides, or other heterocyclic derivatives at the 2-position of the thienopyridines. [0788]
    Figure US20030220365A1-20031127-C00098
  • Scheme 82 describes a method for producing cyclic derivatives between the 2- and 3-positions of thienopyridines. 3-Methyl derivative 115 was treated with N-bromosuccinimide (or alternatively N-chlorosuccinimide) in carbon tetrachloride to give bromomethyl (or chloromethyl) compound 316 (X═Br, Cl). Compound 316 can then be reacted with a primary amine, through alkylation and acylation, leading to the tricyclic lactam 317. Compound 316 may also be treated with sodium alkoxides or aryloxides R[0789] 2=alky, aryl, or heterocycle) leading to the 3-position extended alkoxymethyl derivatives 318. These esters in turn can be reacted with substituted amines to yield the corresponding amides 319.
  • The compounds and processes of the present invention will be better understood in connection with the following examples which are intended as an illustration of and not a limitation upon the scope of the invention.[0790]
    • EXAMPLE 1 methyl 2-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)thio]acetate EXAMPLE 1A methyl 6-ethyl-3,4-dihydro-4-oxothieno[2,3-d]pyrimidine-2-carboxylate
  • The desired compound was prepared as described in J. Heterocylic Chem. 1987, 24, 581-587. [0791]
    • EXAMPLE 1B 6-ethylthieno[2,3-d]pyrimidin-4(3H)-one
  • Example 1A (35 g, 140 mmol) and LiCl (6.5 g, 153 mmol) in DMSO (80 mL) and water (8 mL) was heated to 150° C. for 18 hours, cooled to room temperature, diluted with water, and extracted with ethyl acetate. The extract was dried (MgSO[0792] 4), filtered, and concentrated to provide the designated compound.
    • EXAMPLE 1C 4-chloro-6-ethylthieno[2,3-d]pyrimidine
  • Example 1B (3.97 g, 22.0 mmol) in POCl[0793] 3 (22 mL) was heated to reflux for 2 hours, cooled, poured onto ice, diluted with water, made basic with concentrated ammonium hydroxide, and extracted with ethyl acetate. The extract was dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 10% ethyl acetate-hexane to provide the designated compound.
    • EXAMPLE 1D methyl 2-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)thio)acetate
  • Example 1C (0.25 g, 1.26 mmol) in DMF (1.2 mL) was treated sequentially with methyl thioglycolate (0.134 g, 1.26 mmol) and potassium carbonate (0.174 g, 1.26 mmol), stirred at room temperature for 18 hours, cooled, poured into water, diluted with brine, and extracted with dichloromethane. The extract was washed with water and brine, dried (MgSO[0794] 4), filtered, and concentrated. The residue was triturated then washed with 10% ethyl acetate/hexanes to provide the title compound.
  • mp 36-58° C.; [0795]
  • MS (DCI/NH[0796] 3) m/z 269 (M+H)+;
  • [0797] 1H NMR (300 MHz, DMSO-d6) δ1.33 (t, 3H), 2.99 (q, 2H), 3.75 (s, 2H), 4.26 (s, 3H), 7.23 (s, 1 H), 8.76 (s, 1H).
    • EXAMPLE 2 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine
  • Example 1C was processed as in Example 1D but substituting thiocresol for methyl thioglycolate to provide the title compound. [0798]
  • mp 56-58° C.; [0799]
  • MS (DCI/NH[0800] 3) m/z 286 (M+H)+;
  • [0801] 1H NMR (300 MHz, DMSO-d6) δ1.32 (t, 3H), 2.38 (s, 3H), 2.99 (q, 2H), 7.20 (s, 1H), 7.33 (m, 2H), 7.52 (m, 2H), 8.63 (s, 1H);
  • Anal. calcd for C[0802] 15H14N2S2: C, 62.90; H, 4.93; N, 9.78. Found: C, 63.11; H, 4.82 N, 9.63.
    • EXAMPLE 3 6-ethyl-4-(2-pyridinylthio)thieno[2,3-d]pyrimidine
  • Example 1C was processed as in Example 1D but substituting 2-mercaptopyridine for methyl thioglycolate to provide the title compound. [0803]
  • mp 76.5-79° C.; [0804]
  • MS (DCI/NH[0805] 3) m/z 274 (M+H)+;
  • [0806] 1H NMR (300 MHz, DMSO-d6) δ1.31 (t, 3H), 2.99 (q, 2H), 7.18 (s, 1H), 7.46 (dt, 1H), 7.81 (d, 1H), 7.90 (dt, 1H), 8.60 (m, 1H), 8.74 (s, 1H).
    • EXAMPLE 4 6-ethyl-4-[(2-methylethyl)thio]thieno[2,3-d]pyrimidine
  • Example 1C was processed as in Example 1D but substituting isobutyl mercaptan for methyl thioglycolate to provide the title compound. [0807]
  • MS (DCI/NH[0808] 3) m/z 253 (M+H)+;
  • [0809] 1H NMR (300 MHz, DMSO-d6) δ1.08 (d, 6H), 1.39 (t, 3H), 2.03 (hep, 1H), 2.95 (q, 2H), 3.28 (d, 2H), 7.01 (s, 1H), 8.71 (s, 1H);
  • Anal. calcd for C[0810] 12H16N2S2: C, 57.12; H, 6.38; N, 11.09. Found: C, 57.22; H, 6.29 N, 11.08.
    • EXAMPLE 5 6-ethyl-4-[(phenylmethyl)thio]thieno[2,3-d]pyrimidine
  • Example 1C was processed as in Example 1D but substituting benzyl mercaptan for methyl thioglycolate to provide the title compound. [0811]
  • mp 54-60° C; [0812]
  • MS (DCI/NH[0813] 3) m/z 287 (M+H)+;
  • [0814] 1H NMR (300 MHz, DMSO-d6) δ1.30 (t, 3H), 2.96 (q, 2H), 4.65 (s, 2H), 7.16 (s, 1H), 7.21-7.36 (m, 3H), 7.46 (m, 2H), 8.83 (s, 1H);
  • Anal. calcd for C[0815] 15H14N2S2: C, 62.90; H, 4.93; N, 9.78. Found: C, 62.11; H, 4.94 N, 9.71.
    • EXAMPLE 6 6-ethyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-d]pyrimidine
  • Example 1C was processed as in Example 1D but substituting 5-methyl-1,3,4-thiadiazol-2-thiol for methyl thioglycolate to provide the title compound. [0816]
  • mp 132-135° C.; [0817]
  • MS (DCI/NH[0818] 3) m/z 295 (M+H)+;
  • [0819] 1H NMR (300 MHz, DMSO-d6) δ1.35 (t, 3H), 2.82, (s, 3H), 3.05 (q, 2H), 7.42 (s, 1H), 8.88 (s, 1H);
  • Anal. calcd for C[0820] 11H10N4S3: C, 44.88; H, 3.42; N, 19.03. Found: C, 44.61; H, 3.47 N, 18.92.
    • EXAMPLE 7 ethyl 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine-6-carboxylate
  • Example 1A was processed as in examples 1C and 2 and to provide the title compound. [0821]
  • mp 87.5-90° C.; [0822]
  • MS (DCI/NH[0823] 3) m/z 359 (M+H)+;
  • [0824] 1H NMR (300 MHz, DMSO-d6) δ1.26 (t, 3H), 1.31 (t, 3H), 2.39 (s, 3H), 3.02 (q, 2H), 4.27 (q, 2H), 7.17 (s, 1H), 7.33 (m, 2H), 7.57 (m, 2H);
  • Anal. calcd for C[0825] 18H18N2O2S2: C, 60.31; H, 5.06; N, 7.81. Found: C, 60.44; H, 4.88 N, 7.65.
    • EXAMPLE 8 6-ethyl-N-(phenylmethyl)thieno[2,3-d]pyrimidin-4-amine
  • Example 1C (0.27 g, 1.37 mmol) in isopropanol (1.5 mL) was treated with benzylamine (0.19 mL, 1.71 mmol) and sodium carbonate (0.24 g, 2.3 mmol), stirred at room temperature overnight, filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 25% ethyl acetate/hexanes to provide the title compound. [0826]
  • mp 128-131° C.; [0827]
  • MS (DCI/NH[0828] 3) m/z 270 (M+H)+;
  • [0829] 1H NMR (300 MHz, DMSO-d6) δ1.30 (t, 3H), 2.88 (q, 2H), 4.72 (d, 2H), 7.20-7.40 (m, 6 H), 8.26 (s, 1H), 8.34 (t, 2H); p0 Anal. calcd for C15H15N3S2: C, 66.89; H, 5.61; N, 15.60. Found: C, 66.66; H, 5.43 N, 15.43.
    • EXAMPLE 9 6-ethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine
  • A solution of Example 1C (0.20 g, 1.01 mmol) in isopropanol (2 mL) was treated with 2-amino-5-methyl-1,3,4-thiadiazole (0.15 g, 1.26 mmol) and sodium carbonate (0.18 g, 1.7 mmol), stirred at room temperature for 48. hours, treated with cesium carbonate (0.55 g, 1.7 mmol), stirred at reflux for 24 hours, concentrated, treated with water, and extracted with dichloromethane. The extract was dried (MgSO[0830] 4), filtered, and concentrated. The residue was recrystallized with ethanol/water to provide the title compound.
  • mp 277-280° C.; [0831]
  • MS (DCI/NH[0832] 3) m/z 278 (M+H)+;
  • [0833] 1H NMR (300 MHz, DMSO-d6) δ1.33 (t, 3H), 2.63 (s, 3H), 2.96 (q, 1H), 7.81 (br s, 1H), 8.65 (s, 1H);
  • Anal. calcd for CH[0834] 11H11N5S2: C, 47.63; H, 4.00; N, 25.25. Found: C, 47.48; H, 3.68 N, 24.89.
    • EXAMPLE 10 4-[(5-amino-1,3,4-thiadiazol-2-yl)thiol-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine EXAMPLE 10A 2-amino-5-ethylthiophene-3-carboxamide
  • The designated compound was prepared as described in J. Heterocylic Chem. 1987, 24, pp 581-587. [0835]
    • EXAMPLE 10B 5-ethyl-2-[(phenylacetyl)amino]-3-thiophenecarboxamide
  • Example 10A was processed as in Bull. Soc. Chim. France 1975, p 815 to provide the designated compound. [0836]
    • EXAMPLE 10C 6-ethyl-2-phenylmethylthieno[2,3-d]pyrimidin-4(3H)-one
  • Example 10B was stirred in dioxane/water in the presence of 10% Na[0837] 2CO3 to provide the designated compound.
    • EXAMPLE 10D 4-chloro-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine
  • Example 10C was processed as in Example 1C to provide the designated compound. [0838]
    • EXAMPLE 10E 4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine
  • Example 10D and 5-amino-1,3,4-thiadiazole-2-thiol were processed as in Example 1D to provide the title compound. [0839]
  • MS (DCI/NH[0840] 3) m/z 386 (M+H)+;
  • [0841] 1H NMR (300 MHz, DMSO-d6) δ1.31 (t, 3H), 2.97 (q, 2H), 4.17 (s, 2H), 7.17-7.30 (m, 6H), 7.70 (br s, 2H);
  • Anal. calcd for C[0842] 17H15N5S3: C, 52.96; H, 3.92; N, 18.17. Found: C, 53.10; H, 3.74 N, 18.03.
    • EXAMPLE 11 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine
  • 3-Methyl-7-chlorothieno[3,2-d]pyrimidine was processed as in Example 1D but substituting p-thiocresol for methyl glycolate to provide the title compound. [0843]
  • mp 103-107° C.; [0844]
  • MS (DCI/NH[0845] 3) m/z 273 (M+H)+;
  • [0846] 1H NMR (300 MHz, DMSO-d6) δ2.40 (s, 6H), 7.36 (m, 2H), 7.57 (m, 2H), 8.04 (s, 1H), 8.88 (s, 1H);
  • Anal. calcd for C[0847] 15H12N2OS2: C, 61.73; H, 4.44; N, 10.28. Found: C, 61.73; H, 4.50 N, 10.21.
    • EXAMPLE 12 7-methyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[3,2-d]pyrimidine
  • 3-Methyl-7-chlorothieno[3,2-d]pyrimidine and 5-methyl-1,3,4-thiadiazol-2-thiol were processed as in Example 1D to provide the title compound. [0848]
  • mp 144-147° C.; [0849]
  • MS (DCI/NH[0850] 3) m/z 281 (M+H)+;
  • [0851] 1H NMR (300 MHz, DMSO-d6) δ2.44 (s, 3H), 2.83 (s, 3H), 8.20 (s, 1H), 9.08 (s, 1H);
  • Anal. calcd for C[0852] 10H8N4S3: C, 42.84; H, 2.88; N, 19.98. Found: C, 42.72; H, 2.83 N, 19.64.
    • EXAMPLE 13 7-methyl-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]thieno[3,2-d]pyrimidine
  • 3-Methyl-7-chlorothieno[3,2-d]pyrimidine and 5-(methylthio)-1,3,4-thiadiazol-2-thiol were processed as in Example 1D to provide the title compound. [0853]
  • mp 163-166° C.; [0854]
  • MS (DCI/NH[0855] 3) m/z 313 (M+H)+;
  • [0856] 1H NMR (300 MHz, DMSO-d6) δ2.45 (s, 3H), 2.83 (s, 3H), 8.22 (s, 1H), 9.11 (s, 1H);
  • Anal. calcd for C[0857] 10H8N4S4: C, 38.44; H, 2.58; N, 17.93. Found: C, 38.46; H, 2.63 N, 17.82.
    • EXAMPLE 14 4-[(5-amino-1,3,4-thiadiazol-2-yl)thiol-7-methylthieno[3,2-d]pyrimidine
  • 3-Methyl-7-chlorothieno[3,2-d]pyrimidine and 5-amino-,1,3,4-thiadiazole-2-thiol were processed as in Example 1D to provide the title compound. [0858]
  • mp 221-223° C.; [0859]
  • MS (DCI/NH[0860] 3) m/z 282 (M+H)+;
  • [0861] 1H NMR (300 MHz, DMSO-d6) δ2.43 (s, 3H), 7.80 (br s, 2H), 8.15 (s, 1H), 9.02 (s, 1H);
  • Anal. calcd for C[0862] 9H7N5S3: C, 38.42; H, 2.51; N, 24.89. Found: C, 38.41; H, 2.42 N, 24.97.
    • EXAMPLE 15 7-methyl-N-[(4-(methylthio)phenyl]thieno[3,2-d]pyrimidin-4-amine
  • A solution of 3-methyl-7-chlorothieno[3,2-d]pyrimidine in ethanol was treated with 4-(methylmercapto)aniline, stirred at reflux for 45 minutes, cooled to room temperature, and filtered. The precipitate was recrystallized from ethanol/water to provide the title compound. [0863]
  • mp 212-215° C.; [0864]
  • MS (DCI/NH[0865] 3) m/z 288 (M+H)+;
  • [0866] 1H NMR (300 MHz, DMSO-d6) δ2.37 (s, 3H), 2.48 (s, 3H), 7.29 (m, 2H), 7.76 (m, 2H), 7.87 (br s, 1H), 8.60 (s, 1H), 9.63 (br s, 1H);
  • Anal. calcd for C[0867] 14H13N3S2: C, 58.51; H, 4.56; N, 14.62. Found: C, 58.31; H, 4.49 N, 14.47.
    • EXAMPLE 16 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-6-carboxamide EXAMPLE 16A 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-2-carboxylic acid
  • A solution of LDA (0.1M in THF, 9.6 mL) at −78° C. was treated with Example 11 (0.26 g, 0.96 mmol), warmed to 0° C. over 1 hour, poured onto dry ice with constant swirling, quenched with saturated NH[0868] 4Cl, and extracted with 3:1 chloroform/isopropanol. The extract was concentrated, and the residue was purified by flash chromotograpy on silica gel with 7% methanol/dichloromethane to provide the designated compound.
    • EXAMPLE 16B 7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-2-carboxamide
  • A suspension of Example 16A in dichloromethane (3.3 mL) was treated sequentially with oxalyl chloride (0.03 mL, 0.33 mmol) and DMF (1 drop), and concentrated after formation of the acid chloride. The residue was suspended in THF (10 mL), transferred to a vigorously stirred solution of 1:1 ammonium hydroxide/water (10 mL), and extracted with dichloromethane. The extract was dried (MgSO[0869] 4), filtered, and concentrated. The residue was recrystallized from ethyl acetate/hexanes to provide the title compound.
  • mp 243-246° C.; [0870]
  • MS (DCI/NH[0871] 3) m/z 316 (M+H)+;
  • [0872] 1H NMR (300 MHz, DMSO-d6) δ2.40 (s, 3H), 2.58 (s, 3H), 7.35 (m, 2H), 7.57 (m, 2H), 8.01 (br s, 2H), 8.93 (s, 1H);
  • Anal. calcd for C[0873] 15H13N3OS2: C, 57.12; H. 4.15; N, 13.32. Found: C, 56.81; H, 4.06 N, 13.25.
    • EXAMPLE 17 methyl 4-[(4-methylphenyl)thiol]thieno[2,3-c]pyridine-2-carboxylate EXAMPLE 17A 3,5-dichloropyridine-4-carboxaldehyde
  • Diisopropyl amine (15.6 mL, 0.111 mol) in dry THF, (25 mL) at 0° C. was treated with n-BuLi (44.6 mL, 2.5 M in hexane, 0.111 mol) over 35 minutes, stirred for 30 minutes, cooled to −78° C., diluted with THF (100 mL), and a solution of 3,5-dichloropyridine (15.0 g, 0.101 mol) in THF (175 mL) was added slowly over 3.5 hours in order to maintain an internal temperature <−74° C. The solution was stirred at −78° C. for 30 minutes, treated dropwise over 35 minutes with methyl formate (12.5 mL, 0.203 mmol) in THF (50 mL) maintaining an internal temperature of <−74° C., stirred at −78° C. for 1.4 hours, rapidly cannulated into a ice cold solution of saturated NaHCO[0874] 3 with vigorous stirring, partitioned with ethyl acetate (500 mL), extracted sequentially with saturated NaHCO3 (2×100 mL), brine (3×150 mL), dried (MgSO4), and concentrated. The residue was purified by flash chromatography on silica gel with 10% acetone/hexane.
  • MS (DCI/NH[0875] 3) m/z 176, 178, 180 (M+H)+;
  • [0876] 1H NMR (300 MHz, DMSO-d6) δ8.80 (s, 2H), 10.31 (s, 1H).
    • EXAMPLE 17B 3-(4-methylphenylthio)-5-chloro-4-pyridinecarboxyaldehyde
  • Example 17A (5.05 g, 28.7 mmol) in DMF (70 mL) was treated with p-thiocresol (3.56 g, 28.7 mmol) and potassium carbonate (4.36 g, 31.6 mmol), stirred for 0.5 hours at 0° C. then for 1 hour at room temperature, poured into water, diluted with brine, and extracted with dichloromethane. The extract was washed sequentially with water and brine, dried (MgSO[0877] 4), filtered, and concentrated to provide the designated compound.
    • EXAMPLE 17C methyl 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 17B was processed as in Example 1D to provide the title compound. [0878]
  • mp 116-119° C.; [0879]
  • MS (DCI/NH[0880] 3) m/z 316 (M+H)+;
  • [0881] 1H NMR (300 MHz, DMSO-d6) δ2.28 (s, 3H), 3.91 (s, 3H), 7.20 (m, 2H), 7.29 (m, 2H), 8.00 (s, 1H), 8.44 (s, 1H), 9.36 (s, 1H);
  • Anal. calcd for C[0882] 16H13NO2S2.0.25 H2O C, 60.07; H, 4.25; N, 4.37. Found: C, 60.04; H, 4.08 N, 4.27.
    • EXAMPLE 18 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid
  • A suspension of Example 17C (2.0 g, 6.35 mmol) and LiOH.H[0883] 2O (1.4 g, 32 mmol) in isopropanol (25 mL) and water (15 mL) was heated to 75° C. for 1 hour, cooled, treated with water, and washed with diethyl ether. The aqueous layer was cooled in an ice bath and adjusted to pH 2 with 10% HCl. The resulting solid was collected, washed with water, dried, and recrystallized from ethanol/water to provide the title compound.
  • mp 272-274° C.; [0884]
  • MS (DCI/NH[0885] 3) m/z 302 (M+H)+;
  • [0886] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 7.20 (m, 2H), 7.28 (m, 2H), 7.92 (s, 1H), 8.44 (s, 1H), 9.34 (s, 1H);
  • Anal. calcd for C[0887] 15H12N2OS2: C, 59.78; H, 3.67; N, 4.64. Found: C, 59.48; H, 3.58 N, 4.54.
    • EXAMPLE 19 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • A suspension of Example 18 (0.535 g, 1.78 mmol) in dichloromethane (25 mL) at 0° C. was treated sequentially with oxalyl chloride (0.34 g, 2.67 mmol) and DMF (1 drop), stirred at room temperature for 0.5 hours, and concentrated. The residue was suspended in THF, treated with THF (60 mL), water (30 mL), and concentrated NH[0888] 4OH (30 mL), and stirred for 0.5 hours. The THF layer was separated, washed with brine, partially dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 5% methanol/dichloromethane and recrystallized from 95% ethanol to provide the title compound.
  • mp 198-199° C.; [0889]
  • MS (DCI/NH[0890] 3) m/z 301 (M+H)+;
  • [0891] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 7.20 (m, 2H), 7.30 (m, 2H), 7.89 (br s, 1H), 8.26 (s, 1H), 8.35 (s, 1H), 8.54 (br s, 1H) 9.16 (s, 1H);
  • Anal. calcd for C[0892] 15H12N2OS2: C, 59.97; H, 4.02; N, 9.32. Found: C, 59.84; H, 4.12 N, 9.31.
    • EXAMPLE 20 4-(2-pyridinylthio)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in Examples 17B, 17C, 18, and 19 but substituting 2-mercaptopyridine for p-thiocresol in Example 17B to provide the title compound. [0893]
  • mp 239-242° C.; [0894]
  • MS (DCI/NH[0895] 3) m/z 305 (M+NH4)+;
  • [0896] 1H NMR (300 MHz, DMSO-d6) δ6.99 (d, 1H), 7.17 (dd, 1H), 7.65 (dt, 1H), 7.85 (br s, 1H), 8.18 (s, 1H), 8.36 (m, 1H), 8.49 (br s, 1H), 8.69 (s, 1H), 9.23 (s, 1H);
  • Anal. calcd for C[0897] 13H9N3OS2: C, 54.34; H, 3.16; N, 14.47. Found: C, 54.10; H, 3.14; N, 14.62.
    • EXAMPLE 21 4-[(4-chlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in Examples 17B, 17C, 18, and 19 but substituting 4-chlorothiophenol for p-thiocresol in Example 17B to provide the title compound. [0898]
  • mp 239-241° C.; [0899]
  • MS (DCI/NH[0900] 3) m/z 321 (M+H)+;
  • [0901] 1H NMR (300 MHz, DMSO-d6) δ7.31 (m, 2H), 7.43 (m, 2H), 7.89 (br s, 1H), 8.24 (s, 1H), 8.54 (br s, 1H), 8.56 (s, 1H), 9.38 (s, 1H);
  • Anal. calcd for C[0902] 14H9ClN2OS2: C, 52.42; H, 2.83; N, 8.73. Found: C, 52.33; H, 2.80; N, 8.63.
    • EXAMPLE 22 N-methoxy-N-methyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 18 (0.66 g, 2.2 mmol) in dichloromethane was treated sequentially with oxalyl chloride (0.29 mL, 3.3 mmol) and DMF (1 drop), stirred for 30 minutes, and concentrated. The residue was suspended in THF, transferred to a solution of N,O-dimethylhydroxylamine hydrochloride (0.32 g, 3.3 mmol) and triethylamine (0.92 mL, 6.6 mmol) in 1:1 THF water, and stirred for 5 minutes. The THF layer was separated, dried (MgSO[0903] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 20% ethyl acetate/hexanes to provide the title compound.
  • mp 103-107° C.; [0904]
  • MS (DCI/NH[0905] 3) m/z 345 (M+H)+;
  • [0906] 1H NMR (300 MHz, DMSO-d6) δ2.27 (s, 3H), 3.34 (s, 3H), 3.74 (s, 3H), 7.19 (m, 2H), 7.27 (m, 2H), 8.02 (s, 1H), 8.46 (s, 1H);
  • Anal. calcd for C[0907] 17H16N2O2S2: C, 59.28; H, 4.68; N, 8.13. Found; C, 58.76; H, 4.58; N, 8.06.
    • EXAMPLE 23 N-methoxy-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 18 was processed as in Example 22 but substituting O-methylhydroxyl-aminehydrochloride for N,O-dimethylhydroxylamine hydrochloride to provide the title compound. [0908]
  • mp 200-203° C.; [0909]
  • MS (DCI/NH[0910] 3) m/z 331 (M+H)+;
  • [0911] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 3.76 (s, 3H), 7.20 (m, 2H), 7.30 (m, 2H), 7.89 (br s, 1H), 8.15 (s, 1H), 8.4 (s, 1H), 9.3 (s, 1H);
  • Anal. calcd for C[0912] 16H14N2O2S2.0.25.H2OC, 58.16; H, 4.27; N, 8.48. Found: C, 57.46; H, 4.1 N, 8.01.
    • EXAMPLE 24 N-(4-chlorophenyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 18 (0.1 g, 0.33 mmol) in dichloromethane was treated with oxalyl chloride (0.03 mL, 0.33 mmol) and DMF (1 drop) stirred at reflux for 20 minutes, and concentrated. The residue was suspended in (3:1) benzene/dichloromethane (4 mL), treated with triethylamine (0.5 mL) and 4-chloroaniline (46 mg, 0.36 mmol), stirred at reflux overnight, and concentrated. The residue was treated with water and extracted with dichloromethane. The extract was dried (MgSO[0913] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with ethyl acetate/hexanes to provide the title compound.
  • mp 208-211° C.; [0914]
  • MS (DCI/NH[0915] 3) m/z 411 (M+H)+;
  • [0916] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 7.23 (m, 2H), 7.33 (m, 2H), 7.47 (m, 2H), 7.81 (m, 2H), 8.34 (s, 1H), 8.57 (s, 1H), 9.31 (s, 1H), 10.90 (br s, 1H);
  • Anal. calcd for C[0917] 12H15ClN2OS2: C, 61.38; H, 3.68; N, 6.82. Found: C, 61.22; H, 3.67; N, 6.79.
    • EXAMPLE 25 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde
  • A solution of Example 22 (3.33 g, 9.6 mmol) in THF at −5° C. was treated dropwise with 1M DIBAl—H in THF (14.5 mL, 14.5 mmol), stirred for 45 minutes, poured into ice/HCl with constant stirring, and extracted with dichloromethane. The extract was dried (MgSO[0918] 4), filtered, and concentrated to provide the title compound.
  • MS (DCI/NH[0919] 3) m/z 303 (M+H)+;
  • [0920] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 7.22 (m, 2H), 7.34 (m, 2H), 8.40 (s, 1H), 8.48 (s, 1H), 9.38 (s, 1H), 10.23 (s, 1H);
  • Anal. calcd for C[0921] 15H11NOS2: C, 63.13; H, 3.33; N, 4.91. Found: C, 62.81; H, 3.97; N, 5.01.
    • EXAMPLE 26 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-methyloxime
  • A solution of Example 25 (0.22 g, 0.76 mmol) in 1:1 pyridine:ethanol (8 mL) was treated with methoxylamine hydrochloride (0.51 mL, 1.52 mmol), stirred at room temperature for 3 hours, concentrated, treated with water and extracted with dichloromethane. The ex tract was washed with 1N HCl, dried (MgSO[0922] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 20% ethyl acetate/hexanes to provide the title compound.
  • mp 95-98° C.; [0923]
  • MS (DCI/NH[0924] 3) m/z 315 (M+H)+;
  • [0925] 1H NMR (300 MHz, DMSO-d6) 2.28 (s, 3H), 3.95 (s, 1.8H), 4.08 (s, 1.2H), 7.18 (m, 2H), 7.25 (m, 2H), 7.79 (s, 0.6H), 7.95 (s, 0.4H), 8.27 (s, 0.4H), 8.36 (s, 0.6H), 8.38 (s, 0.4H), 8.68 (s, 0.6H), 9.20 (s, 0.6H), 9.30 (s, 0.4H);
  • Anal. calcd for C[0926] 16H14N2OS2: C, 61.12; H, 4.49; N, 8.91. Found: C, 60.93; H, 4.55; N, 8.98.
    • EXAMPLE 27 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-(phenylmethyl)oxime
  • Example 25 and O-benzylhydroxylamine hydrochloride were processed as in Example 26 but for 18 hours instead of 3 hours to provide the title compound. [0927]
  • mp 127-133° C.; [0928]
  • MS (DCI/NH[0929] 3) m/z 391 (M+H)+;
  • [0930] 1H NMR (300 MHz, DMSO-d6) 2.27 (s, 3H), 5.22 (s, 1.2H), 5.38 (s, 0.8H), 7.15-7.26 (m, 4H), 7.31-7.47 (m, 5H), 7.78 (s, 0.6H), 7.96 (s, 0.4H), 8.31 (s, 0.4H), 8.36 (s, 0.6H), 8.39 (s, 0.4H), 8.74 (s, 0.6H), 9.20 (s, 0.6H), 9.30 (s, 0.4H);
  • Anal. calcd for C[0931] 22H18N2OS2: C, 67.66; H, 4.65; N, 7.17. Found: C, 67.45; H, 4.80; N, 7.13.
    • EXAMPLE 28 2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-ylmethylene]amino]oxy]acetic acid
  • Example 25 was processed as in Example 26 but substituting carboxymethoxyl-amine hemihydrochloride for methoxylamine-hydrochloride to provide the title compound. [0932]
  • mp 227-230° C.; [0933]
  • MS (DCI/NH[0934] 3) m/z 359 (M+H)+;
  • [0935] 1H NMR (300 MHz, DMSO d6) δ2.28 (s, 3H), 4.71 (s, 2H), 7.19 (m, 2H), 7.25 (m, 2H), 7.84 (s, 1H), 8.36 (s, 1H), 8.79 (s, 1H), 9.20 (s, 1H);
  • Anal. calcd for C[0936] 17H14N2O3S2: C, 56.97; H, 3.94; N 7.82. Found C, 56.90; H, 4.10; N, 7.97.
    • EXAMPLE 29 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-phenyloxime
  • Example 25 was processed as in Example 26 but substituting O-phenylhydroxyl-amine hydrochloride for methoxylamine hydrochloride to provide the title compound. [0937]
  • mp 94-97° C.; [0938]
  • MS (DCI/NH[0939] 3) m/z 377 (M+H)+;
  • [0940] 1H NMR (300 MHz, DMSO-d6) δ12.38 (s, 3H), 7.09-7.50 (m, 9H), 7.98 (s, 0.5H), 8.16 (s, 0.5H), 8.39 (s, 0.5H), 8.42 (s, 05H), 8.71 (s, 0.5H), 9.16 (s, 0.5H), 9.27 (s, 0.5H), 9.37 (s, 0.5);
  • Anal. calcd for C[0941] 21H16N2OS2: C, 67.00; H 4.28; N, 7.44. Found: C, 67.14; H, 4.50; N, 7.57.
    • EXAMPLE 30 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, oxime
  • Example 25 was processed as in Example 26 but substituting hydroxylamine hydrochloride for methoxylamine-hydrochloride to provide the title compound. [0942]
  • mp 209-210° C.; [0943]
  • MS (DCI/NH[0944] 3) m/z 301 (M+H)+;
  • [0945] 1H NMR (300 MHz, DMSO-d6) δ2.28 (s, 3H), 7.18 (m, 2H), 7.70 (s, 0.3H), 7.87 (s, 0.7H), 8.19 (s, 0.7H), 8.35 (s, 0.3H), 8.38, (s, 0.7H), 8.56 (s, 0.3H), 9.17 (s, 0.3H), 9.27 (s, 0.7H);
  • Anal. calcd for C[0946] 15H12N2OS2: C, 59.98; H, 4.03; N, 9.33. Found: C, 59.80; H, 4.08, N, 9.30.
    • EXAMPLE 31 2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-ylmethylene]amino]oxy]acetamide
  • Example 28 was processed as in Example 19 to provide the title compound. [0947]
  • mp 152-156° C.; [0948]
  • MS (DCI/NH[0949] 3) m/z 358 (M+H)+;
  • [0950] 1H NMR (300 MHz, DMSO-d6) δ2.27 (s, 3H), 4.52 (s, 0.6H), 4.66 (s, 0.4H), 7.19 (m, 2H), 7.25 (m, 2H), 7.32 (br s, 1H), 7.40 (br s, 1H), 7.84 (s, 0.6H), 7.97 (s, 0.4H), 8.32 (s, 0.4H), 8.37 (s, 0.6H), 8.40 (s, 0.4H), 8.75 (s, 0.6H), 9.21 (s, 0.6H), 9.32 (s, 0.4H);
  • Anal. calcd for C[0951] 17H15N3O2S2.(1.25 H2O): C, 57.12; H, 4.23; N, 11.76. Found C, 56.19; H, 4.48; N, 10.94
    • EXAMPLE 32 (E)-3-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]-2-propionamide
  • Example 25 (0.23 g, 1.27 mmol) in chloroform (10 mL) was treated with carbamoylmethylenetriphenylphosphorane (0.41 g, 1.27 mmol), heated to reflux for 30 minutes, cooled, and concentrated. The residue was purified with flash chromatography on silica gel with 2% methanol/dichloromethane to provide the title compound. [0952]
  • mp 171-174° C.; [0953]
  • MS (DCI/NH[0954] 3) m/z 327 (M+H)+;
  • [0955] 1H NMR (300 MHz, DMSO-d6) δ2.28 (s, 3H), 6.64 (d 1H), 7.19 (m, 2H), 7.25-7.37 (m, 3H), 7.68-7.82 (m, 3H), 8.35 (s, 1H), 9.19 (s, 1H);
  • Anal. calcd for C[0956] 17H14N2OS2.H2O: C, 62.55; H, 4.32; N, 8.58. Found: C, 59.78; H, 4.50; N, 8.20.
    • EXAMPLE33 1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone
  • A solution of Example 22 in THF (25 mL) at 0° C. was treated with methyl magnesium bromide (1.4M in toluene/THF, 1.85 mL, 2.6 mmol), warmed to room temperature, stirred overnight, treated with methylmagnesiumbromide (1.4M in toluene/THF, 0.7 mL, 1.3 mmol) stirred for 1 hour, poured with constant swirling onto ice/NH[0957] 4Cl, and extracted with ethyl acetate. The extract was dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 20% ethyl acetate/hexanes to provide the title compound.
  • mp 134-138° C.; [0958]
  • MS (DCI/NH[0959] 3) m/z 317 (M+NH4)+;
  • [0960] 1H NMR (300 MHz, DMSO-d6) δ2.33 (s, 3H), 2.71 (s, 3H), 7.24 (m, 2H), 7.38 (m, 2H), 8.28 (s, 1H), 8.31 (s, 1H), 9.29 (s, 1H);
  • Anal. calcd for C[0961] 16H13NOS2: C, 64.19; H, 4.38; N, 4.68. Found C, 64.11; H, 4.41; N, 4.61.
    • EXAMPLE 34 2-benzoyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine
  • Example 22 and phenyl lithium were processed as in Example 33 to provide the title compound. [0962]
  • mp 103-107 C; [0963]
  • MS (DCI/NH[0964] 3) m/z 362(M+H)+;
  • [0965] 1H NMR (300 MHz, DMSO d6) δ2.33 (2, 3H), 7.26 (m, 4H), 7.57 (m, 2H), 7.71 (m, 4H), 8.49 (s, 1H), 9.40 (s, 1H);
  • Anal. Calcd for C[0966] 21H15NOS2.1.25 H2O: C, 65.68;, H, 4.59; N, 3.64. Found: C, 65.67; H, 4.09; N, 3.46.
    • EXAMPLE 35 2-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine
  • A solution of Example 33 in ethylene glycol (10 mL) was treated with hydrazine hydrate (0.18 mL, 5.8 mmol), stirred at 160° C. for 30 minutes, cooled to room temperature, treated with potassium hydroxide, stirred at 150° C. for 45 minutes, cooled to room temperature, treated with water, and extracted with ethyl acetate. The extract was washed with water, dried (MgSO[0967] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 10% ethyl acetate/hexanes to provide the title compound.
  • MS (DCI/NH[0968] 3) m/z 286 (M+H)+;
  • [0969] 1H NMR (300 MHz, DMSO-d6) δ1.28 (t, 3H), 2.26 (s, 3H), 2.99 (q, 2H), 7.14-7.27 (m, 5H), 8.34 (s, 1H), 9.11 (s, 1H);
  • Anal. calcd. for C[0970] 16H15NS2.0.25 H2O: C, 67.33; H, 5.30; N, 4.91. Found: C, 66.63; H, 5.38; N. 4.72.
    • EXAMPLE 36 1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone, oxime
  • Example 33 and hydroxylamine hydrochloride were processed as in Example 26 to provide the title compound. [0971]
  • mp 209-213° C.; [0972]
  • MS (DCI/NH[0973] 3) m/z 315 (M+H)+;
  • [0974] 1H NMR (300 MHz, DMSO-d6) δ2.22 (s, 1.5H), 2.28 (s, 3H), 2.32 (s, 1.5H), 7.20 (m, 2H), 7.30 (m, 2H), 7.62 (s, 0.5H), 7.70 (s, 0.5H), 8.30 (s, 0.5H), 8.34 (s, 0.5H), 9.12 (s, 0.5H), 9.24 (s, 0.5H);
  • Anal. calcd for C[0975] 16H14N2OS2: C, 61.16; H, 4.49, N, 8.91. Found C, 60.83, H, 4.61; N, 9.03.
    • EXAMPLE 37 N-(2,3-dihydroxypropyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 18 (2.5 g, 8.3 mmol) and N-hydroxysuccinimide (0.95 g, 8.3 mmol) in dichloromethane (35 mL) was treated with DCC (1.882 g, 9.13 mmol) in methylene chloride (15 mL), stirred at room temperature for 18 hours, and concentrated. The residue was dissolved in ethyl acetate, washed with water, dried (MgSO[0976] 4), filtered, and concentrated. The residue was added to a solution of 3-amino-1,2-propane diol (0.144 g, 1.6 mmol) in 3:1 dioxane/methanol (20 mL), was stirred at room temperature for 18 hours, concentrated, dissolved in ethyl acetate, washed with water, dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 6% methanol/dichloromethane to provide the title compound.
  • mp 120-122° C.; [0977]
  • MS (DCI/NH[0978] 3) m/z 375 (M+H)+;
  • [0979] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3 H), 3.19 (m, 1H), 3.4 (m, 1 H), 3.65 (m, 1 H), 4.62, (t, 1 H), 4.88 (d, 1 H) 7.20 (m, 2 H), 7.30 (m, 2 H), 8.38 (s, 1 H), 9.1 (s, 1 H), 9.28 (s, 1H);
  • Anal. calcd for C[0980] 18H18N2O3S2.0.75H2O: C, 57.73; H, 4.84; N, 7.48. Found: C, 55.54, H, 5.23 N, 6.7.
    • EXAMPLE 38 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid, hydrazide
  • Example 18 was processed as in Example 37 but substituting hydrazine for 3-amino-1,2-propanediol to provide the title compound. [0981]
  • mp 176-178° C.; [0982]
  • MS (DCI/NH[0983] 3) m/z 316 (M+H)+;
  • [0984] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3 H), 4.68 (br s, 2H), 7.20 (m, 2 H), 7.30 (m, 2 H), 8.2 (s, 1 H), 8.4 (s, 1 H), 9.28 (s, 1 H) 10.4 (br s, 1 H);
  • Anal. calcd for C[0985] 15H13N3OS2.0.25.H2O: C, 57.12; H, 4.15; N, 13.32. Found: C, 56.49; H, 4.19 N, 12.29.
    • EXAMPLE 39 N-ω-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]carbonyl]-N6-[(nitroamino)iminomethyl]-L-lysine, methyl ester
  • N-ω-nitroarginine methyl ester hydrochloride and NaHCO[0986] 3 were processed as in Example 37. The residue was purified by flash chromatography on silica gel with 5% methanol/dichloromethane to provide the title compound.
  • mp 84-87° C.; [0987]
  • MS (DCI/NH[0988] 3) m/z 517 (M+H)+;
  • [0989] 1H NMR (300 MHz, DMSO-d6) δ1.60 (m, 2H), 1.85 (m, 2H), 2.29 (s, 3 H), 3.20, (m, 2H), 3.68, (s, 3H), 4.35, (t, 1H), 4.48, (m, 1H, 7.20 (m, 2 H), 7.30 (m, 2 H), 8.32 (s, 1 H), 8.48 (s, 1 H), 8.52, (br s, 1H), 9.30 (s, 1 H), 9.42 (d, 1H);
  • Anal. calcd for C[0990] 22H24N6O5S2.0.25 H2O: C, 51.15; H, 4.68; N, 16.27. Found: C, 50.95; H,4.89; N,15.73.
    • EXAMPLE 40 N-(aminoiminomethyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of guanidine hydrochloride (0.095 g, 1 mmol) in methanol was treated with potassium t-butoxide (0.112 g, 1 mmol), stirred at room temperature for 30 minutes, treated with Example 17 (0.1 g, 0.3 mmol), warmed to room temperature for 16 hours and concentrated. The concentrate was dissolved in ethyl acetate (100 mL), washed with water, dried (MgSO[0991] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 6% methanol/dichloromethane to provide the title compound.
  • mp 202-205° C.; [0992]
  • MS (DCI/NH[0993] 3) m/z 343 (M+H)+;
  • [0994] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 6.90 (br s, 2H), 7.20 (m, 4H), 7.80 (S, 1H), 8.00 (br s, 2H), 8.20 (s, 1H), 8.40 (s, 1H), 9.24 (s, 1H).
    • EXAMPLE 41 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carbothioamide
  • A solution of Example 19 (190 mg, 0.63 mmol) and Lawsesson's reagent (383 mg, 9.48 mmol) in toluene (15 mL) was heated to room temperature for 5 hours and concentrated. The residue purified by flash chromatography on silica gel with 4% methanol/dichloromethane to provide the title compound. [0995]
  • mp 181-183° C.; [0996]
  • MS (DCI/NH[0997] 3) m/z 317 (M+H)+;
  • [0998] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 7.20 (m, 2H), 7.30 (m, 2H), 8.18 (br s, 1H), 8.32 (s, 1H), 9.2 (s, 1H) 10.1 (br s, 1H) 10.2 (br s, 1H);
  • Anal. calcd for C[0999] 15H12N2S3.0.25 H2O: C, 56.93; H, 3.82; N, 8.85. Found: C, 55.89; H,3.83 N, 8.48.
    • EXAMPLE 42 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine
  • Boiling Dowtherm A (2 mL) was treated sequentially with Example 18 (0.6 g, 1.99 mmol) and copper powder (0.3 g), stirred for 5 minutes, cooled, diluted with hexanes, and purified by flash chromatography on silica gel with 15% ethyl acetate/hexanes. The product was then recrystallized from hexanes to provide the title compound. [1000]
  • mp 94-95° C.; [1001]
  • MS (DCI/NH[1002] 3) m/z 258 (M+H)+;
  • [1003] 1H NMR (300 MHz, DMSO-d6) δ2.27 (s, 3H), 7.16 (m, 2H), 7.23 (m, 2H), 7.44 (d, 1H), 8.20 (d, 1H), 8.40 (s, 1H), 9.27 (s, 1H);
  • Anal. calcd for C[1004] 14H11NS2: C, 65.33; H, 4.30; N, 5.44. Found: C, 65.44; H, 4.20, N, 5.26.
    • EXAMPLE 43 methyl 4-[(2-methoxy-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxylate
  • Example 93A was processed as in examples 17B and 17C, but substituting methyl thioglycolate for p-thiocresol in Example 17B to provide the title compound. [1005]
  • MS (DCI/NH[1006] 3) m/z 298 (M+H)+;
  • [1007] 1H NMR (500 MHz, DMSO-d6) δ3.59 (s, 3H), 3.94 (s, 3H), 4.04 (s, 2H), 8.14 (s, 1H), 8.55 (s, 1H), 9.27 (s, 1H).
    • EXAMPLE 44 4-[(2-amino-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 43 was dissolved in 2M methanolic ammonia and warmed to 45° C. in a sealed tube for 18 hours. The precipitate was filtered, washed with methanol-diethyl ether (1:1) and dined under vacuum to provide the title compound. [1008]
  • MS (APCI) mi/z 268 (M+H)[1009] +;
  • [1010] 1H NMR (400 MHz, DMSO-d6) δ3.81 (s, 2H), 7.17 (br s, 1H), 7.59 (br s, 1H), 7.82 (br s, 1H), 8.29 (br s, 1H), 8.46 (s, 1H), 8.52 (br s, 1H), 9.14 (s, 1H).
    • EXAMPLE 45 4-[(4-bromophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 4-bromothiophenol for p-thiocresol in Example 17B to provide the title compound. [1011]
  • MS (DCI/NH[1012] 3) m/z 365 (M+H)+;
  • [1013] 1H NMR (300 MHz, DMSO-d6) δ7.20 (dt, 2H), 7.53 (dt, 2H), 7.87 (br s, 1H), 8.21 (s, 1H), 8.51 (br s, 1H), 8.54 (s, 1H), 9.36 (s, 1H);
  • Anal. calcd for C[1014] 14H9BrN2OS2: C, 46.04; H, 2.48; N, 7.67. Found: C,45.86; H, 2.30; N, 7.51.
    • EXAMPLE 46 4-(phenylthio)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B, 17C, and 44 but substituting thiophenol for p-thiocresol in Example 17B to provide the title compound. [1015]
  • MS (DCI/NH[1016] 3) m/z 287 (M+H)+;
  • [1017] 1H NMR (300 MHz, DMSO-d6) δ7.29-7.40 (m, 5H), 7.86 (br s, 1H), 8.25 (s, 1H), 8.46 (s, 1H), 8.52 (br s, 1H), 9.31 (s, 1H);
  • Anal. calcd for C[1018] 14H10N2OS2: C, 58.72; H, 3.52; N, 9.28. Found: C, 58.62; H, 3.42; N, 9.48.
    • EXAMPLE 47 4-[[4-(trifluoromethyl)phenyl]thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B, 17C, and 44 but substituting α,α,α-trifluorothiocresol for p-thiocresol in Example 17B to provide the title compound. [1019]
  • MS (DCI/NH[1020] 3) m/z 355 (M+H)+;
  • [1021] 1H NMR (300 MHz, DMSO-d6) δ7.31 (d, 2H), 7.65 (d, 2H), 7.85 (br s, 1H), 8.19 (s, 1H), 8.50 (br s, 1H), 8.68 (s, 1H), 9.44 (s 1H);
  • Anal. calcd for C[1022] 15H9F3N2OS2: C, 50.84; H, 2.56; N, 7.91. Found: C, 50.63; H. 2.44; N, 7.82.
    • EXAMPLE 48 4-[(2-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 2-methylthiophenol for p-thiocresol in Example 17B. The residue was purified by column chromatography, eluting with 5% methanol in dichloromethane to provide the title compound. [1023]
  • mp 170-172° C.; [1024]
  • MS (DCI/NH[1025] 3) m/z 301 (M+H)+;
  • [1026] 1H NMR (300 MHz, DMSO-d6) δ2.41 (s, 3H), 7.04 (dd, 1H), 7.15 (dt, 1H), 7.27 (dt, 1H), 7.38 (br d, 1H), 7.86 (br s, 1H), 8.20 (s, 1H), 8.23 (s, 1H), 8.53 (br s, 1H), 9.28 (s, 1H);
  • Anal. calcd for C[1027] 15H12N2OS2: C, 59.97; H, 4.03; N, 9.33. Found: C, 59.86; H, 4.16; N, 9.11.
    • EXAMPLE 49 4-[(3-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 3-methylthiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1028]
  • mp 171-173° C.; [1029]
  • MS (DCI/NH[1030] 3) m/z 301 (M+H)+;
  • [1031] 1H NMR (300 MHz, DMSO-d6) δ2.27 (s, 3H), 7.06-713 (m, 2H), 7.21-7.27 (m, 2H), 7.89 (br s, 1H), 8.26 (s, 1H), 8.42 (s, 1H), 8.55 (br s, 1H), 9.30 (s, 1H);
  • Anal. calcd for C[1032] 15H12N2OS2.0.25H2O: C, 59.08; H, 4.13; N, 9.19. Found: C, 59.10; H, 4.16; N, 9.11.
    • EXAMPLE 50 4-[(3,4-dimethylphenyl)thio]thieno[2,3-c]pyrridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 3,4-dimethylthiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1033]
  • mp 192-194° C.; [1034]
  • MS (APCI) m/z 315 (M+H)[1035] +;
  • [1036] 1H NMR (300 MHz, DMSO-d6) δ2.09 (s, 3H), 2.11 (s, 3H), 7.05 (m, 2H), 7.19 (s, 1 H) 7.81 (br s, 1H), 8.12 (d, 2H), 8.49 (br s, 1H), 9.15 (s, 1H);
  • Anal. calcd for C[1037] 16H14N2OS2.0.25H2O: C, 60.25; H, 4.58; N, 8.78. Found: C, 60.40; H, 4.52; N, 8.75.
    • EXAMPLE 51 4-[(3,5-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 3,5-dimethylthiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1038]
  • mp 177-179° C.; [1039]
  • MS (DCI/NH[1040] 3) m/z 315 (M+H)+;
  • [1041] 1H NMR (300 MHz, DMSO-d6) δ2.13 (s, 6H), 6.83 (s, 1H), 6.92 (s, 1H), 7.81 (br s, 1H), 8.21 (s, 1H), 8.30 (s, 1H), 8.50 (br s, 1H), 9.19 (s, 1H);
  • Anal. calcd for C[1042] 16H14N2OS2: C, 61.12; H, 4.49; N, 8.91. Found: C, 60.82; H, 4.48; N, 8.75.
    • EXAMPLE 52 4-[(2,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 2,4-dimethylthiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1043]
  • mp 193-195° C.; [1044]
  • MS (APCI) m/z 315 (M+H)[1045] +;
  • [1046] 1H NMR (300 MHz, DMSO-d6) δ2.28 (s, 3H), 2.38 (s, 3H), 7.02 (d, 1H), 7.13 (d, 1H), 7.20 (s, 1H), 7.91 (br s, 1H), 8.05 (s, 1H), 8.58 (br s, 1H), 9.22 (s, 1H);
  • Anal. calcd for C[1047] 16H14N2OS2.0.25H2O: C, 60.25; H. 4.58; N, 8.78. Found: C, 60.40; H, 4.52; N, 8.72.
    • EXAMPLE 53 4-[(2-methyl-3-furanyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 2-methyl-3-furanthiol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1048]
  • mp 236-239° C. (decomposes); [1049]
  • MS (ESI) m/z 291 (M+H)[1050] +;
  • [1051] 1H NMR (300 MHz, DMSO-d6) δ2.41 (s, 3H), 6.68 (d, 1H), 7.74 (d, 1H), 7.93 (br s, 1H), 8.19 (s, 1H), 8.38 (s, 1H), 8.60 (br s, 1H), 9.15 (s, 1H);
  • Anal. calcd for C[1052] 13H10N2O2S2.0.25H2O: C, 52.95; H, 3.59; N, 9.50. Found: C, 52.57; H, 3.41; N, 9.30.
    • EXAMPLE 54 4-[[(4-chlorophenyl)methyl]thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 4-chlorobenzylmercaptan for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1053]
  • mp 198-199° C.; [1054]
  • MS (APCI) m/z 335 (M+H)[1055] +;
  • [1056] 1H NMR (300 MHz, DMSO-d6) δ4.40 (s, 2H), 7.31 (s, 4H), 7.86 (br s, 1H), 8.26 (s, 1H), 8.41 (s, 1H), 8.52 (br s, 1H), 9.15 (s, 1H);
  • Anal. calcd for C[1057] 15H11ClN2OS2: C, 53.80; H, 3.31; N, 8.37. Found: C, 53.52; H, 3.18; N, 8.31.
    • EXAMPLE 55 4-[(3,4-dichlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 3,4-dichlorothiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1058]
  • MS (ESI) m/z 355 (M+H)[1059] +;
  • [1060] 1H NMR (300 MHz, DMSO-d6) δ7.10 (dd, 1H), 7.55 (d, 1H), 7.59 (d, 1H), 7.91 (br s, 1H), 8.21 (s, 1H), 8.53 (br s, 1H), 8.62 (s, 1H), 9.41 (s, 1H);
  • Anal. calcd for C[1061] 14H9Cl2N2OS2: C, 47.33; H, 2.27; N, 7.89. Found: C, 47.34; H, 2.52; N, 8.05.
    • EXAMPLE 56 4-[(4-methoxyphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting 4-methoxythiophenol for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1062]
  • mp 219-221° C.; [1063]
  • MS (ESI) m/z 317 (M+H)[1064] +;
  • [1065] 1H NMR (300 MHz, DMSO-d6) δ3.76 (s, 3H), 6.99 (d, 2H), 7.46 (d, 2H), 7.89 (br s, 1H), 8.17 (s, 1H), 8.30 (s, 1H), 8.54 (br s, 1H), 9.18 (s, 1H);
  • Anal. calcd for C[1066] 15H12N2O2S2: C, 56.94; H, 3.82; N, 8.85. Found: C, 56.80; H, 3.78; N, 8.79.
    • EXAMPLE 57 4-(cyclohexylthio)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in examples 17B and 17C, and 44, but substituting cyclohexylmercaptan for p-thiocresol in Example 17B. The residue was purified by flash chromatography with 5% methanol/dichloromethane to provide the title compound. [1067]
  • mp 205-207° C.; [1068]
  • MS (ESI) m/z 293 (M+H)[1069] +;
  • [1070] 1H NMR (300 MHz, DMSO-d6) δ1.14-1.43 (br m, 6H), 1.51-1.61 (br m, 1H), 1.66-1.78 (br m, 2H), 1.83-1.98 (br m, 2H), 7.90 (br s, 1H), 8.33 (s, 1H), 8.52 (s, 1H), 8.57 (br s, 1H), 9.22 (s, 1H);
  • Anal. calcd for C[1071] 14H16N2OS2: C, 57.50; H, 5.51; N, 9.58. Found: C, 57.53; H, 5.39; N, 9.51.
    • EXAMPLE 58 4-[(4-methylphenyl)thio]-N-[3-(4-morpholinyl)propyl]thieno[2,3-c]pyridine-2-carboxamide, trifluoromethylacetate (salt)
  • Example 17C (200 mg, 0.635 mmol) in 9:1 4-(3-aminopropyl)morpholine/acetic acid (2 mL) was warmed at 70° C. for 4 hours, diluted with acetonitrile (6 mL), and purified by C-18 reverse phase HPLC with a gradient of 20% acetonitrile/water to 100% CH[1072] 3CN containing 0.1% trifluoroacetic acid to provide the title compound.
  • MS (APCI) m/z 428 (M+H)[1073] +;
  • [1074] 1H NMR (400 MHz, DMSO-d6) δ1.95 (m, 2H), 3.08 (m, 2H), 3.18 (m, 2H), 3.36 (m, 2H), 3.43 (m, 2H), 3.68 (m, 4H), 7.20 (d, 2H), 7.28 (d, 2H), 8.0 (br s, 1H), 8.27 (s, 1H), 8.34 (m, 1H), 9.27 (m, 1H).
    • EXAMPLE 59 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 59A Methyl 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 17C (144 mg, 0.46 mmol) in dichloromethane (10 mL) at 0° C. was treated with 3-chloroperoxybenzoic acid (57-86%, 82 mg), warmed to room temperature over 4 hours, treated with dichloromethane (50 mL), washed sequentially with 1N NaOH, water, and brine, dried (MgSO[1075] 4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 50% ethyl acetate/hexane to provide the title compound.
  • MS (DCI/NH[1076] 3) m/z 332 (M+H)+;
  • [1077] 1H NMR (300 MHz, DMSO-d6) δ2.25 (s, 3H), 3.84 (s, 3H), 7.38 (d, 2H), 7.65 (d, 2H), 8.41 (s, 1H), 9.0 (s, 1H), 9.58 (s, 1H).
    • EXAMPLE 59B 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 59A was processed as in Example 44 to provide the title compound. [1078]
  • MS (DCI/NH[1079] 3) m/z 317 (M+H)+;
  • [1080] 1H NMR (300 MHz, DMSO-d6) δ2.31 (s, 3H), 7.38 (d, 2H), 7.79 (d, 2H), 7.94 (br s, 1H), 8.43 (s, 1H), 8.62 (br s, 1H), 8.85 (s, 1H), 9.43 (s, 1H).
    • EXAMPLE 60 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 60A methyl 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • Example 17A was processed as in examples 17B and 17C, but substituting p-cresol for p-thiocresol in Example 17B to provide the title compound. [1081]
  • mp 96-98° C.; [1082]
  • MS (DCI/NH[1083] 3) m/z 317 (M+NH4)+, 300 (M+H)+;
  • [1084] 1H NMR (300 MHz, DMSO-d6) δ2.32 (s, 3 H), 3.91 (s, 3 H), 7.05 (m, 2 H), 7.24 (m, 2H), 7.95 (s, 1 H),. 8.12 (s, 1 H), 9.17 (s, 1 H);
  • Anal. calcd for C[1085] 16H13NO3S: C, 64.19; H, 4.37; N, 4.67. Found: C, 64.05; H, 4.34 N, 4.52.
    • EXAMPLE 60B 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 60A was processed as in examples 18 and 19 to provide the title compound. [1086]
  • mp 196-197° C.; [1087]
  • MS (DCI/NH[1088] 3) m/z 285 (M+H)+, 302 (M+NH4)+;
  • [1089] 1H NMR (300 MHz, DMSO-d6) δ2.31 (s, 3 H), 7.04 (m, 2 H), 7.25 (m, 2 H), 7.82 (br s, 1H), 8.00 (s, 1 H), 8.21 (s, 1 H), 8.42 (br s, 1 H) 9.07 (s, 1 H);
  • Anal. calcd for C[1090] 15H12N2O2S. C, 63.36; H, 4.25; N. 9.85. Found: C, 63.29; H, 4.28 N, 9.68.
    • EXAMPLE 61 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 61A methyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • A solution of 4-chlorophenol (2.63 g, 20.5 mmol) in THF (20 mL) at 0° C. was treated dropwise with a solution of potassium tert-butoxide (1.0 M solution in THF, 20.4 mL, 20.5 mmol), stirred at 25° C. for 1 hour, cooled to 0° C., treated with a solution of Example 17A (3.54 g, 20.23 mmol) in THF (40 mL), warmed at 60° C. for 0.5 hours, cooled to 0° C., treated with methylthioglycolate (1.989 mL, 22.25 mmol) and Cs[1091] 2CO3 (6.59 g, 20.23 mmol), warmed at 60° C. for 0.25 hours, cooled to room temperature and filtered. The filtrate was diluted with ethyl acetate, washed sequentially with water and brine, dried (MgSO4), filtered, and concentrated. Purification of the residue by flash chromatography on silica gel with 4% acetonelhexane provided the title compound.
  • mp 99-100° C.; [1092]
  • MS (APCI) m/z 320 (M+H)[1093] +;
  • [1094] 1H NMR (300 MHz, DMSO-d6) δ3.91 (s, 3H, OCH3), 7.14 (d, 2H), 7.48 (d, 2H), 7.95 (s, 1H), 8.23 (s, 1H), 9.23 (s, 1H);
  • [1095] 13C NMR (100 MHz, DMSO-d6) δ56.45 (OCH3), 120.19 (CH), 123.06 (Ar—CH), 128.04 (Ar—CH), 131.34 (C), 132.37 (Ar—CH), 133.38 (Ar—CH), 136.40 (Ar—CH), 139.38 (C), 141.75 (C), 142.09 (C), 144.89 (Ar—CH), 150.91 (C), 158.64 (C), 164.95 (CO);
  • Anal. calcd for C[1096] 15H10ClNO3S: C, 56.34; H, 3.15; N, 4.38. Found: C, 56.23; H, 3.16; N, 4.38.
    • EXAMPLE 61B 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 61A was processed as in Example 44 to provide the title compound. [1097]
  • mp 176-177° C.; [1098]
  • MS (DCI/NH[1099] 3) m/z 305 (M+H)+;
  • [1100] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 2H), 7.50 (m, 2H), 7.95 (b, 1H), 8.25 (d, 2H), 8.45 (b, 1H), 9.15 (s, 1H);
  • Anal. calcd for C[1101] 14H9ClN2O2S.0.25H2O: C, 54.37; H, 3.10; N, 9.06. Found: C, 54.44; H, 2.74; N, 9.06.
    • EXAMPLE 62 4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A was processed as in Example 61 but substituting 4-(trifluoromethyl)phenol for 4-chlorophenol to provide the title compound. [1102]
  • MS (DCI/NH[1103] 3) m/z 339 (M+H)+;
  • [1104] 1H NMR (300 MHz, DMSO-d6) δ7.24 (d, 2H), 7.77 (d, 2H), 7.88 (br s, 1H), 8.10 (s, 1H), 8.33 (s, 1H), 8.45, (br s, 1H), 9.24 (s, 1H);
  • Anal. calcd for C[1105] 15H9F3N2O2S: C, 53.26; H, 2.68; N, 8.28. Found: C, 53.06; H, 2.55; N, 8.19.
    • EXAMPLE 63 4-(4-octylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-octylphenol were processed as in Example 61 to provide the title compound. [1106]
  • MS (DCI/NH[1107] 3) m/z 383 (M+H)+;
  • [1108] 1H NMR (300 MHz, CDCl3) δ0.88 (t, 3H), 1.22-1.38 (m, 10H), 1.62 (m, 2H), 2.61 (t, 2H), 6.05 (br s, 2H), 6.99 (d, 2H), 7.20 (d, 2H), 7.81 (s, 1H), 8.07 (br s, 1H), 8.92 (br s, 1H);
  • Anal. calcd for C[1109] 22H26N2O2S: C, 69.08; H, 6.85; N, 7.32. Found: C, 69.04; H, 6.82, N, 7.22.
    • EXAMPLE 64 4-[4-(1-methylethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-(1-methylethyl)phenol were processed as in Example 61 to provide the title compound. [1110]
  • MS (DCI/NH[1111] 3) m/z 313 (M+H)+;
  • [1112] 1H NMR (300 MHz, DMSO-d6) δ1.21 (d, 6H), 2.92 (septet, 1H), 7.05 (d, 2H), 7.30 (d, 2H), 7.82 (br s, 1H), 8.03 (s, 1H), 8.21 (s, 1H), 8.44 (br s, 1H), 9.09 (s, 1H).
    • EXAMPLE 65 4-(2-bromo-4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 2-bromo-4-chlorophenol were processed as in Example 61 to provide the title compound. [1113]
  • MS (DCI/NH[1114] 3) m/z 383 (M+H)+;
  • [1115] 1H NMR (300 MHz, DMSO-d6) δ7.18 (d, 1H), 7.49 (dd, 1H), 7.90 (br s, 1H), 7.98 (s, 2H), 8.23 (s, 1H), 8.49 (br s, 1H), 9.14 (s, 1H);
  • Anal. calcd for C[1116] 14H8BrClN2O2S: C, 43.83; H, 2.10; N, 7.30. Found: C, 43.53; H, 1.97; N, 6.99.
    • EXAMPLE 66 4-(4-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-ethylphenol were processed as in Example 61 to provide the title compound. [1117]
  • MS (DCI/NH[1118] 3) m/z 299 (M+H)+;
  • [1119] 1H NMR (300 MHz, DMSO-d6) δ1.19 (t, 3H), 2.62 (q, 2H), 7.05 (dt, 2H), 7.26 (dt, 2H), 7.81 (br s, 1H), 8.07 (s, 1H), 8.21 (s, 1H), 8.43 (br s, 1H), 9.08 (s, 1H);
  • Anal. calcd for C[1120] 16H14N2O2S.CH3OH: C, 63.71; H, 4.69; N, 9.14. Found: C, 63.34; H, 4.51; N, 9.51.
    • EXAMPLE 67 4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 67A 4-Vinylphenol
  • A solution of 4-vinylphenol in propylene glycol was treated with water and extracted with diethyl ether in order to remove the propylene glycol and provide the designated compound in diethyl ether. [1121]
    • EXAMPLE 67B 4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and Example 67A were processed as in Example 61 to provide the title compound. [1122]
  • MS (DCI/NH[1123] 3) m/z 297 (M+H)+;
  • [1124] 1H NMR (300 MHz, DMSO-d6) δ5.24 (d, 1H), 5.79 (d, 1H), 6.75 (dd, 1H), 7.10 (d, 2H), 7.54 (d, 2H), 7.87 (br s, 1H), 8.12 (s, 1H), 8.18 (s, 1H), 8.45 (br s, 1H), 9.13 (s, 1H);
  • Anal. calcd for C[1125] 16H12N2O2S.0.25CH3OH: C, 64.13; H, 4.06; N, 9.20. Found: C, 64.40; H, 4.12; N, 9.27.
    • EXAMPLE 68 4-[4-(1,2-dihydroxyethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 67B (35 mg, 0.118 mmol) in pyridine (5 mL) was treated with OsO[1126] 4 (90 mg, 0.354 mmol), stirred for 5 hours, treated with 10% aqueous NaHSO3, stirred for 5 hours, treated with brine, and extracted with ethyl acetate. The extract was dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 1:10 methanol/dichloromethane to provide the title compound.
  • MS (DCI/NH[1127] 3) m/z 331 (M+H)+;
  • [1128] 1H NMR (300 MHz, DMSO-d6) δ3.44 (t, 2H), 4.55 (q, 1H), 4.73 (t, 1H), 5.27 (d, 1H), 7.08 (d, 2H), 7.39 (d, 2H), 7.85 (br s, 1H), 8.03 (s, 1H), 8.21 (s, 1H), 8.47 (br s, 1H), 9.10 (s, 1H);
  • Anal. calcd for C[1129] 16H14N2O4S.0.25CH3OH: C, 57.68; H, 4.24; N, 8.28. Found: C, H, 4.35; N, 8.24.
    • EXAMPLE 69 4-[2-(2-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 2-allylphenol were processed as in Example 61 to provide the title compound. [1130]
  • MS (DCI/NH[1131] 3) m/z 311 (M+H)+;
  • [1132] 1H NMR (300 MHz, DMSO-d6) δ3.43 (d, 2H), 5.01 (m, 1H), 5.05 (m, 1H), 5.98 (m, 1H), 7.00 (dd, 1H), 7.27 (m, 2H), 7.39 (dd, 1H), 7.82 (s, 1H), 7.88 (br s, 1H), 8.27 (s, 1H), 8.49 (brs, 1H), 9.05 (s, 1H);
  • Anal. calcd for C[1133] 17H14N2O2S: C, 65.79; H, 4.55; N, 9.03. Found: C, 65.53; H, 4.37; N, 8.95.
    • EXAMPLE 70 4-[2-(2,3-dihydroxypropyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 69 was processed as in Example 68 to provide the title compound. [1134]
  • MS (DCI/NH[1135] 3) m/z 345 (M+H)+;
  • [1136] 1H NMR (300 MHz, DMSO-d6) δ2.60 (dd, 1H), 2.88 (dd, 1H), 3.29 (t, 2H), 3.76 (m, 1H), 4.55 (t, 1H), 4.63 (d, 1H), 6.94 (dd, 1H), 7.22 (m, 2H), 7.45 (dd, 1H), 7.84 (s, 1H), 7.88 (br s, 1H), 8.26 (s, 1H), 8.46 (br s, 1H), 9.04 (s, 1H);
  • Anal. calcd for C[1137] 17H16N2O4S: C, 59.29; H, 4.68; N, 8.13. Found: C, 59.16; H, 4.51; N, 8.06.
    • EXAMPLE 71 4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, 1-oxide
  • A solution of Example 62 (26 mg, 0.077 mmol) in (1 mL) and dichloromethane (5 mL), at 0° C. was treated with m-CPBA (80-85%, 30 mg, 0.14 mmol), stirred at 0° C. for 1 hour, and at room temperature for 10 hours. The precipitate that formed was collected by filtration and washed with dichloromethane. HPLC analysis of the material (C-18, reverse phase) showed a mixture of desired sulfoxide and starting thiophene in a 8:1 ratio. The mixture was recrystallized from DMF/methanol/dichloromethane to provide the title compound (97.5% pure by HPLC analysis). [1138]
  • MS (HPCI/NH[1139] 3) m/z 355 (M+H)+;
  • [1140] 1H NMR (300 MHz, DMSO-d6) δ7.39 (d, 2H), 7.79 (br s, 1H), 7.81 (d, 2H), 8.02 (s, 1H), 8.05 (d, 1H), 8.36 (br s, 1H), 9.02 (s, 1H);
  • Anal. calcd for C[1141] 15H9F3NO3S.0.25CH3OH: C,50.55; H, 2.57; N, 7.73. Found: C, 50.55; H, 2.59; N. 7.69.
    • EXAMPLE 72 4-[3-(pentadecyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-pentadecylphenol were processed as in Example 61 to provide the title compound. [1142]
  • MS (DCI/NH[1143] 3) m/z 481 (M+H)+;
  • [1144] 1H NMR (300 MHz, DMSO-d6) δ0.84 (t, 3H), 1.20-1.28 (m, 24H), 1.54 (m, 2H), 2.57 (t, 2H), 6.92 (m, 1H), 6.97 (t, 1H), 7.03 (d, 1H), 7.33 (t, 1H), 7.85 (br s, 1H), 8.03 (s, 1H), 8.23 (s, 1H), 8.44 (br s, 1H), 9.09 (s, 1H);
  • Anal. calcd for C[1145] 29H40N2O2S: C, 72.46; H, 8.39; N, 5.83. Found: C, 72.69; H, 8.18; N, 5.47.
    • EXAMPLE 73 Methyl 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • To a solution of 4-bromophenol (4.94 g., 28.55 mmol) in anhydrous tetrahydrofuran (10 mL) under nitrogen atmosphere was added dropwise a solution of potassium t-butoxide (1 M solution in THF, 28.6 mL, 28.6 mmol). The reaction mixture was stirred at ambient temperature for 30 minutes, then a solution of Example 17A (2 g, 11.4 mmol) in anhydrous tetrahydrofuran (20 mL) was added and refluxed for 8 hours. The reaction mixture was allowed to cool to 25° C., methyl thioglycolate (1.23 mL, 13.7 mmol) was added and refluxed for 15 minutes. The cooled reaction mixture was diluted *with ethyl acetate (300 mL) and partitioned with an ice cold solution of 1 N NaOH (3×75 mL). The organic layer was washed with brine (3×100 mL), dried (MgSO[1146] 4) and solvents were removed under reduced pressure to obtain the crude product (4.2 g). This was purified by flash chromatography on silica gel eluting with 10% acetone-hexane to obtain the title compound (1.81 g) in 44% yield.
  • [1147] 1H NMR (300 MHz, DMSO-d6) δ3.91 (s, 3H), 7.10 (d, J=9 Hz, 2H), 7.59 (d, J=9 Hz, 2H), 7.94 (s, 1H), 8.25 (s, 1H), 9.24 (s, 1H);
  • MS (APCI) m/e 364;366 (M+H)[1148] +.
    • EXAMPLE 74 4-(3-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-chlorophenol were processed as in Example 61 to provide the title compound. [1149]
  • MS (DCI/NH[1150] 3) m/z 305 (M+H)+;
  • [1151] 1H NMR (300 MHz, DMSO-d6) δ7.10 (m, 1H), 7.30 (m, 2H), 7.45 (b, 1H), 7.95 (b, 1H), 8.20 (d, 1H), 8.30 (s, 1H), 8.6 (b, 1H), 9.30 (s, 1H).
    • EXAMPLE 75 4-(4-t-butylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-tert-butylphenol were processed as in Example 61 to provide the title compound. [1152]
  • MS (DCI/NH[1153] 3) m/z 327 (M+H)+;
  • [1154] 1H NMR (300 MHz, DMSO-d6) δ1.3 (s, 9H), 7.10 (d, 2H), 7.45 (d, 2H), 7.85 (br s, 1H), 8.05 (s, 1H), 8.20 (s, 1H), 8.45 (br s, 1H), 9.1 (s, 1H).
    • EXAMPLE 76 4-(4-chloro-3-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-chloro-3-methylphenol were processed as in Example 61 to provide the title compound. [1155]
  • MS (DCI/NH[1156] 3) m/z 319 (M+H)+;
  • [1157] 1H NMR (300 MHz, DMSO-d6) δ2.30 (s, 3H), 6.95 (dd, 1H), 7.20 (d, 1H), 7.45 (d, 1H), 7.85 (br s, 1H), 8.15 (s, 1H), 8.19 (s, 1H), 8.45 (br s, 1H), 9.15 (s, 1H).
    • EXAMPLE 77 4-(4-chloro-2-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-chloro-2-methylphenol were processed as in Example 61 to provide the title compound. [1158]
  • MS (DCI/NH[1159] 3) m/z 319 (M+H)+;
  • [1160] 1H NMR (300 MHz, DMSO-d6) δ2.30 (s, 3H), 6.95 (dd, 1H), 7.30 (d, 1H), 7.50 (d, 1H), 7.85 (br s, 1H), 7.95 (s, 1H), 8.25 (s, 1H), 8.45 (br s, 1H), 9.15 (s, 1H).
    • EXAMPLE 78 4-(4-methoxyphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-methoxyphenol were processed as in Example 61 to provide the title compound. [1161]
  • MS (DCI/NH[1162] 3) m/z 301 (M+H)+;
  • [1163] 1H NMR (300 MHz, DMSO-d6) δ3.78 (s, 3H), 7.00 (dd, 2H), 7.15 (d, 2H), 7.85 (b, 1H), 7.90 (s, 1H), 8.30 (s, 1H), 8.45 (b, 1H), 9.05 (s, 1H).
    • EXAMPLE 79 ethyl 3-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate
  • Example 17A and ethyl 3-hydroxybenzoate were processed as in Example 61 to provide the title compound. [1164]
  • MS (DCI/NH[1165] 3) m/z 343 (M+H)+;
  • [1166] 1H NMR (300 MHz, DMSO-d6) δ1.30 (t, 3 H), 4.30 (s, 3 H), 7.40 (dd, 1 H), 7.60 (m, 2 H), 7.80 (dd, 1H), 7.85 (b, 1H), 8.15 (s, 1 H), 8.20 (s, 1 H), 8.42 (b, 1H), 9.17 (s, 1H).
    • EXAMPLE 80 4-phenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and phenol were processed as in Example 61 to provide the title compound. [1167]
  • MS (DCI/NH[1168] 3) m/z 271 (M+H)+;
  • [1169] 1H NMR (300 MHz, DMSO-d6) δ7.15 (dd, 2H), 7.20 (t, 1H), 7.45 (t, 2H), 7.85 (b, 1H), 8.10 (s, 1H), 8.20 (s, 1H), 8.45 (b, 1H), 9.15 (s, 1H).
    • EXAMPLE 81 4-(3-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-bromophenol were processed as in Example 61 to provide the title compound. [1170]
  • MS (DCI/NH[1171] 3) m/z 349, 351 (M+H)+;
  • [1172] 1H NMR (300 MHz, DMSO-d6) δ7.07 (dt, 2 Hz, 1H), 7.36-7.39 (m, 3H), 7.87 (br s, 1H), 8.15 (s, 1H), 8.20 (s, 1H), 8.45 (br s, 1H), 9.17 (s, 1H);
  • Anal calcd for C[1173] 14H9N2O2S.CH3OH: C, 47.26; H, 2.64; N, 7.35. Found: C, 47.26; H, 3.21; N, 7.29.
    • EXAMPLE 82 4-(4-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-fluorophenol were processed as in Example 61 to provide the title compound. [1174]
  • MS (DCI/NH[1175] 3) m/z 289 (M+H)+;
  • [1176] 1H NMR (300 MHz, DMSO-d6) δ7.25 (m, 4 H), 7.85 (b, 1H), 8.05 (s, 1H), 8.20 (s, 1 H), 8.42 (b, 1H), 9.10 (s, 1H).
    • EXAMPLE 83 4-(3,5-dimethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3,5-dimethylphenol were processed as in Example 61 to provide the title compound. [1177]
  • MS (DCI/NH[1178] 3) m/z 299 (M+H)+;
  • [1179] 1H NMR (300 MHz, DMSO-d6) δ3.30 (s, 6H), 6.75 (s, 2H), 6.85 (s, 1H), 7.80 (b, 1H), 8.05 (s, 1H), 8.18 (s, 1H), 8.45 (b, 1H), 9.10 (s,1H).
    • EXAMPLE 84 4-(3-chloro-4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-chloro-4-methylphenol were processed as in Example 61 to provide the title compound. [1180]
  • MS (DCI/NH[1181] 3) m/z 319 (M+H)+;
  • [1182] 1H NMR (300 MHz, DMSO-d6) δ2.35 (s, 3H), 7.00 (dd, 1H), 7.25 (d, 1H), 7.45 (d, 1H), 7.85 (b, 1H), 8.15 (s, 1H), 8.20 (s, 1H), 8.45 (b, 1H), 9.15 (s, 1H).
    • EXAMPLE 85 4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-iodophenol were processed as in Example 61 to provide the title compound. [1183]
  • MS (DCI/NH[1184] 3) m/z 397 (M+H)+;
  • [1185] 1H NMR (300 MHz, DMSO-d6) δ6.94 (d, 2H), 7.74 (d, 2H), 7.86 (br s, 1H), 8.13 (s, 1H), 8.17 (s, 1H), 8.44 (br s, 1H), 9.16 (s, 1H);
  • Anal calcd for C[1186] 14H9IN2O2S: C, 42.44; H, 2.29; N. 7.07. Found: C, 42.58; H, 2.27; N, 7.08.
    • EXAMPLE 86 4-(4-(methoxymethyl)phenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-(methoxymethyl)phenol were processed as in Example 61 to provide the title compound. [1187]
  • mp 168-168.5° C. [1188]
  • MS (DCI/NH[1189] 3) m/z 315 (M+H)+;
  • [1190] 1H NMR (300 MHz, DMSO-d6) δ3.30 (s, 3H), 4.41 (s, 2H), 7.10 (d, 2H), 7.37 (d, 2H), 7.86 (s, 1H), 8.08 (s, 1H), 8.19 (s, 1H), 8.45 (br s, 1H), 9.12 (s, 1H).
    • EXAMPLE 87 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridinium, iodide
  • Example 61 (0.11 g, 0.0033 mole) was treated with methyl iodide (0.2 mL, 0.0033 mmol) at reflux for 2 hours and filtered. The precipitate was washed with ether, dried, and recrystallized from acetonitrile to provide the title compound. [1191]
  • MS (DCI/NH[1192] 3) m/z 305 (M+H)+;
  • [1193] 1H NMR (300 MHz, DMSO-d6) δ4.40 (s, 3H), 7.40 (dd, 2H), 7.65 (dd, 2H), 8.25 (br s, 1H), 8.55 (s, 1H), 8.65 (s, 1H), 8.70 (br s, 1H), 9.70 (s, 1H).
    • EXAMPLE 88 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid
  • Example 61A (354 mg, 1.11 mmol), lithium hydroxide monohydrate (98 mg, 2.33 mmol) in 3:1 methanol/water (4 mL) was stirred at room temperature for 20 hours, acidified with 90% formic acid (0.13 mL), and filtered to provide the title compound. [1194]
  • MS (DCI/NH[1195] 3) m/z 306, 308 (M+H)+;
  • [1196] 1H NMR (300 MHz, DMSO-d6) δ7.26 (m, 2H), 7.47 (m, 2H), 7.83 (s, 1H), 8.23 (s, 1H), 9.21 (s, 1H);
  • Anal. calcd for C[1197] 14H9ClNO3S: C, 55.00; H, 2.64; N, 4.58. Found: C, 54.77; H, 2.60; N, 4.44.
    • EXAMPLE 89 N-(4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl)-O-(3-tetrahydrofuranyl)carbamate
  • A suspension of Example 88 (100 mg, 0.327, mmol) in toluene (2 mL) was treated with ethyldiisopropylamine (63 mg, 0.49 mmol) and diphenylphosphorylazide (109 mg, 0.394 mmol) at 63° C., stirred for 1, treated with (±)-3-hydroxytetrahydrofuran (130 mg, 1.47 mmol) at 110° C., stirred for 18 hours, and concentrated. The residue was purified by flash chromatography on silica gel with 30% ethyl acetate/hexane and recrystallized from ethyl acetate to provide the title compound. [1198]
  • mp 194-201; [1199]
  • MS (APCI) m/z 391 (M+H)[1200] +;
  • [1201] 1H NMR (300 MHz, DMSO-d6) δ1.93-2.04 (m, 1H), 2.13-2.28 (m, 1H), 3.29-3.34 (m, 1H plus HOD), 3.70-3.86 (m, 4H), 5.33 (m, 1H), 6.56 (s, 1H), 7.02 (dt, 2H), 7.43 (dt, 2H), 8.14 (s, 1H), 8.91 (s, 1H);
  • Anal. calcd for C[1202] 18H15ClN2O4S: C, 55.32; H, 3.87; N, 7.17. Found: C, 55.08; H, 3.69; N, 7.05.
    • EXAMPLE 90 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-methanol
  • A solution of Example 61A (254 mg, 0.793 mmol) in absolute ethanol (4 mL) was treated with anhydrous CaCl[1203] 2 (177 mg, 1.59 mmol), stirred for 1 hour, cooled to 0° C., treated with NaBH4 (123 mg, 3.25 mmol), stirred at 0° C. for 4 hours and at room temperature for 18 hours, treated with water and extracted with dichloromethane. The extract was washed with brine, dried (Na2SO4), filtered and concentrated. The residue was purified on silica gel with 30% ethyl acetate/hexane to provided the title compound.
  • mp 90-91° C.; [1204]
  • MS (APCI) m/z 292, 294 (M+H)[1205] +;.
  • [1206] 1H NMR (300 MHz, CDCl3) δ2.2-2.65 (vbr s, 1H), 4.97 (d, 2H), 6.95 (dt, 2H), 7.43 (m, 1H), 7.31 (dt, 2H), 8.13 (s, 1H), 8.89 (s, 1H);
  • Anal. calcd for C[1207] 14H10ClNO2S: C, 57.64; H, 3.45; N, 4.80. Found: C, 57.50; H, 3.58; N, 4.66.
    • EXAMPLE 91 (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoic acid EXAMPLE 91A 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxaldehyde
  • A solution of DMSO (77 mg, 0.99 mmol) in 1.7 mL dichloromethane at −78° C. was treated dropwise with oxalyl chloride (109 mg, 0.86 mmol), stirred for 5 minutes, treated dropwise with Example 90 (123 mg, 0.420 mmol) in 2 mL dichloromethane, stirred at −78° C. for 1 hour, treated with ethyldiisopropylamine (326 mg, 2.53 mmol) warmed to −20° C., stirred 1.5 hours and partitioned between 10 mL dichloromethane and 5 mL water, and extracted. The extract was washed with water (5 mL) and brine (5 mL), dried (Na[1208] 2SO4), and filtered. The residue was rotoevaporated and dried under high vacuum to provide the title compound.
  • MS (APCI) m/z 290, 292 (M+H)[1209] +.
    • EXAMPLE 91B (E)-methyl 3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoate
  • Example 91A (138 mg, 0.42 mmol) and methyl triphenylphosphoranylidene acetate (210 mg, 0.628 mmol) in dichloroethane (2 mL) was stirred at 65° C. for 3 hours and concentrated. The residue was purified by flash chromatography on silica gel with 25% ethyl acetate/hexane to provide the title compound. [1210]
  • MS (APCI) m/z 346, 348 (M+H)[1211] +;
  • [1212] 1H NMR (300 MHz, CDCl3) δ3.83 (s, 3H), 6.43 (d, 1H), 7.00 (dt, 2H), 7.35 (dt, 2H), (s, 1H), 7.84 (d, 1H), 8.11 (s, 1H), 8.88 (s, 1H);
  • Anal. calcd for C[1213] 17H17ClNO3S: C, 59.05; H, 3.50; N, 4.05. Found: C, 58.82; H, 3.46; N, 3.86.
    • EXAMPLE 91C (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoic acid
  • Example 91B was processed as in Example 88 to provide the title compound. [1214]
  • MS (ESI−) m/z 330, 332 (M−H)[1215] −;
  • [1216] 1H NMR (300 MHz, DMSO-d6) δ6.46 (d, 1H), 7.14 (dt, 2H), 7.46 (dt, 2H), 7.83 (s, 1H), 7.92 (d, 1H), 8.15 (s, 1H), 9.10 (s, 1H);
  • Anal. calcd for C[1217] 17H17ClNO3S: C, 59.05; H, 3.50; N, 4.05. Found: C, 58.82; H, 3.46; N, 3.86.
    • EXAMPLE 92 (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propionamide
  • A solution of Example 91C (51.5 mg, 0.155 mmol), N-hydroxybenzotriazole monohydrate (34.5 mg, 0.225 mmol), 4-methylmorpholine (47 mg, 0.464 mmol) and NH[1218] 4Cl (31.6 mg, 0.591 mmol) in DMF (1 mL) at 0° C. was treated with EDC (45.0 mg, 0.235 mmol), stirred at 0° C. for 4 hours and at room temperature for 10 hours, treated with chloroform (5 mL), washed sequentially with 1M NaHCO3 and brine, dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 5% methanol/dichloromethane to provide the title compound.
  • mp 176-178° C.; [1219]
  • MS (ESI) m/z 331, 333 (M+H)[1220] +;
  • [1221] 1H NMR (300 MHz, CDCl3) δ5.60 (br s, 2H), 6.46 (d, 1H), 7.01 (m, 2H), 7.35 (m, 2H), 7.46 (s, 1H), 7.84 (d, 1H), 8.11 (s, 1H), 8.88 (s, 1H);
  • Anal. calcd for C[1222] 16H11ClN2O2S: C, 58.10; H, 3.35; N, 8.47. Found: C, 57.98; H, 3.24; N, 8.45.
    • EXAMPLE 93 4-bromothieno[2,3-c]pyridine-2-carboxamide EXAMPLE 93A 3,5-dibromopyridine-4-carboxaldehyde
  • A solution of diisopropylamine (6.6 mL, 46.43 mmol) in THF (40 mL) at 0° C. was treated with n-butyllithium in hexanes (2.50 M solution, 18.6 mL, 46.43 mmol) over 15 minutes, stirred at 0° C. for 30 minutes, diluted with THF (200 mL), cooled to −78° C., treated with 3,5-dibromopyridine (10 g, 42.21 mmol) in THF (110 mL) over 95 minutes, stirred at −78° C. for 30 minutes, treated dropwise with methylformate (5.2 mL, 84.42 mmol), stirred at −78° C. for 2 hours, transferred to ice-cold saturated NaHCO[1223] 3 solution, stirred for 15 minutes, and extracted with diethyl ether. The extract was washed with brine, dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 10% acetone/hexane to provide the title compound.
  • MS (DCI/NH[1224] 3) m/z 266 (M+H)+;
  • [1225] 1H NMR (300 MHz, DMSO-d6) δ8.91 (s, 2H), 10.09 (s, 1H).
    • EXAMPLE 93B methyl 4-bromothieno[2,3-c]pyridine-2-carboxylate
  • Example 93A was processed as in Example 17C except at 0-25° C. to provide the title compound. [1226]
  • MS (DCI/NH[1227] 3) m/z 274 (M+H)+;
  • [1228] 1H NMR (500 MHz, DMSO-d6) δ3.95 (s, 3H), 7.99 (s, 1H), 8.67 (s, 1H), 9.31 (s, 1H).
    • EXAMPLE 93C 4-bromothieno[2,3-c]pyridine-2-carboxamide
  • Example 93B was processed as in Example 44 to provide the title compound. [1229]
  • MS (DCI/NH[1230] 3) m/z 257 (M+H)+;
  • [1231] 1H NMR (400 MHz, DMSO-d6) δ7.97 (br s, 1 H), 8.11 (s, 1 H), 8.33 (br s, 1H), 8.43 (s, 1H), 9.24 (s, 1 H).
    • EXAMPLE 94 4-chlorothieno[2,3-c]pyridine-2-carboxamide
  • 3,5-Dichloropyridine was processed as in Example 93 to provide the title compound. [1232]
  • MS (DCI/NH[1233] 3) m/z 213 (M+H)+;
  • [1234] 1H NMR (300 MHz, DMSO-d6) δ7.93 (br s, 1H, NH), 8.28 (s, 1H), 8.55 (br s, 1 H, NH), 8.58 (s, 1H), 9.28 (s, 1H).
    • EXAMPLE 95 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 95A methyl 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 93B (272 mg, 1 mmol), 4-(trifluoromethyl)phenyl boronic acid (209 mg, 1.1 mmol) and cesium fluoride (347 mg, 2.1 mmol) in DME (5 mL) was degassed for 15 minutes, treated with tetrakis(triphenylphosphine)palladium(0) (35 mg, 0.03 mmol), warmed at 80° C. for 6 hours, stirred at room temperature for 12 hours, filtered through Celite®, and concentrated. The residue was purified by flash chromatography on silica gel with 5% acetoneihexane to provide the title compound. [1235]
  • MS (DCI/NH[1236] 3) m/z 338 (M+H)+;
  • [1237] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 7.94 (m, 4H), 8.06 (s, 1H), 8.66 (s, 1H), 9.47 (s, 1H).
    • EXAMPLE 95B 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 95A was processed as in Example 44 to provide the title compound. [1238]
  • MS (APCI) m/z 323 (M+H)[1239] +, 321 (M−H)−, and 357 (M+Cl)−;
  • [1240] 1H NMR (400 MHz, DMSO-d6) δ7.81 (br s, 1H), 7.93 (m, 4H), 8.24 (s, 3H), 8.45 (br s, 1H), 8.59 (br s, 1H), 9.37 (br s, 1H).
    • EXAMPLE 96 N-methyl-4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 95A was processed as in Example 44 but substituting methylamine (2.0 M in methanol) for methanolic ammonia to provide the title compound. [1241]
  • MS (APCI) m/z 337 (M+H)[1242] +, 335 (M−H)−, and 371 (M+Cl)−;
  • [1243] 1H NMR (400 MHz, DMSO-d6) δ2.82 (d, 3H), 7.90 (d, 2H), 7.94 (d, 2H), 8.17 (s, 1H), 8.58 (s, 1H), 8.93 (br d, 1H), 9.36 (s, 1H);
  • [1244] 13C NMR (100 MHz, DMSO-d6) δ: 26.1 (CH3), 121.6 (Ar—CH), 123.1, 125.3 (C), 125.7 (CH), 125.8 (CH), 128.3, 128.6, 128.8, 129.1 (CF3), 129.9 (2×Ar—CH), 136.6 (C), 140.6 (C), 142.4(C), 142.5 (CH), 145.0 (2×CH), 146.6 (C), 161.1 (C).
    • EXAMPLE 97 4-phenylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 97A methyl 4-phenylthieno[2,3-c]pyridine-2-carboxylate
  • Example 93B and phenylboronic acid were processed as in Example 95 to provide the designated compound. [1245]
  • MS (DCI/NH[1246] 3) m/z 338 (M+H)+;
  • [1247] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 7.94 (m, 4H), 8.06 (s, 1H), 8.66 (s, 1H), 9.47 (s, 1H).
    • EXAMPLE 97B 4-phenylthieno[2,3-c]pyridine-2-carboxamide
  • Example 97A was processed as in Example 44 to provide the title compound. [1248]
  • MS (DCI/NH[1249] 3) m/z 255 (M+H)+;
  • [1250] 1H NMR (300 MHz, DMSO-d6) δ7.52-7.69 (m, 5H), 7.78 (br s, 1H), 8.23 (s, 1H), 8.44 (br s, 1H), 8.52 (s, 1H), 9.30 (s, 1H);
  • Anal. calcd for C[1251] 14H10N2OS: C, 66.12; H, 3.96; N, 11.02. Found: C, 66.02; H, 3.94; N, 11.00.
    • EXAMPLE 98 4-([1,1′-biphenyl]-4-ylthio)thieno[2,3-c]pyridine-2-carboxamide
  • Example 73 and phenylboronic acid were processed and purified as in Example 95 then repurified by HPLC (C18 reverse phase, 0-90% acetonitrile gradient in water containing 0.1% TFA) to provide the title compound. [1252]
  • MS (DCI/NH[1253] 3) m/z 363 (M+H)+;
  • [1254] 1H NMR (300 MHz, DMSO-d6) δ7.36-7.48 (m, 5H), 7.63-7.68 (m, 4H), 7.91 (br s, 1 H), 8.30 (s, 1H), 8.54 (s, 1H), 8.57 (br s, 1H), 9.36 (s, 1H).
    • EXAMPLE 99 Methyl 4-[3-(2,3,4,5-Tetrahydrofuranyl)oxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 99A Methyl 4-[3-(2,3,4,5-Tetrahydrofuranyl)oxy]thieno[2,3-c]pyridine-2-carboxylate
  • To a solution of Example 236E (110 mg, 0.53 mmol) in anhydrous tetrahydrofuran (10 mL) at room temperature under nitrogen atmosphere was added 3-hydroxy tetrahydrofuran (0.043 mL, 0.53 mmol), triphenylphosphene (138 mg, 0.53 mmol) and diethyl azodicarboxylate (0.083 mL, 0.53 mmol). After 22 hr the reaction mixture was diluted with ethyl acetate (100 mL), filtered and the filtrate was concentrated under reduced pressure. The residue obtained was purified by flash chromatography on silica gel (Biotage Flash 40 S) eluting with 10% acetone-hexane to obtain the title compound in 22% yield. [1255]
  • [1256] 1H NMR (400 MHz, DMSO-d6) δ2.05-2.18 (m, 1H), 2.26-2.49 (m, 1H), 3.61-3.77 (m, 2H), 3.93 (s, 2H), 4.25-4.31 (m, 2H), 5.32-5.39 (m, 1H), 8.10 9s, 1H), 8.26 (s, 1H), 8.99 (s, 1H);
  • MS (APCI) m/e 280 (M+H)[1257] +.
    • EXAMPLE 99B Methyl 4-[3-(2,3,4,5-Tetrahydrofuranyl)oxy]thieno[2,3-c]pyridine-2-carboxamide
  • The title compound (5.7 mg, 19%) was prepared from Example 99A (30 mg, 0.108 mmol) as described in Example 171. The product was isolated by C-18 reverse phase HPLC eluting with a gradient of 20% CH[1258] 3CN—H2O containing 0.1% trifluoroacetic acid.
  • [1259] 1H NMR (400 MHz, DMSO-d6) δ2.05-22.13 (m, 1H), 2.30-2.40 (m, 1H), 2.81 (d, J=5 Hz, 3H), 3.78-3.84 (m, 1H), 3.90-4.01 (m, 3H), 5.32-5.37 (m, 1H), 8.13 (s, 1H), 8.21 (s, 1H), 8.90 (s, 1H), 8.85 (d, J=5 Hz, 1H);
  • [1260] 13C NMR (75 MHz, DMSO-d6) δ26.2 (CH3), 32.5 (CH2), 66.4 (CH2), 72.3 (CH2), 78.5 (CH),119.6 (CH), 126.7 (CH), 135.6 (C),137.3 (C), 137.8 (CH),144.3 (C), 148.6 (C), 161.1 (CO);
  • MS (APCI) m/e 279 (M+H)[1261] +, 313 (M+Cl)−.
    • EXAMPLE 100 ethyl 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate
  • A solution of Example 73 (120 mg, 0.33 mmol), palladium(II)acetate (1 mg, 0.05 mmol), 1,3-bis(diphenylphosphino)propane (20.6 mg, 0.05 mmol), and triethylamine (100 mg, 0.99 mmol) in DMF (6 mL) and ethanol (3 mL) were purged with carbon monoxide, heated at 105° C. under a carbon monoxide atmosphere (balloon) for 12 hours, treated with ether, washed sequentially with brine and water, dried (Na[1262] 2SO4), filtered, and concentrated. The residue was purified by flash chromatography (20% ethyl acetate/hexane) to provide the title compound.
  • MS (DCI/NH[1263] 3) m/z 358 (M+H)+.
    • EXAMPLE 101 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid
  • A solution of Example 100 (50 mg) in DMF (5 mL) and methanol (10 mL) was treated with a solution of NaOH (200 mg) in water (0.5 mL), stirred for 13 hours, treated sequentially with acetic acid (500 mg) and water, and filtered. The residue was recrystallized from DMF/water to provide the title compound. [1264]
  • MS (DCI/NH[1265] 3) m/z 315 (M+H)+;
  • [1266] 1H NMR (300 MHz, DMSO-d6) δ7.13 (dt, 1.8 Hz, 2H), 7.86 (br s, 1H), 7.98 (dt, 2H), 8.09 (s, 1H), 8.31 (s, 1H), 8.44 (br s, 1H), 9.22 (s, 1H);
  • Anal. calcd for C[1267] 15H10N2O4S: C, 57.32; H, 3.21; N, 8.91. Found: C, 57.32; H, 3.30; N, 8.92.
    • EXAMPLE 102 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 102A styrene α-boronic acid
  • A solution of α-bromo styrene (5.5 g, 30 mmol) in diethyl ether (30 mL) at −78° C. was treated with a solution of tert-BuLi (1.7 M solution, 21.2 mL, 36 mmol), stirred at −78° C. for 0.5 hours, treated with triisopropyl borate (8.31 mL, 36 mmol) over 48 minutes, stirred for 1 hour, warmed to room temperature over 18 hours, diluted with diethyl ether (100 mL), treated with 1M HCl (100 mL), stirred at room temperature for 5 hours, concentrated to remove the THF, adjusted pH 14 with 1N NaOH, washed with hexane, adjusted to pH 1 with 1M HCl, and extracted with ethyl acetate. The extract was dried (Na[1268] 2SO4), filtered and concentrated to provide the title compound.
  • [1269] 1H NMR (300 MHz, DMSO-d6) δ5.75 (d, 1H), 5.83 (d, 1H), 7.2-7.39 (m, 5H, Ar—CH).
    • EXAMPLE 102B methyl 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxylate
  • Example 93B and styrene-α-boronic acid were processed as in Example 95 to provide the title compound. [1270]
  • MS (APCI) m/z 296(M+H)[1271] +;
  • [1272] 1H NMR (400 MHz, DMSO-d6) δ3.84 (s, 3H), 5.56 (s, 1H), 5.95 (s, 1H), 7.31 (m, 2H), 7.36 (m, 3H), 7.47 (s, 1H), 8.5 (s, 1H), 9,40 (s, 1H);
  • [1273] 13C NMR (100 MHz, DMSO-d6) δ53.03 (OCH3), 118.37 (vinylic CH2), 126.79 (Ar—CH), 127.60 (Ar—CH), 128.38 (Ar—CH), 128.75 (Ar—CH), 132.55 (Ar—CH), 137.20 (C), 138.10 (C), 139.59 (C), 141.88 (C), 142.97 (3-CH), 144.03 (C), 145.39 (CH), 161.69 (CO).
    • EXAMPLE 102C 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 102B was processed as in Example 44 to provide the title compound. [1274]
  • MS (DCI) m/z 281 (M+H)[1275] +;
  • [1276] 1H NMR (400 MHz, DMSO-d6) δ5.53 (S, 1H), 6.04 (S, 1H), 7.31 (m, 2H), 7.35 (m, 3H), 7.72 (br s, 1H), 7.82 (s, 1H), 8.33 (s, 1H), 8.37 (br s, 1H), 9.29 (s, 1H);
  • [1277] 13C NMR (100 MHz, DMSO-d6) δ118.0 (CH2), 123.10 (CH), 126.73 (Ar—CH), 128.22 (CH), 128.60 (Ar—CH), 132.41 (C), 136.59 (C), 139.42 (C), 142.73 (3-CH), 143.41 (C), 144.01 (C), 144.66 (5-CH), 146.0 (C), 162.5 (CO).
    • EXAMPLE 103 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-methanol
  • A suspension of NaBH[1278] 4 (28 mg, 0.743 mmol) in 2:3 THF/ethanol (2 mL) was stirred at 0° C. for 10 minutes, treated with CaCl2 (41.2 mg, 0.37 mmol), stirred for 15 minutes, treated with a solution of Example 17C (117 mg, 0.37 mmol) in 2:3 THF/ethanol (3 mL), stirred at 0° C. for 4 hours, treated with 20% aqueous acetic acid (5 mL), and concentrated to remove the lower boiling solvents. The resulting mixture was adjusted to pH 7 with saturated NaHCO3 and extracted with ethyl acetate. The extract was dried (MgSO4), filtered, and concentrated. The residue was purified by column chromatography on silica gel eluting with 15% acetone/hexane to provide the title compound.
  • MS (DCI/NH[1279] 3) m/z 288 (M+H)+;
  • [1280] 1H NMR (500 MHz, DMSO-d6) δ2.25 (s, 3H), 4.80 (s, 2H), 5.90 (br s, 1H), 7.14 (d, 2H), 7.18 (d, 2H), 7.32 (s, 1H), 8.36 (s, 1H), 9.15 (s, 1H).
    • EXAMPLE 103A 4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 61A (100 mg, 0.3135 mmol) and methylamine (2M solution in THF, 0.467 mL, 0.941 mmol) in THF (2 mL) at 0° C. was treated with NaH (12 mg, 0.47 mmol), stirred at room temperature for 1 hour, treated with water (0.1 mL), and concentrated. The residue was purified by flash chromatography on silica gel with 20% acetone/hexane to provide the title compound. [1281]
  • MS (APCI) m/z 319 (M+H)[1282] +;
  • [1283] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H), 7.13 (d, 2H), 7.45 (d, 2H), 8.06 (s, 1H), 8.19 (s, 1H), 8.94 (d, 1H), 9.16 (s, 1H).
    • EXAMPLE 104 4-(4-chlorophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 6 1A and dimethylamine were processed as in Example 103A to provide the title compound. [1284]
  • MS (APCI) m/z 333 (M+H)[1285] +;
  • [1286] 1H NMR (300 MHz, DMSO-d6) δ3.03 (br s, 3H), 3.12 (br s, 3H), 7.17 (d, 2H), 7.46 (d, 2H), 7.62 (s, 1H), 8.18 (s, 1H), 9.15 (s, 1H).
    • EXAMPLE 105 4-(4-chlorophenoxy)-N,N-diethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and diethylamine were processed as in Example 103A to provide the title compound. [1287]
  • MS (APCI) m/z 361 (M+H)[1288] +;
  • [1289] 1H NMR (300 MHz, DMSO-d6) δ1.09 (m, 6H), 3.42 (m, 4H), 7.15 (d, 2H), 7.45 (d, 7.49 (s, 1H), 8.74 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 106 4-(4-chlorophenoxy)-N-cyclopropylthieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and cyclopropylamine were processed as in Example 103A to provide the title compound. [1290]
  • MS (APCI) m/z 345 (M+H)[1291] +;
  • [1292] 1H NMR (500 MHz, DMSO-d6) δ2.85 (m, 1H), 7.12 (d, 2H), 7.46 (d, 2H), 8.11 (s, 1H), 8.13 (s, 1H), 8.93 (d, 1H), 9.12 (s, 1H).
    • EXAMPLE 107 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]pyrrolidine
  • Example 61A and pyrrolidine were processed as in Example 103A to provide the title compound. [1293]
  • [1294]
  • MS (APCI) m/z 359 (M+H)[1295] +;
  • [1296] 1H NMR (400 MHz, DMSO-d6) δ1.83-1.93 (m, 4H), 3.53 (t, 2H), 3.71 (t, 2H), 7.17 (d, 2H), 7.47 (d, 2H), 7.70 (s, 1H), 8.16 (s, 1H), 9.12 (s, 1H).
    • EXAMPLE 108 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]piperidine
  • Example 61A and piperidine were processed as in Example 103A to provide the title compound. [1297]
  • MS (APCI) m/z 373 (M+H)[1298] +;
  • [1299] 1H NMR (400 MHz, DMSO-d6) δ1.52 (m, 3H), 1.62 (m, 2H), 3.53 (m, 5H), 7.14 (d, 2H), 7.46 (d, 2H), 7.47 (s, 1H), 8.20 (s, 1H), 9.14 (s, 1H).
    • EXAMPLE 109 4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]morpholine
  • Example 61A and morpholine were processed as in Example 103A to provide the title compound. [1300]
  • MS (APCI) m/z 375 (M+H)[1301] +;
  • [1302] 1H NMR (500 MHz, DMSO-d6) δ3.6 (m, 8H), 7.14 (d, 2H), 7.45 (d, 2H), 7.55 (s, 1H), 8.17 (s, 1H), 9.14 (s, 1H).
    • EXAMPLE 110 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-methylpiperazine
  • Example 61A and methylpiperazine were processed as in Example 103A to provide the title compound. [1303]
  • MS (APCI) m/z 388 (M+H)[1304] +;
  • [1305] 1H NMR (400 MHz, DMSO-d6) δ2.2 (s, 3H), 2.32 (br s, 4H), 8.58 (br s, 4H), 7.15 (dd, 1H), 7.47 (dd, 1H), 7.49 (s, 1H), 8.2 (d, 1H), 9.15 (s, 1H).
    • EXAMPLE 111 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-phenyllpiperazine
  • Example 61A and phenylpiperazine were processed as in Example 103A to provide the title compound. [1306]
  • MS (APCI) m/z 450 (M+H)[1307] +;
  • [1308] 1H NMR (500 MHz, DMSO-d6) δ3.18 (br s, 4H), 3.73 (br s, 4H), 6.81 (t, 1H), 6.95 (d, 2H), 7.15 (d, 2H), 7.24 (d, 2H), 7.46 (d, 2H), 7.57 (s, 1H), 8.20 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 112 1-[[4-(4-chlorophenoxy)thieno [2,3-c]pyridin-2-yl]carbonyl]-4-(phenylmethyl)piperazine
  • Example 61A and benzylpiperazine were processed as in Example 103A to provide the title compound. [1309]
  • MS (APCI) m/z 464 (M+H)[1310] +;
  • [1311] 1H NMR (500 MHz, DMSO-d6) δ2.38 (br s, 4H), 3.51 (s, 2H), 3.58 (br s, 4H), 7.13 (d, 2H), 7.32 (m, 5H), 7.45 (d, 2H), 7.47 (s, 1H), 8.91 (s, 1H), 9.13 (s, 1H).
    • EXAMPLE 113 1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(2-pyridinyl)piperazine
  • Example 61A and 2-pyridylpiperazine were processed as in Example 103A to provide the title compound. [1312]
  • MS (APCI) m/z 451 (M+H)[1313] +;
  • 1H NMR (500 MHz, CDCl[1314] 3-d) δ3.65 (br s, 4H), 3.85 (br s, 4H), 6.70 (m, 2H), 7.07 (d, 2H), 7.34 (d, 2H), 7.50 (s, 1H), 7.54 (m, 1H), 8.15 (s, 1H), 8.29 (m, 1H), 8.96 (s, 1H).
    • EXAMPLE 114 4-(4-chlorophenoxy)-N-(2-hydroxyethyl)lthieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and ethanolamine were processed as in Example 103A to provide the title compound. [1315]
  • MS (DCI/NH[1316] 3) m/z 349 (M+H)+;
  • [1317] 1H NMR (400 MHz, DMSO-d6) δ3.33 (m, 2H), 3.51 (m, 2H), 5.76 (t, 1H), 7.12 (d, 2H), 7.26 (d, 2H), 8.17 (s, 2H), 8.98 (br t, 1H), 9.14 (s, 1H);
  • [1318] 13C NMR (100 MHz, DMSO-d6) δ42.3 (N—CH2), 59.4 (O—CH2), 119.2 (CH), 119.3 (Ar—CH), 127.6 (C), 130.0 (Ar—CH), 133.2 (CH), 137.5 (C), 137.9 (C), 141.4 (CH), 146.4 (C), 147.1(C), 155.6 (C), 160.6 (CO).
    • EXAMPLE 115 4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-N-(1-methylethyl)-1-piperazineacetamide, trifluoroacetate (salt)
  • Example 61A and N-isopropylpiperazine acetamide were processed as in Example 103A to provide the title compound. The residue was purified by C-18 reverse phase HPLC with a gradient of 20% CH[1319] 3CN/water and 100% CH3CN containing 0.1% trifluoroacetic acid to provide the title compound.
  • MS (APCI) m/z 473 (M+H)[1320] +;
  • [1321] 1H NMR (400 MHz, DMSO-d6) δ1.09 (m, 6H), 3.05 (br s, 4H), 3.43 (s, 2H), 3.87 (br s, 4H), 7.16 (d, 2H), 7.67 (d, 2H), 7.68 (s, 1H), 8.20 (s, 1H), 9.18 (s, 1H).
    • EXAMPLE 116 4-(4-chlorophenoxy)-N-[1-(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and DL-2-amino-1-propanol were processed as in Example 103A to provide the title compound. [1322]
  • MS (APCI) m/z 363 (M+H)[1323] +, 361 (M−H)−, 397 (M+Cl)−;
  • [1324] 1H NMR (400 MHz, DMSO-d6) δ1.14 (d, 3H), 3.36-3.40 (m, 1H), 3.43-3.5 (m, 1H), 3.97-4.04 (m, 1H), 4.77 (t, 1H), 7.15 (d, 2H), 7.48 (d, 2H), 8.14 (s, 1H), 8.26 (d, 1H), 9.14 (s, 1H);
  • [1325] 13C NMR (100 MHz, DMSO-d6) δ16.87 (CH3), 47.74 (CH), 64.06 CH2OH), 119.16 (3-CH), CH), 119.46 (2×Ar—CH), 127.72 (C), 130.08 (2×Ar—CH), 132.84 (5-CH), 137.51 (C), 137.91 (C), 141.20 (7-CH), 146.62 (C), 147.28 (C), 155.53 (C), 160.01 (CO).
    • EXAMPLE 117 4-(4-chlorophenoxy)-N-[1,1-bis(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and 2-amino-2-methyl-1,3-propanediol were processed as in Example 103A to provide the title compound. [1326]
  • MS (APCI) m/z 393 (M+H)[1327] +, 391 (M−H)−, 393 (M+Cl)−;
  • [1328] 1H NMR (400 MHz, DMSO-d6) δ1.28 (s, 3H), 3.56-3.66 (m, 4H), 4.71 (t, 2H), 7.16 (d, 2H), 7.48 (d, 2H), 7.92 (s, 1H), 8.11 (s, 1H), 8.31 (s, 1H), 9.12 (s, 1H);
  • [1329] 13C NMR (100 MHz, DMSO-d6) δ18.45 (CH3), 59.80 (C), 63.08 (CH2), 119.46 (CH), 119.74 (2×Ar—CH), 127.83 (C), 130.09 (2×Ar—CH), 132.53 (CH), 137.43 (C), 137.84 (C), 140.99 (CH), 147.38 (C), 147.50 (C), 155.40 (C), 160.59 (CO);
    • EXAMPLE 118 (D,L)-4-(4-chlorophenoxy)-N-(2-hydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and DL-1-amino-2-propanol were processed as in Example 103A to provide the title compound. [1330]
  • MS (APCI) m/z 363 (M+H)[1331] + and 397 (M+Cl)−;
  • [1332] 1H NMR (400 MHz, DMSO-d6) δ1.08 (d, 3H), 3.21 (m, 2H), 3.75-3.84 (m, 1H), 4.8 (br s, 1H), 7.14 (d, 2H), 7.48 (d, 2H), 8.17 (s, 1H), 8.22 (s, 1H), 8.98 (br s, 1H), 9.15 (s, 1H),
  • [1333] 13C NMR (100 MHz, DMSO-d6) δ21.13 (CH3), 47.24 (CH2), 64.84 (CH), 119.30 (3-CH), CH), 119.42 (2×Ar—CH), 127.66 (C), 130.04 (2×Ar—CH), 133.05 (CH), 137.48 (C), 137.92 (C), 141.30 (CH), 146.37 (C), 147.16 (C), 155.58 (C), 160.59 (CO).
    • EXAMPLE 119 4-(4-chlorophenoxy)-N-[2-(4-morpholinyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 61A and 4-(2-aminoethyl)morpholine were processed as in Example 103A to provide the title compound. [1334]
  • MS (APCI) m/z 418 (M+H)[1335] +, 452 (M+Cl)−;
  • [1336] 1H NMR (400 MHz, DMSO-d6) δ2.41 (t, 4H), 2.48 (m, 2H), 3.40 (m, 2H), 3.56 (t, 4H), 7.15 (d, 2H), 7.47 (d, 2H), 8.13 (s, 1H), 8.17 (s, 1H), 8.94 (t, 1H), 9.04 (s, 1H);
  • [1337] 13C NMR (100 MHz, DMSO-d6) δ36.73 (N—CH2), 53.21 (morpholine ring 2×N—CH2), 57.07 (N—CH2), 66.12 (morpholine ring 2×-OCH2), 119.14 (3-CH), 119.50 (2×Ar—CH), 127.73 (C), 130.06 (2×Ar—CH), 132.96 (pyridyl ring CH), 137.35 (C), 137.91 (C), 141.29 (pyridyl ring CH), 146.20 (C), 147.20 (C), 155.40 (C), 160.45 (CO).
    • EXAMPLE 120 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide
  • To a solution of Example 124A (261 mg, 1 mmol) in anhydrous THF (5 mL) at −78° C. was added tert-BuLi (1.7 M solution in hexanes, 0.647 mL, 1.1 mmol) under nitrogen atmosphere. The reaction mixture was stirred at −78° C. for 15 minutes and SO[1338] 2 gas was bubbled into the solution for 15 minutes. Then this was stirred at −72° C. for 2.5 hours and at 0° C. for 4 hours. The reaction mixture was diluted with hexane (10 mL) and evaporated, and the residue obtained was suspended in CH2Cl2 (5 mL) and treated with N-chlorosuccinimide (214 mg, 1.6 mmol) at 0° C. After 2 hours at ambient temperature the reaction mixture was diluted with CH2Cl2, washed with 10% aqueous NaHSO3 solution (3×25 mL) followed by brine (3×25 mL). The dried (MgSO4) organic layer was evaporated to dryness under reduced pressure to obtain the crude sulfonyl chloride as an oil. This was dissolved in acetone (5 mL) and treated with ice cold solution of NH4OH (5 mL) at 0° C. After 2 hr at 0° C. reaction mixture was evaporated from toluene to obtain the crude product as an oil. The title compound (57 g, 16%) was obtained by flash chromatography on silica gel eluting with 20% acetone-hexane followed by 40% acetone-hexane.
  • [1339] 1H NMR (400 MHz, DMSO-d6) δ7.21 (d, J=9 Hz, 2H), 7.51 (d, J=9 Hz, 2H), 7.79 (s, 1H), 8.14 (br s, 2H), 8.30 (s, 1H), 9.27 (s, 1H);
  • [1340] 13C NMR (100 MHz, DMSO-d6) δ119.65 (CH), 120.88 (CH), 127.94 (C), 130.12 (CH), 133.67 (CH), 135.61 (C), 141.65 (CH)152.11 (C), 155.41 (C);
  • MS (APCI) m/e 341 (M+H)[1341] +, 339 (M−H)−, 375 (M+Cl)−.
    • EXAMPLE 121 4-[(4-methylphenyl)methyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 121A methyl 4-[(4-methylphenyl)methyl]thieno[2,3-c]pyridine-2-carboxylate
  • Example 121A is processed as in J. Org. Chem, 1988, 53, pp. 2392-2394. For example, a suspension of Zn dust (92 mg, 1.4 mM) in THF (2 ml) containing 1,2-dibromoethane (0.05 ml, 0.054 mmol) is heated at 65° C. for 2 minutes, cooled to 25° C., treated with trimethylsilyl chloride (0.009 ml, 0.043 mM), stirred at room temperature for 25 minutes, cooled to 0° C., slowly treated with a solution of 4-methylbenzyl bromide (0.248 mL, 1.0 mmol) in THF (5 mL), warmed to 40° C. for 3 hours, cooled to −10° C., treated with CuCN (106 mg, 1.18 mM) and LiCl (100 mg, 2.35 mM) in THF (10 mL), stirred at 0° C. for 30 minutes, treated slowly with a solution of Example 93B (272 mg, 1 mmol) in THF (5 mL), stirred at 0° C. for 3 hours, warmed to 25° C. over 18 hours, treated with ethyl acetate, washed sequentially with saturated NH[1342] 4Cl and brine, dried (MgSO4), filtered and concentrated. The residue is purified by flash chromatography on silica gel to provide the title compound.
    • EXAMPLE 121B 4-[(4-methylphenyl)methyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 121A is processed as in Example 44 to provide the title compound. [1343]
    • EXAMPLE 122 Methyl 4-(Morpholino)thieno[2,3-c]pyridine-2-carboxamide
  • Example 122 (241 mg, 72%) was prepared as described in Example 308, substituting 1,4-dioxo-8-azaspiro[4,5]decane (0.256 mL, 2 mmol) for 4-methylaniline. [1344]
  • [1345] 1H NMR (400 MHz, DMSO-d6) δ1.91 (m, 4H), 2.85 (d, J=4 Hz, 3H), 3.25 (m, 4H), 3.96 (s, 4H), 8.10 (s, 1H), 8.12 (s, 1H), 8.87 (s, 1H), 8.96 (d, J=4 Hz, 1H);
  • [1346] 13C NMR (100 MHz, DMSO-d6) δ26.1 (CH3), 35.0 (CH2); 49.7 (CH2), 63.8 (CH2), 69.8 (CH2), 106.1 (C), 121.3 (CH), 132.0 (CH), 136.9 (C), 138.3 (C), 138.7 (CH), 143.6 (C), 143.8 (C), 161.3 (C);
  • MS (APCI) m/e 334 (M+H)[1347] +, 368 (M+Cl)−.
    • EXAMPLE 123 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, N-oxide EXAMPLE 123A methyl (4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-oxide
  • A solution of methyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate (319 mg, 1 mmol) in dichloromethane (15 mL) at 0° C. was treated with 3-chloroperoxybenzoic acid (302 mg, 1.75 mmol), stirred 0.5 hours at 0° C. and 4 hours at room temperature washed sequentially with water, saturated sodium bicarbonate, water, and brine, dried (Na[1348] 2SO4), filtered and concentrated to provide the title compound.
  • MS (DCI/NH[1349] 3) m/z 336 (M+H)+;
  • [1350] 1H NMR (300 MHz, DMSO-d6) δ3.89 (s, 3H), 7.30 (m, 2H), 7.52 (m, 2H), 7.84 (s, 1H), 7.88 (s, 1H), 9.02 (s, 1H).
    • EXAMPLE 123B 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, N-oxide
  • Example 123A was processed as in Example 44 to provide the title compound. [1351]
  • [1352] 1H NMR (300 MHz, DMSO-d6) δ7.30 (m, 2H), 7.52 (m, 2H), 7.74 (d, 1H), 7.81 (br s, 1H), 8.10 (s, 1H), 8.34 (br s, 1H), 8.93 (s, 1H).
    • EXAMPLE 124 4-(4-chlorophenoxy)-2-(2-methoxyphenyl)thieno[2,3-c]pyridine EXAMPLE 124A 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine
  • Example 88 (4.5 g, 14.75 mmol) was added to a solution of diphenyl ether (55 ml) at 210° C. and kept at this temperature for 10 hours. The cooled reaction mixture was directly purified by flash chromatography on silica gel eluting with hexane followed by 10% acetone-hexane to obtain the title compound (3.83 g, 99.5%). [1353]
  • mp 87-89° C.; [1354]
  • MS (DCI/NH) m/e 262 (M+H)[1355] +;
  • [1356] 1H NMR (300 MHz, DMSO-d6) δ7.09 (d, J=9 Hz, 2H), 7.35 (d, J=6 Hz, 1H), 7.45 (d, J=9 Hz, 2H), 8.13 (d, J=6 Hz, 1H), 8.18 (s, 1H), 9.15 (s, 1H);
  • Anal. calcd for C[1357] 13H8Cl1N1O1S1: C, 59.66; H, 3.08; N, 5.35. Found: C, 59.52; H, 3.08; N, 5.15.
    • EXAMPLE 124B 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-boronic acid
  • A solution of sec-butyllithium (0.92 mmol) in THF (2 mL) at −78° C. was treated dropwise with Example 124A in THF (1 mL), stirred at −78° C. for 30 minutes, treated dropwise with tributylborate, stirred for 5 minutes at −78° C., stirred at room temperature for 45 minutes, treated with 2M NaOH (3 mL), stirred for 5 minutes, washed with hexanes, and acidified to pH 2 with 6M HCl. The precipitate that found was collected and dried under vacuum to provide the title compound. [1358]
  • MS (APCI) m/z 262, 264 (M+H—B(OH)[1359] 2)+, 340, and 342 (M+Cl−)−,
  • [1360] 1H NMR (300 MHz, CD3OD) δ7.29 (d, 2H), 7.53 (d, 2H), 8.08 (s, 1H), 8.11 (s, 1H), 9.40 (s, 1H).
    • EXAMPLE 124C 4-(4-chlorophenoxy)-2-(2-methoxyphenyl)thieno[2,3-c]pyridine
  • Example 124B is processed as in Example 95 but substituting of 2-iodoanisole for Example 93B and Example 124B for 4-(trifluoromethyl)phenylboronic acid to provide the title compound. [1361]
    • EXAMPLE 125 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 125A Methyl 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylate
  • 4-Chlorophenol was dissolved in THF (20 mL) and treated with 1 M potassium t-butoxide (13 mL, 13 mmol) and stirred at room-temperature for 1 hour. To this solution was added Example 17A (1.76 g, 10 mmol) in THF (5 mL). The reaction was heated at 70° C. for 4 hours, and cooled to room temperature. Poured into water diluted with brine and extracted with ethyl acetate. The ethyl acetate was then washed (3×20 mL), dried and evaporated. The residue was dissolved in THF (20 mL) and cooled in an ice bath, to which 3 M methyl magnesium bromide in ethyl ether (4 mL, 12 mmol) was added. The reaction was stirred at room temperature overnight. The excess Grignard reagent was decomposed with a saturated ammonia chloride solution (25 mL) and then extracted with ethyl acetate (3×25 mL). The ethyl acetate was washed with brine (3×25 mL), dried and evaporated to give the desired phenoxy alcohol. This alcohol was then subjected to an Swern oxidation, using the following conditions. To a solution of oxalyl chloride (1.1 mL, 12 mmol) in anhydrous methylene chloride (20 ml) cooled to −78° C. was added dimethylsulfoxide (1.85 mL, 24 mmol) over 30 minutes. Then a solution of the above phenoxy alcohol in methylene chloride (20 mL) was added over 15 minutes. Triethylamine (7.5 mL) was added and the reaction allowed to come to room temperature over 2 hours. Ice water was then added and the mixture was extracted with ethyl acetate. The ethyl acetate was washed with brine (3×20 mL), dried and evaporated. To a 0° C. solution of this residue in THF (20 mL) was added methyl thioglycolate (0.88 mL, 10 mmol) and cesium carbonate (3.2 g, 10 mmol). The reaction was then heated at 70° C. for 1 hour, cooled, poured into water, diluted with brine and extracted with ethyl acetate. The ethyl acetate was then washed with 1 N NaOH (2×20 mL), brine (3×20 mL), dried and evaporated to give an oil. This oil was triturated with methanol to give the desired compound. [1362]
  • mp 140-141° C.; [1363]
  • MS (DCI/NH[1364] 3) m/e 334 (M+H)+;
  • [1365] 1H NMR (300 MHz, DMSO-d6) δ2.80 (s, 3H), 3.90 (s, 3H), 7.22 (d, 2H), 7;45 (d, 2H), 8.12 (s, 1H), 9.15 (s, 1H);
  • Anal. Calcd for C[1366] 16H12ClNO3S.0.5 H2O: C, 56.06; H, 3.82; N, 4.09. Found: C, 56.03; H, 3.43; N, 3.71.
    • EXAMPLE 125B 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid
  • A solution of Example 125A (1.1 g, 3.3 mmol) and LiOH.H[1367] 2O (0.30 g, 6.9 mmol) in THF (20 mL) and H2O (10 mL) was heated at 50° C. for 1 hour, then cooled, acidified with formic acid, and extracted with ethyl acetate. The ethyl acetate extract was washed with brine (3×15 mL), then dried and evaporated to give the desired product as white solid.
  • mp 315-317° C.; [1368]
  • MS (DCI/NH[1369] 3) m/e 320 (M+H)+;
  • [1370] 1H NMR (300 MHz, DMSO-d6) δ2.76 (s, 3H), 3.30 (m, 1H), 7.10 (d, 2H), 7.45 (d, 2H), 8.12 (s, 1H), 9.15 (s, 1H);
    • EXAMPLE 125C 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 125B was processed as in Example 92 to provide the title compound. [1371]
  • mp 174-175° C.; [1372]
  • MS (DCI/NH[1373] 3) m/e 319 (M+H)+;
  • [1374] 1H NMR (300 MHz, DMSO-d6) δ2.55 (s, 3H), 7.05 (d, 2H), 7.45 (d, 2H), 7.90 (m, 1H), 7.95 (m, 1H), 8.15 (s, 1H), 9.12 (s, 1H);
  • Anal. calcd for C[1375] 15H11ClN2O2S: C, 56.52; H, 3.48; N, 8.79. Found: C, 56.36; H, 3.50; N, 8.69.
    • EXAMPLE 126 4-(4-chlorophenoxy)-3-hydroxythieno[2,3-c]pyridine-2-carboxamide EXAMPLE 126A ethyl 3,5-dichloropyridine-4-carboxylate
  • To a stirred solution of lithium diisopropylamide (45 mL, 1.5 M in THF, 67.6 mmol) in 150 mL THF at −78° C. is treated with 3,5-dichloropyridine (10 g, 67.6 mmol) in 40 mL THF over 1.5 hours, stirred for 1 hour at −78° C., treated with ethyl chloroformate (9.5 mL, 100 mmol), stirred for 2 hours, transferred into saturated sodium bicarbonate (200 ml) at 0° C., treated with diethyl ether (200 ml), and extracted with ethyl ether (2×100 mL). The extract is washed sequentially with saturated sodium bicarbonate solution (2×100 mL), brine (2×100 mL), dried (MgSO[1376] 4), and concentrated. The residue is purified by flash chromatography on silica gel with hexane/ethyl acetate to provide the title compound.
    • EXAMPLE 126B methyl 4-(4-chlorophenoxy)-3-hydroxythieno[2,3-c]pyridine-2-carboxylate
  • Example 126A is treated as in Example 61A to provide the title compound. [1377]
    • EXAMPLE 126C 4-(4-chlorophenoxy)-3-hydroxythieno[2,3-c]pyridine-2-carboxamide
  • Example 126B is treated as in Example 61B to provide the title compound. [1378]
    • EXAMPLE 127 4-(4-chlorophenoxy)-3-(1-methylethoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 127 is processed as in J. Medicinal. Chem. 1992, 35, p. 958. Example 126C (0.10 g, 0.3 mmol) in 50 ml of THF and cesium carbonate (1.0 g, 0.1 mmol) are treated with 2-bromopropane (0.37 g, 0.3 mmol), heated for 2 hours, poured on ice, extracted with ethyl ether, washed sequentially with 1 N aqueous sodium hydroxide and brine, and concentrated. The residue is purified by flash chromatography on silica gel with hexane-acetone (7:3) to provide the title compound. [1379]
    • EXAMPLE 128 3-bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine
  • The method described in (Arkiv For Kemi (1970-74), 32, p. 249) may be adapted. Example 124A in thionyl chloride is treated with bromine at 90° C. for 4 hours to provide the title compound. [1380]
    • EXAMPLE 129 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylic acid
  • The method described in (Arkiv For Kemi (1970-74), 32, p. 249) may be adapted. Example 128 cooled to −78° C. is treated with ethyllithium followed by reaction with carbon dioxide to provide the title compound. [1381]
    • EXAMPLE 130 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxamide
  • Example 129 may be treated as in Example 19 to provide the title compound. [1382]
    • EXAMPLE 131 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 131A 3,5-Dichloropyridine-4-carbonitrile
  • Example 17A (2.0 g, 11.4 mmol) in formic acid (10 mL) is treated with hydroxylamine hydrochloride (1.04 g, 11.4 mmol) and concentrated sulfuric acid (0.05 mL), stirred at reflux for 18 hours and concentrated. The residue was partitioned between 1:1 ethyl acetate-water, and washed sequentially with saturated sodium bicarbonate, water, brine, dried (Na[1383] 2SO4), and concentrated. The residue is recrystallized from hexanes to provide the title compound.
  • mp 117-118° C.; [1384]
  • [1385] 1H NMR (300 MHz, CDCl3) δ8.70 (s);
  • IR (KBr, v cm[1386] −1) 1710, 1525, 1400, 1250, 1190, 1100, 920, 820, 800, 750.
    • EXAMPLE 131B methyl 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • A solution of 4-chlorophenol (1.12 g, 8.72 mmol) in THF (20 mL) at 0° C. is treated with a solution of potassium t-butoxide (8.72 mL, 8.72 mmol, 1 M in THF), stirred at 0° C. for 1 hour, treated with Example 131A (1.5 g, 8.72 mmol) in THF (10 mL) at 0° C., warmed to room temperature, stirred overnight, concentrated, partitioned between 1:1 ethyl acetate-water, and extracted. The extract is washed with brine, dried (Na[1387] 2SO4), and concentrated. A solution of concentrate in DMF (50 mL) at 0° C. was treated with potassium carbonate (2.42 g, 17.51 mmol) and methyl thioglycolate (778 μL, 8:72 mmol), warmed to room temperature, stirred overnight, and poured into ether (400 mL). The organic layer was washed with brine, dried (Na2SO4), and concentrated. The residue was purified by flash chromatography on silica gel with 0-5% acetone-hexane to provide the title compound.
  • mp 194-196° C.; [1388]
  • MS (APCI) m/z 335 (M+H)[1389] +;
  • [1390] 1H NMR (300 MHz, DMSO-d6) δ3.81 (s, 3H), 6.86 (br s, 2H), 7.22-7.32 (m, 2H), 7.45-7.56 (m, 2H), 7.88 (s, 1H), 8.89 (s, 1H);
  • Anal. Calcd for C[1391] 15H11ClN2O3S: C, 53.81; H, 3.31; N, 8.36. Found: C, 53.80; H, 3.27; N, 8.27.
    • EXAMPLE 131C 3-Amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid
  • The title compound was prepared from Example 131B using the procedure of Example 18. [1392]
  • mp 173-176° C. (dec); [1393]
  • [1394] 1H NMR (300 MHz, DMSO-d6) δ7.29.(m, 2H), 7.52 (m, 2H), 7.88 (s, 1H), 8.89 (s, 1H);
  • MS (ESI) m/e 321 (M+H)[1395] +;
  • Anal. Calcd for C[1396] 14H9ClN2O3S.0.25H2O: C, 51.70; H, 2.94; N, 8.61. Found??
    • EXAMPLE 131D 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 131C (96 mg, 0.3 mmol) in DMF (2 mL) is treated with 1-hydroxybenzotriazole hydrate (67 mg, 0.44 mmol), NH[1397] 4Cl (61 mg, 1.14 mmol) and 4-methylmorpholine (100 μL, 0.9 mmol), cooled to 0° C., treated with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (86 mg, 0.45 mmol), warmed to room temperature, stirred overnight, poured into saturated NaHCO3, collected, washed with water and dried. The residue is recrystallized from methanol/toluene/hexanes to provide the title compound.
  • mp 202-204° C.; [1398]
  • MS (APCI) m/z 320 (M+H)[1399] +;
  • [1400] 1H NMR (300 MHz, DMSO-d6) δ6.84 (br s, 2H), 7.21-7.30 (m, 2H), 7.39 (br s, 2H), 7.47-7.56 (m, 2H), 7.88 (s, 1H), 8.90 (s, 1H);
  • Anal. Calcd for C[1401] 14H10ClN3O2S: C, 52.58; H, 3.15; N, 13.14. Found: C, 52.63; H, 3.18; N, 13.12.
    • EXAMPLE 132A ethyl 4-chlorothieno[2,3-b]pyridine-5-carboxylate
  • Example 132A was processed as in J. Heterocyclic Chem. 1977, 14, pp. 807-812 to provide the title compound. [1402]
  • mp 71-72° C.; [1403]
  • MS (DCI/NH[1404] 3) m/z 259 (M+H)+; 242 (M+NH4)+;
  • [1405] 1H NMR (300 MHz, DMSO-d6) δ1.37 (t, 3 H), 4.41 (q, 2 H), 7.64 (d, 1 H), 8.17 (d, 1 H), 8.95 (s, 1 H);
  • Anal. calcd for C[1406] 10H8ClNO2S: C, 49.69; H, 3.33; N, 5.79; S, 13.26. Found: C, 49.46; H, 3.13; N, 5.62; S, 13.42.
    • EXAMPLE 132B ethyl 4-[(4-methylphenyl)thio]thieno[2,3-b]pyrridine-5-carboxylate
  • Example 132A and thiocresol were processed as in Example 2 to provide the title compound. [1407]
  • mp 60-63° C.; [1408]
  • MS (DCI/NH[1409] 3) m/z 347 (M+NH4)+ and 330 (M+H)+;
  • [1410] 1H NMR (300 MHz, DMSO-d6) 1.30 (t, 3H), 2.28 (s, 3H), 4.26 (q, 2H), 7.00 (d, 1H), 7.17 (m, 2H), 7.24 (m, 2H), 7.91 (d, 1H), 8.81 (s, 1H);
  • Anal. calcd for C[1411] 17H15NO2S2: C, 61.98, H 4.59; N, 4.25. Found C, 61.92, H, 4.53, N, 4.21.
    • EXAMPLE 132C 4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine
  • Example 132B was processed as in Example 18 and 42 to provide the title compound. [1412]
  • mp 90-92° C.; [1413]
  • MS (DCI/NH[1414] 3) m/z 275 (M+NH4)+ and 258 (M+H)+;
  • [1415] 1H NMR (300 MHz, DMSO-d6) δ2.39 (s, 3 H), 6.66 (d, 1 H), 7.38 (m, 2 H), 7.46 (d, 1 H), 7.53 (m, 2 H), 7.46 (d, 1 H), 7.53 (m, 2 H), 7.95. (d, 1 H), 8.12 (d, 1 H);
  • Anal. calcd for C[1416] 14H11NS2: C, 65.33; H, 4.30; N, 5.44. Found: C, 65.40; H, 4.26, N, 5.26.
    • EXAMPLE 132D 4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide
  • Diisopropylamine (0.056 g, 0.56 mmol) in THF (10 mL) at −78° C. was treated with n-butyllithium (0.22 mL, 0.56 mmol, 2.5 M in hexanes), stirred for 15 minutes, treated with Example 132C (0.13 g, 0.51 mmol) in THF (5 mL), stirred for 0.5 hours, warmed to 0° C. for 1 minutes, recooled to −78° C., poured onto solid CO[1417] 2, stirred for 0.5 hours, diluted with saturated NH4Cl, and extracted with ethyl acetate. The extract was washed with brine, dried (MgSO4) and concentrated to provide the title compound.
  • mp 280-282° C.; [1418]
  • MS (DCI/NH[1419] 3) m/z 318 (M+NH4)+ and 301 (M+H)+;
  • [1420] 1H NMR (300 MHz, DMSO-d6) δ2.41 (s, 3 H), 6.62 (d, 1 H), 7.40 (m, 2 H), 7.57 (m, 2 H), 7.77 (br s, 1 H), 8.26 (s, 1 H), 8.36 (d, 1 H), 8.43 (br s, 1 H);
  • Anal. calcd for C[1421] 15H12N2OS2: C, 59.97; H, 4.02; N, 9.32. Found: C, 59.83; H, 4.03 N, 9.11.
    • EXAMPLE 133 4-chloro-N-(4-chlorophenyl)thieno[2,3-b]pyridine-5-carboxamide
  • Example 132A was processed as in examples 18 and 19 but substituting 4-chloroaniline for concentrated NH[1422] 4OH in Example 19 to provide the title compound.
  • mp 199-202° C.; [1423]
  • MS (DCI/NH[1424] 3) m/z 340 (M+NH4)+, 342 (M+NH4)+, 323 (M+H)+, 325 (M+H)+;
  • [1425] 1H NMR (300 MHz, DMSO-d6) δ7.6 (m, 2H), 7.62 (d, 1H), 7.77 (m, 2H), 8.19 (d, 1H), 8.79 (s, 1H);
  • Anal. calcd for C[1426] 14H8Cl2N2OS2: C, 52.03; H, 2.49; N, 8.67. Found: C, 52.02; H, 2.15; N, 8.50.
    • EXAMPLE 134 ethyl 4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-b]pyridine-5-carboxylate
  • Example 132A and 5-methyl-1,3,4-thiadiazol-2-thiol were processed as in Example 17B to provide the title compound. [1427]
  • mp 93-94° C.; [1428]
  • MS (DCI/NH[1429] 3) m/z 355 (M+NH4)+ and 238 (M+H)+;
  • [1430] 1H NMR (300 MHz, DMSO-d6) δ1.32 (t, 3 H), 2.66 (s, 3H), 4.36 (q, 2 H), 7.34 (d, 1H), 8.13 (d, 1H), 9.00 (s, 1 H);
  • Anal. calcd for C[1431] 13H11N3O2S3: C, 46.27; H, 3.28; N, 12.45; S, 28.50. Found: C, 46.04; H, 3.20; N, 12.32; S, 28.39.
    • EXAMPLE 135 7-[(4-methylphenyl)thio]thieno[3,2-b]pyridine-2-carboxamide
  • Ethyl 7-chlorothieno[3,2-b]pyridine-6-carboxylate was processed as in Example 17B, 18, and 19 to provide the title compound. [1432]
  • MS (DCI/NH[1433] 3) m/z 301 (M+H)+;
  • [1434] 1H NMR (300 MHz, DMSO-d6) δ2.38 (s, 3H), 6.83 (d, 1H), 7.37 (m, 2H), 7.56 (m, 2H), 7.83 (br s, 1H), 8.25 (s, 1H), 8.41 (br s, 1H), 8.53 (d, 1H);
  • Anal. calcd for C[1435] 15H12N2OS2: C, 59.98; H, 4.03; N, 9.33. Found: C, 59.79; H, 4.01; N, 9.16.
    • EXAMPLE 136 methyl 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxylate EXAMPLE 136A 2,6,dichloro-3-pyridinecarbonitrile EXAMPLE 136B methyl 3-amino-6-chlorothieno[2,3-b]pyridine-2-carboxylate
  • Example 136A and methyl thioglycolate were processed as in Example 1D to provide the designated compound. [1436]
    • EXAMPLE 136C methyl 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxylate
  • Example 136B (32 g, 1.34 mmol) in 75% H[1437] 2SO4 (7.4 mL) at 0° C. was treated dropwise with aqueous NaNO2 (0.24 g/1.5 mL, 3.5 mmol), stirred for 30 minutes, poured into cold 50% H2PO3 (11.8 mL), stirred for 30 minutes, stored at 0° C. for 60 hours, warmed to room temperature, treated with NaHCO3, and extracted with ether. The extract was dried (MgSO4), filtered, and concentrated. The residue was dissolved in methanol (7 mL), heated to 50° C., treated sequentially with NaOCH3 (0.08 g, 1.45 mmol) and p-thiocresol (0.18 g, 1.45 mmol), stirred at room temperature for 18 hours, and concentrated. The residue was treated with 10% citric acid and extracted with dichloromethane. The extract was dried (MgSO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel with 25% ethyl acetate/hexanes to provide the title compound.
  • mp 127-130° C.; [1438]
  • MS (DCI/NH[1439] 3) m/z 316 (M+H)+;
  • [1440] 1H NMR (300 MHz, DMSO-d6) 2.39 (s, 3H), 3.89 (s, 3H) 7.02 (d, 7.36 (m, 2H), 7.57 (m, 2H), 8.13 (s, 1H), 8.23 (d, 1H);
  • Anal. calcd for C[1441] 16H13NO2S2: C, 60.93; H, 4.15; N, 4.44. Found: C, 60.79; H, 4.18; N, 4.35.
    • EXAMPLE 137 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide
  • The title compound can be prepared from Example 136C using the procedure of Example 44. [1442]
    • EXAMPLE 138 2-bromo-4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine
  • Para-thiocresol (500 mg, 4 mmol) in DMF (10 mL) was treated with potassium t-butoxide (451 mg, 4 mmol) at room temperature, after 15 minutes cooled to 0° C., treated with 2-bromo-4-chlorothieno[3,2-c]pyridine (prepared in 6 steps according to the method of F. Eloy and A. Deryckere (Bull. Soc. Chim. Belg. 1970, 79, 301)(1.0 g, 4.0 mmol), stirred at 0° C. for 2 hours and at room temperature for 12 hours, poured into water and extracted with diethyl ether. The extract was washed with water, dried (Na[1443] 2SO4), and concentrated under vacuum. The residue was purified by flash chromatography on silica gel with 1:20 ethyl acetate-hexane to provide the title compound.
  • MS (DCI/NH[1444] 3) m/z 336, 338 (M+H)+;
  • [1445] 1H NMR (300 Hz, CDCl3) δ2.36 (s, 3H), 7.18(d, 2H), 7.40 (d, 2H), 7.48 (br s, 1H), 7.52 (br d, 1H), 8.16 (d, 1H).
    • EXAMPLE 139 4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carboxamide EXAMPLE 139A 4-chlorothieno[3,2-c]pyridine-2-carbonitrile
  • A solution of 4-oxo-4,5-dihydrothieno[3,2-c]pyridine-2-nitrile (500 mg, 2.84 mmol) prepared as in F. Eloy and A. Deryckere, Bull. Soc. Chim. Belg. 1970, 79, 301) and phosphoryl chloride (5 mL) was heated at reflux for 1 hour. The formed red solution was poured onto ice and extracted with methylene chloride (2×150 mL). The dichloromethane solution was dried over anhydrous Na[1446] 2SO4, filtered, and concentrated. The residue was purified by flash chromatography with 1:10 EtOAc/hexanes to provide the title compound.
  • MS (DCI/NH[1447] 3) m/z 195 (M+H)+;
  • [1448] 1H NMR (300MHz, CDCl3) δ7.74 (d, 1H), 8.10 (s, 1H), 8.41 (d, 1H).
    • EXAMPLE 139B 4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carbonitrile
  • Para-thiocresol (192 mg, 1.54 mmol) in DMF (5 mL) at room temperature was treated with potassium tert-butoxide (173 mg, 1.54 mmol), stirred for 15 minutes, cooled to 0° C., treated with Example 139A (200 mg, 1.03 mmol), stirred first at 0° C. and then at room temperature for 48 hours, treated with water, and extracted with dichloromethane. The extract was dried (MgSO[1449] 4), filtered, and concentrated. The residue was purified by flash chromatography on silca gel with 1:7 ethyl acetate-hexane to provide the title compound.
  • IR (KBr, cm[1450] −1) 2200 (w, CN), 1550 (s), 1520 (s) cm−1;
  • MS (DCI/NH[1451] 3) m/z 283 (M+H)+;
  • [1452] 1H NMR (300 MHz, CDCl3) δ2.40 (s, 3H), 7.25 (d, 2H), 7.47 (d, 2H), 7.49 (d, 1H), 8.07 (s, 1H), 8.33 (d, 1H);
  • Anal. calcd for C[1453] 15H10N2S2: C, 63.80; H, 3.57; N, 9.92. Found: C, 63.80; H, 3.52; N, 9.98.
    • EXAMPLE 139C 4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carboxamide
  • Example 139B (198 mg, 0.7 mmol) in polyphosphoric acid (5 mL) was heated at 110° C. for 3 hours, cooled, treated with water, and extracted with dichloromethane. The extract was dried (MgSO[1454] 4), filtered, and concentrated. The residue was purified by flash chromatography on silca gel with 4:5 ethyl acetate-hexane to provide the title compound.
  • IR (KBr) 3300 (m), 3130 (s), 1660 (s), 1600 (s); [1455]
  • MS (DCI/NH[1456] 3) m/z 301 (M+H)+;
  • [1457] 1H NMR (300 MHz, DMSO-d6) δ2.36 (s, 3H), 7.28 (d, 2H), 7.47 (d, 2H), 7.78 (br s, 1H), 7.84 (d, 1H), 8.19 (d, 1H), 8.34 (s, 1H), 8.46 (br s, 1H);
  • Anal. calcd for C[1458] 15H12N2OS2: C, 59.98; H, 4.03; N, 9.33. Found: C, 59.77; H, 3.88; N, 9.15.
    • EXAMPLE 140 4-(4-methylphenoxy)thieno[3,2-c]pyridine-2-carboxamide EXAMPLE 140A 4-(4-methylphenoxy)thieno[3,2-c]pyridine-2-carbonitrile
  • Example 139A and 4-methylphenol were processed as in Example 139B to provide the title compound. [1459]
  • IR (KBr) 2200 (w), 1580 (s), 1540 (s), 1500 (s), 1440 (s) cm[1460] −1;
  • MS (DCI/NH[1461] 3) m/z 267 (M+H)+;
  • [1462] 1H NMR (300 MHz, CDCl3) δ2.39 (s, 3H), 7.09 (dt, 2H), 7.25 (br d, 2H), 7.43 (dd, 1H), 8.10 (d, 1H), 8.21 (s, 1H);
  • Anal. calcd for C[1463] 15H10N2OS: C, 67:65; H, 3.78; N, 10.52. Found: C, 67.60; H, 3.66; N, 10.48.
    • EXAMPLE 140B 4-(4-methylphenoxy)thieno[3,2-c]pyridine-2-carboxamide
  • Example 140A was processed as in Example 139C to provide the title compound. [1464]
  • IR (KBr) 3400 (m), 1680 (m), 1650 (s), 1600 (s), 1500 (s) cm[1465] −1;
  • MS (DCI/NH[1466] 3) m/z 285 (M+H)+;
  • [1467] 1H NMR (300 MHz, DMSO-d6) δ2.34 (s, 3H), 7.13 (d, 2H), 7.25 (d, 2H), 7.75 (d, 1H), 7.76 (br s, 1H), 7.95 (d, 1H), 8.38 (br s, 1H), 8.41 (s, 1H);
  • Anal. calcd for C[1468] 15H12N2O2S: C, 63.36; H, 4.25; N, 9.85. Found: C, 63.16; H, 4.18; N, 9.77.
    • EXAMPLE 141 7-(4-methylphenoxy)oxazolo[5,4-c]pyridine-2-carboxamide EXAMPLE 141A 3-chloropyridine-N-oxide
  • Example 141A was processed as in Caldwell and Martin (J. Heterocyclic Chem., 1980, 17, 989). A solution of 3-chloropyridine (15.0 g, 132 mmol) in acetic anhydride (75 mL) with cooling to maintain an internal temperature below 30° C. was treated with hydrogen peroxide (75 mL of 30% aqueous solution), stirred at room temperature for 3 hours, heated at 60° C. for 18 hours, diluted with water (200 mL), concentrated, and solid sodium bisulfite added in portions until peroxides could no longer be detected (by enzymatic peroxide test), and the remaining solvent was removed tinder reduced pressure. The residue was triturated With ethyl acetate. The washes were filtered and concentrated to provide the designated compound. [1469]
    • EXAMPLE 141B 4-nitro-3-chloropyridine-N-oxide
  • Example 141B was processed as in Caldwell and Martin (J. Heterocyclic Chem., 1980, 17, 989). Example 141A (16.8 g, 130 mmol) in sulfuric acid (25 μL, 98%), fuming sulfuric acid (30% SO[1470] 3, 10 mL), and nitric acid (60 mL, 90%) was heated at 120° C. for 2 hours, cooled to room temperature, poured into ice water (200 mL), solid ammonium carbonate was added to bring the solution to pH 9, and extracted with methylene chloride (4×100 mL). The extracts were dried (Na2SO4) and concentrated. The residue was recrystallized from ethyl acetate-hexanes to provide a clean first crop of the title compound. Second crop recrystallizations provided mixtures of title compound and side products.
  • MS (DCI/NH[1471] 3) m/z 194 (37Cl)/192 (35Cl), (M+NH4)+; 177 (37Cl)/175 (35Cl), (M+H)+;
  • [1472] 1H NMR (CDCl3, 300 MHz) δ8.01 (d, 1H), 8.14 (dd, 1H), 8.32 (d, 1H).
    • EXAMPLE 141C 4-nitro-3-(4-methylphenoxy)pyridine-N-oxide
  • NaH (834 mg, 34.8 mmol) in DMF (20 mL) at room temperature was treated sequentially with p-Cresol (3.57 g, 33.0 mmol) Example 141 (5.75 g, 32.9 mmol), stirred for 10 minutes at room temperature and partitioned between ethyl acetate and 1 N aqueous HCl. The aqueous phase was separated and washed with ethyl acetate. The organic phases were washed with 1 N aqueous HCl, dried (Na[1473] 2SO4), and concentrated. Recrystallization from diethyl ether provided the title compound.
  • MS (DCI/NH[1474] 3) m/z 264 (M+NH4)+, 247 (M+H)+;
  • [1475] 1H NMR (CDCl3, 300 MHz) δ2.39 (s, 3H), 7.02 (d, 2H), 7.26 (d, 2H),; 7.78 (d, 1H), 7.89 (dd, 1H), 7.98 (d, 1H).
    • EXAMPLE 141D 3-(4-methylphenoxy)-4-pyridinamine
  • Example 141C (3.65 g, 14.8 mmol) was dissolved in methanol (100 mL), treated with raney nickel (1.00 g), flushed with hydrogen, pressurized to 4 atm., at 37° C. for 2.5 hours, and filtered. The filtrate was concentrated to provide the title compound. [1476]
  • MS (DCI/NH[1477] 3) m/z 201 (M+H)+;
  • [1478] 1H NMR (CDCl3, 300 MHz) δ2.32 (s, 3H), 4.40 (br s, 2H), 6.68 (br s, 1H), 6.88 (d, 2H), 7.12 (d, 2H), 8.01 (m, 2H).
    • EXAMPLE 141E 2,2-dimethyl-N-[3-(4-methylphenoxy)-4-pyridinyl]propionamide
  • Example 141D (2.80 g, 14.0 mmol) was dissolved in methylene chloride (50 mL), cooled to 0° C., treated sequentially with triethylamine (1.78 g, 17.6 mmol) and trimethylacetyl chloride (1.86 g, 15.4 mmol), stirred at room temperature for 15 hours, and poured into water (100 mL) containing a trace of sodium chloride. The organic layer was separated, treated with activated charcoal, filtered through Celite®, washed with saturated sodium bicarbonate, dried (Na[1479] 2SO4), and concentrated to provide the title compound.
  • MS (DCI/NH[1480] 3) m/z 285 (M+H)+;
  • [1481] 1H NMR (CDCl3, 300 MHz) δ1.24 (s, 9H), 2.35 (s, 3H), 6.93 (d, 2H), 7.18 (d, 2H), 8.14 (brs, 1H), 8.15 (s, 1H), 8.32 (d, 1H), 8.42 (d, 1H).
    • EXAMPLE 141F 5-Hydroxy-4-(N-trimethylacetyl)amino-3-(4-methylphenoxy)pyridine
  • The procedure of Chu-Moyer and Berger ([1482] J. Org. Chem. 1995, 60, 5721) was adapted. Example 141E (5.50 g, 19.3 mmol) was dissolved in diethyl ether and cooled to −78° C. tert-Butyllithium (24.0 mL of 1.7 M solution in pentane, 40.8 mmol) was added dropwise and let stir 2 h at −78° C. Trimethylborate (5.01 g, 48.3 mmol) was added, and the reaction was slowly warmed to room temperature and stirred for 18 h. Glacial acetic acid (3.9 mL) was added, followed by the addition of 30% aqueous hydrogen peroxide (5.8 mL). The reaction was stirred 2 h at room temperature and then poured into water. The resulting mixture was washed twice with CH2Cl2, and the organic layers were treated with activated charcoal and filtered through celite. The filtrate was washed once with water, once with brine, dried (Na2SO4), and concentrated under reduced pressure to give a mixture of two compounds, the higher Rf being desired. The mixture was purified by flash silica chromatography using a 40M Biotage cartridge, 1.5% methanol in CH2Cl2 eluent, to give 0.15 mmol (15% yield) of the desired product and 0.73 mmol (73%) of the title compound.
  • MS (DCI/NH[1483] 3) m/e 301 (M+H)+;
  • [1484] 1H NMR (CDCl3, 300 MHz) δ1.20 (s, 9H), 2.27 (s, 3H), 6.84 (d, 2H), 7.09 (d, 2H), 7.65 (br s, 1H), 8.08 (s, 1H), 8.14 (br s, 1H), 10.26 (br s, 1H).
    • EXAMPLE 141G 5-Hydroxy-4-amino-3-(4-methylphenoxy)pyridine
  • Example 141F (850 mg, 2.83 mmol) was suspended in 3 N aqueous HCl and stirred at 90° C. for 18 h. The reaction was then cooled to 0° C., neutralized with 6 N aqueous NaOH, and extracted with CH[1485] 2Cl2. The organic layers were combined, dried (Na2SO4), and concentrated under reduced pressure to give the desired product (612 mg, 100% yield).
  • MS (DCI/NH[1486] 3) m/e 217 (M+H)+;
  • [1487] 1H NMR (300 MHz, DMSO-d6) δ2.25 (s, 3H), 5.16 (s, 2H), 6.81 (d, 2H), 7.12 (d, 2H), 7.50 (s, 1H), 7.71 (s, 1H), 8.14 (s, 1H), 9.55 (br s, 1H).
    • EXAMPLE 141H Methyl Oxazolo[5,4-c]-4-(4-methylphenoxy)pyridine-2-carboxylate
  • To Example 141G (1.00 mmol3 in DMF is added pyridine (1.10 mmol) and methyl oxalyl chloride (1.10 mmol), and the resulting solution is stirred at room temperature overnight. The reaction is then partitioned between methylene chloride and 1 N aqueous HCl, and the organic phase is separated, dried (Na[1488] 2SO4), and concentrated under reduced pressure to give the title compound.
    • EXAMPLE 141I Oxazolo[5,4-c]-4-(4-methylphenoxy)pyridine-2-carboxamide
  • Example 141H may be treated according to the procedure of Example 44 to give the title compound. [1489]
    • EXAMPLE 142 7-(4-Methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide EXAMPLE 142A 5-(N,N-Dimethylthiuram)sulfide-4-(N-trimethylacetyl)amino-3-(4-methylphenoxy)pyridine
  • Example 141E (284 mg, 1.00 mmol) in diethylether (12 mL) at −78° C. was treated dropwise with tert-butyllithium (1.3 mL of 1.7 M solution in pentanes, 2.21 mmol, Aldrich) followed by stirring for 3 h at −78° C. Tetramethyl thiuram disulfide (529 mg, 2.20 mmol) was added to the resultant dianion, and stirring and temperature elevation was continued for 18 h. The reaction was quenched with water and extracted with CH[1490] 2Cl2. The organic phase is dried (Na2SO4) and concentrated under reduced pressure. The title compound (50 mg, 12% yield) was isolated by flash silica gel column chromatograpby.
  • MS (DCI/NH[1491] 3) m/e 404 (M+H)+;
  • [1492] 1H NMR (CDCl3, 300 MHz) δ2.32 (s, 3H), 3.55 (s, 3H), 3.58 (s, 3H), 6.92 (d, 2H), 7.12 (d, 2H), 7.93 (s, 1H), 8.43 (s, 1H), 8.45 (s, 1H).
    • EXAMPLE 142B 5-(N,N-Dimethylthiuram)sulfide-4-amino-3-(4-methylphenoxy)pyridine
  • Example 142A (270 mg, 0.67 mmol) was combined with formic acid (20 mL of 96%, Aldrich) and stirred at 90° C. for 72 hr. The reaction is then cooled to room temperature, and the formic acid is removed under reduced pressure. The resulting residue is purified by flash silica gel chromatography (70% EtOAc in hexane) to provide the title compound (96 mg, 45% yield). [1493]
  • MS (DCI/NH[1494] 3) m/e 320 (M+H)+;
  • [1495] 1H NMR (CDCl3, 300 MHz) δ2.33 (s, 3H), 3.56 (s, 3H), 3.58 (s, 3H), 4.93 (br s, 2H), 6.94 (d, 2H), 7.15 (d, 2H), 8.04 (s, 1H), 8.12 (s, 1H).
    • EXAMPLE 142C 5-(N,N-Dimethylthiuram)sulfide-4-methyloxamate-3-(4-methylphenoxy)pyridine
  • Example 142B (90 mg, 0.28 mmol) was combined with CH[1496] 2Cl2 (7.0 mL). Triethyl amine (0.39 mL, 2.2 mmol) was added, followed by the addition of methyl oxalyl chloride (120 mL, 1.30 mmol, Aldrich). After 6 h, the mixture was combined with saturated aqueous sodium bicarbonate and extracted thrice with CH2Cl2. The organic layers were combined, dried (Na2SO4), filtered, and concentrated under reduced pressure.
  • MS (DCI/NH[1497] 3) m/e 406 (M+H)+;
  • [1498] 1H NMR (CDCl3, 300 MHz) δ2.33 (s, 3H), 3.54 (s, 3H), 3.58 (s, 3H), 3.90 (s, 3H), 7.00 (d, 2H), 7.15 (d, 2H), 8.37 (s, 1H), 8.41 (s, 1H), 9.20 (br s, 1H).
    • EXAMPLE 142D Methyl 4-(4-Methylphenoxy)thiazolo[5,4-c]-pyridine-2-carboxylate
  • Example 142C (50 mg, 0.12 mmol) was dissolved in formic acid (14 mL, 96%, Aldrich), and heated to reflux. After 4 h, the reaction was cooled, and volatiles were removed. Flash silica gel column chromatography (60% EtOAc in hexane) provided the title compound (15 mg, 39% yield) as a white solid. [1499]
  • MS (DCI/NH[1500] 3) m/e 301 (M+H)+, 318 (M+NH3)+;
  • [1501] 1H NMR (CDCl3, 300 MHz) δ2.39 (s, 3H), 4.10 (s, 3H), 7.08 (d, J=8.5 Hz, 2H), 7.22 (d, J=8.5 Hz, 2H), 8.14 (s, 1H), 9.00 (s, 1H).
    • EXAMPLE 142E 4-(4-Methylphenoxy)thiazolo[5,4-c]-pyridine-2-carboxamide
  • Example 142D (2.0 mg, 6.7 mmol) was treated according to the procedure of Example 44 to give the title compound (1.5 mg, 75%) as a white solid. [1502]
  • MS (DCI/NH[1503] 3) m/e 286 (M+H)+, 303 (M+NH3)+;
  • [1504] 1H NMR (CDCl3, 300 MHz) δ2.39 (s, 3H), 5.66 (br s, 1H), 7.06 (d, J=8.2 Hz, 2H), 7.22 (d, J=7.8 Hz, 2H), 7.32 (br s, 1H), 8.20 (s, 1H), 9.04 (s, 1H).
    • EXAMPLE 143 7-(4-methylphenoxy)-3H-imidazo[4,5-c]pyridine-2-carboxamide EXAMPLE 143A N-[3-amino-5-(4-methylphenoxy)-4-pyridinyl]-2,2-dimethylpropionamide
  • Example 141F (1.00 mmol) is suspended in ammonium hydroxide (28%), saturated with sulfur dioxide, heated to 150° C. in a pressure vessel for 27 hours, and cooled, and extracted with ethyl acetate. The extract is concentrated to provide the title compound. [1505]
    • EXAMPLE 143B 5-(4-methylphenoxy)-3,4-pyridinediamine
  • Example 143A (1.00 mmol) is suspended in HCl (3N aqueous) and stirred at 90° C. for 18 hours, cooled to 0° C., neutralized with 6 N aqueous NaOH, and the water removed. The resulting residue is triturated with methanol. The washes are concentrated to provide the title compound. [1506]
    • EXAMPLE 143C methyl 7-(4-methylphenoxy)-3H-imidazo[4,5-c]pyridine-2-carboxylate
  • Example 143B (1.00 mmol) in DMF is treated with pyridine (1.10 mmol) and methyl oxalyl chloride (1.10 mmol), stirred at room temperature overnight, and partitioned between methylene chloride and 1 N aqueous HCl. The organic phase is separated, dried (Na[1507] 2SO4), and concentrated to provide the title compound.
    • EXAMPLE 143D 7-(4-methylphenoxy)-3H-imidazo[4,5-c]pyridine-2-carboxamide
  • Example 143C can be treated as in Example 44 to give the title compound. [1508]
    • EXAMPLE 144 4-(4-chlorophenoxy)thieno[2,3-d]pyridazine-2-carboxamide EXAMPLE 144A 3-Bromothiophene-2-carboxaldehyde
  • Example 144A can be processed as in Prugh, et. al. (J. Med. Chem. 1991, 34, 1805). A solution of dibromothiophene (14 g, 58 mmol) in THF (100 mL) at −78° C. was treated with n-butyllithium (24 mL, 59 mmol), stirred for 15 minutes, treated with dry DMF (6.8 mL, 87 mmol), stirred at −78° C. for 10 minutes, slowly warmed to 0° C. over a period of 15 minutes, poured into cold 1 N aqueous HCl, and extracted with diethyl ether. The extract was washed with 1 N aqueous HCl, water, and saturated sodium bicarbonate. The washes were extracted with diethyl ether. The organic layers were combined, dried (MgSO[1509] 4), filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel with 5% ethyl acetate/hexanes to provide the title compound.
  • [1510] 1H NMR (CDCl3, 300 MHz) δ7.16 (d, 1H), 7.74 (d, 1H), 10.0 (s, 1H).
    • EXAMPLE 144B 3-bromo-2-(2-dioxolanyl)thiophene
  • Example 144B can be processed as in Prugh, et. al. (J. Med. Chem. 1991, 34, 1805). A three-necked flask equipped with a Dean-Stark trap is charged with Example 144A (5.24 g, 27.4 mmol), ethylene glycol (6.2 mL, 110 mmol), pyridinium tosylate (276 mg, 1.10 mmol), and toluene (30 mL), heated at reflux for 14 hours, cooled to room temperature, poured into water, and extracted with diethyl ether. The organic layer is washed with water and saturated sodium bicarbonate, dried (MgSO[1511] 4), filtered, and concentrated. The residue is purified by flash chromatography on silica gel with 5% ethyl acetate/hexanes to provide the title compound.
  • MS (DCI/NH[1512] 3) m/z 252 (79Br)/254 (81Br), (M+NH4)+; 235 (79Br)/237 (81Br), (M+H)+;
  • [1513] 1H NMR (CDCl3, 300 MHz) δ4.11−4.02 (m, 4H), 6.14 (s, 1H), 6.97 (d, 1H), 7.30 (d, 2H).
    • EXAMPLE 144C ethyl-2-(2-dioxylanyl)thiophene-3-carboxylate
  • Example 144C can be processed as in Prugh et al. (J. Med. Chem., 1991, 34, 1805). Example 144B (1.00 g, 4.25 mmol) in THF (12 mL) is treated with n-butyllithium (1.7 mL, 4.25 mmol) while maintaining temperature between −105 and −95° C., treated with diethyl carbonate (0.57 mL, 4.68 mmol), and warmed to room temperature. The solution is poured into water and extracted with diethyl ether. The extract is washed with brine, dried (MgSO[1514] 4), filtered, and concentrated under reduced pressure. The residue is purified by flash chromatography on silica gel 5% ethyl acetate/hexanes to provide the title compound.
    • EXAMPLE 144D 2-formylthiophene-3-carboxylic acid
  • Example 144C (1.0 mmol) and ethanol (1.0 mL) are treated with 1 N aqueous sodium hydroxide solution (100 mmol), stirred for 1 hour, brought to pH=5 by the addition of glacial acetic acid, stirred for 1 hour, diluted with water, and extracted with ethyl acetate. The extracts are combined, washed with brine, washed with saturated sodium bicarbonate, dried (MgSO[1515] 4), filtered, and concentrated. The designated compound is used without further purification.
    • EXAMPLE 144E 4-oxothieno[2,3-d]pyridazine
  • Example 144D is processed as in Bull. Soc. Chim. Fr. 1967, 2495. [1516]
    • EXAMPLE 144F 4-chlorothieno[2,3-d]pyridazine
  • Example 144E is processed as in Bull. Soc. Chim. Fr. 1967, 2495. [1517]
    • EXAMPLE 144G 4-(4-Chlorophenoxy)thieno[2,3-d]pyridazine
  • Adapting the method of Robba and others (Bull. Soc. Chim. Fr., 1967, 4220), Example 144F (100 mg, 0.59 mmol) was combined with 4-chlorophenol (1.0 mL, 10.0 mmol) and sodium metal (21 mg, 0.90 mmol). The mixture was heated at 100° C. for 14 h. After cooling to room temperature, the residue was diluted with chloroform and washed once with 2 N aqueous sodium hydroxide and once with brine. The organic layer was dried (MgSO[1518] 4), filtered, and concentrated under reduced pressure. Recrystallization from diethyl ether gave the title compound (124 mg, 85%) as a white solid.
  • MS (DCI/NH[1519] 3) m/e: 363 (M+H)+;
  • [1520] 1H NMR (CDCl3, 300 MHz) δ7.27 (d, J=8.9 Hz, 2H), 7.42 (d, J=8.9 Hz, 2H), 7.72 (d, J=5.5 Hz, 1H), 7.88 (d, J=5.2 Hz, 1H), 9.41 (s, 1H).
    • EXAMPLE 144H 4-(4-chlorophenoxy)thieno[2,3-d]pyridazine-2-carboxylic acid
  • Example 144G (1.0 mmol) in THF (1.0 mL) at −78° C. is treated with n-Butyllithium (1.0 mmol), stirred for 15 minutes, saturated with CO[1521] 2, Slowly warmed to room temperature, partitioned between 1 N aqueous sodium hydroxide and diethyl ether, separated, and glacial acetic acid added to the aqueous layer until pH=5. The acidic solution is extracted thrice with methylene chloride. The extracts are combined, washed with dilute sodium bicarbonate, dried (MgSO4), filtered, and concentrated to provide the title compound.
    • EXAMPLE 144I 4-(4-chlorophenoxy)thieno[2,3-d]pyridazine-2-carbamide
  • Example 144I can be processed as in Desai and Stramiello (Tetrahedron Lett, 1993, 34, 7685). Example 144H (1.0 mmol), 1-hydroxybenzotriazole (1.4 mmol), N-methylmorpholine (12 mmol), and DMF (1.0 mL) are combined and cooled to 0° C., treated with 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.4 mmol), stirred at 0° C. for 1 hour, and partitioned between methylene chloride, saturated sodium bicarbonate, and separated. The extract is dried (MgSO[1522] 4), filtered, and concentrated. Recrystallization from hot methanol will provide the title compound.
    • EXAMPLE 145 7-(4-chlorophenoxy)thieno[3,2-c]pyridine-2-carbamide EXAMPLE 145A 2,5-dibromo-3-thiophenecarboxaldehyde
  • A solution of 3-thiophenecarboxaldehyde is processed as in Bull. Soc. Chim. Fr., 1974, 3040 to provide the title compound. [1523]
    • EXAMPLE 145B dimethylacetyl-(2,5-dibromo-3-thienyl)carboxamido ethane
  • Example 145A is processed as in Bull. Soc. Chim. Fr., 1974, 3040 to provide the title compound. [1524]
    • EXAMPLE 145C 6,7-dihydro-7-oxothieno[3,2-c]pyridine
  • Example 145B is processed as in Bull. Soc. Chim. Fr., 1974, 3040 to provide the title compound. [1525]
    • EXAMPLE 145D 7-(4-chlorophenoxy)thieno[3,2-c]pyridine
  • Example 145D can be processed as in Lindley (Tetrahedron, 1983, 1433). A solution of Example 145C (1.0 mmol) and DMF (2.0 mL) is treated at 0° C. with sodium hydride (1.0 mmol), slowly warmed to room temperature, treated with 1-chloro-4-iodobenzene (1.0 mmol) and copper iodide (0.1 mmol), heated at 80° C. overnight, and cooled. The solution is poured into water and extracted with diethyl ether. The extracts are combined, dried (MgSO[1526] 4), filtered, and concentrated. Recrystallization from ethyl acetate/hexanes provides the title compound.
    • EXAMPLE 145E 7-(4-chlorophenoxy)thieno[3,2-c]pyridine-2-carboxylic acid
  • The designated compound is processed in the manner described for Example 144H. [1527]
    • EXAMPLE 145F 7-(4-chlorophenoxy)thieno[3,2-c]pyridine-2-carboxamide
  • The designated compound is processed in the manner described for Example 144I. [1528]
    • EXAMPLE 146 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carbothioamide
  • A solution of Example 61 (50 mg, 0.16 mmol) and Lawesson's reagent (73 mg, (0.18 mmol) in toluene (2 mL) was heated at reflux for 4 hours. The solvent was removed under reduced pressure to obtain the crude product (150 mg) as a yellow residue. The purified title compound (24 mg, 47%) was obtained by flash chromatography on silica gel eluting with 10% methanol in dichloromethane. [1529]
  • MS (DCI/NH[1530] 3) m/e 321 (M+H)+;
  • [1531] 1H NMR (300 MHz, DMSO-d6) δ7.14 (m, 2H), 7.47 (m, 2H), 8.18 (s, 1H), 8.21 (s, 1H), 9.14 (s, 1H); 9.86 (s, 1H); 10.15 (s, 1H).
    • EXAMPLE 147 4-(4-Chlorophenoxy)-N-ethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 61A (200 mg, 0.627 mmol) was prepared as in Example 171 but substituting ethylamine (1 ml, 17.65 mmol) for methylamine to provide the title compound (209 mg, 100%). [1532]
  • MS (DCI/NH[1533] 3) m/e 333 (M+H)+, 303;
  • [1534] 1H NMR (400 MHz, DMSO-d6) δ1.14 (t, J=8 Hz, 3H), 3.30 (m, 2H), 7.14 (d, J=9 Hz, 2H), 7.47 (d, J=9 Hz, 2H, 8.13 (s, 1H), 8.17 (s, 1H), 8.91 (t, J=6 Hz, 1H), 9.15 (s, 1H).
    • EXAMPLE 148 4-(4-Chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 148 was prepared in a similar manner as Example 103A, by combining 3-amino-1,2-propanediol (60 mL, 0.782 mmol) with Example 61A (250 mg, 0.782 mmol) to provide the title compound (133 mg, 45% yield) as a white solid. [1535]
  • mp 106-115° C.; [1536]
  • MS (DCI/NH[1537] 3) m/e: 379 (M+H)+;
  • [1538] 1H NMR (300 MHz, DMSO-d6) δ3.16 (m, 2H), 3.38 (m, 2H), 3.63 (m, 1H), 4.56 (t, J=5.7 Hz, 1H), 4.81 (d, J=5.1 Hz, 1H), 7.13 (d, J=9.2, 2H), 7.47 (d, J=9.2 Hz, 2H), 8.18 (s, 1H), 8.21 (s, 1H), 8.95 (t, J=5.7 Hz, 1H), 9.16 (s, 1H);
  • Anal. calcd for C[1539] 17H15ClN2O4S.0.25 H2O: C, 53.27; H, 4.08; N, 7.31. Found: C, 53.19; H, 4.22; N, 6.22.
    • EXAMPLE 149 4-(4-Bromophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 149 was prepared according to the procedure of Example 114, with the substitution of methyl 4-(4-bromophenoxy)-thieno[2,3-c]pyridine-2-carboxylate for Example 61A. [1540]
  • mp 76-77° C.; [1541]
  • MS (DCI/NH[1542] 3) m/e: 423,425 (M+H)+;
  • [1543] 1H NMR (300 MHz, DMSO-d6) δ3.12 (m, 2H), 3.41 (m, 3H), 3.63 (m, 2H), 7.06 (d, 2H, J=8.8 Hz), 7.59 (d, 2H, J=8.8 Hz), 8.20 (s, 1H), 8.22 (s, 1H), 8.99 (t, 1H, J=5.5 Hz), 9.18 (s, 1H).
    • EXAMPLE 150 N-(2-Chloroethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • To a solution of Example 114 (0.32 g, 0.92 mmol) in anhydrous THF (5 mL) was slowly added thionyl chloride (0.34 mL, 4.60 mmol). The reaction was heated to 50° C. for 18 hr, cooled to room temperature, and neutralized with sat. NaHCO[1544] 3. The aqueous suspension was extracted with dichloromethane (100 mL) and the organic layer washed with dilute NaHCO3 (2×100 mL), brine (50 mL), partially dried (Na2SO4); and concentrated to a solid. The crude product was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to yield the title compound as a solid (0.27 g, 80%).
  • mp 60-62° C. (dec); [1545]
  • MS (DCI/NH[1546] 3) m/e 367 (M+H)+;
  • [1547] 1H NMR (300 MHz, DMSO-d6) δ3.60 (m, 2H), 3.75 (t, J=6.1 Hz, 2H), 7.15 (m, 2H), 7.48 (m,2H), 8.18 (s, 1H), 8.18 (s, 1H), 9.17 (s, 1H), 9.26 (m, 1H);
  • Anal. calcd for C[1548] 16H12Cl2N2O2S: C, 52.33; H, 3.29; N, 7.63. Found: C, 52.22; H, 3.47; N, 7.35.
    • EXAMPLE 151 4-(4-Bromophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 151 was prepared according to the procedure of Example 114, with the substitution of methyl 4-(4-bromophenoxy)-thieno[2,3-c]pyridine-2-carboxylate for Example 61A. [1549]
  • mp 158-159° C.; [1550]
  • MS (DCI/NH[1551] 3) m/e: 393,395 (M+H)+;
  • [1552] 1H NMR (300 MHz, DMSO-d6) δ3.32 (m, 2H), 3.51 (m, 3H), 4.79 (t, 1H, J=5.9 Hz), 7.06 (d, 2H, J=8.8 Hz), 7.59 (d, 2H, J=8.8 Hz), 8.17 (s, 1H), 8.20 (s, 1H), 9.02 (t, 1H, J=5.5 Hz), 9.17 (s, 1H).
    • EXAMPLE 152 4-(2-Bromo-4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 152 was prepared according to the procedure of Example 114, with the substitution of 2-bromo-4-chlorophenol for 4-chlorophenol. [1553]
  • MS (DCI/NH[1554] 3) m/e: 428 (M+H)+;
  • [1555] 1H NMR (300 MHz, DMSO-d6) δ2.86 (q, 1H, J=5.4 Hz), 3.34 (m, 2H), 3.55 (m, 2H); 7.15 (d, 1H, J=8.8 Hz), 7.48 (dd, 1H, J=2.4, 8.8 Hz), 7.97 (d, 1H, J=2.7 Hz), 8.02 (s, 1H), 8.25 (s, 1H), 9.05 (t, 1H, J=5.4 Hz), 9.16 (s, 1H).
    • EXAMPLE 153 N-(2-Hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 62A (322 mg, 0.912 mmol) in 10 mL of dichloromethane was treated with 226 mg (3.65 mmol) of ethanolamine. The solution was heated to reflux for 4 hours. Upon cooling crystals formed. Recrystallization from ethyl acetate afforded 170 mg (48.8%) of white crystals. [1556]
  • mp 181-182° C.; [1557]
  • MS (DCI/NH[1558] 3) m/e: 383 (M+H)+;
  • [1559] 1H NMR (300 MHz, DMSO-d6) δ3.3-3.4 (m, 2H), 3.5-3.6 (m, 2H), 4.80 (t, 1H), 7.21 (d, 2H), 7.79 (d, 2H), 8.15 (s, 1H), 8.38 (s, 1H), 9.01 (t, 1H), 9.25 (s, 1H);
  • Anal. calcd for C[1560] 17H13F3N2O3S: C, 53.40; H, 3.43; N, 7.33. Found: C, 53.41; H, 3.62; N, 7.30.
    • EXAMPLE 154 N-(2-Aminoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • To a suspension of Example 88 (0.50 g, 1.64 mmol) in anhydrous methylene chloride (15 mL) was added N,N-diisopropylethylamine (0.57 mL, 3.28 mmol). The reaction was cooled in an ice bath and pivaloyl chloride (0.24 mL, 1.97 mmol) was slowly added. After 10 minutes, the ice bath was removed and reaction stirred at ambient temperature for 1.5 hr. The reaction contents were slowly transferred via cannula into an anhydrous solution of ethylenediamine (0.33 mL, 4.92 mmol) in methylene chloride. (5 mL) at 0° C. over a period of 5 minutes. The reaction was stirred 15 minutes and the cold bath was removed. The reaction was stirred 1 hr and then partitioned between CHCl[1561] 3/Sat.NaHCO3. The organic layer was washed with dilute aqueous NaHCO3, brine, dried (Na2SO4), and concentrated to yield a light yellow foam. The crude product was purified by preparative HPLC using a gradient of 25%-65% acetonitrile/water +0.1% TFA over 40 minutes. The product was neutralized with saturated aqueous NaHCO3, precipitate collected by filtration, and dried in a desiccator to yield the title compound as a white solid (0.45 g, 79%).
  • mp 111-114° C.; [1562]
  • MS (APCI) m/e 348 (M+H)[1563] +;
  • [1564] 1H NMR (300 MHz, DMSO-d6) δ2.69 (t, J=6.4 Hz, 2H), 3.25 (t, J=6.4 Hz, 2H), 7.14 (m, 2H), 7.47 (m, 2H), 8.16 (s, 1H), 8.18 (s, 1H), 9.15 (s, 1H).
    • EXAMPLE 155 4-(4-Chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide
  • Example 155 was prepared as in Example 92 by combining Example 88 (161 mg, 0.527 mmol) with hydroxylamine hydrochloride (37.0 mg, 0.527 mmol) to provide the title product (40 mg, 24% yield) as a white solid. [1565]
  • mp 145° C. (decomposes); [1566]
  • MS (DCI/NH[1567] 3) m/e: 321 (M+H)+,
  • [1568] 1H NMR (300 MHz, CD3OD) δ7.11 (d, J=9:2 Hz, 2H), 7.42 (d, J=9.2 Hz, 2H), 7.90 (s, 1H), 8.05 (s, 1H), 9.01 (s, 1H);
  • IR (KBr) 3200-2800 (m), 1660 (s), 1640 (s), 1560 (m), 1485 (s), 1420 (s) cm[1569] −1;
  • Anal. calcd for C[1570] 14H9ClN2O3S+0.25 H2O: C, 51.70; H, 2.94; N, 8.61. Found: C, 51.68; H, 2.71; N, 8.80.
    • EXAMPLE 156 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide
  • Example 61A (0.50 g, 1.56 mmol) was dissolved in dichloromethane (10 mL) and anhydrous hydrazine (1 mL) was added. After 24 hours, the precipitate was collected by filtration and washed with dichloromethane (2×25 mL) and water (2×50 mL). The product was dried in a desiccator to yield the title compound as a white solid (0.35 g, 70%). [1571]
  • mp 197-199° C.; [1572]
  • MS (APCI) m/e: 320 (M+H)[1573] +;
  • [1574] 1H NMR (300 MHz, DMSO-d6) δ4.62 (broad s, 2H), 7.12 (m, 2H), 7.46 (m, 2H), 8.03 (s, 1H), 8.19 (s, 1H), 9.15 (s, 1H), 10.24 (br s, 1H);
  • Anal. calcd for C[1575] 14H10ClN3O2S: C, 52.59; H, 3.15; N, 13.14. Found: C, 52.59; H, 3.12; N, 13.18.
    • EXAMPLE 157 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide
  • Example 73A (0.21 g, 0.58 mmol) was dissolved in dichloromethane (2 mL) and anhydrous hydrazine (1 mL) added. After 18 hours, the precipitate was collected by filtration and washed with dichloromethane (2×5 mL), water (2×5 mL), acetonitrile (2×5 mL) to yield white solid. The washes were combined, diluted with sat. NaHCO[1576] 3 (100 mL) and extracted with dichloromethane (4×25 mL). Organic extracts were combined, partially dried (Na2SO4), and concentrated to yield a white solid which was combined with the collected precipitate and dried in a desiccator (0.21 g, 99%).
  • mp 176-178° C.; [1577]
  • MS (APCI) m/e: 364 (M+H)[1578] +;
  • [1579] 1H NMR (300 MHz, DMSO-d6) δ4.62 (br s, 2H), 7.06 (m, 2H), 7.58 (m, 2H), 8.02 (s, 1H), 8.21 (s, 1H), 9.16 (s, 1H), 10.24 (br s, 1H);
  • Anal calcd for C[1580] 14H10BrN3O2S: C, 46.17; H, 2.77; N, 11.54. Found: C, 46.08; H, 2.90; N, 11.41.
    • EXAMPLE 158 4-[4-(Trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carbohydrazide
  • Example 62A was treated according to the procedure of Example 157 to provide the title compound. [1581]
  • mp 146-147° C.; [1582]
  • MS (ESI) m/e: 353.9 (M+H)[1583] +;
  • [1584] 1H NMR (300 MHz, DMSO-d6) δ3.18 (d, 2H), 4.11 (t, 1H), 7.19 (d, 2H), 7.77 (d, 2H), 7.78 (s, 1H), 8.36 (s, 1H), 9.21 (s, 1H).
    • EXAMPLE 159 2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid EXAMPLE 159A 4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-carboxylic acid
  • A suspension of Example 61A (354 mg, 1.11 mmol) in 3 mL methanol and 1 mL water was treated with lithium hydroxide monohydrate (98 mg, 2.33 mmol) and the resulting mixture was stirred at room temperature (under N[1585] 2) for 20 hours. The reaction was acidified with 0.13 mL of 90% formic acid, and the white suspension was stirred for 5 minutes, then the solid was isolated by suction filtration. The solid was washed sequentially with 15 mL water and 5 mL diethyl ether, then dried under vacuum to provide 302 mg (89%) of the title compound.
  • MS (DCI/NH[1586] 3) m/e: 306, 308 (M+H)+;
  • [1587] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 2H), 7.47 (m, 2H), 7.82 (s, 1H), 8.23 (s, 1H), 9.21 (s, 1H), 13-15 (vbr s, 1H);
  • Anal. calcd for C[1588] 17H8ClNO3S: C, 55.00; H, 2.64; N, 4.58. Found: C, 54.77; H. 2.60; N, 4.44.
    • EXAMPLE 159B Methyl 2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetate
  • The title compound was prepared from Example 159A in analogy to Example 92, with the substitution of glycine methyl ester hydrochloride for ammonium chloride. [1589]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 19.04 minutes; [1590]
  • MS (APCI) m/e: 377 (M+H)[1591] +;
  • [1592] 1H NMR (300 MHz, DMSO-d6) δ3.68 (s, 3H), 4.05 (d, J=6 Hz, 2H), 7.13 (m, 2H), 7.49 (m, 2H), 8.19 (s, 1H), 8.21 (s, 1H), 9.19 (s, 1H), 9.50 (br t, J=6 Hz, 1H);
  • Anal. calcd for C[1593] 17H13ClN2O4S: C, 54.19; H, 3.48; N, 7.43. Found: C, 53.92; H, 3.61; N, 7.52.
    • EXAMPLE 159C 2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid
  • The title compound was prepared from Example 159B using the procedure of Example 18 to provide the title compound. [1594]
  • MS (APCI) m/e: 363 (M+H)[1595] +;
  • [1596] 1H NMR (300 MHz, DMSO-d6) δ3.95 (d, J=6 Hz, 2H), 7.13 (m, 2H), 7.48 (m, 2H), 8.19 (s, 1H), 8.21 (s, 1H), 9.19 (s, 1H), 9.41 (br t, J=6 Hz, 1H), 12.77 (br s, 1H);
  • Anal. calcd for C[1597] 16H11ClN2O4S.1 H2O: C, 50.46; H, 3.44; N, 7.36. Found: C, 50.33; H, 3.38; N, 7.29.
    • EXAMPLE 160 N-(2-Amino-2-oxoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • The title compound was prepared from Example 159C in analogy to Example 92. [1598]
  • mp 222-225° C.; [1599]
  • MS (APCI) m/e: 362 (M+H)[1600] +;
  • [1601] 1H NMR (300 MHz, DMSO-d6) δ3.82 (br s, 2H), 7.12 (m, 2H), 7.49 (m, 2H), 8.19 (s, 1H), 8:21 (s, 1H), 9.20 (s, 1H), 9.29 (br s, 1H);
  • Anal. calcd for C[1602] 16H12ClN3O3S.1.35 H2O: C, 49.77; H, 3.84; N, 10.88. Found: C, 49.86; H, 3.79; N, 10.59.
    • EXAMPLE 161 N-(2-Amino-2-oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 161A Methyl N-(2-amino-2-oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • Example 73A was hydrolyzed according to the procedure of Example 18. The derived carboxylic acid was coupled to glycine methyl ester hydrochloride in analogy to Example 92. [1603]
  • MS (DCI/NH[1604] 3) m/e: 421 (M+H)+;
  • [1605] 1H NMR (300 MHz, DMSO-d6) δ370 (s, 3H), 4.11 (br d, 2H), 7.11 (br d, 2H), 7.61 (br d, 2H), 8.22 (br d, 2H), 9.19 (s, 1H), 9.51 (br t, 1H);
  • [1606] 13C NMR (100 MHz, DMSO-d6) δ41.15, 51.84, 104.95, 115.57, 119.74, 119.97, 132.93, 133.32, 137.36, 138.04, 141.45, 145.06, 147.03, 156.10, 161.09, 169.80;
  • Anal. calcd for C[1607] 17H13BrN2O4S: C, 48.47; H, 3.11; N, 6.65. Found: C, 48.16; H, 3.27; N, 6.65.
    • EXAMPLE 161B 2-({[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid
  • The title compound was prepared from Example 161A using the procedure of Example 18 to provide the title compound. [1608]
  • MS (DCI/NH[1609] 3) m/e: 407 (M+H)+;
  • [1610] 1H NMR (300 MHz, DMSO-d6) δ4.11 (br d, 2H), 7.10 (br d, 2H), 7.60 (br d, 2H), 8.21 (br d, 2H), 9.19 (s, 1H), 9.40 (br t, 1H);
  • 13C NMR (100 MHz, DMSO-d[1611] 6) δ41.50, 115.85, 120.00, 120.09, 133.25, 133.67, 137.76, 138.34, 141.79, 145.74, 147.29, 156.46, 161.28, 171.05;
  • Anal. calcd for C[1612] 16H11BrN2O4S.H2O: C, 45.19; H, 3.08; N, 6.59. Found: C, 45.20; H, 3.15; N, 6.45.
    • EXAMPLE 161C N-(2-Amino-2-oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • The title compound was prepared from Example 161B in analogy to Example 92. [1613]
  • MS (APCI) m/e: 406 (M+H)[1614] +;
  • [1615] 1H NMR (300 MHz, DMSO-d6) δ3.81 (br d, J=6 Hz, 2H), 7.08 (m, 2H), 7.10 (br s, 1H), 7.60 (m, 2H), 8.19 (s, 1H), 8.22 (s, 1H), 9.20 (s, 1H), 9.28 (br t, J=6 Hz, 1H);
  • Anal. calcd for C[1616] 16H12BrN3O3S.0.3 H2O: C, 46.68; H, 3.09; N, 10.21. Found: C, 46.68; H, 3.30; N, 10.16.
    • EXAMPLE 162 N-[(1 S)-2-Amino-1-(hydroxymethyl)-2-oxoethyl]-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 162A (2S)-2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid
  • Example 162A was prepared in analogy to Example 92, with the substitution of L-serine ethyl ester hydrochloride for ammonium chloride. The intermediate ester was then hydrolyzed according to the procedure of Example 18 to provide the title compound. [1617]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 15.93 minutes; [1618]
  • MS (APCI) m/e: 392 (M+H)[1619] +;
  • [1620] 1H NMR (300 MHz, DMSO-d6) δ3.70 (m, 2H), 4.43 (br t, 2H), 5.04 (br s, 1H), 7.13 (m, 3H), 7.49 (m, 3H), 8.18 (s, 1H), 8.37 (s, 1H), 8.98 (brs, 1H), 9.18 (s, 1H).
    • EXAMPLE 162B N-[(1S)-2-Amino-1-(hydroxymethyl)-2-oxoethyl]-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 162B was prepared from Example 162A in analogy to Example 92. [1621]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 15.93 minutes; [1622]
  • MS (APCI) m/e: 392 (M+H)[1623] +;
  • [1624] 1H NMR (300 MHz, DMSO-d6) δ3.70 (m, 2H), 4.43 (br t, 2H), 5.04 (br s, 1H), 7.13 (m, 3H), 7.49 (m, 3H), 8.18 (s, 1H), 8.37 (s, 1H), 8.98 (br s, 1H), 9.18 (s, 1H).
    • EXAMPLE 163 (2R)-2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid
  • Example 163 was prepared in analogy to Example 92, using D-serine methyl ester hydrochloride in place of ammonium chloride. The derived ester was hydrolyzed according to the procedure of Example 18 to give the title compound. [1625]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 16.47 minutes; [1626]
  • MS (ESI) m/e: 393 (M+H)[1627] +;
  • [1628] 1H NMR (300 MHz, DMSO-d6) δ3.78 (br d, 2H), 4.49 (m, 1H), 5.02 (br s, 1H), 7.13 (m, 2H), 7.48 (m, 2H), 8.18 (s, 1H), 8.39 (s, 1H), 9.14 (d, 1H), 9.18 (s, 1H), 12.81 (br s, 1H).
    • EXAMPLE 164 4-(4-Chlorophenoxy)-N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 164A (2R)-2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid
  • Example 164A was prepared in analogy to Example 92, using D-alanine methyl ester hydrochloride in place of ammonium chloride. The derived ester was hydrolyzed according to the procedure of Example 18 to give the title compound. [1629]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 18.36 minutes; [1630]
  • MS (DCI/NH[1631] 3) m/e: 377 (M+H)+;
  • [1632] 1H NMR (300 MHz, DMSO-d6) δ1.40 (d, J=7 Hz, 3H), 4.41 (q, J=7 Hz, 1H), 7.15 (m, 2H), 7.49 (m, 2H), 8.19 (s, 1H), 8.32 (s, 1H), 9.17 (s, 1H), 9.23 (d, J=7 Hz, 1H), 12.71 (br s, 1H).
    • EXAMPLE 164B 4-(4-Chlorophenoxy)-N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 164 was prepared in analogy to Example 92, using D-alanine methyl ester hydrochloride in place of ammonium chloride. The derived ester was treated according to the procedure of Example 171 to give the title compound. [1633]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30, minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 17.46 minutes; [1634]
  • MS (DCI/NH[1635] 3) m/e: 390 (M+H)+;
  • [1636] 1H NMR (300 MHz, DMSO-d6) δ1.32 (d, 3H), 2.60 (d, 3H), 4.41 (m, 1H), 7.13 (m, 2H), 7.49 (m, 2H), 7.96 (br d, 1H), 8.19 (s, 1H), 8.38 (s, 1H), 9.13 (br d, 1H), 9.19 (s, 1H).
    • EXAMPLE 165
  • 4-(4-Chlorophenoxy)-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide [1637]
    • EXAMPLE 165A (2S)-2-({[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid
  • Example 165A was prepared in analogy to Example 92, using L-alanine methyl ester hydrochloride in place of ammonium chloride. The derived ester was hydrolyzed according to the procedure of Example 18 to give the title compound. [1638]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 18.40 minutes; [1639]
  • MS (DCI/NH[1640] 3) m/e: 377 (M+H)+;
  • [1641] 1H NMR (300 MHz, DMSO-d6) δ1.40 (d, J=7 Hz, 3H), 4.41 (q, J=7 Hz, 1H), 7.15 (m, 2H), 7.48 (m, 2H), 8.18 (s, 1H), 8.31 (s, 1H), 9.16 (s, 1H), 9.21 (d, J=7 Hz, 1H), 12.71 (br s, 1H);
  • [1642] 13C NMR (100 MHz, DMSO-d6) δ16.78, 48.46, 119.52, 119.80, 119.97, 127.84, 130.13, 132.97, 137.54, 137.60, 138.09, 141.30, 145.59, 147.38, 155.59, 160.54, 173.68.
    • EXAMPLE 165B 4-(4-Chlorophenoxy)-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 165B was prepared from Example 165A in analogy to Example 92, with the substitution of L-alanine methyl ester for ammonium chloride. The intermediate ester was converted to the title compound according to the procedure or Example 171, using methanolic methylamine. [1643]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 17.48 minutes; [1644]
  • MS (DCI/NH[1645] 3) m/e: 390 (M+H)+;
  • [1646] 1H NMR (300 MHz, DMSO-d6) δ1.32 (d, 3H), 2.59 (d, 3H), 4.41 (m, 1H), 7.13 (m, 2H), 7.49 (m, 2H), 7.94 (br d, 1H), 8.18 (s, 1H), 8.36 (s, 1H), 9.12 (br d, 1H), 9.19 (s, 1H).
    • EXAMPLE 166 4-(4-Chlorophenoxy)-N-[(1R)-1-(hydroxyethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide
  • The title compound was made in analogy to the procedure of Example 164B, using D-serine methyl ester. [1647]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 16.10 minutes; [1648]
  • MS (APCI) m/e: 404 (M−H)[1649] −;
  • [1650] 1H NMR (300 MHz, DMSO-d6) δ2.59 (d, 2H), 3.69 (m, 2H), 4.45 (m, 1H), 4.96, (t, 1H), 7.14 (m, 2H), 7.49 (m, 2H), 7.97 (m, 1H), 8.18 (s, 1H), 8.49 (s, 1H), 9.01 (br d, 1H), 9.19 (s, 1H).
    • EXAMPLE 167 4-(4-Chlorophenoxy)-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide
  • The title compound was made in analogy to the procedure of Example 164B, using L-serine methyl ester. [1651]
  • HPLC: Supelco C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 16.18; [1652]
  • MS (APCI) m/e: 404 (M−H)[1653] −;
  • [1654] 1H NMR (300 MHz, DMSO-d6) δ2.59 (d, 2H), 3.69 (m, 2H), 4.45 (m, 1H), 4.96, (t, 1H), 7.14 (m, 2H), 7.49 (m, 2H), 7.97 (br d, 1H), 8.18 (s, 1H), 8.49 (s, 1H), 9.01 (br d, 1H), 9.19 (s, 1H).
    • EXAMPLE 170 4-(3-Pyridinyloxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-Hydroxypyridine were processed as in Example 61 to provide the title compound. [1655]
  • MS (DCI/NH[1656] 3) m/e: 272 (M+H)+;
  • [1657] 1H NMR (300 MHz, DMSO-d6) δ7.50 (m, 2H), 7.85 (m, 1H), 8.20 (s, 2H), 8.45 (dd, 2H), 8.55 (d, 1H), 9.20 (s, 1H);
  • Anal. Calcd for C[1658] 13H9N3O2S.0.25 H2O: C, 56.61; H, 3.47; N, 15.24. Found: C, 57.01; H, 3.50; N, 15.16.
    • EXAMPLE 171 Methyl 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 73A (2 g, 5.5 mmol) was suspended in a solution of methylamine in methanol (2 M solution, 15 mL) and refluxed for 1 hour under nitrogen atmosphere. Then the solvent was removed and the residue was purified by flash chromatography on silica gel eluting with 30% acetone in hexane to obtain the title compound (1.96 g, 98%). [1659]
  • mp 78-80° C.; [1660]
  • MS (DCI/NH[1661] 3) m/e: 363, 365 (M+H)+;
  • [1662] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.8 Hz), 7.06 (d, 2H, J=8.8 Hz), 7.59 (d, 2H, J=8.8 Hz), 8.06 (s, 1H), 8.20 (s, 1H), 8.96 (q, 1H, J=4.8 Hz), 9.17 (s, 1H).
    • EXAMPLE 172 4-(4-Bromophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 172 was prepared according to the procedure of Example 104, with the substitution of methyl 4-(4-bromophenoxy)-thieno[2,3-c]pyridine-2-carboxylate for Example 61A. [1663]
  • mp 93-95° C.; [1664]
  • MS (DCI/NH[1665] 3) m/e: 377, 379 (M+H)+;
  • [1666] 1H NMR (300 MHz, DMSO-d6) δ3.02 (br s, 3H), 3.13 (br s, 3H), 7.09 (d, 2H, J=8.8 Hz), 7.5 d, 2H, J=8.8 Hz), 7.60 (s, 1H), 8.19 (s, 1H), 9.15 (s, 1H) ppm.
    • EXAMPLE 173 N,N-Dimethyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 173 was prepared according to the procedure of Example 104, with the substitution of methyl 4-(4-trifluoromethylphenoxy)-thieno[2,3-c]pyridine-2-carboxylate for Example 61A. [1667]
  • mp 74-76° C.; [1668]
  • MS (DCI/NH[1669] 3) m/e: 367 (M+H)+;
  • [1670] 1H NMR (300 MHz, CDCl3) δ3.17 (br s, 6H), 7.11 (d, 2H, J=8.0 Hz), 7.45 (s, 1H), 7.63 (d, 2H, J=8.0 Hz), 8.24 (br s, 1H), 9.01 (br s, 1H).
    • EXAMPLE 174 4-(4-Chloro-3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 174 was prepared as in Example 103 but substituting 4-chloro-3-fluorophenol for 4-chlorophenol to provide the title compound. [1671]
  • mp 62-64° C.; [1672]
  • MS (DCI/NH[1673] 3) m/e: 337 (M+H)+;
  • [1674] 1H NMR (300 MHz, DMSO-d6) δ3.05 (d, 3H, J=4.7 Hz), 6.24 (br s, 1H), 6.77 (d, 1H, J=9.8 Hz), 6.84 (dd, 1H, J=2.4, 9.5 Hz), 7.26 (s,2H), 7.37 (t, 1H, J=8.5 Hz), 7.69 (s 1H), 8.21 (s, 1H), 9.00 (s, 1H);
  • Anal. calcd for C[1675] 15H10N2ClFO2S: C, 53.50; H, 2.99; N, 8.32. Found: C, 53.78; H, 3.26; N, 8.02.
    • EXAMPLE 175 4-(4-Chloro-3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 175 was prepared as in Example 61 but substituting 4-chloro-3-fluorophenol for 4-chlorophenol to provide the title compound. [1676]
  • mp 227-228° C.; [1677]
  • MS (DCI/NH[1678] 3) m/e: 323 (M+H)+;
  • [1679] 1H NMR (300 MHz, DMSO-d6) δ6.94 (m, 1H), 7.34 (dd, 1H, J=3.0, 10.5 Hz), 7.60 (t, 1H, J=8.7 Hz), 7.87 (s, 1H), 8.11 (s, 1H), 8.26 (s, 1H), 8.44 (s, 1H), 9.19 (s, 1H);
  • Anal. calcd for C[1680] 14H8N2ClFO2S: C, 52.10; H, 2.50; N, 8.68. Found: C, 52.06; H, 2.49; N, 8.52.
    • EXAMPLE 176 4-(4-Chloro-3-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-Chloro-3-ethylphenol were processed as in Example 61 to provide the title compound. [1681]
  • mp 185-187° C.; [1682]
  • MS (DCI/NH[1683] 3) m/e: 333 (M+H)+;
  • [1684] 1H NMR (300 MHz, DMSO-d6) δ1.15 (t, 3H), 2.70 (q, 2H), 6.95 (dd, 1H), 7.20 (d, 1H), 7.45 (d, 1H), 7.85 (br s, 1H), 8.15 (s, 1H), 8.45 (m, 1H), 9.15 (s, 1H).
    • EXAMPLE 177 4-(3-Fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 177 was prepared according to the procedure of Example 61, with the substitution 3-fluorophenol for 4-chlorophenol. [1685]
  • mp 215-216° C.; [1686]
  • MS (DCI/NH[1687] 3) m/e: 289 (M+H)+;
  • [1688] 1H NMR (300 MHz, DMSO-d6) δ6.9,0 (m, 1H), 7.05 (m, 2H), 7.43 (q, 1H, J=8.6 Hz), 7.86 (br s, 1H), 8.14 (s, 1H), 8.20 (s, 1H), 8.45 (br s, 1H), 9.17 (s, 1H).
    • EXAMPLE 178 4-(2,3-Difluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 178 was prepared according to the procedure of Example 61, with the substitution 2,3-difluorophenol for 4-chlorophenol. [1689]
  • mp 207-209° C.; [1690]
  • MS (DCI/NH[1691] 3) m/e: 307 (M+H)+;
  • [1692] 1H NMR (300 MHz, DMSO-d6) δ6.97 (t, 1H, J=8.5 Hz), 7.22 (q, 1H, J=8.5 Hz), 7.32 (q, 1H, J=8.5 Hz), 7.87 (br s, 1H), 8.18 (s, 1H), 8.21 (s, 1H), 8.43 (br s, 1H);
    • EXAMPLE 179 4-(2,3-Difluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 179 was prepared according to the procedure of Example 103, with the substitution 2,3-difluorophenol for 4-chlorophenol. [1693]
  • mp 169-171° C.; [1694]
  • MS (DCI/NH[1695] 3) m/e: 321 (M+H)+;
  • [1696] 1H NMR (300 MHz, DMSO-d6) δ2.88 (d, 3H, J=4.4 Hz), 6.94 (t, 1H, J=8.5 Hz), 7.21 (q, 1H, J=8.5 Hz), 7.31 (q, 1H, J=8.5 Hz), 8.14 (s, 1H), 8.21 (s, 1H), 8.95 (q, 1H), 9.17 (s, 1H).
    • EXAMPLE 180 4-(3-Fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 180 was prepared according to the procedure of Example 103, with the substitution 3-fluorophenol for 4-chlorophenol. [1697]
  • mp 194-195° C.; [1698]
  • MS (DCI/NH[1699] 3) m/e: 303 (M+H)+;
  • [1700] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.4 Hz), 6.87 (d, 1H, J=8.5 Hz), 7.05 (m, 2H), 7.42 (q, 1H, J=8.5 Hz), 8.05 (s, 1H), 8.23 (s, 1H), 8.95 (q, 1H, J=4.4 Hz), 9.17 (s, 1H).
    • EXAMPLE 181 N-Methyl-4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 181 was prepared according to the procedure of Example 103, with the substitution 2,3,4-trifluorophenol for 4-chlorophenol. [1701]
  • mp 170-171° C.; [1702]
  • MS (DCI/NH[1703] 3) m/e: 339 (M+H)+;
  • [1704] 1H NMR (300 MHz, DMSO-d6) δ2.82 (d, 3H, J=4.4 Hz), 7.13 (m, 1H), 7.35 (q, 1H, J=8.5 Hz), 8.16 (s, 1H), 8.17 (s, 1H), 8.97 (q, 1H, J=4.5 Hz), 9.16 (s, 1H).
    • EXAMPLE 182 4-(2,3,4-Trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 182 was prepared according to the procedure of Example 61, with the substitution 2,3,4-trifluorophenol for 4-chlorophenol. [1705]
  • mp 218-219° C.; [1706]
  • MS (DCI/NH[1707] 3) m/e: 325 (M+H)+;
  • [1708] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 1H), 7.38 (q, 1H, J=8.5 Hz), 7.89 (br s, 1H), 8.15 (s, 1H), 8.23 (s, 1H), 8.45 (brs, 1H), 9.15 (s, 1H).
    • EXAMPLE 183 N-Methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 183 was prepared according to the procedure of Example 103, with the substitution 4-trifluoromethylphenol for 4-chlorophenol. [1709]
  • mp 157-158° C.; [1710]
  • MS (DCI/NH[1711] 3) m/e: 353 (M+H)+;
  • [1712] 1H NMR (300 MHz, DMSO-d6) δ2.78 (d, 3H, J=4.4 Hz), 7.22 (d, 2H, J=8.5 Hz), 7.76 (d, 2H, J=8.5 Hz), 8.01 (s, 1H), 8.34 (s, 1H), 8.92 (q, 1H, J=4.4 Hz), 9.24 (s, 1H).
    • EXAMPLE 184 4-[3-(Trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 3-trifluoromethylphenol were processed as in Example 183 to provide the title compound. [1713]
  • mp 175-176° C.; [1714]
  • MS (DCI/NH[1715] 3) m/e: 353 (M+H)+;
  • [1716] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H), 7.35 (d, 1H), 7.20 (d, 1H), 7.60 (m, 3H), 8.10 (s, 1H), 8.30 (s, 1H), 9.00 (b, 2H), 9.25 (s, 1H);
  • Anal. Calcd for C[1717] 16H11F3N2O2S.0.25 H2O: C, 53.86; H, 3.25; N, 7.85. Found: C, 53.60; H, 3.06; N, 7.78.
    • EXAMPLE 185 N,N-Dimethyl-4-(4-vinylphenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 185 was prepared according to the procedure of Example 104, with the substitution 4-vinylphenol for 4-chlorophenol. [1718]
  • mp 80-81° C.; [1719]
  • MS (DCI/NH[1720] 3) m/e: 325 (M+H)+;
  • [1721] 1H NMR (300 MHz, DMSO-d6) δ3.02 (br s, 3H), 3.13 (br s, 3H), 5.24 (d, 1H, J=11.4 Hz), 5.78 (d, 1H, J=17.3 Hz), 6.74 (dd, 1H, J=11.4, 17.3 Hz), 7.09 (d, 2H, J=8.5 Hz), 7.53 (d, 2H, J=8.5 Hz), 7.61 (s, 1H), 8.16 (s, 1H), 9.13 (s, 1H).
    • EXAMPLE 186 4-(4-Cyanophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 186 was prepared as in Example 103 but substituting 4-cyanophenol for 4-chlorophenol to provide the title compound. [1722]
  • MS (ESI/NH[1723] 3) m/e: 310 (M+H)+;
  • [1724] 1H NMR (300 MHz, DMSO-d6) δ2.78 (d, 3H, J=4.4 Hz), 7.20 (d, 2H, J=8.8 Hz), 7.89 (d, 2H, J=8.8 Hz), 7.97 (s, 1H), 8.37 (s, 1H), 8.94 (q, 1H, J=4.4 Hz), 9.26 (s, 1H);
  • Anal. calcd for C[1725] 16H11N3O2S.0.05 CH2Cl2: C, 61.46; H, 3.56; N, 13.30. Found: C, 61.29; H, 3.53; N, 13.23.
    • EXAMPLE 187 4-(4-Cyanophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 187 was prepared as in Example 61 but substituting 4-cyanophenol for 4-chlorophenol to provide the title compound. [1726]
  • mp 255-257° C.; [1727]
  • MS (ESI/NH[1728] 3) m/e: 296 (M+H)+;
  • [1729] 1H NMR (300 MHz, DMSO-d6) δ7.20 (d, 2H, J=8.8 Hz), 7.84 (s, 1H), 7.89 (d, 2H, J=8.8 Hz), 8.05 (s, 1H), 8.36 (s, 1H), 8.41 (q, 1H, J=4.4 Hz), 9.26 (s, 1H);
  • Anal. calcd for C[1730] 15H9N3O2S.1.5CH3OH: C, 57.71; H, 3.08; N, 12.24. Found: C, 57.45; H, 3.28; N, 12.43.
    • EXAMPLE 188 4-(4-Aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 188A 3-Chloro-5-(4-(tert-butyloxycarbonyl)amino)phenoxy-4-pyridinecarboxaldehyde
  • A solution of Example 17A (2.0 g, 11.4 mmol) and tert-butyl N-(4-hydroxyphenyl)carbamate (2.38 g, 11.4 mmol) which was prepared according to literature method (A. Vigroux, M. Bergon, C. Zedde; J. Med. Chem. 1995, 38, 3983) in DMF (30 mL) was treated with CsCO[1731] 3 (3.70 g, 11.4 mmol) at room temperature for 1 hour, and at 70° C. for 30 minutes. Brine (150 mL) was added, and the mixture was extracted with ether/ethyl acetate (2×200 mL). The combined organic phases were dried (MgSO4), and concentrated. Flash chromatography of the residue on silica gel with 1:6 ethyl acetate/hexane provided the designated compound (2.65 g, 67%).
  • MS (ESI/NH[1732] 3) m/e: 349 (M+H)+.
    • EXAMPLE 188B Methyl 4-((4-tert-butyloxycarbonylamino)phenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 188A (2.64 g, 7.58 mmol) in THF (30 mL) was treated with methyl thioglycolate (804 mg, 7.58 mmol) at 0° C. for 0.5 hour, and at room temperature for 1 hour, after which Cs[1733] 2CO3 (2.47 g, 7.58 mmol was added. The reaction mixture was stirred at room temperature for 1 hour, and at 70° C. for 0.5 hour. Brine (150 mL) was added and the mixture was extracted with ethyl acetate (2×150 mL). The combined organic phases were dried (MgSO4) and concentrated. The residue was flash chromatographed on silica gel with 20% ethyl acetate in hexane to provide designated compound (1.29 g, 43%).
  • MS (ESI/NH[1734] 3) m/e: 401 (M+H)+.
    • EXAMPLE 188C 4-[(4-tert-Butyloxycarbonylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 188C was prepared as in Example 44 but substituting Example 188B for Example 43 to provide the title compound. [1735]
  • MS (ESI/NH[1736] 3) m/e: 386 (M+H)+.
    • EXAMPLE 188D 4-(4-Aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 188C was dissolved in trifluoroacetic acid (20 mL), and the solution was kept at room temperature for 1 hour before TFA was removed. The residual oil was treated with a mixture of ethyl acetate and aqueous NaHCO[1737] 3 solution. The formed solid was collected by filtration, washed successively with ethyl acetate, aqueous NaHCO3 solution, water, methanol and ethyl acetate, and dried to provide the title compound (492 mg, 86% from Example 188B) as a yellow solid.
  • mp>250° C.; [1738]
  • MS (DCI/NH[1739] 3) m/e: 286 (M+H)+;
  • [1740] 1H NMR (300 MHz, DMSO-d6) δ5.62 (br s, 2H), 6.65 (d, 2H, J=8.8 Hz), 6.93 (d, 2H, J=8.8 Hz), 7.86 (s, 1H), 8.30 (s, 1H), 8.44 (s, 1H), 9.00 (br s, 1H);
  • Anal. calcd for C[1741] 14H11N3O2S.0.5 CH3OH: C, 57.79; H, 3.85; N, 13.94. Found: C, 57.69; H, 3.95; N, 13.57.
    • EXAMPLE 189 4-[4-(Acetylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 189 was prepared as in Example 188C but substituting 4-(acetylamino)phenol for t-butyl N-(4-hydroxyphenyl)carbamate to provide the title compound. [1742]
  • MS (DCI/NH[1743] 3) m/e: 328 (M+H)+;
  • [1744] 1H NMR (300 MHz, DMSO-d6) δ2.04 (s, 3H), 7.10 (d, 2H, J=8.8 Hz), 7.65 (d, 2H, J=8.8 Hz), 7.82 (br s, 1H), 7.99 (s, 1H), 8.20 (s, 1H), 8.43 (br s, 1H), 9.06 (s, 1H), 9.99 (s, 1H);
  • Anal. calcd for C[1745] 16H13N3O3S.1.0 CH3OH: C, 56.81; H, 3.93; N, 11.69. Found: C, 56.51; H, 3.93; N, 11.57.
    • EXAMPLE 190 N-Methyl-4-[4-(4-morpholinyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 190A Methyl-4-[4-(4-iodophenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • Example 190A was prepared as in Example 61A but substituting 4-iodophenol for 4-chlorophenol to provide the designated compound. [1746]
  • MS (DCI/NH[1747] 3) m/e: 412 (M+H)+.
    • EXAMPLE 190B N-Methyl-4-[4-(4-iodophenoxy)]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 190A (1.4 g, 3.4 mmol) in methylamine/methanol (2.0 M solution, 70 mL) was stirred at 45° C. for 15 hours, and concentrated under vacuum. The residue was flash chromatographed on silica gel with EtOAc/hexane (1.5/1) to provide the designated compound (1.3 g, 93%). [1748]
  • MS (DCI/NH[1749] 3) m/e: 411 (M+H)+.
  • EXAMPLE 190C [1750]
    • N-Methyl-4-[4-(4-morpholinyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • A two necked flask was charged with Example 190B (150 mg, 0.37 mmol), NaOBu-t (71 mg, 0.74 mmol), Pd[1751] 2(dba)3 (14 mg, 0.014 mmol), BINAP (27 mg, 0.044 mmol) and 18-crown-6 (196 mg, 0.74 mmol), and purged with nitrogen. Anhydrous degassed THF (10 mL) and morpholine (64 mg, 0.74 mmol) were added successively. The clear dark red solution was heated at 60° C. for 70 hours, and quenched with brine. The mixture was extracted with methylene chloride. The organic layer was dried (MgSO4) and concentrated. The crude was flash chromatographed on silica gel (EtOAc/hexane) and was further purified on HPLC (C-18, CH3CN/H2O) to provide the title compound (26 mg).
  • MS (DCI/NH[1752] 3) m/e: 370 (M+H)+;
  • [1753] 1H NMR (300 MHz, DMSO-d6) δ2.81 (d, 3H, J=4.5 Hz), 3.1 (m, 2H), 3.74 (m, 2H), 6.99 (d, 2H, J=8.8 Hz), 7.05 (d, 2H, J=8.8 Hz), 7.92 (s, 1H), 8.20 (s, 1H), 8.98 (q, 1H, J=4.8 Hz), 9.04 (s, 1H).
    • EXAMPLE 191 4-[4-(Hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 191A Methyl 4-{4-[(trityloxy)methyl]phenoxyl}thieno[2,3-c]pyridine-2-carboxylate
  • Example 191A was prepared as in Example 61A but substituting 4-trityloxymethylphenol which was prepared according to literature method (Frank, R. Doring, R. Tetrahedron 1988, 44, 6031) for 4-chlorophenol to provide the title compound. [1754]
  • MS (DCI/NH[1755] 3) m/e: 558 (M+H)+.
    • EXAMPLE 191B 4-{4-[(Trityloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide
  • Example 191A was prepared as in Example 61 but substituting 4-trityloxymethylphenol for 4-chlorophenol to provide the title compound. [1756]
  • MS (DCI/NH[1757] 3) m/e: 543 (M+H)+;
  • [1758] 1H NMR (300 MHz, DMSO-d6) δ4.10 (s, 2H), 7.11 (d, 2H, J=8.5 Hz), 7.26-7.46 (m, 17H), 7.87 (brs, 1H), 8.09 (s, 1H), 8.21 (s, 1H), 8.46 (brs, 1H), 9.12 (s, 1H) ppm.
  • Anal. calcd for C[1759] 34H26N2O3S: C, 75.25; H, 4.83; N, 5.16. Found: C, 75.17; H, 4.76; N, 5.15.
    • EXAMPLE 191C Methyl 4-[4-(hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 191A (5.05 g, 9 mmol) in a mixture of chloroform (20 mL) and methanol (8 mL) was treated with trifluoroacetic acid (10 mL) at 0° C. for 6 hours, and was then poured into a mixture of ice and saturated NaHCO[1760] 3. The mixture was extracted with methylene chloride (2×200 mL). The combined organic layers were dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 66% EtOAc/hexane to give the designated compound (2.11 g, 74%).
  • MS (DCI/NH[1761] 3) m/e: 316 (M+H)+.
    • EXAMPLE 191D 4-[4-(Hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 191D was prepared as in Example 61 but substituting Example 191C for Example 61A to provide the title compound. [1762]
  • MS (DCI/NH[1763] 3) m/e: 301 (M+H)+;
  • [1764] 1H NMR (300 MHz, DMSO-d6) δ4.50 (d, 2H, J=5.8 Hz), 5.19 (t, 1H, J=5.8 Hz), 7.10 (d, 2H, J=8.5 Hz), 7.37 (d, 2H, J=8.5 Hz), 7.82 (br s, 1H), 8.03 (s, 1H), 8.20 (s, 1H), 8.43 (br s, 1H), 9.09 (s, 1H);
  • Anal. calcd for C[1765] 15H12N2O3S: C, 59.99; H, 4.03; N, 9.33. Found: C, 59.82; H, 3.93; N, 8.82.
    • EXAMPLE 192 4-[4-(Hydroxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 192 was prepared as in Example 103 but substituting Example 191C for Example 61A to provide the title compound. [1766]
  • mp 195-196° C.; [1767]
  • MS (DCI/NH[1768] 3) m/e: 315 (M+H)+;
  • [1769] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H, J=4.5 Hz), 4.49 (d, 2H, J=4.5 Hz), 5.19 (t, 1H, J=4.5 Hz), 7.08 (d, 2H, J=8.5 Hz), 7.37 (d, 2H, J=8.5 Hz), 8.07 (s, 1H), 8.11 (s, 1H), 8.94 (q, 1H, J=4.5 Hz), 9.10 (s, 1H);
  • Anal. calcd for C[1770] 16H14N2O3S.0.75 CH3OH: C, 59.45; H, 4.39; N, 8.28. Found: C, 59.31; H, 4.35; N, 8.49.
    • EXAMPLE 193 4-[4-(Methoxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 193 was prepared as in Example 188C but substituting 4-methoxymethylphenol for 4-tert-butyloxycarbonylamino and substituting methylamine for ammonia to provide the title compound. [1771]
  • mp 163-164° C.; [1772]
  • MS (DCI/NH[1773] 3) m/e: 329 (M+H)+;
  • [1774] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.4 Hz), 3.29 (s, 3H), 4.40 (s, 2H), 7.08 (d, 2H, J=8.5 Hz), 7.37 (d, 2H, J=8.5 Hz), 8.09 (s, 1H), 8.12 (s, 1H), 8.94 (q, 1H, J=4.4 Hz), 9.12 (s, 1H);
  • Anal. calcd for C[1775] 17H16N2O3S: C, 62.18; H, 4.91; N, 8.53. Found: C, 61.86; H, 4.79; N, 8.40.
    • EXAMPLE 194 4-4-[(2-Methoxyethoxy)methyl]phenoxylthieno[2,3-c]pyridine-2-carboxamide
  • Example 194 was prepared as in Example 188C but substituting 4-(2-methoxyethoxymethyl)phenol for 4-tert-butyloxycarbonylaminophenol to provide the title compound. [1776]
  • MS (DCI/NH[1777] 3) m/e: 359 (M+H)+;
  • [1778] 1H NMR (300 MHz, CDCl3) δ3.40 (s, 3H), 3.60 (m, 2H), 3.65 (m, 2H), 4.56 (s, 2H), 7.02 (d, 2H, J=8.5 Hz), 7.36 (d, 2H, J=8.5 Hz), 7.80 (s, 1H), 8.13 (s, 1H), 8.94 (s, 1H);
  • Anal. calcd for C[1779] 18H18N2O4S: C, 60.32; H, 5.06; N, 7.82. Found: C, 60.33; H, 5.03; N, 7.63.
    • EXAMPLE 195 4-{4-[(2-Methoxyethoxy)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 195 was prepared as in Example 188C but substituting 4-(2-methoxyethoxymethyl)phenol for 4-tert-butyloxycarbonylaminophenol and substituting methylamine for ammonia to provide the title compound. [1780]
  • mp 133-134° C.; [1781]
  • MS (DCI/NH[1782] 3) m/e: 373 (M+H)+;
  • [1783] 1H NMR (300 MHz, CDCl3) δ3.01 (d, 3H, J=5.1 Hz), 3.40 (s, 3H), 3.60 (m, 2H), 3.65 (m, 2H), 4.54 (s, 2H), 6.51 (q, 1H, J=5.1 Hz), 7.00 (d, 2H, J=8.5 Hz), 7.34 (d, 2H, J=8.5 HZ), 7.73 (s, 1H), 8.14 (s, 1H), 8.94 (s, 1H);
  • Anal. calcd for C[1784] 19H20N2O4S: C, 61.27; H, 5.41; N, 7.52. Found: C, 61.28; H, 5.35; N, 7.46.
    • EXAMPLE 196 4-(4-{[2-(2-Methoxyethoxy)ethoxyl]methyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 196 was prepared as in Example 188C but substituting 4-{2-(2-methoxyethoxy)ethoxymethyl}phenol for 4-tert-butyloxycarbonylaminophenol to provide the title compound. [1785]
  • MS (DCI/NH[1786] 3) m/e: 403 (M+H)+;
  • [1787] 1H NMR (300 MHz, CDCl3) δ3.38 (s, 3H), 3.57 (m, 2H), 3.63-3.70 (m, 6H), 4.55 (s, 2H), 7.02 (d, 2H, J=8.5 Hz), 7.36 (d, 2H, J=8.5 Hz), 7.71 (s, 1H), 8.15 (s, 1H), 8.95 (s, 1H).
    • EXAMPLE 197 4-(4-{[2-(2-Methoxyethoxy)ethoxy]methyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 197 was prepared as in Example 188C but substituting 4-{2-(2-methoxyethoxy)ethoxymethyl}phenol for 4-tert-butyloxycarbonylaminophenol and substituting methylamine for ammonia to provide the title compound. [1788]
  • MS (DCI/NH[1789] 3) m/e: 417 (M+H)+;
  • [1790] 1H NMR (300 MHz, CDCl3) δ3.02 (d, 3H, J=4.8 Hz), 3.38 (s, 3H), 3.57 (m, 2H), 3.63-3.70 (m, 6H), 4.54 (s, 2H), 6.45 (m, 1H), 7.00 (d, 2H, J=8.5 Hz), 7.34 (d, 2H, J=8.5 Hz), 7.72 (s, 1H), 8.15 (s, 1H), 8.94 (s, 1H).
    • EXAMPLE 198 4-{4-[(2,3,4,5-Tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 198A Methyl 4-{4-{[(2,3,4,5-tetrahydro-2H-pyran-2-yl)oxy]methyl}phenoxy}thieno[2,3-c]pyridine-2-carboxylate
  • Example 198A was prepared as in Example 188B but substituting 4-[(2,3,4,5-tetrahydro-2H-pyran-2-yl)oxy]methylphenol (P. A. Grieco, et al, J. Org. Chem. 1977, 42, 3772) for 4-tert-butyloxycarbonylaminophenol to provide the designated compound. [1791]
  • MS (DCI/NH[1792] 3) m/e: 400 (M+H)+.
    • EXAMPLE 198B 4-{4-[(2,3,4,5-Tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide
  • Example 198B was prepared as in Example 61 but substituting Example 198A for Example 61A to provide the designated compound. [1793]
  • mp 95-96° C.; [1794]
  • MS (DCI/NH[1795] 3) m/e: 385 (M+H)+;
  • [1796] 1H NMR (300 MHz, DMSO-d6) δ1.49 (m, 4H), 1.69 (m, 2H), 3.49 (m, 1H), 3.80 (m, 1H), 4.44 (d, 1H, J=12.1 Hz), 4.67,(d, 1H, J=12.1 Hz), 4.70 (m, 1H), 7.10 (d, 2H, J=8.8 Hz), 7.41 (d, 2H, J=8.8 Hz), 7.87 (s, 1H), 8.08 (s, 1H), 8.20 (s, 1H), 8.46 (s, 1H), 9.12 (s, 1H);
  • Anal. calcd for C[1797] 20H20N2O4S.CH3OH: C, 60.56; H, 5.08; N, 6.73. Found: C, 60.51; H, 5.07; N, 6.59.
    • EXAMPLE 199 N-Methyl-4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide
  • Example 199 was prepared as in Example 103 but substituting Example 198A for Example 61 A to provide the designated compound. [1798]
  • mp 195-196° C.; [1799]
  • MS (DCI/NH) m/e: 399 (M+H)[1800] +;
  • [1801] 1H NMR (300 MHz, DMSO-d6) δ1.49 (m, 4H), 1.69 (m, 2H), 2.79 (d, 3H, J=4.8 Hz), 3.50 (m, 1H), 3.80 (m, 1H), 4.44 (d, 1H, J=12.1 Hz), 4.67 (d, 1H, J=12.1 Hz), 4.70 (m, 1H), 7.09 (d, 2H, J=8.8 Hz), 7.40 (d, 2H, J=8.8 Hz), 8.11 (s, 1H), 8.12 (s, 1H), 8.97 (q, 1H, J=4.8 Hz), 9.13 (s, 1H);
  • Anal. calcd for C[1802] 21H22N2O4S: C, 63.30; H, 5.56; N, 7.03. Found: C, 63.22; H, 5.58; N, 6.93.
    • EXAMPLE 200 4-{[2-(Aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy}benzyl 2-furoate
  • A solution of Example 191D (40 mg, 0.133 mmol) in DMF (5 mL) was treated with 2-furoic acid (45 mg, 0.4 mmol), HOBt (54 mg, 0.4 mmol), EDC (77 mg, 0.4 mmol) and 2 drops of triethylamine at room temperature for 48 hours. Brine was added and the mixture was extracted with EtOAc. The combined organic phases were washed with water, dried (MgSO[1803] 4) and concentrated. The residue was flash chromatographed on silica gel with 65% EtOAc/hexane to provide the designated compound.
  • mp 180-182° C.; [1804]
  • MS (DCI/NH[1805] 3) m/e: 395 (M+H)+;
  • [1806] 1H NMR (300 MHz, DMSO-d6) δ5.31 (s, 2H), 6.70 (dd, 1H, J=1.7, 3.4 Hz), 7.14 (d, 2H, J=8.5 Hz), 7.36 (d, 1H, J=3.4 Hz), 7.50 (d, 2H, J=8.5 Hz), 7.84 (s, 1H), 8.00 (dd, 1H, J=1.1, 3.7 Hz), 8.13 (s, 1H), 8.17 (s, 1H), 8.44 (s, 1H), 9.14 (s, 1H).
    • EXAMPLE 201 4-[4-({[(2R, 4R, 5S, 6R)-4,5-Dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 201A Methyl 4-[4-({[(2R, 4R, 5S, 6R)-4,5-Diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-yl]oxy}methyl)phenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 191C (200 mg, 0.63 mmol) and tri-O-acetyl-D-glycol (520 mg, 1.92 mmol) in dry CH[1807] 2Cl2 (10 mL) was treated with Sc(OTf)3 (380 mg, 0.75 mmol) at room temperature for 12 hours, and was directly flash chromatographed on silica gel with 40% EtOAc/hexane to provide the designated compound.
  • MS (DCI/NH[1808] 3) m/e: 528 (M-OAc)+.
    • EXAMPLE 201B 4-[4-({[(2R, 4R, 5S, 6R)-4,5-Dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 201A (167 mg) in a 2M solution of methylamine in methanol (10 mL) was heated at 45° C. for 12 hours, and was concentrated. The residual oil was chromatographed on silica gel with 8% MeOH/CH[1809] 2Cl2 to give the designated compound (120 mg, 91%).
  • MS (ESI/NH[1810] 3) m/e: 443 (M-OH)+;
  • [1811] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.8 Hz), 3.53 (m, 3H), 3.67 (m, 1H), 3.87 (m, 1H), 4.50 (d, 1H, J=11.5 Hz), 4.64 (t, 1H, J=5.4 Hz), 4.76 (d, 1H, J=11.5 Hz), 5.06 (m, 2H), 5.70 (dt, 1H, J=10.2, 2.4 Hz), 5.86 (d, 1H, J=10.2 Hz), 7.08 (d, 2H, J=8.5 Hz), 7.40 (d, 2H, J=8.5 Hz), 8.10 (s, 1H), 8.11 (s, 1H), 8.95 (q, 1H, J=4.8 Hz), 9.12 (s, 1H).
    • EXAMPLE 202 4-(4-Acetylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A flask, purged with nitrogen, was charged with Example 190B (500 mg, 1.2 mmol), Pd(OAc)[1812] 2 (27 mg, 0.12 mmol), (Tol)3P (110 mg, 0.36 mmol), dry degassed DMF (20 mL), tributylethoxyvinyltin (810 mL, 2.4 mmol), and triethylamine (835 mL, 6 mmol). This suspension was stirred at 80° C. for 14 hours. After diluting with ethyl acetate, the reaction mixture was washed with 1% HCl aqeous solution, water, dried (MgSO4), and concentrated. The residue was separated by HPLC (C-18, CH3CN/H2O containing 0.1% TFA) to provide the title compound (476 mg, 89%).
  • MS (DCI/NH[1813] 3) m/e: 327 (M+H)+,
  • [1814] 1H NMR (300 MHz, DMSO-d6) δ2.56 (s, 3H), 2.78 (d, 3H, J=4.8 Hz), 7.15 (d, 2H, J=8.8 Hz), 8.00 (d, 2H, J=8.8 Hz) 8.03 (s, 1H), 8.36 (s, 1H), 8.98 (q, 1H, J=4.8 Hz), 9.28 (s, 1H);
  • Anal. calcd for C[1815] 17H14N2O3S.1.35 CF3CO2H: C, 49.25; H, 3.45; N, 5.83. Found: C, 49.31; H, 3.60; N, 5.93.
    • EXAMPLE 203 4-[4-(4-Morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 203A Methyl 4-[4-(4-carboxy)phenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • A suspension of methyl 4-bromophenoxythieno[2,3-c]pyridine-2-carboxylate (1.0 g, 2.74 mmol), PdCl[1816] 2DPPFCH2Cl2 (0.284 g), and triethylamine (0.55 g) in a mixture of THF(15 mL) and H2O (15 mL) was heated at 130° C. under CO atmosphere (400 psi) for 19 hours. EtOAc (200 mL) was added, and the mixture was washed with brine, dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 5% CH3OH/CH2Cl2 to provide the designated compound (311 mg, 34%).
  • MS (DCI/NH[1817] 3) m/e: 330 (M+H)+.
    • EXAMPLE 203B Methyl 4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 203A (200 mg, 0.61 mmol) in a mixture DMF (5 mL) and CH[1818] 2Cl2 (15 mL) was treated with morpholine (80 mg, 0.91 mmol), PyBOP (474 mg, 0.91 mmol) and DIPEA (296 mg, 2.28 mmol) at room temperature for 2 hours. After diluting with CH2Cl2, the solution was washed with brine, dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 90% EtOAc/hexane to give the designated compound (277 mg, 100%).
  • MS (DCI/NH[1819] 3) m/e: 399 (M+H)+.
    • EXAMPLE 203C 4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 203C was prepared as in Example 61 but substituting Example 203B for Example 61 A to provide the title compound. [1820]
  • mp>260° C.; [1821]
  • MS (DCI/NH[1822] 3) m/e: 401 (M+NH4)+;
  • [1823] 1H NMR (300 MHz, DMSO-d6) δ3.50 (m, 4H), 3.60 (m, 4H), 7.14 (d, 2H, J=8.5 Hz), 7.48 (d, 2H, J=8.5 Hz), 7.86 (s, 1H), 8.15 (s, 1H), 8.22 (s, 1H), 8.45 (s, 1H), 9.17 (s, 1H);
  • Anal. calcd for C[1824] 19H17N3O4S: C, 59.52; H, 4.47; N, 10.96. Found: C, 59.64; H, 4.52; N, 10.90.
    • EXAMPLE 204 N-Methyl-4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 204 was prepared as in Example 103 but substituting Example 203B for Example 61A to provide the title compound. [1825]
  • mp 173-175° C.; [1826]
  • MS (DCI/NH[1827] 3) m/e: 415 (M+NH4)+;
  • [1828] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.4 Hz), 3.50 (m, 4H), 3.60 (m, 4H), 7.12 (d, 2H, J=8.5 Hz), 7.48 (d, 2H, J=8.5 Hz), 8.07 (s, 1H), 8.24 (s, 1H), 8.96 (q, 1H), J=4.4 Hz), 9.18 (s, 1H);
  • Anal. calcd for C[1829] 20H19N3O4S.1.5 CH3OH: C, 57.96; H, 4.64; N, 9.43. Found: C, 57.99; H, 4.86; N, 9.63.
    • EXAMPLE 206 4-[4-({[2-(4-Morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 206A Methyl 4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 203A (200 mg, 0.61 mmol) in DMF (11 mL) was treated with 4-(2-aminoethyl)morpholine (158 mg, 1.21 mmol), EDC (232 mg, 1.21 mmol), HOBt (164 mg, 1.21 mmol) and triethylamine (122 mg, 1.21 mmol) at room temperature for 18 hours. After diluting with EtOAc, the reaction mixture was washed with brine, dried (MgSO[1830] 4) and concentrated. The residue was flash chromatographed on silica gel with 10% MeOH/EtOAc to provide the designated compound (239 mg, 89%).
  • MS (DCI/NH[1831] 3) m/e: 442 (M+H)+.
    • EXAMPLE 206B 4-[4-({[2-(4-Morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2 3-c]pyridine-2-carboxamide
  • Example 206B was prepared as in Example 61 but substituting Example 206A for Example 61A to provide the title compound. [1832]
  • mp 214-216° C.; [1833]
  • MS (DCI/NH[1834] 3) m/e: 427 (M+H)+;
  • [1835] 1H NMR (300 MHz, DMSO-d6) δ2.41 (t, 4H, J=4.8 Hz), 3.37 (q, 2H, J=6.1 Hz), 3.56 (t, 4H, J=4.8 Hz), 7.14 (d, 2H, J=8.8 Hz), 7.84 (s, 1H), 7.87 (d, 2H, J=8.8 Hz), 8.11 (s, 1H), 8.22 (s, 1H), 8.39 (t, 1H, J=6.0 Hz), 8.43 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 207 N-Methyl-4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 207 was prepared as in Example 103 but substituting Example 206A for Example 61 A to provide the title compound. [1836]
  • mp 226-228° C.; [1837]
  • MS (DCI/NH[1838] 3) m/e: 441 (M+H)+;
  • [1839] 1H NMR (300 MHz, DMSO-d6) δ2.42 (m, 4H), 2.78 (d, 3H, J=4.4 Hz), 3.36 (q, 2H, J=6.1 Hz), 3.56 (t, 4H, J=4.8 Hz), 7.12 (d, 2H, J=8.5 Hz), 7.89 (d, 2H, J=8.5 Hz), 8.03 (s, 1H), 8.26 (s, 1H), 8.41 (t, 1H, J=6.0 Hz), 8.95 (q, 1H, J=4.4 Hz), 9.20 (s, 1H).
    • EXAMPLE 208 4-{4-[(E)-3-(4-Morpholinyl)-3-oxo-1-propenyl]phenoxyl}thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 208A Methyl 4-{4-[(E)-3-(tert-butyloxy)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxylate
  • A flask, purged with nitrogen, was charged with Example 73 (50 mg, 1.37 mmol), Pd[1840] 2(dba)3 (63 mg, 0.069 mmol), tri-o-tolylphosphine (64 mg, 0.21 mmol), dry degassed DMF (20 mL), t-butyl acrylate (602 mL, 4.11 mmol), and triethylamine (575 mL, 4.11 mmol). This suspension was stirred at 100° C. under nitrogen for 12 hours. After diluting with ethyl acetate, the reaction mixture was washed with brine, water, dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 20% EtOAc/hexane to provide the title compound (323 mg, 57%).
  • MS (DCI/NH[1841] 3) m/e: 412 (M+H)+.
    • EXAMPLE 208B Methyl 4-{4-[(E)-propenoic acid-1-yl]phenoxy}thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 208A (1.76 g, 4.2 mmol) in chloroform (50 mL) was treated with trifluoroacetic acid (10 mL) at room temperature for 4 hours, and was then poured into ice-cold aqueous NaHCO[1842] 3. The formed white solid was collected by filtration, washed with water, MeOH, CH2Cl2, and dried to provide the designated compound (1.38 g, 100%).
  • MS (DCI/NH[1843] 3) m/e: 356 (M+H)+.
    • EXAMPLE 208C Methyl 4-{4-[(E)-3-(4-morpholinyl)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 208B (260 mg, 0.73 mmol) in a mixture of DMF (5 mL) and CH[1844] 2Cl2 (10 mL) was treated with morpholine (127 mg, 1.46 mmol), PyBOP (760 mg, 1.46 mmol) and DIPEA (380 mg, 2.92 mmol) at room temperature for 12 hours. After diluting with CH2Cl2, the solution was washed with brine, dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 90% EtOAc/hexane to give the designated compound.
  • MS (DCI/NH[1845] 3) m/e: 425 (M+H)+.
    • EXAMPLE 208D 4-{4-[(E)-3-(4-morpholinyl)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide
  • Example 208D was prepared as in Example 61 but substituting Example 208C for Example 61 A to provide the title compound. [1846]
  • MS (DCI/NH[1847] 3) m/e: 410 (M+H)+;
  • [1848] 1H NMR (300 MHz, DMSO-d6) δ3.59 (m, 6H), 3.70 (m, 2H), 7.13 (d, 2H, J=8.5 Hz), 7.20 (d, 1H, J=15.5 Hz), 7.52 (d, 1H, J=15.5 Hz), 7.79 (d, 2H, J=8.5 Hz), 7.86 (s, 1H), 8.16 (s, 1H), 8.18 (s, 1H), 8.45 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 209 4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 209A Methyl 4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxylthieno-2,3-c]pyridine-2-carboxylate
  • Example 209A was prepared as in Example 208C but substituting 4-(2-aminoethyl)morpholine for morpholine to provide the designated compound. [1849]
  • MS (DCI/NH[1850] 3) m/e: 468 (M+H)+.
    • EXAMPLE 209B 4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 209B was prepared as in Example 61 but substituting Example 209A for Example 61A to provide the title compound. [1851]
  • MS (DCI/NH[1852] 3) m/e: 453 (M+H)+;
  • [1853] 1H NMR (300 MHz, DMSO-d6) δ2.44 (m, 4H), 3.30 (m, 4H), 3.59 (t, 4H, J=4.8 Hz), 6.60 (d, 1H, J=15.8 Hz), 7.13 (d, 2H, J=8.8 Hz), 7.42 (d, 1H, J=15.8 Hz), 7.61 (d, 2H, J=8.8 Hz), 7.87 (s, 1H), 8.06 (t, 1H, J=4.8 Hz), 8.16 (s, 1H), 8.21 (s, 1H), 8.45 (s, 1H), 9.17 (s, 1H).
    • EXAMPLE 210 N-methyl-4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxylthieno[2,3-c]pyridine-2-carboxamide
  • Example 210 was prepared as in Example 103 but substituting Example 209A for Example 61A to provide the title compound. [1854]
  • MS (DCI/NH[1855] 3) m/e: 467 (M+H)+;
  • [1856] 1H NMR (300 MHz, DMSO-d6) δ2.38 (m, 4H), 2.79 (d, 3H, J=4.4 Hz), 3.59 (m, 8H), 6.58 (d, 1H, J=15.8 Hz), 7.11 (d, 2H, J=8.8 Hz), 7.42 (d, 1H, J=15.8 Hz), 7.61 (d, 2H, J=8.8 Hz), 8.05 (s, 1H), 8.23 (s, 1H), 8.95 (q, 1H, J=4.4 Hz), 9.17 (s, 1H).
    • EXAMPLE 211 4-(4-{(E)-3-[(2,3-Dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE211A Methyl 4-(4-{(E)-3-[(2,3-Dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 208B (250 mg, 0.71 mmol)) in DMF (10 mL) was treated with 3-amino-1,2-propanediol (128 mg, 1.41 mmol), EDC (270 mg, 1.41 mmol), HOBt (191 mg, 1.41 mmol) and triethylamine (142 mg, 1.41 mmol) at room temperature for 18 hours. After diluting with EtOAc, the reaction mixture was washed with brine, dried (MgSO[1857] 4) and concentrated. The residue was flash chromatographed on silica gel to provide the designated compound (189 mg, 63%).
  • MS (DCI/NH[1858] 3) m/e: 429 (M+H)+.
    • EXAMPLE 211B 4-(4-{(E)-3-[(2,3-Dihydroxypropyl)amino]-3-oxo-1-propeny}phenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 211B was prepared as in Example 61 but substituting Example 211A for Example 61A to provide the title compound. [1859]
  • mp 185-187° C.; [1860]
  • MS (DCI/NH[1861] 3) m/e: 414 (M+H)+;
  • [1862] 1H NMR (300 MHz, DMSO-d6) δ3.10 (m, 1H), 3.30 (m, 2H), 3.54 (m, 1H), 4.60 (t, 1H, J=5.9 Hz), 4.84 (d, 1H, J=4.8 Hz), 6.66 (d, 1H, J=15.8 Hz), 7.13 (d, 2H, J=8.8 Hz), 7.42 (d, 1H, J=15.8 Hz), 7.61 (d, 2H, J=8.8 Hz), 7.86 (s, 1H), 8.08 (t, 1H, J=5.5 Hz), 8.16 (s, 1H), 8.21 (s, 1H), 8.45 (s, 1H), 9.17 (s, 1H);
  • Anal. calcd for C[1863] 20H19N3O5S: C, 58.10; H, 4.63; N, 10.16. Found: C, 57.99; H, 4.54; N, 10.08.
    • EXAMPLE 212 4-(4-{(E)-3-[(2,3-Dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 212 was prepared as in Example 103 but substituting Example 211A for Example 61A to provide the title compound. [1864]
  • mp 225-226° C.; [1865]
  • MS (DCI/NH[1866] 3) m/e: 428 (M+H)+;
  • [1867] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.8 Hz), 3.10 (m, 1H), 3.30 (m, 2H), 3.54 (m, 1H), 4.60 (t, 1H, J=5.5 Hz), 4.84 (d, 1H, J=4.8 Hz), 6.66 (d, 1H, J=15.8 Hz), (d, 2H, J=8.8 Hz), 7.42 (d, 1H, J=15.8 Hz), 7.61 (d, 2H, J=8.8 Hz), 8.06 (s, 1H), 8.08 (s, 1H, J=5.5 Hz), 8.23 (s, 1H), 8.97 (q, 1H, J=4.8 Hz), 9.18 (s, 1H);
  • Anal. calcd for C[1868] 21H21N3O5S: C, 59.00; H, 4.95; N, 9.83. Found: C, 58.85; H, 4.90; N, 9.58.
    • EXAMPLE 213 4-[4-((E)-3-{[2-(1H-Imidazole-4-yl)ethyl]amino}-3-oxo-1-propenyl)phenoxyl-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 213 was prepared as in Example 212 but substituting 2-(1H-imidazol-5-yl)ethylamine for 3-amino-1,2-propanediol to provide the title compound. [1869]
  • MS (DCI/NH[1870] 3) m/e: 448 (M+H)+;
  • [1871] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.5 Hz), 2.85 (t, 2H, J=6.6 Hz), 3.49 (q, 2H, J=6.0 Hz), 6.53 (d, 1H, J=15.8 Hz), 7.11 (d, 2H, J=8.5 Hz), 7.42 (d, 1H, J=15.8 Hz), 7.47 (s, 1H), 7.61 (d, 2H, J=8.5 Hz), 8.07 (s, 1H), 8.24 (s, 1H), 8.27 (t, 1H, J=5.5 Hz), 8.97 (q, 1H, J=4.8 Hz), 9.01 (s, 1H), 9.21 (s, 1H).
    • EXAMPLE 214 4-{4-[(E)-3-({2-[bis(2-Hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 214 was prepared as in Example 212 but substituting 2-[bis(2-hydroxyethyl)amino]ethylamine for 3-amino-1,2-propanediol to provide the title compound. [1872]
  • MS (DCI/NH[1873] 3) m/e: 485 (M+H)+;
  • [1874] 1H NMR (300 MHz, DMSO-d6) δ2.79 (d, 3H, J=4.8 Hz), 3.34 (m, 6H), 3.58 (q, 2H, J=6.1 Hz), 3.77 (t, 4H, J=5.1 Hz), 6.55 (d, 1H, J=15.6 Hz), 7.13 (d, 2H, J=8.5 Hz), 7.48 (d, 1H, J=15.6 Hz), 7.64 (d, 2H, J=8.5 Hz), 8.07 (s, 1H), 8.24 (s, 1H), 8.43 (t, 1H, J=4.8 Hz), 8.97 (q, 1H, J=4.8 Hz), 9.20 (s, 1H).
    • EXAMPLE 215 4-{4-[(E)-3-({2-[Bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 215 was prepared as in Example 211 but substituting bis(2-hydroxyethyl)aminoethylamine for 3-amino-1,2-propanediol to provide the title compound. [1875]
  • MS (DCI/NH[1876] 3) m/e: 471 (M+H)+;
  • [1877] 1H NMR (300 MHz, DMSO-d6) δ2.56 (m, 4H), 3.21 (m, 2H), 3.41 (m, 4H), 4.37 (t, 2H, J=5.6 Hz), 6.56 (d, 1H J=15.4 Hz), 7.13 (d, 2H, J=8.8 Hz), 7.42 (d, 1H, J=15.4 Hz), 7.61 (d, 2H, J=8.8 Hz), 7.86 (s, 1H), 8.00 (t, 1H, J=5.5 Hz), 8.15 (s, 1H), 8.21 (s, 1H), 8.45 (s, 1H), 9.17 (s, 1H);
  • Anal. calcd for C[1878] 23H26N4O5S.CH3OH: C, 56.36; H, 5.41; N, 11.15. Found: C, 56.40; H, 5.76; N, 11.40.
    • EXAMPLE 216 4-(4-{3-Hydroxy-3-[4-({2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-4-yl}oxy)phenyl]butanoyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 202 (200 mg, 0.45 mmol) in THF (5 mL) was treated with methylmagnesium bromide (3 M solution in ether, 0.18 mL, 0.55 mmol) at −50° C. for 30 minutes, and slowly warmed up to room temperature for 10 minutes. An aqueous NH[1879] 4Cl solution was added, and the mixture was extracted with ether. The combined organic phases were washed with brine, water, dried (MgSO4), and concentrated. The residue was flash chromatographed on silica gel with 5% MeOH/EtOAc to provide the title compound (60 mg, 40%).
  • MS (ESI/NH[1880] 3) m/e: 653 (M+H)+;
  • [1881] 1H NMR (300 MHz, DMSO-d6) δ1.58 (s, 3H), 2.77 (d, 3H, J=4.8 Hz), 2.80 (d, 3H, J=4.8 Hz), 3.35 (d, 1H, J=13.0 Hz), 3.49 (d, 1H, J=13.0 Hz), 5.27 (s, 1H), 7.02 (d, 2H, J=8.8 Hz); 7.08 (d, 2H, J=8.8 Hz), 7.53 (d, 2H, J=8.8 Hz), 7.96 (d, 2H, J=8.8 Hz), 7.99 (s, 2H), 8.13 (s, 1H), 8.30 (s, 1H), 8.94 (m, 2H), 9.08 (s, 1H), 9.21 (s, 1H);
  • Anal. calcd for C[1882] 34H28N4O6S2.CH3OH: C, 61.39; H, 4.27; N, 8.18. Found: C, 61.26; H, 4.29; N, 7.95.
    • EXAMPLE 217 4-[4-(1H-imidazol-1-yl)phenoxyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 217A Methyl 4-[4-(1H-imidazol-1-yl)phenoxy]thieno[[2,3-c]pyridine-2-carboxylate
  • Example 17A (0.88 g, 5 mmol) in THF (15 mL) and DMF (5 mL) was treated with 4-(1-imidazolyl)phenol and potassium t-butoxide (1 N in THF, 5.0 mL, 5 mmol) at 70° C. for 4 hours, then cooled to 0° C., added methyl thioglycolate (0.4 mL, 5 mmol) and cesium carbonate (1.62 g, 5 mmol) then refluxed for 1 hour. The reaction was poured into water, diluted with brine and extracted with ethyl acetate. The ethyl acetate was then washed with 1 N NaOH (2×20 mL), then brine (3×20 mL), dried (MgSO[1883] 4) to give the titled compound.
  • MS (DCI/NH[1884] 3) m/e: 352 (M+H)+;
  • [1885] 1H NMR (300 MHz, DMSO-d6) δ3.90 (s, 3H), 7.10 (s, 1H), 7.30 (d, 2H), 7.70 (s, 1H), 7.25 (d, 2H), 8.00 (s, 1H), 8.25 (d, 2H), 9.25 (s, 1H).
    • EXAMPLE 217B 4-[4-(1H-Imidazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 217A was dissolved in 2 M methanolic ammonia and warmed at 50° C. in a sealed tube for 24 hours. The reaction was then evaporated and crystallized from methanol to give the titled compound. [1886]
  • mp 310-312° C.; [1887]
  • MS (DCI/NH[1888] 3) m/e: 337 (M+H)+;
  • [1889] 1H NMR (300 MHz, DMSO-d6) δ7.10 (s, 1H), 7.28 (m, 2H), 7.68 (t, 1H), 7.25 (dd, 2H), 7.85 (br s, 1H), 8.15 (s, 1H), 8.20 (d, 2H), 8.45 (br s, 1H), 9.15 (s, 1H);
  • Anal. Calcd for C[1890] 17H12N4O2S.0.50 H2O: C, 59.12; H, 3.79; N, 16.22. Found: C, 59.40; H, 33.63; N, 16.30.
    • EXAMPLE 218 N-Methyl-4-[4-(1H-pyrazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 218A Methyl-4-(4-(1H-pyrazol-1-yl)phenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • Example 17A (0.8 g, 5 mmol) in THF (15 mL) was treated with 4-(1H-pyrazol-1-yl)phenol and cesium carbonate (1.6 g, 5 mmol) under reflux for 4 hours, then cooled to 0° C., then methyl thioglycolate (0.4 mL, 5 mmol) and cesium carbonate (1.62 g, 5 mmol) were added, then the mixture was refluxed for 1 hour. The mixture was poured into water, diluted with brine and extracted with ethyl acetate. The ethyl acetate was then washed with 1 N NaOH (2×20 mL), then brine (3×20 mL), dried (MgSO[1891] 4) to give the titled compound.
  • MS (DCI/NH[1892] 3) m/e: 352 (M+H)+;
  • [1893] 1H NMR (300 MHz, DMSO-d6) δ3.80 (s, 3H), 6.55 (m, 1H), 7.30 (d, 2H), 7.42 (d, 1H), 7.75 (d, 1H), 7.90 (d, 2H), 8.25 (s, 1H), 8.50 (d, 1H), 9.22 (s, 1H).
    • EXAMPLE 218B N-Methyl-4-[4-(1H-pyrazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 218A was dissolved in 2 M methanolic methylamine and warmed at 50° C. in a round bottom flask for 4 hours. The reaction was then evaporated and crystallized from methanol to give the titled compound. [1894]
  • mp 192-194° C.; [1895]
  • MS (DCI/NH[1896] 3) m/e: 351 (M +H)+;
  • [1897] 1H NMR (300 MHz, DMSO-d6) δ2.70 (d, 3H), 6.55 (m, 1H), 7.25 (d, 2H), 7.75 (br s, 1H), 7.90 (d, 2H), 8.12 (s, 1H), 8.20 (s, 1H), 8.50 (d, 1H), 9.00 (m, 1H), 9.18 (s, 1H);
  • Anal. Calcd for C[1898] 18H14N4O2S.0.25 H2O: C, 60.15; H, 4.21; N, 15.59. Found: C, 60.30; H, 3.93; N, 15.73.
    • EXAMPLE 219 N-Methyl-4-[4-(1H-1,2,4-triazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-(1H-1,2,4-triazol-1-yl)phenol were processed as in Example 218 to provide the title compound. [1899]
  • mp 214-215° C.; [1900]
  • MS (DCI/NH[1901] 3) m/e: 352 (M+H)+;
  • [1902] 1H NMR (300 MHz, DMSO-d6) δ2.70 (d, 3H), 7.30 (d, 2H), 7.55 (b, 1H), 7.90 (d, 2H), 8.12 (s, 1H), 8.25 (d, 1H), 9.00 (q, 1H), 9.30 (s, 1H).
    • EXAMPLE 220 N-Methyl-4-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 220A N-Methyl-4-[4-(N-hydroxylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 186 (500 mg, 1.62 mmol) in a mixture of DMF (10 mL) and EtOH (10 mL) was treated with triethylamine (279 mg, 2.75 mmol) and hydroxylamine hydrochloride (169 mg, 2.43 mmol) at room temperature for 18. hours. The formed white solid was collected by filtration, washed with EtOH, dried to provide the designated compound (376 mg, 68%). [1903]
  • MS (ESI/NH[1904] 3) m/e: 343 (M+H)+.
    • EXAMPLE 220B N-Methyl-4-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxyl}thieno[2,3-c]pyridine-2-carboxamide
  • A suspension of Example 220A (200 mg, 0.58 mmol) in pyridine (8 mL) was treated with trifluoroacetic anhydride (178 mg, 0.85 mmol) at room temperature for 1 hour. The resultant yellow solution was heated at 120° C. for 18 hours, and was then concentrated. The residue was separated by HPLC (C-18, CH[1905] 3CN/H2O containing 0.1% TFA) to provide the title compound (169 mg, 69%).
  • mp 174-176° C.; [1906]
  • MS (ESI/NH[1907] 3) m/e: 421 (M+H)+;
  • [1908] 1H NMR (300 MHz, DMSO-d6) δ2.78 (d, 3H, J=4.4 Hz), 7.26 (d, 2H, J=8.8 Hz), 8.03 (s, 1H), 8.10 (d, 2H, J=8.8 Hz), 8.38 (s, 2H), 8.96 (q, 1H, J=4.4 Hz), 9.25 (s, 1H);
  • Anal. calcd for C[1909] 18H11N4O3SF3: C, 51.43; H, 2.64; N, 13.33. Found: C, 51, 56; H, 2.76; N, 13.32.
    • EXAMPLE 221 4-[4-(4,5-Dihydro-1H-imidazol-2-yl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 186 (800 mg, 2.6 mmol) in a mixture of MeOH (30 mL), Et[1910] 2O (20 mL), and CH2Cl2 (30 mL) was introduced hydrogen chloride gas at 0° C. for 1.5 hours, stirred at room temperature for 24 hours, and concentrated. The residue was dissolved in MeOH (30 mL) and ethylenediamine (3 mL), and heated at 70° C. for 2 hours. After the reaction was cooled, the resultant white solid was collected by filtration, washed with methanol, and dried to provide the title compound (804 mg, 88%).
  • mp>280° C.; [1911]
  • MS (ESI/NH[1912] 3) m/e: 353 (M+H)+;
  • [1913] 1H NMR (300 MHz, DMSO-d6) δ2.78 (d, 3H, J=4.4 Hz), 3.32 (br s, 4H), 6.88 (br s, 1H), 7.11 (d, 2H, J=8.8 Hz), 7.85 (d, 2H, J=8.8 Hz), 8.04 (s, 1H), 8.22 (s, 2H), 8.93 (q, 1H, J=4.4 Hz), 9.17 (s, 1H);
  • Anal. calcd for C[1914] 18H16N4O2S: C, 59.36; H, 4.46; N, 14.57. Found: C, 59.60; H, 4.55; N, 14.40.
    • EXAMPLE 222 N-Methyl-4-[4-(2-thienyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • A flask, purged with nitrogen, was charged with Example 190B (200 mg, 0.48 mmol), Pd(OAc)[1915] 2 (11 mg, 0.048 mmol), tri-o-tolylphosphine (44 mg, 0.14 mmol), dry degassed DMF (10 mL), 2-tributylstannylthiophene (305 mL, 0.96 mmol), and triethylamine (334 mL, 2.4 mmol). This suspension was stirred at 80° C. for 15 hours. After diluting with ethyl acetate, the reaction mixture was washed with brine, H2O, dried (MgSO4), and concentrated. The residue was separated by HPLC (C-18, CH3CN/H2O containing 0.1% TFA) to provide the title compound (212 mg, 90%).
  • MS (ESI/NH[1916] 3) m/e: 367 (M+H)+;
  • [1917] 1H NMR (300 MHz, DMSO-D6) δ2.80 (d, 3H, J=4.4 Hz), 7.13 (m, 1H), 7.17 (d, 2H, J=8.8 Hz), 7.48 (d, 1H, J=3.7 Hz), 7.54 (d, 1H, J=5.1 Hz), 7.71 (d, 2H, J=8.8 Hz), 8.15 (s, 1H), 8.24 (s, 1H), 9.02 (q, 1H, J=4.4 Hz), 9.22 (s, 1H).
    • EXAMPLE 223 4-([1,1′-Biphenyl]-4-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 223 was prepared as in Example 222 but substituting tributylphenyltin for (tributylstannyl)thiophene to provide the title compound. [1918]
  • MS (ESI/NH[1919] 3) m/e: 361 (M+H)+;
  • [1920] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H, J=4.5 Hz), 7.19 (d, 2H, J=8.8 Hz), 7.36 (t, 1H, J=7.4 Hz), 7.47 (t, 2H, J=7.3 Hz), 7.66 (d, 2H, J=7.3 Hz), 7.72 (d, 2H, J×8.8 Hz), 8.15 (s, 1H), 8.23 (s, 1H), 9.00 (q, 1H, J=4.4 Hz), 9.19 (s, 1H).
    • EXAMPLE 224 N-Methyl-4-[4-(1-methyl-1H-imidazol-5-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 224 was prepared as in Example 222 but substituting 1-methyl-(5-tributylstannyl)imidazole, which was prepared according to a literature method (K. Gaare, et al., Acta Chem. Scand. 1993, 47, 57), for 2-tributylstannylthiophene to provide the title compound. [1921]
  • mp 256-258° C.; [1922]
  • MS (ESI/NH[1923] 3) m/e 365(M+H)+;
  • [1924] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H, J=2.1 Hz), 3.67 (s, 3H), 7.03 (s, 1H), 7.17 (d, 2H, J=8.8 Hz), 7.53 (d, 2H, J=8.8 Hz), 7.69 (s, 1H), 8.12 (s, 1H), 8.22 (s, 1H), 9.00 (q, 1H, J=2.1 Hz), 9.16 (s, 1H);
  • Anal. calcd for C[1925] 19H16N4O2S: C, 62.62; Hi 4.43; N, 15.37. Found: C, 62.38; H, 4.23; N, 15.13.
    • EXAMPLE 225 4-{4-[1-(Hydroxymethyl)cyclopropyl]phenoxyl}-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 225A 4-(1-Hydroxymethylcyclopropyl)anisole
  • A solution of 1-(4-methoxyphenyl)-1-cyclopropane-carboxylic acid (5.0 g, 26 mmol) in THF (100 mL) was slowly treated with LiAlH[1926] 4 (0.95 g, 25 mmol) at −20° C. for 0.5 hour, and was then warmed to room temperature for 2 hours. The excess LiAlH4 was consumed by slowly adding EtOH. After diluting with ether, the reaction mixture was washed with 2% HCl in brine, water, dried (MgSO4) and concentrated to provide the designated compound (5.0 g, 100%).
  • MS (DCI/NH[1927] 3) m/e: 196 (M+NH4)+.
    • EXAMPLE 225B 4-(1-Hydroxymethylcyclopropyl)phenol
  • To a suspension of NaH (60% in mineral oil, 392 mg, 9.8 mmol) in DMF (10 mL) was slowly added neat ethanethiol (610 mg, 9.8 mmol) at room temperature. The reaction mixture was stirred for 10 minutes to form a clear solution. Example 225A (500 mg, 2.8 mmol) was then added, and the mixture was heated at 145° C. for 4 hours. After diluting with ether, the reaction mixture was washed with 2% HCl in brine, dried (MgSO[1928] 4) and concentrated. The residue was flash chromatographed on silica gel with 50% EtOAc/hexane to provide the designated compound (373 mg, 81%).
  • MS (DCI/NH[1929] 3) m/e: 182 (M+NH4)+.
    • EXAMPLE 225C 4-(1-Triphenylmethoxymethylcyclopropyl)phenol
  • A solution of Example 225B (1.0 g, 6 mmol) in pyridine (7 mL) was treated with triphenylmethyl chloride (1.87 g, 6.7 mmol) at room temperature for 18 hours. After diluting with ether, the reaction mixture was washed 1% aqeous HCl, water and dried (MgSO[1930] 4). The residue was flash chromatographed on silica gel with 12% EtOAc/hexane to provide the designated compound.
  • MS (DCI/NH[1931] 3) m/e: 407 (M+H)+.
    • EXAMPLE 225D Methyl 4-[4-(1-triphenylmethoxymethyl)cyclopropyl]phenoxy-[2,3-c]pyridine-2-carboxylate
  • Example 225D was prepared as in Example 61A but substituting Example 225C for 4-chlorophenol to provide the designated compound. [1932]
  • MS (DCI/NH[1933] 3) m/e: 598 (M+H)+.
    • EXAMPLE 225E Methyl 4-[4-(1-hydroxymethyl)cyclopropyl]phenoxy-]2,3-c]pyridine-2-carboxylate
  • A solution of Example 225D (230 mg, 0.38 mmol) in a mixture of CH[1934] 2Cl2 (10 mL) and MeOH (5 mL) was treated with trifluoroacetic acid (1 mL) at 0° C. for 1 hour, allowed to warm to room temperature and stir for 1 hour, and was poured into aqueous NaHCO3 solution. The mixture was extracted with methylene chloride. The combined organic phases were washed with water, and dried (MgSO4). The residue was flash chromatographed on silica gel with 65% EtOAc/hexane to provide the designated compound (78 mg, 58%).
  • MS (DCI/NH[1935] 3) m/e: 356 (M+H)+.
    • EXAMPLE 225F 4-[4-(1-Hydroxymethyl)cyclopropyl]phenoxy-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 225F was prepared as in Example 103 but substituting Example 225E for Example 61A to provide the designated compound. [1936]
  • MS (ESI/NH[1937] 3) m/e: 355 (M+H)+;
  • [1938] 1H NMR (300 MHz, DMSO-d6) δ0.72 (m, 2H), 0.82 (m, 2H), 2.80 (d, 3H, J=4.7 Hz), 3.51 (d, 2H, J=5.8 Hz), 4.66 (t, 1H, J=5.8 Hz), 7.01 (d, 2H, J=8.8 Hz), 7.34 (d, 2H, J=8.8 Hz), 8.06 (s, 1H), 8.13 (s, 1H), 8.96 (q, 1H, J=4.7 Hz), 9.10 (s, 1H).
    • EXAMPLE 226 4-[4-(1-{2-(2-Ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxyl-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 226A 4-(2-(2-Ethoxyethoxy)ethoxy)methylcyclopropyl)anisole
  • A solution of Example 225A (1.0 g, 5.6 mmol) in THF (15 mL) was treated with NaH (60% in mineral oil, 312 mg, 7.8 mmol) and 15-crown-5 (1.33 mL, 6.7 mmol) at room temperature for 15 minutes followed by addition of 2-(2-ethoxyethoxy)ethyl tosylate (1.93 g, 6.7 mmol) which was prepared according to literature method (C. Almansa, et al, Tetrahedron 1991, 47, 5867). The brown slurry was stirred at room temperature for 5 hours and was poured into brine. The mixture was extracted with CH[1939] 2Cl2, and the combined organic phases were dried (MgSO4) and concentrated. The residue was flash chromatographed on silica gel with 25% EtOAc/hexane to provide the designated compound (1.58 g, 95%).
  • MS (ESI/NH[1940] 3) m/e: 312(M+NH4)+.
    • EXAMPLE 226B 4-(2-(2-Ethoxyethoxy)ethoxy)methylcyclopropyl)phenol
  • A solution of Example 226A (1.5 g, 5.1 mmol) in DMF (15 mL) was treated with sodium thiomethoxide (1.25 g, 17.8 mmol) at 145° C. for 5 hours. After cooling to room temperature methylene chloride (100 mL) was added, and the mixture was washed with 2% HCl in brine. The organic layer was dried (MgSO[1941] 4), concentrated and the residue was flash chromatographed on silica gel with 35% EtOAc/hexane to provide the designated compound (1.33 g, 93%).
  • MS (ESI/NH[1942] 3) m/e: 298(M+NH4)+.
    • EXAMPLE 226C Methyl 4-[4-(1-{[2-(2-Ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxyl]-N-methylthieno[2,3-c]pyridine-2-carboxylate
  • Example 226C was prepared as in Example 61A but substituting Example 226B for 4-chlorophenol to provide the designated compound. [1943]
  • MS (ESI/NH[1944] 3) m/e: 472 (M+H)+.
    • EXAMPLE 226D 4-[4-(1-{[2-(2-Ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 226D was prepared as in Example 103 but substituting Example 226C for Example 61A to provide the title compound. [1945]
  • MS (ESI/NH[1946] 3) m/e: 471 (M+H)+;
  • [1947] 1H NMR (300 MHz, DMSO-d6) δ0.84 (m, 2H), 0.87 (m, 2H), 1.06 (t, 3H, J=6.7 Hz), 2.82 (d, 3H, J=4.4 Hz), 3.37 (t, 2H, J=6.7 Hz), 3.39-3.55 (m, 10H), 7.07 (d, 2H, J=8.8 Hz), 7.36 (d, 2H, J=8.8 Hz), 8.13 (s, 1H), 8.26 (s, 1H), 9.10 (q, 1H, J=4.4 Hz), 9.28 (s, 1H);
  • Anal. calcd for C[1948] 25H30N4O5S: C, 59.22; H, 6.16; N, 5.52. Found: C, 59.50; H, 6.16; N, 5.26.
    • EXAMPLE 227 N-Methyl-4-[4-(trifluoromethoxy)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 227 was prepared as in Example 103 but substituting 4-trifluoromethoxyphenol for 4-chlorophenol to provide the title compound. [1949]
  • mp 132-133° C.; [1950]
  • MS (ESI/NH[1951] 3) m/e: 368 (M+H)+;
  • [1952] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H, J=4.4 Hz), 7.20 (d, 2H, J=9.2 Hz), 7.41 (d, 2H, J=9.2 Hz), 8.08 (s, 1H), 8.21 (s, 1H), 8.95 (q, 1H, J=4.4 Hz), 9.18 (s, 1H);
  • Anal. calcd for C[1953] 16H11N2O3SF3: C, 52.17; H, 3.01; N, 7.61. Found: C, 52.21; H, 3.26; N, 7.29.
    • EXAMPLE 228 5-{4-[4-(1-{[2-(2-Ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine
  • Example 228 was prepared as in Example 275 and Example 156 but substituting Example 226C for Example 61A to provide the title compound. [1954]
  • mp 113-114° C.; [1955]
  • MS (ESI/NH[1956] 3) m/e: 497 (M+H)+;
  • [1957] 1H NMR (300 MHz, DMSO-d6) δ0.82 (m, 2H), 0.85 (m, 2H), 1.05 (t, 3H, J=7.1 Hz), 3.40 (t, 2H, J=7.1 Hz), 3.42-3.54 (m, 10H), 7.00 (d, 2H, J=8.8 Hz), 7.33 (d, 2H, J=8.8 Hz), 7.55 (s, 1H), 7.58 (s, 2H), 8.18 (br s, 1H), 9.15 (br s, 1H).
    • EXAMPLE 229 4-[4-(1,1-Difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 229A 4-[4-(1,1-Difluoro-2-ethoxy-2-oxoethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A suspension of activated copper (512 mg, 8 mmol) in dry DMSO (5 mL) was treated with ethyl iododifluoroacetate (1.0 g, 4 mmol) at room temperature for 10 minutes. Phenol (188 mg, 2 mmol) and Example 190B were then added. The reaction mixture was stirred at room temperature for 20 hours. After diluted with 1:1 ether/EtOAc, the mixture was washed with 1% HCl in brine, water, dried (MgSO[1958] 4) and concentrated. The residue was flash chromatographed on silica gel with 65% EtOAc/hexane, and was further purified on HPLC (C-18, CH3CN/H2O containing 0.1% TFA) to provide the designated compound (85 mg, 15%).
  • MS (ESI/NH[1959] 3) m/e: 407 (M+H)+.
    • EXAMPLE 229B 4-[4-(1,1-Difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 229A (40 mg, 0.1 mmol) in MeOH (5 mL) was treated NaBH[1960] 4 (50 mg) at room temperature for 2 hours. Brine was added, and the mixture was extracted with EtOAc. The combined organic phases were dried (Na2SO4) and concentrated. The residue was purified by HPLC (C-18, CH3CN/H2O containing 0.1% TFA) to provide the title compound (44.4 mg, 94%).
  • MS (ESI/NH[1961] 3) m/e: 365 (M+H)+;
  • [1962] 1H NMR (300 MHz, CD3OD) δ2.94 (s, 3H), 3.93 (t, 2H, J=13.5 Hz), 7.27 (d, 2H, J=9.2 Hz), 7.65 (d, 2H, J=9.2 Hz), 8.15 (s, 2H), 9.24 (s, 1H);
  • Anal. calcd for C[1963] 17H14N2O3SF2. TFA: C, 47.70; H, 3.16; N, 5.86. Found: C, 47.67; H, 3.10; N, 5.76.
    • EXAMPLE 230 -4-(4-{2-[2-(2-Ethoxyethoxy)ethoxy]-1,1-difluoroethyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • A solution of Example 229B (40 mg, 0.11 mmol) in THF (3 mL) was treated with NaH (60% in mineral oil, 7 mg, 0.16 mmol) and 15-crown-5 (35 mg, 0.16 mmol) at room temperature for 15 minutes. 2-(2-ethoxyethoxy)ethyl tosylate (46 mg, 0.16 mmol) which was prepared according to literature method (C. Almansa, et al, Tetrahedron 1991, 47, 5867), was then added. The reaction mixture was stirred at room temperature for 15 hours, and was then directly separated on HPLC (C-18, CH[1964] 3CN/H2O containing 0.1% TFA) to provide the title compound (46 mg, 81%).
  • MS (ESI/NH[1965] 3) m/e: 481 (M+H)+;
  • [1966] 1H NMR (300 MHz, CD3OD) δ1.16 (t, 3H, J=7.1 Hz), 2.97 (s, 3H), 3.49 (q, 2H, J=7.1 Hz), 3.57 (m, 6H), 3.70 (m, 2H), 4.01 (t, 2H, J=12.7 Hz), 7.37 (d, 2H, J=8.8 Hz), 7.72 (d, 2H, J=8.8 Hz), 8.22 (s, 1H), 8.33 (s, 1H), 9.46 (s, 1H).
    • EXAMPLE 231 4-(4-Chlorophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium Trifluoroacetate
  • Example 103 (47.4 mg, 0.149 mmol) was dissolved (under N[1967] 2 atmosphere) in 1.5 mL dry acetonitrile (with warming), and chloromethyl pivalate (25 mg, 0.167 mmol) was added at room temperature. The reaction was stirred for 16 hours, then tetrabutylammonium iodide (1 mg) was added, and then the solution was warmed to reflux for 48 hours. The reaction mixture was concentrated under reduced pressure, and the residue was purified by preparative HPLC (C-18 column, gradient eluent 20-70% acetonitrile-0.1% aqueous TFA, 60 minutes elution) to provide 24 mg (34%) of the title compound as a foam.
  • HPLC: Supelco C-18 column, gradient eluent of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 in, flow rate of 0.8 mL/min, RT 20.0 minutes. [1968]
  • MS (APCI+) m/e: 433 (M)[1969] +;
  • [1970] 1H NMR (300 MHz, DMSO-d6) δ1.18 (s, 9H), 3.01 (s, 3H), 6.4-6.6 (br s, 2H), 7.1-7.3 (br s, approx. 2H), 7.49 (br s, 2H), 7.74 (br s, 1H), 8.41 (br s, 1H), 8.64 (br s, 1H), 9.3-9.9 (vbr s, 1H);
  • Anal. calcd for C[1971] 23H22F3Cl2O6S: C, 45.43; H, 3.51; N, 4.24. Found: C, 45.93; H, 4.34.1
    • EXAMPLE 232 4-(4-Bromophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium
  • Example 171 (69.4 mg, 0.191 mmol) was dissolved in 2 mL acetonitrile, then tetrabutylammonium iodide (1 mg) was added, followed by chloromethyl pivalate (22 mg, 0.146 mmol). The reaction solution was warmed to reflux for 24 hours. An additional portion of chloromethyl pivalate (11 mg, 0.073 mmol) was added, and the reaction was refluxed for an additional 72 hours. The reaction was concentrated under reduced pressure, and the solid was partitioned between 15% water and 15 mL EtOAc. The aqueous phase was extracted with 2×15 mL EtOAc, then the aqueous phase was concentrated under reduced pressure to a yellow solid (93.5 mg). HPLC purification (C-18 column, 20-75% acetonitrile-0.1% aqueous TFA) provided pure title compound (55.9 mg, 49%). [1972]
  • HPLC: Supelco C-18 column, gradient eluent of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 20.3 minutes; [1973]
  • MS (APCI−) m/e: 475, 477 (M−H)[1974] −;
  • [1975] 1H NMR (300 MHz, DMSO-d6) δ1.17 (s, 9H), 3.02 (br m, 3H), 6.0-6.7 (vbr s, 2H), 7.14 (br d, 2H), 7.64 (br d, 2H), 7.78 (s, 1H), 8.07-8.17 (br s, 1H), 8.34 (s, 1H), 9.44-9.65 (vbr s, 1H);
  • Anal. calcd for C[1976] 23H22F3BrN2O6S.1.5 H2O: C, 40.99; H, 3.58; N, 3.82. Found: C, 4.94; H, 3.25; N, 3.76.
    • EXAMPLE 233 2-(Aminocarbonyl)-4-(4-chlorophenoxy)-6-{[(isopropoxycarbonyl)oxy]methyl}thieno[2,3-c]pyridin-6-ium
  • To a solution of Example 61 (300 mg, 0.94 mmol) in acetonitrile (15 mL) under a nitrogen atmosphere was added tetraphenylboron sodium (387 mg, 1.13 mmol), sodium iodide (169 mg, 1.13 mmol), and [(isopropoxycarbonyl)oxy]methyl chloride (172 mg, 1.13 mmol). The reaction mixture was heated at reflux for 4 hours, cooled to room temperature and diluted with acetonitrile (100 mL) before filtering through Celite®. The filtrate was concentrated to a foam that was triturated in methanol to afford the pyridinium tetraphenylborate salt (550 mg) as a yellow solid. The tetraphenylborate salt dissolved in 1:1 CH[1977] 3CN:i-PrOH and passed over an ion exchange column using Dowex 1×2 chloride, 50-100 mesh. The eluent was concentrated and the resulting residue triturated with Et2O to afford example 233 as a white solid (210 mg, 49%).
  • MS (FAB) m/e: 421 (M+H)[1978] +;
  • [1979] 1H NMR (300 MHz, DMSO-d6) δ1.26 (d, J=7 Hz, 6H), 4.81 (q, J=7 Hz, 1H), 6.44 (s, 2H), 7.41 (m, 2H), 7.62 (m, 2H), 8.31 (br s, 1H), 8.59 (s, 1H), 8.68 (s, 1H), 8.80 (br s, 1H), 9.98 (s, 1H);
  • Anal. calcd for C[1980] 19H18Cl2N2O5S.: C, 49.90; H, 3.96; N, 6.13. Found: C, 49.74; H, 6.14.
    • EXAMPLE 234 4-(Cyclopentyloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 234A 5-chloro-3-cyclopentyloxypyridine
  • The title compound (5.91 g, 77%) was prepared as described in Example 236A except substituting cyclopentanol (4.2 mL, 46.31 mmol) for benzyl alcohol. [1981]
  • MS (APCI) m/e: 198 (M+H)[1982] +;
  • [1983] 1H NMR (300 MHz, DMSO-d6) δ1.53-1.76 (m, 6H), 1.86-2.02 (m, 2H), 4.92-4.99 (m, 1H), 7.55 (t, J=2.25 Hz, 1H), 8.18 (d, J=2.25 Hz, 1H), 8.22 (d, J=3 Hz, 1H).
    • EXAMPLE 234B 5-Chloro-3-cyclopentyloxy pyridine-4-carboxaldehyde
  • The title compound (5.22 g, 77%) was prepared as described in Example 236B except substituting Example 234A (5.9 g, 30 mmol) for Example 236A. [1984]
  • MS (APCI) m/e: 226 (M+H)[1985] +;
  • [1986] 1H NMR (300 MHz, DMSO-d6) δ1.55-1.85 (m, 6H), 1.93-2.04 (m, 2H), 5.14-5.22 (m, 1H), 8.36 (s, 1H), 8.63 (s, 1H), 10.31 (s, 1H).
    • EXAMPLE 234C Methyl 4-[cyclopentyloxy]thieno[2,3-c]pyridine-2-carboxylate
  • The title compound (4.31 g, 67%) was prepared as described in Example 236C except substituting 234B (5.2 g, 23.11 mmol) for Example 236B. [1987]
  • MS (APCI) m/e: 278 (M+H)[1988] +;
  • [1989] 1H NMR (400 MHz, DMSO-d6) δ1.59-1.69 (m, 2H), 1.74-1.81 (m, 2H), 1.83-1.90 (m, 2H), 1.97-2.07 (m, 2H), 3.93 (s, 3H), 5.12-5.17 (m, 1H), 8.05 (s, 1H), 8.24 (s, 1H);
  • [1990] 13C NMR (100 MHz, DMSO-d6) δ23.63 (CH2), 32.30 (CH2), 52.98 (OCH3), 80.33 (CH), 125.52 (CH), 127.09 (CH), 134.72 (C), 136.45 (C), 137.44 (CH), 138.05 (C), 149.27 (C), 161.90 (C═O).
    • EXAMPLE 234D 4-[Cyclopentyloxy]thieno[2,3-c]pyridine-2-N-methylamide
  • Example 234C (1.6 g, 61%) was prepared as described in Example 171 except substituting Example 234C (2.6 g, 9.4 mmol) for Example 73A. [1991]
  • mp 216-217° C., [1992]
  • MS (APCI) m/e: 277 (M+H)[1993] +, 244 (M−Cl)−;
  • [1994] 1H NMR (400 MHz, DMSO-d6) δ1.60-1.69 (m, 2H), 1.73-1.90 (m, 4H), 1.97-2.08 (m, 2H), 2.83 (d, J=4 Hz, 3H), 5.10-5.17 (m, 1H), 8.11 (s, 1H), 8.19 (s, 1H), (d, J=4 Hz, 1H);
  • [1995] 13C NMR (100 MHz, DMSO-d6) δ23.60 (CH2), 26.14 (NCH3), 32.34 (CH2), 80.14 (CH), 119.68 (CH), 126.91 (CH), 135.73 (C), 137.17 (CH), 144.2 (C), 149.02 (C), 161.18 (C).
    • EXAMPLE 235 4-(2-Cyclohexen-1-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 235A Methyl 4-[2-cyclohexene-3-oxy]thieno[2,3-c]pyridine-2-carboxylate
  • The title compound (158 mg, 57%) was prepared as described in Example 99A except substituting 2-cyclohexenol (0.113 mL, 0.115 mmol) for 3-hydroxy tetrahydrofuran. Pure product was obtained by flash chromatography on silica gel eluting with 10% acetone-hexane. [1996]
  • MS (APCI) m/e: 290 (M+H)[1997] +, 288 (M−H)−, 324 (M+Cl)−;
  • [1998] 1H NMR (300 MHz, DMSO-d6) δ1.95-1.62 (m, 1H), 1.66-2.14 (m, 5H), 3.92 (s, 3H, OCH3), 5.22-5.26 (m, 1H), 5.91-5.99 (m, 2H), 8.03 (s, 1H, CH), 8.36 (s, 1H, CH), 8.95 (s, 1 H, CH).
    • EXAMPLE 235B 4-(2-Cyclohexen-1-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • The title compound Example 235 (59 mg, 40%) was prepared from Example 235A (150 mg, 0.519 mmol) as described in Example 171. [1999]
  • MS (APCI) m/e: 289 (M+H)[2000] +, 287 (M−H)−, 323 (M+Cl)−;
  • [2001] 1H NMR (500 MHz, DMSO-d6) δ1.62-1.70 (m, 1H), 1.78-1.91 (m, 2H), 1.96-2.17 (m, 3H), 2.82 (d, J=5 Hz, 3H), 5.21 (br s, 1H), 5.93-5.98 (m, 1H), 6.01-6.05 (m, 1H), 8.14 (s, 1H), 8.30 (s, 1H), 8.87 (s, 1H), 8.75 (d, J=5 Hz, 1H);
  • [2002] 13C NMR (75 MHz, DMSO-d6) δ18.2 (CH2), 24.6 (CH2), 26.2 (CH3), 27.7 (CH2), 71.3 (CH), 119.7 (CH), 125.6 (CH), 127.4 (CH), 132.6 (CH), 136.0 (C), 137.3 (C), 137.4 (CH), 144.1 (C), 149.0 (C), 161.2 (C).
    • EXAMPLE 236 4-(Benzyloxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 236A 5-Chloro-3-benzyloxypyridine
  • To a stirred solution of 5-chloro-3-pyridinol (10 g, 77.19 mmol) in anhydrous tetrahydrofuran (155 mL) at 0° C. and under nitrogen atmosphere was added benzyl alcohol (9.6 mL, 92.63 mmol), triphenylphosphine (26.32 g, 100.35 mmol)) and diethyl azodicarboxylate (15.8 mL, 100.35 mmol). The reaction mixture was stirred at room temperature overnight and the solvent was removed under reduced pressure. The residue (70 g) obtained was treated with diethyl ether (2×300 mL) and the solids were removed by filtration. The filtrate obtained was concentrated under reduced pressure and the residue was purified by silica gel flash chromatography eluting with 5% acetone and hexane to obtain the title compound in 36% (5.8 g) yield. [2003]
  • MS (APCI) m/e: 220 (M+H)[2004] +;
  • [2005] 1H NMR (300 MHz, DMSO-d6) δ5.22 (s, 2H), 7.33-7.49 (m, 5H), 7.77 (t, J=5 Hz, 1H), 8.23 (d, J=5 Hz, 1H), 8.34 (d, J=5 Hz, 1H).
    • EXAMPLE 236B 5-Chloro 3-benzyloxy pyridine-4-carboxaldehyde
  • To a stirred solution of diisopropylamine (4.5 mL, 31.78 mmol) in anhydrous tetrahydrofuran (20 mL) under nitrogen atmosphere at −5° C. was added dropwise n-BuLi in hexanes (2.5 M solution, 12.8 mL, 31.78 mmol) maintaining internal temperature of the reaction mixture below 0° C. The reaction mixture was stirred at −10° C. for 10 minutes, then at 0° C. for 30 minutes. This was cooled to −78° C. and a solution of Example 236A (5.8 g, 26.5 mmol) in anhydrous tetrahydrofuran (30 mL) was added slowly. Stirring at −78° C. was continued for 1 hour. Then the reaction was quenched with dropwise addition of methyl formate (5 mL, 79.5 mmol) in anhydrous THF (15 mL) and stirred at −78° C. for 3.5 hours. Internal temperature of the reaction mixture was maintained at or below −74° C. throughout the reaction. After 3.5 hours, the reaction mixture was poured into an ice cold saturated aqueous solution of NaHCO[2006] 3 (200 mL) and stirred for 15 minutes. The mixture was partitioned with ethyl acetate (250 mL), organic layer was separated and washed with brine (2×60 mL). The dried (MgSO4) organic layer was concentrated under reduced pressure to obtain the crude product (8.5 g). The title compound was obtained in 75% yield (4.2 g) by flash chromatography on silica gel eluting with 6% acetone-hexane.
  • MS (APCI) m/e: 248 (M+H)[2007] +;
  • [2008] 1H NMR (300 MHz, DMSO-d6) d: 5.42 (s, 2H), 7.33-7.45 (m, 3H), 7.48-7.52 (m, 2H), 8.41 (s, 1H), 8.72 (s, 1H), 10.39 (s, 1H).
    • EXAMPLE 236C Methyl 4-benzyloxythieno[2,3-c]pyridine-2-carboxylate
  • To an ice cold solution of Example 236B (4.2 g, 17 mmol) in anhydrous tetrahydrofuran (42 mL) under nitrogen atmosphere was added methyl thioglycolate (1.83 mL, 20.4 mmol) followed by powdered cesium carbonate (6.65 g, 20.4 mmol). Then the reaction mixture was allowed to warm to room temperature with stirring under nitrogen. After 30 minutes the reaction was refluxed for 15 minutes and cooled to room temperature. The reaction mixture was quenched with ice (50 mL) and partitioned with ethyl acetate (250 mL). The organic layer separated was washed with an ice cold solution of saturated NaCl (3×60 mL), dried (Na[2009] 2SO4), and concentrated under reduced pressure to obtain the crude product which was recrystallized from methanol. The mother liquor was purified by flash chromatography on silica gel eluting with 7% acetone-hexane. The combined fractions gave the title compound in 55% yield (3.07 g).
  • MS (APCI) m/e: 300 (M+H)[2010] +;
  • [2011] 1H NMR (300 MHz, DMSO-d6) d: 3.92 (s, 3H), 5.42 (s, 2H), 7.35-7.47 (m, 3H), 7.52-7.57 (m, 2H, Ar—CH), 8.12 (s, 1H,), 8.36 (s, 1H), 8.98 (s, 1H).
    • EXAMPLE 236D Methyl 4-hydroxylthieno[2,3-c]pyridine-2-carboxylate
  • To a suspension of 10 wt % Pd on activated carbon (38 mg, 10% w/w) in absolute ethanol (3 mL) was added a cold solution of Example 236C (380 mg, 1.3 mmol) in ethanol (82 mL) under nitrogen atmosphere. Then the reaction mixture was degassed and stirred at room temperature under hydrogen atmosphere. After one over night reaction mixture was treated with additional 10 wt % Pd on activated carbon (190 mg, 50% w/w) and stirred under hydrogen atmosphere. Additional catalyst (100 mg, 26% w/w) was added to the reaction mixture after 48 hours. The reaction mixture was stirred under hydrogen atmosphere for further 24 hours and filtered through Celite®. The filtrate was evaporated to dryness under reduced pressure to obtain the crude product ( 320 mg). The title compound Example 236E was obtained in 75% yield (200 mg) by flash chromatography on silica gel eluting with 5% acetone-hexane followed by 40% acetone-hexane. [2012]
  • MS (APCI) m/e: 210 (M+H)[2013] +, 208 (M−H)−, 244 (M+Cl)−;
  • [2014] 1H NMR (300 MHz, DMSO-d6) δ3.93 (s, 3H), 8.08 (s, 1H), 8.21 (s, 1H), 8.81 (s, 1H), 10.66-10.90 (br s, 1H).
    • EXAMPLE 236E 4-Benzyloxythieno[2,3-c]pyridine-2-carboxamide
  • The title compound (50 mg, 67%) was prepared as described in Example 44 using Example 236C (75 mg, 0.25 mmol). [2015]
  • MS (APCI) m/e: 285 (M+H)[2016] +, 319 (M+Cl)−;
  • [2017] 1H NMR (400 MHz, DMSO-d6) δ5.43 (s, 2H), 7.49-7.50 (m, 3H), 7.58-7.63 (m, 2H), 7.79 (br s, 1H), 8.30 (s, 1H), 8.36 (s, 1H, ), 8.48 (br s, 1H), 8.93 (s, 1H);
  • [2018] 13C NMR (100 MHz, DMSO-d6) d: 70.13 (CH2), 120.56 (CH), 126.21 (CH), 127.5 (CH), 128.14 (CH), 128.51 (CH), 135.30 (C), 136.35 (C), 137.48 (C), 137.86 (CH), 144.75 (C), 149.82 (C), 162.61 (C).
    • EXAMPLE 237 4-(4-Chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 237A Methyl 4-chlorothieno[2,3-c]pyridine-2-carboxylate
  • Example 17A (15.00 g, 85.22 mmol) was dissolved in THF (80 mL) and cesium carbonate (27.77 g, 85.22 mmol) added. Methyl thioglycolate (7.62 mL, 85.22) diluted in THF (20 mL) was added dropwise over a period of 20 minutes. The reaction was stirred for 1.5 hours then heated to 40° C. for 1 hour. The reaction mixture was poured into 850 mL of stirring water. After 10 minutes, the precipitate was collected by filtration and washed twice with water. The product was dried in a desiccator to yield the title compound as a solid (15.2 g, 78%). [2019]
  • MS (DCI/NH[2020] 3) m/e: 228 (M+H)+;
  • [2021] 1H NMR (300 MHz, DMSO-d6) δ3.96 (s, 3H), 8.15 (s, 1H), 8.6 5 (s, 1H), 9.3 8 (s, 1H).
    • EXAMPLE 237B 4-Chlorothieno[2,3-c]pyridine-2-carboxylic acid
  • Example 237A (15.17 g, 66.63 mmol) was suspended in a solution of 1:4 MeOH/water (500 mL) and LiOH hydrate (4.34 g, 103.50 mmol) was added. The reaction was stirred 1.5 hours then concentrated (100 mL). The aqueous phase was washed with Et[2022] 2O and then acidified to pH 5 with 1 N HCl (aq). The precipitate was isolated by filtration, washed once with water, then twice with acetonitrile. The product was dried in a desiccator to yield 4-chlorothieno[2,3-c]pyridine-2-carboxylic acid as a solid (12.10 g, 85%).
  • MS (DCI/NH[2023] 3) m/e: 214 (M+H)+;
  • [2024] 1H NMR (300 MHz, DMSO-d6) δ8.05 (s, 1H), 8.62 (s, 1H), 9.34 (s, 1H).
    • EXAMPLE 237C Dimethylethyl 4-chlorothieno[2,3c]pyridine-2-carboxylate
  • To a suspension of Example 237B (12.07 g, 56.50 mmol) in THF (200 mL) at 0° C., was added tert-butyl 2,2,2-trichloroacetamidate (25.00 g, 114.41 mmol) followed by dropwise addition of boron trifluoride-diethyl etherate (2.14 mL, 16.95 mmol). The reaction was allowed to warm to room temperature and stirred 18 hours. Additional tert-butyl 2,2,2-trichloroacetamidate (12.50 g,57.21 mmol) was added and the reaction was stirred 3 hours. The stirred reaction was treated with NaHCO[2025] 3 (14 g) and then diluted with water (300 mL). The reaction was partitioned between water (300 mL) and 50% EtOAc/Et2O. Organic layer was washed with sat. NaHCO3, washed with brine, partially dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel neutralized with Et3N using EtOAc/hexane as eluent. The title compound was isolated as a solid (10.04 g, 66%).
  • MS (DCI/NH[2026] 3) m/e: 270 (M+H)+;
  • [2027] 1H NMR (300 MHz, DMSO-d6) δ1.59 (s, 9H), 8.04 (s, 1H), 8.64 (s, 1H), 9.35 (s, 1H).
    • EXAMPLE 237D Dimethylethyl 4-(ethoxycarbonyl)thieno[2,3-c]pyridine-2-carboxylate
  • To a solution of Example 237C (1.00 g, 3.71 mmol), 1,3-bis(diphenylphosphino)propane (0.46 g, 1.11 mmol), triethylamine (1.55 mL, 11.13 mmol), in 2:3 EtOH/DMF (25 mL), was added palladium(II) acetate (0.25 g, 1.11 mmol). The reaction was aspirated with a stream of CO(g) for 15 minutes. A balloon of CO(g) was applied and reaction heated to 105° C. for 16 hours then cooled to room temperature. The reaction was poured into water (400 mL). The aqueous was diluted with brine (25 mL) and sat. NaHCO[2028] 3 (25 mL), then extracted with EtOAc (4×50 mL). The organic extracts were combined, washed with 20% sat. NaHCO3 (2×200 mL), brine (2×100 mL), partially dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to provide the title compound as a solid (0.60 g, 53%),
  • MS (APCI) m/e: 308 (M+H)[2029] +;
  • [2030] 1H NMR (300 MHz, CD2Cl2) δ1.44 (t, J=7.1 Hz, 3H),. 1.59 (s, 9H), 4.44 (q, J=7.1 Hz, 2H), 8.65 (s, 1H), 9.12 (s, 1H), 9.25 (s, 1H).
    • EXAMPLE 237E Dimethylethyl 4-formylthieno[2,3-c]pyridine-2-carboxylate
  • To a stirred solution of NaBH[2031] 4 (0.18 g, 4.89 mmol) in anhydrous 50% MeOH/THF at 0° C. was added powdered CaCl2 (0.54 g, 4.89 mmol). The suspension was stirred 20 minutes and a solution of Example 237D (0.50 g, 1.63 mmol) in anhydrous 50% MeOH/THF was slowly added over a period of 10 minutes. The reaction stirred 1 hour at 0° C. followed by 16 hours at room temperature. Reaction was quenched into a slurry of dilute AcOH (aq)/ice. After all gas evolution ceased with occasional stirring, aqueous was made basic with sat. NaHCO3. Aqueous was extracted with dichloromethane (3×40 mL) and extracts combined. The organic phase was dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to provide dimethylethyl 4-(hydroxymethyl)-thieno[2,3-c]pyridine-2-carboxylate compound as a solid (0.14 g, 32%).
  • MS (APCI) m/e: 266 (M+H)[2032] +;
  • [2033] 1H NMR (300 MHz, CD2Cl2) δ1.54 (s, 9H), 4.94 (s, 2H), 8.08 (s, 1H), 8.40 (s, 1H), 9.02 (s, 1H).
  • To a stirred solution of oxalyl chloride (0.10 mL, 1.17 mmol) in anhydrous dichloromethane (1 mL) at −78° C. was added DMSO (0.19 mL, 2.65 mmol). After 20 minutes, a solution of dimethylethyl 4-(hydroxymethyl)-thieno[2,3-c]pyridine-2-carboxylate (0.28 g, 1.06 mmol) in anhydrous dichloromethane (4 mL) was added dropwise. The reaction was stirred 1 hours at −78° C. then treated with triethylamine (0.74 mL, 5.30 mmol). After 5 minutes, reaction was allowed to warm to room temperature over 30 minutes. The reaction was quenched with water (5 mL) and partitioned between dichloromethane (50 mL) and 50% sat. aq NaHCO[2034] 3 (50 mL). The organic phase was washed with 50% sat. aq NaHCO3 (1×50 mL), dried (Na2SO4), filtered, and concentrated and dried in a desiccator to yield the title as a solid (0.25 g, 90%).
  • MS (APCI) m/e: 264 (M+H)[2035] +;
  • [2036] 1H NMR (300 MHz, CD2Cl2) δ1.59 (s, 9H), 8.74 (s, 1H), 8.91 (s, 1H), 9.31 (s, 1H), 10.24 (s, 1H).
    • EXAMPLE 237F Dimethylethyl 4-[(4-chlorophenyl)(hydroxy)methyl]thieno[2,3-c]pyridine-2-carboxylate
  • To a solution of Example 237E (0.25 g, 0.95 mmol) in anhydrous THF (5 mL) at −5° C. was slowly added a 1 M solution of p-chlorophenylmagnesium bromide in diethyl ether (2.85 mL, 2.85 mmol). The reaction was quench after 10 minutes with dropwise addition of water (1 mL) and partitioned between dichloromethane (25 mL) and 50% sat. aq NaHCO[2037] 3 (50 mL). The aqueous phase was extracted with dichloromethane (25 mL) and the organic extracts combined, dried (Na2SO4), filtered, and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to provide the title compound as a foam, which was crushed and dried in a desiccator to yield a powder (0.36 g, 100%).
  • MS (APCI) m/e: 376 (M+H)[2038] +;
  • [2039] 1H NMR (300 MHz, CD2Cl2) δ1.52 (s, 9H), 6.18 (d, 1H), 7.25-7.34 (series of m, 4H), 7.96 (s, 1H), 8.47 (s, 1H), 9.03 (s, 1H).
    • EXAMPLE 237G Methyl 4-[(4-chlorophenyl)(hydroxy)methyl]thieno[2,3-c]pyridine-2-carboxylate
  • Example 237F (0.12 g, 0.32 mmol) was dissolved in a solution of 10% H[2040] 2SO4/MeOH (10 mL) and heated to 50° C. for 18 hours. The reaction was quenched into sat. NaHCO3 (100 mL). The aqueous phase was extracted with dichloromethane (2×50 mL) and the organic extracts combined. The organic layer was washed with sat. NaHCO3 (1×100 mL), brine (1×100 mL), partially dried (Na2SO4), filtered, and concentrated. The product was dried in a desiccator to yield the title compound as a solid (0.10 g, 94%).
  • MS (APCI) m/e: 334 (M+H)[2041] +;
  • [2042] 1H NMR (300 MHz, CD2Cl2) δ3.85 (s, 3H), 6.17 (d, 1H), 7.23-7.33 (series of m, 4H) 8.05 (s, 1H), 8.48 (s, 1H), 9.05 (s, 1H).
    • EXAMPLE 237H Methyl 4-(4-chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxylate
  • To a stirred solution of oxalyl chloride (0.023 mL, 0.26 mmol) in anhydrous dichloromethane (1 mL) at −78° C. was added DMSO (0.045 mL, 0.63 mmol). After 15 minutes, a solution of Example 237G (0.07 g, 0.21 mmol) in anhydrous 1:4 DMSO/dichloromethane (5 mL) was added dropwise. The reaction was stirred 1 hour at 78° C. then treated with triethylamine (0.15 mL, 1.05 mmol). After 5 minutes, reaction was allowed to warm to room temperature over 1 hour. The reaction was quenched with water (2 mL) and partitioned between EtOAc (50 mL) and sat. aq. NaHCO[2043] 3 (50 mL). The organic layer was washed with 50% sat. aq. NaHCO3 (2×50 mL), brine (1×50 mL), dried (Na2SO4), filtered, and concentrated. The product was dried in a desiccator to yield the title compound as a white solid (0.07 g, 100%).
  • MS (APCI) m/e: 332 (M+H)[2044] +;
  • [2045] 1H NMR (300 MHz, DMSO-d6) δ3.95 (s, 3H), 7.68 (m, 2H), 7.87 (m, 2H), 8.31 (s, 1H), 8.74 (s, 1H), 9.66 (s, 1H); )+;
  • IR (KBr) 3208, 2959, 1719, 1657, 1585, 1567, 1434, 1308, 1268 cm[2046] −1.
    • EXAMPLE 237I 4-(4-Chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 237H (70 mg, 0.21 mmol) was suspended in MeOH (5 mL) and chloroform was added until the solid dissolved. A balloon of ammonia was applied and reaction heated to 50° C. for 20 hours. The reaction was concentrated and the residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent. The obtained title compound was dried in a desiccator to yield a white solid (35 mg, 53%). [2047]
  • mp 216-218° C.; [2048]
  • MS (APCI) m/e: 317 (M+H)[2049] +;
  • [2050] 1H NMR (DMSO-d6) δ7.68 (m, 2H), 7.86 (br s, 1H), 7.88 (m, 2H), 8.38 (s, 1H), 8.53 (br s, 1H), 8.67 (s, 1H), 9.55 (s, 1H);
  • [2051] 13C NMR (DMSO-d6) δ123.4, 128.0, 129.3, 132.0, 135.9, 137.9, 138.9, 143.2, 145.1, 148.8, 148.9, 162.7, 193.6;
  • IR(KBr)3289,3145, 1681, 1655, 1399, 1270cm[2052] −1;
  • Anal calcd for C[2053] 15H9ClN2O2S.0.1 C6H14: C, 57.59; H, 3.22; N, 8.61. Found: C, 57.58; H, 3.22; N, 8.41.
    • EXAMPLE 238 N-4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2,4-dicarboxamide EXAMPLE 238A 4-(Ethoxycarbonyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 94 was treated according to the procedure of Example 237D to provide the title compound. [2054]
    • EXAMPLE 238B 4-(Carboxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 238A was treated according to the procedure of Example 159A to provide the title compound. [2055]
    • EXAMPLE 238C
  • N-4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2,4-dicarboxamide [2056]
  • Example 238B was treated according to the procedure of Example 24 to provide the title compound. [2057]
  • mp>270° C.; [2058]
  • MS (ESI) m/e: 332 (M+H)[2059] +;
  • [2060] 1H NMR (300 MHz, DMSO-d6) δ7.46 (m, 2H), 7.84 (br s, 1H), 7.85 (m, 2H), 8.52 (m, 1H), 8.56 (br s, 1H), 8.90 (m, 1H), 9.47 (m, 1H), 10.79 (br s, 1H).
    • EXAMPLE 239 [4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]methanol
  • Example 239 (900 mg, 97%) was prepared as described in Example 90 except substituting Example 73 (1 g, 2.74 :mmol) for Example 61A. [2061]
  • MS (APCI) m/e: 336; 338 (M+H)[2062] +, 370; 372 (M+Cl)−;
  • [2063] 1H NMR (300 MHz, DMSO-d6) δ4.78 (d, J=6 Hz, 2H), 5.88 (t, J=6 Hz, 1H), 6.98 (d, J=9 Hz, 2H), 7.14 (s, 1H), 7.55 (d, J=9 Hz, 2H), 8.19 (s, 1H), 9.06 (s, 1H).
    • EXAMPLE 240 4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde
  • Example 240 (400 mg, 80%) was prepared as described in Example 91A except substituting Example 239 (500 mg, 1.49 mmol) for Example 90. [2064]
  • MS (APCI) m/e: 334; 336 (M+H)[2065] +, 333; 335 (M−H)−;
  • [2066] 1H NMR (300 MHz, DMSO-d6) δ7.62 (d, J=9 Hz, 2H), 7.62 (d, J=9 Hz, 2H), 8.26 (s, 1H), 8.40 (s, 1H), 9.27 (s, 1H), 10.21 (s, 1H).
    • EXAMPLE 241 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde oxime
  • The title compound was prepared from Example 91A in a manner similar to Example 30. [2067]
  • HPLC: Supelco C-18 column, water:acetonitrile 0:90-90:0, 30 minute elution, flow rate 0.8 mL/min, rt 19.61 min. and 20.28 min; MS (DCI/NH[2068] 3) m/e: 305 (M+H)+;
  • [2069] 1H NMR (300 MHz, DMSO-d6) δ2.40 (s, 3H, toluene), 7.15 (m, 4H), 7.25 (m, 5H, toluene), 7.48 (m, 4H), 7.58 (s, 1H), 7.75 (s, 1H), 8.16 (m, 3H), 8.51 (s, 1H), 9.05 (s, 1H), 9.14 (s, 1H), 11.91 (s, 1H), 12.66 (s, 1H);
  • [2070] 13C NMR (100 MHz, DMSO-d6) δ119.28, 119.33, 120.58, 122.21, 125.25, 127.51, 128.13, 128.82, 129.99, 133.03, 133.84, 135.37, 136.10, 136.60, 137.11, 139.40, 139.95, 140.83, 141.28, 143.24, 143.66, 146.31, 146.58, 155.69;
  • Anal. calcd for C[2071] 14H9ClN2O2S.0.4 toluene: C, 59.07; H, 3.60; N. 8.20. Found: C, 59.15; H, 3.65; N, 8.25.
    • EXAMPLE 242 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde O-methyloxime
  • Example 242 was prepared from Example 91A similarly to Example 26. [2072]
  • Spectral data for E isomer: [2073]
  • HPLC: Supelco C-18 column, water:acetonitrile 0:90-90:0, 30 minute elution, flow rate 0.8 mL/min, rt 22.72 min. and 23.60 min.; [2074]
  • MS (ESI) m/e 319 (M+H)[2075] +;
  • [2076] 1H NMR (300 MHz, DMSO-d6) δ3.94 (s, 3H), 7.12 (m, 2H), 7.47 (m, 2H), 7.65 (s, 1H), 8.18 (s, 1H), 8.61 (s, 1H), 9.08.(s, 1H);
  • [2077] 13C NMR (100 MHz, DMSO-d6) δ62.29, 119.35, 122.26, 124.01, 127.60, 130.01, 133.77, 136.85, 140.91, 141.38, 144.34, 146.46, 155.58.
    • EXAMPLE 243A Mike Staeger 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime
  • Example 159A was treated similarly to the Example 22 procedure. The derived amide was treated according to Example 33 procedure, to produce the corresponding methyl ketone. This ketone was treated according to the procedure of Example 26 to provide the title compound as a mixture of E- and Z-isomers. The isomers were separated by column chromatography using type H (Sigma) silica gel and eluting with 25% EtOAc:hexanes. [2078]
  • Spectral data for Z-isomer: [2079]
  • mp 126-128° C.; [2080]
  • MS (APCI) m/e: 333 (M+H)[2081] +;
  • [2082] 1H NMR (300 MHz, DMSO-d6) δ2.29 (s, 3H), 3.97 (s, 3H), 7.15 (m, 2H), 7.48 (m, 2H), 7.72 (s, 1H), 8.09 (s, 1H), 9.01 (s, 1H);
  • [2083] 13C NMR (100 MHz, DMSO-d6) δ12.18, 62.32, 118.85, 119.88, 127.77, 130.01, 132.98, 136.94, 136.98, 140.32, 145.60, 146.94, 150.84, 155.40;
  • Anal. calcd for C[2084] 16H13ClN2O2S: C, 57.74; H, 3.94; N, 8.42. Found: C, 58.03; H, 3.92, N, 8.14.
    • EXAMPLE 243B 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime E-isomer isolated from Example 243A preparation:
  • MS (APCI) m/e: 333 (M+H)[2085] +;
  • [2086] 1H NMR (300 MHz, DMSO-d6) δ2.38 (s, 3H), 4.04 (s, 3H), 7.18 (m, 2H), 7.48 (m, 2H) 7.82 (s, 1H), 8.11 (s, 1H), 9.12 (s, 1H);
  • [2087] 13C NMR (100 MHz, DMSO-d6) δ19.25, 62.16, 119.88, 120.17, 121.60, 127;95, 130.04, 131.98, 134.49, 136.52, 138.85, 140.68, 146.21, 147.39, 155.22;
    • EXAMPLE 244A 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime
  • Example 244A was prepared similarly to Example 243A, with the substitution of hydroxylamine hydrochloride for methoxylamine hydrochloride. [2088]
  • MS (APCI) m/e: 319 (M+H)[2089] +;
  • [2090] 1H NMR (300 MHz, DMSO-d6) δ2.23 (s, 3H), 7.15 (m, 2H), 7.48 (m, 2H), 7.62 (s, 1H), 8.10 (s, 1H), 9.02 (s, 1H), 11.89 (s, 1H);
  • [2091] 13C NMR (100 MHz, DMSO-d6) δ11.41, 117.45, 119.73, 124.45, 127.65, 129.97, 133.14, 136.78, 137.17, 140.28, 146.72, 147.39, 149.85, 155.51;
  • Anal. calcd for C[2092] 15H11ClNO2S: C, 54.96; H, 3.69; N, 8.55. Found: C, 55.37; H, 3.47; N, 8.37.
    • EXAMPLE 244B 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime Z-isomer isolated from Example 244A.
  • MS (APCI) m/e: 319 (M+H)[2093] +;
  • [2094] 1H NMR (300 MHz, DMSO-d6) δ2.38 (s, 3H), 7.15 (d, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H), 7.73 (s, 1H), 8.10 (s, 1H), 9.12 (s, 1H), 12.35 (s, 1H);
  • [2095] 13C NMR (100 MHz, DMSO-d6) δ19.32, 118.36, 119.96, 120.01, 127.81, 130.02, 132.08, 134.60, 136.99, 138.95, 140.73, 145.08, 147.18, 155.40.
    • EXAMPLE 245 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone
  • Title compound was prepared in analogy to Example 33, substituting ethylmagnesium bromide for methylmagnesium bromide. [2096]
  • mp 101-102° C.; [2097]
  • MS (APCI) m/e: 318 (M+H)[2098] +;
  • [2099] 1H NMR (300 MHz, DMSO-d6) δ1.11 (t, J=8 Hz, 3H), 3.18 (d, J=8 Hz, 2H); 7.21 (m, 2H), 7.51 (m, 2H), 8.13 (s, 1H), 8.32 (s, 1H), 9.19 (s, 1H).
    • EXAMPLE 246 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone oxime
  • The title compound was prepared from Example 245 in analogy to Example 26, substituting hydroxylamine hydrochloride to provide a mixture of E- and Z-oxime isomers. [2100]
  • mp 195-198° C. (dec); [2101]
  • MS (APCI) m/e: 333 (M+H)[2102] +;
  • [2103] 1H NMR (300 MHz, DMSO-d6) δ1.10 (m, 6H), 2.77 (m, 4H), 7.17 (m, 4H), 7.48 (m, 4H) 7.61 (s, 1H), 7.71 (s, 1H), 8.09 (s, 1H), 8.11 (s, 1H), 9.00 (s, 1H), 9.12 (s, 1H), 11.88 )s, 1H), 12.42 (s, 1H);
  • HPLC Supelco C-18 column, water:acetonitrile 0:90-90:0 in 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT =20.20 min and 21.10 min (E- and Z-isomers); [2104]
  • Anal. calcd for C[2105] 16H13ClN2O2S: C, 57.74; H, 3.94; N, 8.42. Found: C, 57.51; H, 4.12; N, 8.22.
    • EXAMPLE 247 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methoxy-N-methyl-2-oxoacetamide
  • Example 88 (0.38 mmol) was prepared as reported in Example 42 and then combined with THF (1.0 mL) and LDA (0.92 mL of a freshly prepared 0.5 M solution in THF, 0.46 mmol) at −78° C. The clear, pale yellow solution was stirred at −78° C. for 1.25 hours before the solution was transferred by canula to a solution of bis(N,O-dimethylhydroxyl)oxamide (88 mg, 0.50 mmol) in THF (1.0 mL) at −78° C. The solution was slowly warmed to room temperature, diluted with 2N aqueous HCl (20 mL), and extracted with CH[2106] 2Cl2 (3×20 mL). The organic extracts were combined, washed with brine (1×10 mL), dried (MgSO4), and concentrated to a yellow solid. Flash silica gel column chromatography (15% acetone in hexane) gave the title compound (25 mg, 17% yield) as a yellow solid.
  • mp 135.0-137.8° C.; [2107]
  • MS (DCI/NH[2108] 3) m/e: 377 (35Cl)/379 (37Cl);
  • [2109] 1H NMR (300 MHz, DMSO-d6) δ3.31 (s, 3H), 3.64 (s, 3H), 7.27 (d, J=8.8 Hz, 2H), 7.52 (d, J=8.8 Hz, 2H), 8.15 (s, 1H), 8.22 (s, 1H), 9.26 (s, 1H).
    • EXAMPLE 248 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carbonitrile
  • A solution of the resultant compound from Example 61B (500 mg, 1.64 mmol) in pyridine (7 mL) under nitrogen at −78° C. was treated with trifluoroacetic anhydride (1 mL, 6.6 mmol), stirred at −78° C. for 40 minutes, allowed to slowly warm to room temperature, and stirred an additional two hours. This mixture was diluted with ethyl acetate, washed with saturated NaHCO[2110] 3, brine, dried (MgSO4) and concentrated. The resultant light purple solid was dissolved in a minimal amount of ethyl acetate, filtered through a plug of silica, washed through with 50/50 hexane/ethyl acetate and concentrated to give 395 mg of the title compound as a white solid (84%).
  • mp 140-142° C.; [2111]
  • MS (APCI—NH[2112] 3) m/e: 287 (M+H)+;
  • [2113] 1H NMR,(300 MHz, CDCl3) δ7.04 (d, 2H), 7.40 (d, 2H), 8.00 (s, 1H), 8.14 (s, 1H), 8.96 (s, 1H);
  • Anal. calcd for C[2114] 14H7ClN2OS: C, 58.64; H, 2.46; N, 9.77. Found: C, 58.45; H, 2.62; N, 9.52.
    • EXAMPLE 249 4-(4-Chlorophenoxy)-N′-hydroxythieno[2,3-c]pyridine-2-carboximidamide
  • A solution of the resultant compound from Example 248 (100 mg, 0.35 mmol) in ethanol (2. mL) under nitrogen at room temperature was treated with triethylamine (90 mL, 0.6 mmol), hydroxylamine hydrochloride (40 mg, 0.53 mmol) and stirred for 18 hours. The resultant white, heterogeneous mixture was diluted with ethyl acetate, washed with saturated NaHCO[2115] 3, brine, dried (MgSO4), and concentrated to give 120 mg of an off-white foam. This foam was dissolved in ethyl acetate, filtered through a plug of silica and concentrated to give the title compound as a white solid (110 mg, 98%).
  • mp 194-196° C.; [2116]
  • MS (APCI—NH[2117] 3) m/e: 320 (M+H)+;
  • [2118] 1H NMR (300 MHz, DMSO-d6) δ10.23 (s, 1H), 9.02 (s, 1H), 8.13 (s, 1H), 7.87 (s, 1H), 7.46 (d, 2H), 7.11 (d, 2H), 6.26 (br s, 2H);
  • Anal. calcd for C[2119] 14H10ClN3O2S: C, 52.59; H, 3.15; N, 13.14. Found: C, 52.72; H, 3.05; N, 12.82.
    • EXAMPLE 250 4-(4-Chlorophenoxy)-N′-cyanothieno[2,3-c]pyridine-2-carboximidamide
  • A solution of the resultant compound from Example 248 (100 mg, 0.35 mmol) in THF (2 mL) under nitrogen at ambient temperature was treated with cyanamide (74 mg, 1.75 mmol), 1,8-diazabicylco [5.4.0]undec-7-ene (52 mL, 0.35 mmol) and stirred for 24 hours. The resultant yellow, homogeneous solution was diluted with ethyl acetate, washed with saturated NaHCO[2120] 3, brine, dried (MgSO4), concentrated to give a light yellow solid, triturated with CH2Cl2 to give 123 mg of a white powder, dissolved in ethyl acetate and THF, washed with distilled water, brine, dried (MgSO4), concentrated to give 99 mg of a white powder (MgSO4) which was triturated with CH2Cl2 and then placed in a vacuum oven overnight at 60° C. to give the title compound as a white powder (78 mg, 69%).
  • mp 265-268° C.; [2121]
  • MS (APCI—NH[2122] 3) m/e: 329 (M+H)+;
  • [2123] 1H NMR (300 MHz, DMSO-d6) δ9.58 (br s, 1H), 9.17 (s, 1H), 9.05 (br s, 1H), 8.41 (s, 1H), 8.19 (s, 1H), 7.48 (d, 2H), 7.15 (d, 2H);
  • Anal. calcd for C[2124] 15H9ClN4OS: C, 54.80; H, 2.76; N, 17.04. Found: C, 54.50; H, 3.01; N, 17.16.
    • EXAMPLE 251 (2-Aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone EXAMPLE 251A [4-(4-Chlorophenoxy)thieno[[2 3-c]pyridin-2-yl](2-nitrophenyl)methanol
  • To a stirred solution of Example 124A (1.00 g, 3.82 mmol) in THF (40 mL) at −78° C., a 1.3 M suspension of sec-butyllithium in cyclohexane (3.52 mL, 4.58 mmol) was added dropwise over a 10-minute period. After 40 minutes, the reaction was transferred via cannula into a stirred solution of 2-nitrobenzaldehyde (1.43 g, 9.55 mmol) in THF (10 mL) at 48° C. After 20 minutes, the reaction was quenched by slow addition of MeOH (6 mL). The reaction was diluted with EtOAc (125 mL) and the organic washed with 1:1 sat. NaHCO[2125] 3/water (1×75 mL), brine (1×75 mL), partially dried (Na2SO4), and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluant to yield the title compound as a solid (1.49 g, 95%).
  • mp 85-90° C.; [2126]
  • MS (APCI) m/e: 413 (M+H)[2127] +;
  • [2128] 1H NMR (300 MHz, DMSO-d6) δ6.54 (s, 1H), 6.95 (s, 1H), 7.03 (m, 1H), 7.06 (m, 2H) 7.42 (m, 2H), 7.60 (m, 1H), 7.78 (m, 1H), 7.85 (m, 1H), 7.98 (m, 1H), 8.12 (s, 1H), 9.02 (s, 1H);
  • Anal. calcd for C[2129] 20H13ClN2O4S.0.3 H2O: C, 57.43; H, 3.28; N, 6.70. Found: C, 57.42H, ; 3.45; N, 6.42.
    • EXAMPLE 251B (2-Aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol
  • Example 251A (0.10 g, 0.24 mmol) was dissolved in EtOH (1.7 mL) and a solution of tin(II) chloride dihydrate (0.43 g, 1.92 mmol) in concentrated HCl (0.70 mL) was slowly added. The reaction was stirred 18 hours, then partitioned between CHCl[2130] 3 (50 mL) and sat. NaHCO3 (75 mL). The aqueous layer was extracted with EtOAc (1×50 mL) and all organic extracts combined, partially dried (Na2SO4), and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to yield the title compound as a lightly colored solid (0.08 g, 87%).
  • mp 92-96° C.; [2131]
  • MS (APCI) m/e: 383 (M+H)[2132] +;
  • [2133] 1H NMR (300 MHz, DMSO-d6) δ5.08 (br s, 2H), 6.10 (d, J=4.3 Hz, 1H), 6.54 (d, J=4.3 Hz, 1H), 6.55 (m, 1H), 6.61 (m, 1H), 6.98 (m, 1H), 7.05 (m, 2H), 7.13 (m, 1H), 7.19 (m, 1H), 7.42 (m, 2H), 8.09 (s, 1H), 8.98 (s, 1H);
  • Anal. calcd for C[2134] 20H15ClN2O2S: C, 62.74; H, 3.95; N, 7.32. Found: C, 63.09; H, 4.05; N, 7.06.
    • EXAMPLE 251C (2-Aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone.
  • [2135]
  • To an anhydrous stirred suspension of silica gel (0.13 g) and celite (0.13 g) in dichloromethane (6 mL) was added pyridinium chlorochromate (0.13 g, 0.59 mmol). A solution of Example 251B (0.15 g, 0.39 mmol) in anhydrous dichloromethane (9 mL) was slowly added dropwise. After 1 hour, sat. NaHCO[2136] 3 (5 mL) was added, and the reaction stirred for 1 hour. The reaction was filtered and the black solid was crushed and washed with 5% MeOH/dichloromethane (3×20 mL). The organic filtrate and washes were combined and washed with sat. NaHCO3 (2×100 mL), brine (1×75 mL), partially dried (Na2SO4), and concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluant to yield the title compound as a brightly colored solid (45 mg, 39%).
  • mp 152-154° C.; [2137]
  • MS (APCI) m/e: 381 (M+H)[2138] +;
  • [2139] 1H NMR (300 MHz, DMSO-d6) δ6.54 (m, 1H), 6.87 (m, 1H), 7.05 (broad s, 2H), 7.18 (m, 2H), 7.33 (m, 1H), 7.47 (m, 2H), 7.57 (s, 1H), 7.58 (m, 1H), 8.24 (s, 1H), 9.21 (s, 1H);
  • [2140] 13C NMR (300 MHz, DMSO-d6) δ114.5, 115.9, 117.1, 120.1, 123.8, 128.0, 130.0, 132.5, 133.0, 134.9, 136.0, 138.2, 141.2, 147.8, 148.5, 151.8, 155.3, 188.5;
  • IR(KBr)3440, 3411, 3293, 3190, 1616, 1587, 1552, 1483, 1409, 1267, 1245, 1219, 1155 cm[2141] −1;
  • Anal. calcd for C[2142] 20H13ClN2O2S: C, 63.08; H, 3.44; N, 7.36. Found: C, 62.94; H, 3.51; N, 7.25.
    • EXAMPLE 252 (3-Aminophenyl)[-4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone EXAMPLE 252A [4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl](3-nitrophenyl)methanol
  • The procedure of Example 251A was used, substituting 3-nitrobenzaldehyde for 2-nitrobenzaldehyde. [2143]
  • mp 79-83° C.; [2144]
  • MS (APCI) m/e: 413 (M+H)[2145] +;
  • [2146] 1H NMR (300 MHz, DMSO-d6) δ6.33 (d, J=4.4 Hz, 1H), 6.99 (d, J=4.4 Hz, 1H), 7.07 (m, 2H), 7.27 (m, 1H), 7.43 (m, 2H), 7.66 (m, 1H), 7.92 (m, 1H), 8.13 (s, 1H), 8.15 (m, 1H), 8.34 (m, 1H), 9.01 (s, 1H);
  • Anal. calcd for C[2147] 20H13ClN2O4S: C, 58.19; H, 3.17; N, 6.79. Found: C, 57.97; H, 3.23; N, 6.70.
    • EXAMPLE 252B (3-Aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol
  • Example 252A was treated according to the procedure of Example 251B to provide the title compound. [2148]
  • mp 73-78° C.; [2149]
  • MS (APCI) m/e: 383 (M+H)[2150] +;
  • [2151] 1H NMR (300 MHz, DMSO-d6) δ5.03 (s, 2H), 5.88 (s, 1H), 6.45 (series of m, 2H), 6.57 (m, 1H), 6.64 (m, 1H), 6.96 (m, 1H), 7.06 (m, 2H), 7.11 (m, 1H), 7.42 (m, 2H), 8.08 (s, 1H), 8.97 (s, 1H);
  • Anal. calcd for C[2152] 20H15ClN2O2S: C, 62.74; H, 3.95; N, 7.32. Found: C, 63.06; H, 4.22; N, 6.92.
    • EXAMPLE 252C (3-Aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone
  • Example 252B was treated according to the procedure of Example 251C to provide the title compound. [2153]
  • mp 174-178° C.; [2154]
  • MS (APCI) m/e: 481 (M+H)[2155] +;
  • [2156] 1H NMR (300 MHz, DMSO-d6) δ5.47 (br s, 2H), 6.86-6.96 (series of m, 2H), 7.06 (m, 1H), 7.16-7.23 (series of m, 3H), 7.48 (m, 2H), 7.77 (s, 1H), 8.20 (s, 1H), 9.22 (s, 1H).
    • EXAMPLE 253 4-(4-Bromophenoxy)-2-vinylthieno[2,3-c]pyridine
  • To a stirred suspension of methyl triphenylphosphonium bromide (113 mg, 0.314 mmol) in anhydrous tetrahydrofuran (2 mL) at −78° C. was added dropwise a solution of n-BuLi (2.5 M solution in hexanes, 0.125 mL, 0.314 mmol) under nitrogen atmosphere. Then the reaction mixture was stirred at 0° C. for 40 minutes and cooled down to −78° C. To this a solution of Example 240 (100 mg, 0.3 mmol) in anhydrous tetrahydrofuran (2 mL) was added while maintaining the internal temperature below −72° C. Once the addition was completed the reaction mixture was stirred at 0° C. for 15 minutes and at ambient temperature for 1 hour. Then the reaction mixture was partitioned between ethyl acetate (60 mL) and brine (20 mL). The organic layer was washed with brine (2×20 mL), dried (MgSO[2157] 4) and evaporated to dryness under reduced pressure to obtain the crude product (145 mg). The title compound was obtained in 26% yield (26 mg) by flash chromatography on silica gel eluting with 25% acetone-hexane.
  • MS (APCI) m/e: 332; 334 (M+H)[2158] +;
  • [2159] 1H NMR (400 MHz, DMSO-d6) δ5.53 (d, J=10 Hz, 1H), 5.86 (d, J=16 Hz, 1H), 7.02 (d, J=9 Hz, 2H), 7.06-7.14 (m, 1H), 7.37 (s, 1H), 7.57 (d, J=9 Hz, 1H), 8.17 (s, 1H), 9.04 (s, 1H).
    • EXAMPLE 254 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol EXAMPLE 254A 4-(4-Chlorophenoxy)-2-ethenylthieno[2,3-c]pyridine
  • Example 254A (70 mg, 10%) was prepared as in Example 253 except substituting Example 91A (700 mg, 2.42 mmol) for Example 240. [2160]
  • [2161] 1H NMR (300 MHz, DMSO-d6) δ5.53 (d, J=10.5 Hz, 1H), 5.86 (d, J=18 Hz, 1H), 7.04-7.14 (m, 1H), 7.10 (d, J=9 Hz, 2H), 7.38 (s, 1H), 7.45 (d, J=9 Hz, 2H), 8.16 (s, 1H), 9.04 (s, 1H).
    • EXAMPLE 254B 1-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol
  • Example 254A (22 mg, 28%) was prepared as in Example 255 except substituting Example 254A (70 mg, 0.26 mmol) for Example 253. [2162]
  • MS (APCI) m/e: 322 (M+H)[2163] +, 356 (M+Cl)−;
  • [2164] 1H NMR (400 MHz, DMSO-d6) δ3.50-3.64 (m, 2H), 4.86-4.91 (m, 1H), 5.0 (t, J=6 Hz, 1H), 6.04 (d, J=4 Hz, 1H), 7.07 (d, J=9 Hz, 2H), 7.21 (s, 1H), 7.43 (d, J=9 Hz, 2H), 8.14 (s, 1H), 9.04 (s, 1H);
  • [2165] 13C NMR (100 MHz, DMSO-d6) d: 66.52 (CH2), 70.24 (CH), 114.60 (CH), 119.06 (CH), 127.22 (C), 129.91 (CH), 133.36 (CH), 137.16 (C), 137.42 (C), 140.79 (CH), 145.79 (C), 155.91 (C), 156.59 (C).
    • EXAMPLE 255 1-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol
  • To a solution of Example 253 (90 mg, 0.271 mmol) in tetrahydrofuran (2 mL) was added 4-methylmorpholine N-oxide (63.5 mg, 0.542 mmol) and osmium tetroxide (14 mg, 0.054 mmol) in water (0.5 mL) at room temperature. The reaction mixture was stirred for 48 hours and solvents were removed. The residue obtained was directly purified by flash chromatography on silica gel eluting with 20% acetone-hexane to obtain the title compound (52 mg, 53%). [2166]
  • MS (APCI) m/e: 366;368 (M+H)[2167] +, 402 (M+Cl)−;
  • [2168] 1NMR (400 MHz, DMSO-d6) δ3.50-3.64 (m, 2H), 4.89 (m, 1H), 5.01 (t, J=6 Hz, 1H), 6.05 (d, J=4 Hz, 1H), 7.01 (d, J=9 Hz, 2H), 7.21 (s, 1H), 7.55 (d, J=9 Hz, 2H), 8.15 (s, 1H), 9.04 (s, 1H);
  • [2169] 13C NMR (100 MHz, DMSO-d6) δ66.52 (CH2), 70.25 (CH), 114.60 (CH), 115.08 (C), 119.24 (CH), 132.84 (CH), 133.49 (CH), 137.18 (C), 137.48 (C), 140.87 (CH), 145.67 (C), 156.46 (C), 156.65 (C).
    • EXAMPLE 256 [4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanamine
  • Diethyl azodicarboxylate (180 mL, 1.13 mmol) was added to Example 90 (220 mg, 0.750 mmol), THF (7.5 mL), triphenyl phosphine (297 mg, 1.13 mmol), and phthalimide (166 mg, 1.13 mmol). After 16 hours, the orange solution was concentrated under vacuum to an orange solid. Flash silica gel column chromatography (20% acetone in hexane) provided one compound (100% yield) as the major product, which was combined with hydrazine hydrate (230 mL, 7.50 mmol) and ethanol (75 mL) and heated at reflux. After four hours, the solution was cooled to room temperature, concentrated, diluted with 5 N HCl (30 mL), and filtered through a fritted glass funnel. The filtrate was combined with 3 N NaOH until pH>12 and extracted with EtOAc (3×30 mL). The organic extracts were combined, washed once with brine (30 mL), dried (MgSO[2170] 4), filtered, and concentrated under vacuum to provide the title compound (190 mg, 87% yield) as a white solid.
  • mp 78.6-79.8° C.; [2171]
  • MS (DCI/NH[2172] 3) m/e: 321 (M+H)+;
  • [2173] 1H NMR (300 MHz, DMSO-d6) δ2.24 (br s, 2H), 4.02 (s, 2H), 7.03 (d, J=9.1 Hz, 2H), 7.15 (s, 1H), 7.42. (d, J=9.1 Hz, 2H), 8.14 (s, 1H), 9.01 (s, 1H);
  • Anal. calcd for C[2174] 14H11ClN2OS0.25 H2O: C, 56.95; H, 3.93; N, 9.49. Found: C, 56.86; H 3.81; N, 9.62.
    • EXAMPLE 257 [4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl carbamate
  • Example 90 (50 mg, 0.17 mmol) was combined with CH[2175] 2Cl2 (0.5 mL), sodium cyanate (22 mg, 0.34 mmol), and trifluoroacetic acid (40 mL, 0.34 mmol); gas evolutions was observed. After 24 hours, the mixture was partitioned between distilled water (15 mL) and CH2Cl2 (50 mL). The layers were separated, and the organic layer was dried (MgSO4), filtered, and concentrated. Silica gel column chromatography (30% acetone in hexane) provided the title compound (21 mg, 37% yield) as a white solid.
  • mp 113-115° C.; [2176]
  • MS (DCI/NH[2177] 3) m/e: 335 (35Cl)/337 (37Cl);
  • [2178] 1H NMR (300 MHz, DMSO-d6) δ5.30 (s, 2H), 6.80 (br s, 2H), 7.06 (d, J=9.2 Hz, 2H), 7.37 (s, 1H), 7.45 (d, J=8.8 Hz, 2H), 8.18 (s, 1H), 9.10 (s, 1H).
    • EXAMPLE 258 N-{[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl}urea
  • Potassium cyanate (41 mg, 0.50 mmol) was added to a mixture of Example 256 (130 mg, 0.45 mmol), distilled water (2.0 mL), and concentrated HCl (40 mL, 0.45 mmol), and the solution was heated at 50° C. After 3 hours, the solution was slowly cooled to 0° C., and the resulting precipitate was isolated by filtration. Flash silica gel column chromatography (20% acetone in hexane, switching to 10% MeOH in EtOAc) provided the title compound (63 mg, 42% yield) as a white solid. [2179]
  • mp 202-204° C.; [2180]
  • MS (DCI/NH[2181] 3) m/e: 334 (35 Cl)+/336 (37 Cl)+;
  • [2182] 1H NMR (300 MHz, DMSO-d6) δ4.47 (d, J=6.1 Hz, 2H), 5.68 (s, 2H), 6.68 (t, J=6.1 Hz, 1H), 7.05 (d, J=8.8 Hz, 2H), 7.14 (s, 1H), 7.43 (d, J=8.8 Hz, 2H), 8.14 (s, 1H), 9.02 (s, 1H);
  • Anal. calcd for C[2183] 15H12ClN3O2S: C, 53.97; H, 3.62; N. 12.59. Found: C, 53.80; H, 3.67; N, 12.37.
    • EXAMPLE 259 (E)-3-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]propenamide EXAMPLE 259A Methyl 3-(4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-yl)propenoate
  • Example 259A (590 mg, 57%) was prepared as in Example 91B except substituting Example 240 (890 mg, 2.67 mmol) for Example 91A. [2184]
  • MS (APCI) m/e: 390;392 (M+H)[2185] +, 389; 391 (M−H)−;
  • [2186] 1H NMR (300 MHz, DMSO-d6) δ3.75 (s, 3H), 6.58 (d, J=16 Hz, 1H), 7.07 (d, J=9 Hz, 2H), 7.59 (d, J=9 Hz, 2H), 7.89 (s, 1H), 8.02 (d, J=16 Hz, 1H), 8.17 (s, 1H), 9.12 (s, 1H).
    • EXAMPLE 259B 3-(4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-yl)propenoic acid
  • Example 259A and the procedure of Example 88 was used to provide the title compound (270 mg, 93%). [2187]
  • MS (APCI) m/e: 376;378 (M+H)[2188] +;
  • [2189] 1H NMR (300 MHz, DMSO-d6) d: 6.45 (d, J=16 Hz, 1H), 7.07 (d, J=9 Hz, 2H), 7.58 (d, J=9 Hz, 2H), 7.81 (s, 1H), 7.90 (d, J=16 Hz, ;H), 8.16 (s, 1H), 9.10 (s, 1H).
    • EXAMPLE 259C 3-(4-(4-Bromophenoxy)thieno[2,3-c]pyridine-2-yl)propenamide
  • Example 259B (222 mg, 81%) and the procedure in Example 92, except substituting Example 259B for Example 91C, was used to provide the title compound. [2190]
  • mp95-196° C.; [2191]
  • MS (APCI) m/e: 375;377 (M+H)[2192] +, 409; 411 (M+Cl)−;
  • [2193] 1H NMR (400 MHz, DMSO-d6) δ6.62 (d, 16 Hz, 1H), 7.04 (d, J=9 Hz, 2H), 7.26 (s, 1H), 7.56 (d, J=9 Hz, 2H), 7.64 (s, 1H), 7.68 (s, 1H), 7.72 (d, J=16 Hz, 1H), 8,13 (s, 1H), 9.05 (s, 1H);
  • [2194] 13C NMR (100 MHz, DMSO-d6) δ115.55 (C), 119.98 (CH), 122.11 (CH), 126.68 (CH), 131.80 (CH), 132.91 (CH) 133.71 (CH), 136.69 (C), 137.48 (C), 140.84 (CH), 145.79 (C), 146.43 (C), 156.07 (C), 165.37 (C).
    • EXAMPLE 260 Methyl (E)-3-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]propenamide
  • Example 260 (25 mg, 50%) was prepared from Example 259A (50 mg, 0.13 mmol) as described in Example 171. [2195]
  • MS (APCI) m/e: 389 (M+H)[2196] +;
  • [2197] 1H NMR (400 MHz, DMSO-d6) δ2.71 (d, J=4.5 Hz, 3H), 6.62 (d, J=16 Hz, 1H), 7.06 (d, J=9 Hz, 2H), 7.58 (d, J=9 Hz, 2H), 7.69 (s, 1H), 7.74 (d J=16 Hz, 1H), 8.15 (s, 1H), 8.27 (d, J=4.5 Hz, 1H), 9.08 (s, 1H);
  • [2198] 13C NMR (100 MHz, DMSO-d6) δ25.7 (CH3), 115.6 (C), 120.0 (CH), 122.1 (CH), 126.4 (CH), 131.1 (CH), 132.9 (CH), 133.7 (CH), 136.7(C), 137.5 (C), 140.9 (CH), 145.9(C), 146.4 (C), 156.1 (C), 164.3 (C).
    • EXAMPLE 261 Methyl 3-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2,3-dihydroxypropanamide
  • Example 260 (52 mg, 53%) was prepared as described in Example 255, except substituting Example 260 (90 mg, 0.232 mmol), to provide the title compound. [2199]
  • MS (APCI) m/e: 423;425 (M+H)[2200] +, 456 (M+Cl)−;
  • [2201] 1H NMR (300 MHz, DMSO-d6) δ2.61 (d, J=4.5 Hz, 3H), 4.09 (br d, J=3 Hz, 1H), 5.27 (br d, J=3 Hz, 1H), 5.68 (d, J=6 Hz, 1H), 6.09 (d, J=6 Hz, 1H), 7.00 (d, J=9 Hz, 2H), 7.23 (s, 1H), 7.56 (d, J=9 Hz, 2H), 7.77 (d, J=4.5 Hz, 1H), 8.14 (s, 1H), 9.04 (s, 1H);
  • [2202] 13C NMR (75 MHz, DMSO-d6) δ25.5 (CH3), 70.3 (CH), 75.1 (CH), 115.0 (CH), 115.1 (C), 119.5 (CH), 132.9 (CH), 133.5 (CH), 137.5 (C), 137.5 (C), 140.9 (CH), 145.8 (C), 156.3 (C), 156.5 (C), 171.7 (C).
    • EXAMPLE 262 3-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2,3-dihydroxypropanamide
  • The procedure of Example 261 and the product from Example 259C may be used to prepare the title compound. [2203]
    • EXAMPLE 263 4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-ylamine
  • A mixture of Example 159A (0.500 g, 1.64 mmol) and 1, 8-bis(dimethylamino)naphthalene, N,N,N′, N′-tetramethyl-1,8-naphthalenediamine (0.350 g, 1.64 mmol) in 90 mL of anhydrous THF was warmed until all the solids went into solution. The solution was stirred for 15 m, whereupon diphenylphosphoryl azide (0.450 g, 1.64 mmol) was added. The solution was heated to reflux for 18 hours. The resulting deep red solution was evaporated to dryness under reduced pressure. The product was passed through 5 g of silica gel, eluting with 20% ethyl acetate/hexanes to provide 422 mg of the intermediate isocyanate as a bright orange solid. The resulting product was dissolved in 100 mL of toluene and the solution was heated to reflux for 6 hours. The product was evaporated to dryness. The resulting dark orange solid was dissolved in 20 mL of 2.0 M hydrogen chloride in dioxane. The solution was evaporated, leaving 313 mg (84.9%) of the title compound. [2204]
  • MS (APCI) m/e. 277 (M+H)[2205] +;
  • [2206] 1H NMR (300 MHz, DMSO-d6) δ6.91 (s, 1H), 7.18 (d, 2H), 7.47 (d, 2H), 8.34 (s, 1H), 9.21 (s, 1H).
    • EXAMPLE 264 4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-ylformamide
  • A mixture of 5 mL of acetic anhydride and 1.8 mL of 96% formic acid was heated to 70° C. for 3 hours. The solution was allowed to cool whereupon the obtained amine from Example 263 (32 mg, 0.12 mmol) was added. The mixture was stirred for 4 days and then poured into 50 mL of dilute HCl. The mixture was extracted with ethyl acetate, the combined extracts were washed with saturated sodium carbonate and then water, dried (MgSO[2207] 4), and evaporated. Purification of the resulting product by preparative HPLC using a gradient of 30%-70% acetonitrile/water+0.1% TFA over 40 minutes afforded 18 mg (49%) of the title compound.
  • MS (APCI) m/e: 305 (M+H)[2208] +;
  • [2209] 1H NMR (300 MHz, CD3OD) δ7.16 (s, 1H), 7.24 (d, 2H), 7.46 (d, 2H), 8.08 (s, 1H), 8.61 (s, 1H), 9.13 (s, 1H).
    • EXAMPLE 265 N-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]urea
  • A mixture of the obtained isocyanate from Example 263 (110 mg, 0.364 mmol) in 10 mL of ammonium hydroxide was vigorously stirred for 18 hours. The resulting red solid was collected and dried under vacuum, affording 60.7 g (52.2%) of the title compound. [2210]
  • MS (APCI) m/e: 320 (M+H)[2211] +;
  • [2212] 1H NMR (300 MHz, DMSO-d6) δ7.20 (d, 2H), 7.34 (s, 1H), 7.50 (d, 2H), 7.65-7.79 (m, 4H), 8.06-8.16 (m, 2H), 9.18 (s, 1H).
    • EXAMPLE 266 N-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N′-methylthiourea
  • A solution of obtained amine from Example 263 (150 mg, 0.542 mmol) in 5 mL of pyridine was treated with methyl isothiocyanate (198 mg, 2.71 mmol). The solution heated to 100° C. under a nitrogen atmosphere for 5 days. All volatiles were removed under reduced pressure. The resulting product was purified by flash column chromatography on silica gel eluting with chloroform/NH[2213] 4OH, affording 110 mg (58.1%) of the title compound.
  • MS (APCI) m/e: 350 (M+H)[2214] +;
  • [2215] 1H NMR (300 MHz, CD3OD) δ3.31 (s, 3H), 6.61 (bs, 1H), 6.96 (d, 2H), 7.34 (d, 2H), 7.88 (s, 1H), 7.96 (s, 1H), 8.67 (s, 1H).
    • EXAMPLE 267 Methyl 4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide
  • To a solution of Example 124A (261 mg, 1 mmol) in anhydrous THF (2 mL) at −78° C was added n-BuLi (2.5 M solution in hexanes, 0.60 mL, 1.5 mmol) under nitrogen atmosphere. This was stirred at −78° C. for 2 hours and a rapid stream of SO[2216] 2 was introduced on the surface of the reaction mixture. After 15 minutes the reaction mixture was allowed to warm to 0° C. with continuous introduction of SO2. The stream of SO2 gas was discontinued after 10 minutes at 0° C. and the reaction mixture was allowed to warm to 10° C. Then the solvent and excess SO2 gas were removed under reduced pressure to obtain the sulfinic acid lithium salt as a cream colored solid. This material was dissolved in a saturated aqueous solution of NaHCO3 (1 mL) and treated with N-chlorosuccinimide (200 mg, 1.5 mmol) at 0° C. The reaction mixture was stirred at 0° C. for 1 hour and at room temperature for 2 hours. The product formed was extracted into CH2Cl2 (2×50 mL) and washed with water (2×20 mL). The dried (Na2SO4) organic layer was evaporated to dryness under reduced pressure to obtain the sulfonyl chloride derivative. A portion of this material (143 mg, 0.398 mmol) was dissolved in CH2Cl2 (1 mL) at −5° C. and treated with diisopropylethylamine (0.083 mL, 0.478 mmol) and 2 M solution of methylamine in methanol (0.239 mL, 1.2 mmol) under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 1 hour. This was directly purified by silica gel flash chromatography eluting with 10% acetone-hexane followed by 25% acetone-hexane to obtain the title compound (19 mg, 13.5%).
  • MS (APCI) m/e: 355 (M+H)[2217] +, 353 (M−H)−;
  • [2218] 1H NMR (300 MHz, DMSO-d6) δ2.57 (s, 3H), 7.19 (d, J=9 Hz, 2H), 7.49 (d, J=9 Hz, 2H), 7.76 (s, 1H), 8.16 (br d, J=3 Hz, 1H), 8.24 (s, 1H), 9.24 (s, 1H).
    • EXAMPLE 268 2,3-Dihydroxypropyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide
  • Example 268 (8.6 mg, 7.5%) was prepared as described in Example 267 except substituting 3-amino-1,2-propanediol (0.086 mL, 1.12 mmol) for methylamine. [2219]
  • MS (APCI) m/e: 415 (M+H)[2220] +, 413 (M−H)−;
  • [2221] 1H NMR (300 MHz, DMSO-d6) δ2.76 (d, J=7.5 Hz, 1H), 2.81 (d, J=7.5 Hz, 1H), 3.02 (d, J=4.5 Hz, 1H), 3.08 (d, J=4.5 Hz, 1H), 3.44-3.55 (m, 1H), 4.47-4.64 (m, 1H), 4.80 (d, J=6 Hz, 1H), 7.17 (d, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H), 7.77 (s, 1H), 8.23 (s, 1H), 9.22 (s, 1H).
    • EXAMPLE 269 2-Hydroxyethyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide
  • Example 269 (25 mg, 16%) was prepared s described in Example 267 except substituting 2-hydroxyethylamine (0.072 mL, 1.2 mmol) for methylamine. [2222]
  • MS (APCI) m/e: 385 (M+H)[2223] +, 383 (M−H)−;
  • [2224] 1H NMR (300 MHz, DMSO-d6) δ2.97 (t, J=6 Hz, 2H), 3.38-3.45 (m, 2H), 4.69-4.78 (m, 1H), 7.18 (d, J=9 Hz, 2H), 7.48 (d, J=9 Hz, 2H), 7.78 (s, 1H), 8.23 (s, 1H), 9.21 (s, 1H);
  • [2225] 13C NMR (75 MHz, DMSO-d6) δ45.4 9CH2), 59.7 (CH2), 119.9 (CH), 122.2 (CH), 128.0 (C), 130.1 (CH), 133.3 (CH), 135.5 (C), 138.2 (C), 141.4 (CH), 147.5 (C), 148.4 (C), 155.2 (C).
    • EXAMPLE 270 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]phenol EXAMPLE 270A 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-boronic acid
  • A 1.3 M suspension of sec-butyllithium in cyclohexane (3.52 mL, 4.58 mmol) was added to THF (10 mL) at −78° C. A solution of Example 124A (1.00 g, 3.82 mmol) in THF (5 mL) was added dropwise. The reaction was stirred 30 minutes and tributyl borate (1.55 mL, 5.73 mmol) was slowly added. The cold bath was removed and the reaction stirred 45 minutes while warming to room temperature. A solution of2 N NaOH (15 mL) was added. After 10 minutes, the reaction was diluted with hexane (15 mL) and the aqueous layer collected. The organic layer was extracted with 2 N NaOH (2×5 mL) and all * aqueous extracts combined, acidified to pH 2 with 6 N HCl, and extracted with 10% MeOH/CH[2226] 2Cl2 (4×25 mL). The organic extracts were combined and concentrated. The *resulting solid was washed with acetonitrile (1×25 mL) and dried in a desiccator to yield the title compound as a tan solid (0.83 g, 71%).
  • MS (APCI) m/e: 262 (M+H−B(OH)[2227] 2)+, m/e: 340 (M+Cl−)−;
  • [2228] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 2H), 7.48 (m, 2H), 8.03 (s, 1H), 8.24 (s, 1H), 9.29 (s, 1H).
    • EXAMPLE 270B 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]anisol
  • A mixture of Example 270A (0.25 g, 0.82 mmol), 4-iodoanisole (0.19 g, 0.82 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) (0.10 g, 0.12 mmol), cesium fluoride (0.37 g, 2.46 mmol), triethylamine (0.11 mL, 0.82 mmol), in DME (7 mL) was aspirated 10 minutes with anhydrous nitrogen. The reaction was heated to 75° C. for 18 hours and then partitioned between EtOAc (100 mL) and sat. NaHCO[2229] 3 (100 mL). The organic layer was washed with sat. NaHCO3 (100 mL), brine (75 mL), partially dried (Na2SO4), and concentrated to a colored wet solid. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluant to yield a colored solid. The title product was crystallized from hot acetonitrile (0.11 g, 37%).
  • mp 121-123° C.; [2230]
  • MS (APCI) m/e: 368 (M+H)[2231] +;
  • [2232] 1NMR (300 MHz, DMSO-d6) δ3.82 (s, 3H), 7.05 (m, 2H), 7.13 (m, 2H), 7.45 (m, 2H) 7.67 (s, 1H), 7.81 (m, 2H), 8.13 (s, 1H), 9.05 (s, 1H);
  • Anal. calcd for C[2233] 20H14ClNO2S: C, 65.30; H, 3.84; N, 3.81. Found: C, 65.06; H, 3.69; N, 4.05.
    • EXAMPLE 270C 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]phenol
  • To a solution of Example 270B (0.09 g, 0.24 mmol) in anhydrous CH[2234] 2Cl2 (4 mL) was added a 1 M solution of boron tribromide in CH2Cl2 (0.96 mL, 0.96 mmol). After 2 hours, the reaction was quenched by slow addition of MeOH (2 mL) and then concentrated. The residue was diluted with CH2Cl2 (50 mL) and organic washed with 1:1 sat. NaHCO3brine (50 mL), partially dried (Na2SO4), then concentrated. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to yield the title compound as a solid (0.08, 96%).
  • mp 213-215° C.; [2235]
  • MS (ESI) m/e: 354 (M+H)[2236] +;
  • [2237] 1H NMR (300 MHz, DMSO-d6) δ6.86 (m, 2H), 7.11 (m, 2H), 7.45 (m, 2H), 7.56 (s, 1H), 7.68 (m, 2H), 8.13 (s, 1H), 9.03 (s, 1H), 9.99 (s, 1H);
  • Anal. calcd for C[2238] 19H12ClNO2S. 0.5 H2O: C, 62.90; H, 3.61; N, 3.86. Found: C, 62.96; H, 3.61; N, 3.52.
    • EXAMPLE 271 3-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline EXAMPLE 272 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline EXAMPLE 272A 4-[4-(4-Chlorophenoxy)thieno[2,3 -c]pyridin-2-yl]nitrobenzene
  • A mixture of Example 170A (0.25 g, 0.82 mmol), 1-iodo-4-nitrobenzene (0.20 g, 0.82 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) (0.10 g, 0.12 mmol), cesium fluoride (0.37 g, 2.46 mmol), triethylamine (0.11 mL, 0.82 mmol), in DME (8 mL) was aspirated 10 minutes with anhydrous nitrogen. The reaction was heated to 70° C. for 18 hours and then partitioned between EtOAc (100 mL)and sat. NaHCO[2239] 3 (100 mL). The organic layer was washed with sat. NaHCO3 (100 mL), brine (75 mL), partially dried (Na2SO4), and concentrated to a colored oil. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to yield the title compound as a colored solid (0.15 g, 48%).
  • mp [2240] 193-195° C.;
  • MS (ESI).m/e: 383 (M+H)[2241] +;
  • [2242] 1H NMR (300 MHz, DMSO-d6) δ7.17 (m, 2H), 7.48 (m, 2H), 8.15 (m, 1H), 8.17 (s, 1H), 8.19 (m, 2H), 8.32 (m, 2H), 9.17 (s, 1H);
  • Anal. calcd for C[2243] 19H11ClN2O3S: C, 59.61 H, 2.90; N. 7.32. Found: C, 59.35; H, 2.94; N, 7.22.
    • EXAMPLE 272B 4-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline
  • To a suspension of Example 272A (0.13 g, 0.34 mmol) in EtOH (3.5 mL), a solution of tin(II) chloride dihydrate (0.31 g, 1.36 mmol) in conc. HCl (0.68 mL) was slowly added. The reaction was stirred for 22 hours and partitioned between dichloromethane (75 mL) and 1 N NaOH (75 mL). The organic layer was washed with 1 N NaOH (1×50 mL), brine (1×50 mL), partially dried (Na[2244] 2SO4), and concentrated to a colored solid (0.13 g). The desired product was crystallized from acetonitrile to yield colored crystals (0.08 g, 68%).
  • mp 178-182° C.; [2245]
  • MS (APCI) m/e: 353 (M+H)[2246] +;
  • [2247] 1H NMR (300 MHz, DMSO-d6) δ5.68 (br s, 2H), 6.62 (m, 2H), 7.09 (m, 2H), 7.39 (s, 1H), 7.44 (m, 2H), 7.51 (m, 2H), 8.11 (s, 1H), 8.97 (s, 1H);
  • Anal. calcd for C[2248] 19H13ClN2OS: C, 64.68; H, 3.71; N, 7.94. Found: C, 64.65; H, 3.73; N,: 8.13.
    • EXAMPLE 273 6-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-pyridinamine EXAMPLE 273A 6-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-nitropyridine
  • Example 273A (120 mg, 32%) was prepared as in Example 272A substituting 2-bromo-5-nitropyridine for 1-iodo-4-nitrobenzene. [2249]
  • mp 221-223° C.; [2250]
  • MS (APCI) m/e: 384 (M+H)[2251] +;
  • [2252] 1H NMR (300 MHz, DMSO-d6) δ7.20 (m, 2 H), 7.49 (m, 2 H), 8.16 (s, 1 H), 8.50 (s, 1 H), 8.61 (d, J=8.8 Hz, 1 H), 8.70 (dd, J=8.8, 2.4 Hz, 1 H), 9.17 (s, 1 H), 9.44 (d, J=2.4 Hz, 1 H).
    • EXAMPLE 273B 6-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-pyridinamine
  • Example 273B (0.07 g, 59%) was prepared as in Example 272B [2253]
  • mp 225-227° C.; [2254]
  • MS (APCI) m/e: 354 (M+H)[2255] +;
  • [2256] 1H NMR (300 MHz, DMSO-d6) δ5.82 (broad s, 2 H), 6.92 (dd, J=8.5, 2.6 Hz, 1 H), 7.05 (m, 2 H), 7.39 (m, 2 H), 7.60 (m, 1 H), 7.79 (d, J=8.5 Hz, 1 H), 7.91 (d, J=2.6 Hz, 1 H), 8.04 (s,1 H), 8.93 (s, 1 H);
  • Anal. calcd for C[2257] 18H12ClN3OS: C, 61.10; H, 3.42; N, 11.88. Found: C, 60.97; H, 3.39; N, 12.08.
    • EXAMPLE 274 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-pyridinamine
  • A mixture of Example 270A (0.20 g, 0.65 mmol), 2-amino-5-bromopyridine (0.11 g, 0.65 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) (0.11 g, 0.13 mmol), cesium fluoride (0.30 g, 1.95 mmol), triethylamine (0.09 mL, 0.65 mmol), in DME (6 mL) was aspirated 20 minutes with anhydrous nitrogen. The reaction was heated to reflux for 4 hours then concentrated. The residue was dissolved in 10% [2258] iPrOH/CHCl3 (100 mL), filtered, and the organic washed with sat. NaHCO3 (2×100 mL), partially dried (Na2SO4), then concentrated to yield a crude colored solid (0.25 g). The crude material was purified by preparative HPLC using a gradient of 25%-65% acetonitrile/water+0.1% TFA over 40 minutes. The product was neutralized with sat NaHCO3, precipitate collected by filtration, and dried in a desiccator to yield the title compound as a lightly colored solid (54 mg, 23%).
  • mp 208-210° C.; [2259]
  • MS (APCI) m/e: 254 (M+H)[2260] +;
  • [2261] 1H NMR (300 MHz, DMSO-d6) δ6.50 (br s, 2H), 6.53 (dd, J=8.9, 0.9 Hz, 1H), 7.11 (m, 2H), 7.44 (m, 2H), 7.55 (s, 1H), 7.85 (dd, J=8.9, 2.6 Hz, 1H), 8.11 (s, 1H), 8.41 (dd, J=2.6, 0.9 Hz, 1H), 9.00 (s, 1H);
  • Anal. calcd for C[2262] 18H12ClN3OS: C, 61.10; H, 3.42; N, 11.88. Found: C, 60.92; H, 3.45; N, 11.90.
    • EXAMPLE 275 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-amine
  • Example 156 (0.15 g, 0.47 mmol) was suspended in 1, 4-dioxane (3 mL) and a 5 M solution of cyanogen bromide in acetonitrile (0.10 mL, 0.50 mmol) was added. The reaction was allowed to stir 10 minutes and a solution of NaHCO[2263] 3 (0.04 g, 0.50 mmol) in water (1.4 mL) was added dropwise. The colored reaction was stirred 2 hours, then poured into sat. NaHCO3 (75 mL). The aqueous phase was extracted with 10% isopropanol/CHCl3 (4×25 mL). The organic extracts were combined, dried (Na2SO4), and concentrated to yield a solid (0.13 g). A portion of the crude was purified by HPLC using a gradient of 3 0%-70% acetonitrile/water+0.1% TFA over 40 minutes to yield the title compound as a tan solid.
  • mp 262-263° C.; [2264]
  • MS (APCI) m/e: 345 (M+H)[2265] +;
  • [2266] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 2H), 7.47 (m, 2H), 7.52 (s, 1H), 7.60 (broad s, 2H), 8.24 (s, 1H), 9.17 (s, 1H);
  • [2267] 13C NMR (DMSO-d6) δ164.3, 155.6, 153.1, 146.6, 141.2, 137.0, 136.9, 134.0, 131.4, 130.1 (2C), 127.7, 119.5 (2C), 117.5;
  • IR (KBr) 3325, 3234, 3080, 1665, 1578, 1547, 1486, 1411, 1287,1257, 1229,1203cm[2268] −1;
  • Anal calcd for C[2269] 15H9ClN4O2S: C, 52.26; H, 2.63; N, 16.25. Found: C, 52.40; H, 2.68; N, 16.23.
    • EXAMPLE 276 5-[4-(4-Bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-ylamine
  • Example 157 (0.15 g, 0.41 mmol) was suspended in 1,4-dioxane (4 mL) and a 5 M solution of cyanogen bromide in acetonitrile (0.10 mL, 0.50 mmol) was added. The reaction was allowed to stir 10 minutes and a solution of NaHCO[2270] 3 (0.04 g, 0.50 mmol) in water (1.4 mL) was added dropwise. The colored reaction was stirred 3 hours, then poured into sat. NaHCO3 (75 mL). The aqueous was extracted with 10% EPA/CHCl3 (4×25 mL). The organic extracts were combined, partially dried (Na2SO4), and concentrated to yield a solid. A portion of the crude was purified by HPLC using a gradient of 30%-70% acetonitrile/water+0.1% TFA over 40 minutes to yield the title compound as a tan solid.
  • mp 270-273° C.; [2271]
  • MS (APCI) m/e: 389 (M+H)[2272] +;
  • [2273] 1H NMR (300 MHz, DMSO-d6) δ7.08 (m, 2H), 7.52 (s, 1H), 7.56 (br s, 2H), 7.59 (m, 2H), 8.27 (s, 1H), 9.19 (s, 1H);
  • Anal calcd for C[2274] 15H9BrN4O2S: C, 46.29; H, 2.33; N, 14.39. Found: C, 46.08; H, 2.59; N, 14.12.
    • EXAMPLE 277 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4H-1,2,4-triazol-3-amine
  • To a dry flask containing 61A (0.33 g, 1.03 mmol) and aminoguanidine hydrochloride (3.45 g, 31.20 mmol) was added slowly a solution of 25% wt NaOMe/MeOH (7.13 mL, 34.32 mmol). The reaction was stirred at ambient temperature for 1 hour then heated to 50° C. for 20 hours, then 70° C. for 24 hours. The reaction was poured into water (200 mL) and aqueous neutralized with 3 N HCl (10 mL). The precipitate was collected by filtration, washed with water (2×20 mL), and dried in a desiccator. The crude material was purified by preparative HPLC using a gradient of 25%-65% acetonitrile/water+0.1% TFA over 40 minutes. The product was-neutralized with sat. NaHCO[2275] 3, and the precipitate was collected by filtration then dried in a desiccator to yield the title compound as a white solid (0.16 g, 45%).
  • mp>270° C.; [2276]
  • MS (APCI) m/e: 344 (M+H)[2277] +;
  • [2278] 1H NMR (300 MHz, DMSO-d6) δ6.46 (br s, 2H), 7.27 (m, 2H), 7.58 (m, 2H), 7.67 (s, 1H), 8.31 (s, 1H), 9.21 (s, 1H);
  • Anal. calcd for C[2279] 15H10ClN5OS: C, 52.41; H, 2.93; N, 20.37. Found: C, 52.21; H, 3.02; N, 20.45.
    • EXAMPLE 278 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-thiadiazol-2-amine
  • Example 88 (0.36 g, 1.18 mmol) was suspended in thionyl chloride (4 mL) and the suspension was heated to 45° C. for 2 hours. The reaction was concentrated and the residue diluted with CH[2280] 2Cl2 (2×5 mL) and concentrated to yield a colored solid. The crude solid was dissolved in DMF (5 mL) and thiosemicarbazide (2.69 g, 29.50 mmol) was added and the reaction stirred 24 hours. The reaction was poured into water (250 mL) and the aqueous suspension treated with sat. aq. NaHCO3 (10 mL) until pH>7. The precipitate was collected, washed with water (2×20 mL), and dried in a desiccator to yield the corresponding acyl semicarbazate as a solid (0.30 g) [MS (APCI) m/e: 377 (M+H)+]. The crude material (0.20 g) was suspended in toluene (2 mL) and methanesulfonic acid (0.10 mL, 1.60 mmol) added. The reaction was heated to reflux for 4 hours, then allowed to coot to room temperature. The heterogeneous mixture was diluted with hexane (5 mL) and the solvent decanted away from the colored residue. The residue was triturated with hexane (2×10 mL) and dried in-vacuo. The solid was suspended in water (15 mL) and treated with NH4OH until pH 9 was attained. The precipitate was collected and washed with water (2×5 mL). The crude material was partially purified on silica gel by flash chromatography using acetone as eluent. This product was further purified by preparative HPLC using a gradient of 25%-65% acetonitrile/water+0.1% TFA over 40 minutes. The product was neutralized with sat. aq. NaHCO3, and the precipitate collected by filtration, then dried in a desiccator to yield the title compound as a tan solid (0.04 mg, 14% overall).
  • mp>270° C.; [2281]
  • MS (APCI) m/e: 361 (M+H)[2282] +;
  • [2283] 1H NMR (300 MHz, DMSO-d6) δ7.15 (m, 2H), 7.46 (m, 2H), 7.68 (s, 1H), 7.75 (br s, 2H), 8.11 (s, 1H), 9.06 (s, 1H);
  • Anal. calcd for C[2284] 15H9ClN4OS2: C, 49.93; H, 2.51; N, 15.53. Found: C, 49.82; H, 2.64; N, 15.58.
    • EXAMPLE 279 4-(4-Chlorophenoxy)-2-(5-meth-1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine
  • A solution of the resultant compound from Example 249 (160 mg, 0.5 mmol) in pyridine (2.0 mL) under nitrogen at ambient temperature was treated with acetyl chloride (50 mL, 0.55 mmol) and heated to reflux for 15 hours. The resultant dark yellow homogeneous solution was diluted with ethyl acetate, washed with saturated NaHCO[2285] 3, brine, dried (MgSO4), filtered through a plug of silica and concentrated to give 169 mg of an off-white powder. This solid was flash chromatographed on silica gel with 30-50% ethyl acetate/hexane to provide the title compound (150 mg, 87%).
  • mp 120-121° C.; [2286]
  • MS (APCI—NH[2287] 3) m/e: 344 (M+H)+;
  • [2288] 1H NMR (300 MHz, DMSO-d6) δ9.24 (s, 1H), 8.27 (s, 1H), 7.89 (s, 1H), 7.48 (d, 2H) 7.16 (d, 2H), 2.69 (s, 3H);
  • Anal. Calcd for C[2289] 16H10 ClN3O2S: C, 55.90; H, 2.93; N; 12.22. Found: C, 56.10; H, 3.16; N, 12.01.
    • EXAMPLE 280 5-{4-[4-(Trifluoromethyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine
  • Example 158 was treated according to the procedure of Example 275 to provide the title compound. [2290]
  • MS (APCI) m/e: 358.9 (M+H)[2291] +;
  • [2292] 1H NMR (300 MHz, DMSO-d6) δ7.22 (d, 2H), 7.51 (s, 1H), 7.60 (s, 2H) 7.79 (d, 2H), 8.40 (s, 1H), 9.25 (s, 1H).
    • EXAMPLE 281 4-(4-Chlorophenoxy)-2-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]thieno[2,3-c]pyridine EXAMPLE 281A 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3 4-oxadiazole-2-thiol
  • The compound from Example 156 (100 mg, 0.31 mmol) was suspended in ethanol (2 ml) and cooled to 0° C. Carbon disulfide (0.04 ml, 0.71 mmol) was added follow by potassium hydroxide (20 mg, 0.31 mmol). The reaction was stirred 1 hr and the cold bath removed. After 1 hr at ambient temperature, the reaction was refluxed for 3 hours then concentrated to a solid. The crude solid was triturated with chloroform (1×5 ml) and concentrated. The residue was dissolved in water (15 ml) and acidified with formic acid. The resulting precipitate was isolated by filtration, washed with water (2×15 ml), and dried in a desiccator to yield the title compound (106 mg, 94%). [2293]
  • mp 236-240° C.; [2294]
  • MS (ESI) m/e: 362 (M+H)[2295] +;
  • [2296] 1H NMR (300 MHz, CD2Cl2) δ7.15 (m, 2H), 7.46 (m, 2H), 7.65 (m, 1H), 8.24 (s, 1H), 9.18 (s, 1H);
  • Anal. calcd for C[2297] 15H8ClN3O2S2: C, 47.89; H, 2.57; N, 11.17. Found: C, 47.89; H, 2.49; N, 10.97.
    • EXAMPLE 281B 4-(4-Chlorophenoxy)-2-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl thieno[2,3-c]pyridine
  • To a stirred suspension of 281A (100 mg, 0.28 mmol) in THF (1 ml) at 0° C. was added an aqueous 1 M sodium hydroxide solution (0.28 ml, 0.28 mmol). After 30 minutes all solid had dissolved and iodomethane (0.02 ml, 0.31 mmol) was slowly added dropwise. The reaction was stirred 30 minutes and water (8 ml) was added. Solid was collected by filtration, washed with water (2×15 ml), and dried in a desiccator to yield 80 mg of a pale yellow solid. The crude product was purified by flash chromatography on silica gel using acetone/hexane as eluent to yield the title compound as a solid (41 mg, 39%). [2298]
  • mp 158-160° C.; [2299]
  • MS (ESI) m/e: 376 (M+H)[2300] +;
  • [2301] 1H NMR (300 MHz, CD2Cl2) δ2.75 (s, 3 H), 7.01 (m, 2 H), 7.33 (m, 2 H), 7.91 (s, 1 H), 8.12 (s, 1 H), 8.93 (s, 1 H);
  • Anal. calcd for C[2302] 16H10ClN3O2S2: C, 51.13; H, 2.68; N, 11.18. Found: C, 51.25; H, 3.02; N, 10.89.
    • EXAMPLE 282 4-(4-Chlorophenoxy)-2-(2-methyl-1,2,3,4-tetrazol-5-yl)thieno[2,3-c]pyridine EXAMPLE 282A 4-(4-Chlorophenoxy)-2-(1,2,3,4-tetrazol-5-yl)thieno[2,3-c]pyridine
  • A solution of the resultant compound from Example 248 (90 mg, 0.314 mmol) in toluene (1.5 mL) under nitrogen at room temperature was treated with dibutyltin oxide (8 mg, 0.031 mmol), trimethylsilylazide (125 mL, 0.942 mmol) and heated to reflux for 24 hours, then stirred at room temperature an additional 2.5 days. The resultant yellow heterogeneous mixture was concentrated and then flash chromatographed with 20% methanol/dichloromethane to give 105 mg of a light yellow powder. This powder was dissolved in ethyl acetate, extracted with 10% NaHCO[2303] 3 (2×), the aqueous extracts combined, acidified to pH 2 with 6 N HCl, extracted with ethyl acetate, dried (Na2SO4) and concentrated to give the title compound as a white powder (63 mg, 61%).
  • mp 250-254° C.; [2304]
  • MS (APCI—NH[2305] 3) m/c: 330 (M+H)+;
  • [2306] 1H NMR (300 MHz, DMSO-d6) δ9.26 (s, 1H), 8.27 (s, 1H), 8.01 (s, 1H), 7.48 (d, 2H) 7.19 (d, 2H);
  • Anal. Calcd for C[2307] 14H8ClN5OS 0.25 H2O: C, 50.30; H, 2.56; N, 20.95. Found: C, 50.27; H, 2.69; N, 20.78.
    • EXAMPLE 282B 4-(4-Chlorophenoxy)-2-(2-methyl-1,2,3,4-tetraazol-5-yl)thieno[2,3-c]pyridine
  • A solution of the resultant compound from Example 282A (100 mg, 0.3 mmol) in methanol (4 mL) under nitrogen at room temperature was treated with diazomethane in diethyl ether (generated from N-methyl-N′-nitro-N-nitrosoguanidine in diethyl ether and 40% KOH) until a yellow color persisted for more than 5 minutes, stirred an additional 15 minutes and then quenched by slow, dropwise addition of glacial acetic acid till yellow color disappeared (vigorous gas evolution) and then concentrated. The resultant light yellow solid was filtered through a plug of silica gel with 5% methanol/dichloromethane and then flash chromatographed on reverse phase silica gel (Dynamax 21.4 mm C-18 column) with 25-65% CH[2308] 3CN with 0.1% TFA/H2O with 0.1% TFA to provide the title compound as a white powder (40 mg, 39%).
  • mp 131-133° C.; [2309]
  • MS (APCI—NH[2310] 3) m/e: 344 (M+H)+;
  • [2311] 1H NMR (300 MHz, DMSO-d6) δ9.25 (s, 1H), 8.28 (s, 1H), 7.89 (s, 1H), 7.48 (d, 2H) 7.18 (d, 2H), 4.47 (s, 3H);
  • Anal. Calcd for C[2312] 15H10ClN5OS 0.25 H2O: C, 51.73; H, 3.04; N, 20.11. Found: C, 51.74; H, 2.93; N, 19.93.
    • EXAMPLE 283 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4-methyl-4H-1,2,4-triazol-3-amine
  • Sodium hydride (60% in oil, 0.02 g, 0.42 mmol) was suspended in DMF (1 mL) at 0° C. A solution of Example 277 (0.11 g, 0.32 mmol) in DMF (1 mL) was added dropwise and the reaction stirred 20 minutes. Iodomethane (0.06 mL, 0.96 mmol) was added and after 30 minutes the reaction was poured into water (75 mL). The resulting precipitate was collected by filtration, washed with water (1×20 mL), and with 50% EtOAc/hexane (2×25 mL). The crude solid was dried to yield a colored solid (0.11 g). The title compound was isolated by preparative HPLC using a gradient of 25%-65% acetonitrile/water+0.1% TFA over 40 minutes. The product was neutralized with sat. aq. NaHCO[2313] 3, and the precipitates collected by filtration, then dried in a desiccator to provide (31 mg, 27%).
  • mp 233-235° C.; [2314]
  • MS (APCI) m/e: 358 (M+H)[2315] +;
  • [2316] 1H NMR (300 MHz, DMF-d7) δ3.75 (s, 3H), 6.58 (br s, 2H), 7.23 (m, 2H), 7.54 (m, 2H), 7.61 (s, 1H), 8.27 (s, 1H), 9.18 (s, 1H);
  • Anal. calcd for C[2317] 16H12ClN5OS: C, 53.71; H, 3.38; N, 19.57. Found: C, 54.00; H, 3.56; N, 19.68.
    • EXAMPLE 284 4-(4-Chlorophenoxy)-2-[5-(trifluoromethyl)-1,2,4-6oxadiazol-3-yl]thieno[2,3-c]pyridine
  • A solution of the resultant compound from Example 249 (100 mg, 0.31 mmol) in pyridine (1.5 mL) under nitrogen at room temperature was treated with trifluoroacetic anhydride (50 mL, 0.31 mmol), stirred for 20.5 hours, then heated to reflux for three hours. The brown solution was diluted with ethyl acetate, washed with saturated NaHCO[2318] 3, brine, dried (MgSO4), concentrated, then filtered through a plug of silica gel with 50/50 hexane/ethyl acetate and concentrated to give 120 mg of a yellow residue. This residue was flash chromatographed on silica gel twice using 20-33% ethyl acetate/hexane and then 0-1% methanol/CH2Cl2 to give the title compound as a white solid (67 mg, 54%).
  • mp 52-54° C.; [2319]
  • MS (APCI—NH[2320] 3) m/e: 398 (M+H)+, 416 (M+NH4)+;
  • [2321] 1H NMR (300 MHz, DMSO-d6) δ9.30 (s, 1H), 8.29 (s, 1H), 8.10 (s, 1H), 7.48 (d, 2H), 7.20 (d, 2H);
  • Anal. Calcd for C[2322] 16H7ClF3N3O2S0.25 H2O: C, 47.77; H. 1.88; N, 10.45. Found: C, 48.15; H, 2.09; N, 10.14.
    • EXAMPLE 285 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-3-amine
  • A solution of the resultant compound from Example 250 (100 mg, 0.3 mmol) in methanol (1.5 mL) under nitrogen at ambient temperature was treated with hydroxylamine hydrochloride (40 mg, 0.45 mmol), triethylamine (70 mL, 0.5 mmol) and stirred for 18 hours, 4 mL THF was added and stirred for two days, solvent switched to 50/50 dichloromethane/methanol, additional hydroxylamine hydrochloride (100 mg, 1.4 mmol) and triethylamine (200 mL, 2.7 mmol) added, stirred at ambient temperature for 24 hours and then reflux for 8 hours. The reaction mixture was diluted with ethyl acetate, washed with dilute NaHCO[2323] 3, brine, dried (MgSO4) and concentrated to give 105 mg of an off-white solid. The resultant solid was flash chromatographed twice on reverse phase silica gel (Dynamax 21.4 mm C-18 column) with 25-65% CH3CN with 0.1% TFA/H2O with 0.1% TFA, followed by 20-80% CH3CN with 0.1% TFA/H2O with 0.1% TFA to provide the title compound as a white powder (26 mg, 25%).
  • mp 217-219° C.; [2324]
  • MS (APCI—NH[2325] 3) m/e: 345 (M+H)+,
  • [2326] 1H NMR (300 MHz, DMSO-d6) δ9.26 (s, 1H), 8.25 (s, 1H), 8.02 (s, 1H), 7.49 (d, 2H), 7.14 (d, 2H), 6.62 (br s, 2H);
  • Anal. Calcd for C[2327] 15H9ClN4O2S: C, 52.25; H, 2.63; N, 16.25. Found: C, 51.94; H, 2.88; N, 15.98.
    • EXAMPLE 286 5-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-1,3,4-thiadiazol-2-amine
  • The title compound (4% overall yield) was prepared as in Example 278, substituting 4-methylthiosemicarbazide for thiosemicarbazide. [2328]
  • mp 226-229° C.; [2329]
  • MS (APCI) m/e 375 (M+H)[2330] +;
  • [2331] 1H NMR (300 MHz, DMSO-d6) δ2.95(d, J=1.7 Hz, 3 H), 7.14 (m, 2 H), 7.45 (m, 2 H), 7.69 (s, 1 H), 8.17 (s, 1 H), 8.19 (br m, 1 H), 9.07 (s, 1 H);
  • Anal. calcd for C[2332] 16H11ClN4OS2: C, 51.27; H. 2.96; N, 14.95. Found: C, 51.24; H, 3.03; N, 14.85.
    • EXAMPLE 287 4-(4-Chlorophenoxy)-2-(1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine EXAMPLE 287A 4-(4-Chlorophenoxy)-N′-(diethoxymethoxy)thieno[2,3,-c]pyridine-2-carboxaimidamide
  • A solution of the resultant compound from Example 249 (100 mg, 0.31 mmol) in triethylorthoformate (1.3 mL) under nitrogen was heated to 140° C. for 5 hours, 160° C. for 2 hours and stirred at room temperature for 14 hours. The resultant light yellow oil (110 mg) was flash chromatographed on silica gel 20-70% ethyl acetate/hexane to provide the title compound as a white solid (50 mg, 38%). [2333]
  • MS (APCI—NH[2334] 3) m/e: 422 (M+H)+;
  • [2335] 1H NMR (300 MHz, DMSO-d6) δ9.05 (s, 1H), 8.15 (s, 1H), 7.97 (s, 1H), 7.46 (d, 2H), 7.10 (d, 2H), 6.65 (br s, 2H), 5.66 (s, 1H), 3.62-3.71 (m, 4H), 1.15 (t, 6H).
    • EXAMPLE 287B 4-(4-Chlorophenoxy)-2-(1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine
  • A solution of the resultant compound from Example 287A (50mg, 0.119 mmol) in toluene (6 mL) under nitrogen was heated at reflux for 20 hours then allowed to cool and concentrated. The yellow residue (46 mg) was flash chromatographed on silica gel 25-50% ethyl acetate/hexane to provide the title compound as a white solid (39 mg, 100%). Analytical HPLC: 4.6×250 mm C-18 column, 0.8 mL/min, 254 nm, CH[2336] 3CN:H2O with 0.1% TFA, 0:100 (0-3 min), ramp to 90:10 (3-30 min), 90:10 (30-35 min), ramp to 0:100 (35-40 min), Rt=22.47 min (100% peak area);
  • mp 151-152° C.;. [2337]
  • MS (APCI—NH[2338] 3) m/e: 330 (M+H)+;
  • [2339] 1H NMR (300 MHz, DMSO-d6) δ9.86 (s, 1H), 9.26 (s, 1H), 8.27 (s, 1H), 7.98 (s, 1H) 7.48 (d, 2H), 7.19 (d, 2H).
    • EXAMPLE 288 2-(1,3,4-Oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine
  • A solution of Example 183 (100 mg, 0.283 mmol) in triethyl orthoformate (15 mL) was heated to reflux under an atmosphere of nitrogen for 28 hours. All volatiles were removed under reduced pressure. The resulting oil was purified by flash column chromatography eluting with hexane/ethyl acetate (2:1), affording 65 mg (63%) of the title compound as a colorless oil that solidified on standing. [2340]
  • MS (ESI) m/e: 364 (M+H)[2341] +;
  • [2342] 1H NMR (300 MHz, CDCl3) δ7.14 (d, 2H), 7.66 (d, 2H), 8.05 (s, 1H), 8.24 (s, 1H), 8.50 (s, 1H), 9.07 (s, 1H);
  • Anal. calcd for C[2343] 16H8N3F3O2S: C, 52.89; H, 2.22; N, 11.57. Found: C, 53.03; H, 2.25; N, 11.48.
    • EXAMPLE 289 3-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-5-amine EXAMPLE 289A 3-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-5-(trichloromethyl-1,2,4-oxadiazole
  • A solution of the resultant compound from Example 249 (50 mg, 0.156 mmol) pyridine (2 mL) under nitrogen at ambient temperature was treated with trichloroacetyl chloride (20 mL, 0.17 mmol) and heated at reflux for 1.5 hours, allowed to cool to room temperature, stirred overnight, treated with additional trichloroacetyl chloride (100 mL, 0.86 mmol) and stirred 4 hours. The reaction mixture was then diluted with ethyl acetate, washed with saturated NaHCO[2344] 3, brine, dried (MgSO4) and concentrated. The resultant brown residue was flash chromatographed on silica gel with 25-50% ethyl acetate/hexane to give the title compound as a clear residue (37 mg, 53%).
  • MS (APCI—NH[2345] 3) m/e: 448 (M+H)+;
  • [2346] 1H NMR (300 MHz, DMSO-d6) δ9.25 (s, 1H), 8.24 (s, 1H), 8.09 (s, 1H), 7.46 (d, 2H), 7.18 (d, 2H).
    • EXAMPLE 289B 3-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-5-amine
  • A solution of the resultant compound from Example 289A (30 mg, 0.067 mmol) in 2.0 M ammonia in methanol (6 mL) in a pressure tube was heated to 60° C. for 15 hours then allowed to cool ambient temperature, rinsed out of the flask with methanol and distilled water. The bulk of the methanol was removed under vacuum and the cloudy white mixture was filtered and washed with distilled water. The resultant yellow-brown solid was flash chromatographed twice on reverse phase silica gel (Dyanamax C-18, 21.4 mm column) with 25-65%, and then 20-80% CH[2347] 3CN with 0.1% TFA/H2O with 0.1% TFA to give the title compound as a white solid (4.mg, 17%).
  • Analytical HPLC: 4.6×250 mm C-18 column, 0.8 mL/min, 254 rnm, CH[2348] 3CN:H2O with 0.1% TFA, 0:100 (0-3 min), ramp to 90:10 (3-30 min), 90:10 (30-35 min), ramp to 0:100 (35-40 min), Rt=19.44 min (100% peak area);
  • mp 268-270° C.; [2349]
  • MS (APCI—NH[2350] 3) m/e: 345 (M+H)+;
  • [2351] 1H NMR (300 MHz, DMSO-d6) δ9.21 (s, 1H), 8.27 (s, 1H), 8.22 (br s, 2H), 7.67 (s, 1H), 7.47 (d, 2H), 7.15 (d, 2H).
    • EXAMPLE 290 2-(5-Methyl-1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine
  • The title compound was prepared as described for Example 288 using triethyl orthoacetate as the solvent. Reflux was maintained for 5 days with the yield being 29%. [2352]
  • MS (APCI) m/e: 377 (M+H)[2353] +;
  • [2354] 1H NMR (300 MHz, CDCl3) δ2.65 (s, 3H), 7.13 (d, 2H), 7.65 (d, 2H), 7.94 (s, 1H), 8.27 (s, 1H),.9.06 (s, 1H).
    • EXAMPLE 291 4-(4-Chlorophenoxy-2-(2-furyl)thieno[2,3-c]pyridine
  • A mixture of Example 270A (0.30 g, 0.98 mmol), 2,5-dibromofuran (0.66 g, 2.94 mmol), cesium fluoride (0.45 g, 2.94 mmol), triethylamine (0.14 mL, 0.98 mmol), in DME (9 mL) was aspirated 25 minutes with anhydrous nitrogen and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) dichloromethane complex (1:1) (0.16 g, 0.20 mmol) was added. The reaction was heated to reflux for 4 hr and then stirred at ambient temperture overnight. The reaction was diluted with EtOAc (100 mL) and filtered. The organic layer was washed with sat. NaHCO[2355] 3 (3×50 mL), brine (75 mL), partially dried (Na2SO4), and concentrated to a colored oil. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent to yield a colored oil (0.12 g, 0.30 mmol) [MS (APCI) m/e 406 (M+H)+]. This material was dissolved in EtOH (10 mL) and 5% Pd/C (3 mg, 0.02 mmol) was added. A balloon of hydrogen gas was applied and reaction stirred 3 days at ambient temperature. Reaction was filtered through celite and celite wash with MeOH (10 mL) and dichloromethane (10 mL). The filtrate and washes were combined and concentrated to a colored wet foam. The crude material was purified by preparative HPLC using a gradient of 30%-70% acetonitrile/water+0.1% TFA over 40 minutes. The product was neutralized with sat NaHCO3, precipitate collected by filtration, and dried in a desiccator to yield the title compound as a lightly colored solid (15 mg, 5% overall yield).
  • mp 75-77° C.; [2356]
  • MS (APCI) m/e: 328 (M+H)[2357] +;
  • [2358] 1H NMR (300 MHz, DMSO-d6) δ6.70 (dd, J=3.4, 1.7 Hz, 1 H), 7.12 (m, 2 H), 7.24 (d, J=3.4 Hz, 1 H), 7.46 (m, 2 H), 7.59 (s, 1 H), 7.88 (d, J=1.7 Hz, 1 H), 8.16 (s, 1 H), 9.08 (s, 1 H).
    • EXAMPLE 292 4-(4-Chlorophenoxy)-2-(2-thienyl)thieno[2,3-c]pyridine
  • Example 292 (50 mg, 22%) was prepared as in Example 272A, substituting 2-iodothiophene for 1-iodo-4-nitrobenzene. [2359]
  • mp 101-103-° C; [2360]
  • MS (APCI) m/e: 344 (M+H)[2361] +;
  • [2362] 1H NMR (300 MHz, DMSO-d6) δ7.14 (m, 2 H), 7.19 (dd, J=5.0, 3.4 Hz, 1 H), 7.46 (m, 2 H), 7.54 (d, J=0.9 Hz, 1 H), 7.67 (dd, J=3.4, 1.3 Hz, 1 H), 7.73 (dd, J=5.0, 1.3 Hz, 1 H), 8.14 (s, 1 H), 9.05 (s, 1 H);
  • Anal. calcd for C[2363] 17H10ClNOS2 0.2H2O: C, 58.77; H, 3.02; N, 4.03. Found: C, 58.74; H, 2.84; N, 3.72.
    • EXAMPLE 293 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1, 3-thiazole-4-carboxamide EXAMPLE 293A Ethyl 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxylate
  • Ethyl bromopyruvate (390 mL, 2.30 mmol) was combined with Example 146 (672 mg, 2.09 mmol) and absolute ethanol (100 mL), and the orange, homogenous solution was heated at 60° C. After 48 hours, the mixture was cooled to ambient temperature and concentrated under vacuum. Purification was achieved by means of flash silica gel chromatography (15% acetone in hexane), and the title compound (297 mg, 34% yield) was obtained as a white solid. [2364]
  • MS (DCI/NH[2365] 3) m/e: 417 (35Cl)/419 (37Cl);
  • [2366] 1H NMR (300 MHz, CDCl3) δ8.94 (s, 1H), 8.24 (s, 1H), 8.12 (s, 1H), 7.88 (s, 1H), 7.36 (d, J=8.8 Hz, 2H), 7.04 (d, J=8.8 Hz, 2H), 4.45 (q, J=7.0 Hz, 2H), 1.45 (t, J=7 Hz, 3H).
    • EXAMPLE 293B 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxamide
  • Example 293A (32 mg, 77 mmol) was combined with ammonia in methanol (4 mL of a 2.0 M solution), and the solution was heated in a sealed tube at 40° C. After 16 hours, the homogeneous solution was cooled to room temperature and concentrated to a brown solid that was dry-loaded on flash silica gel and eluted with 20% acetone in hexane, followed by 40% acetone in hexane to recover the title compound (8 mg, 27% yield). [2367]
  • mp 215-218° C.; [2368]
  • MS (DCI/NH[2369] 3) m/e: 388 (M+H)/405 (M+NH3), 407 (37Cl+NH3);
  • [2370] 1H NMR (300 MHz, CDCl3) δ5.67 (br s, 2H), 7.06 (d, J=8.5 Hz, 2H), 7.38 (d, J=8.8 Hz, 2H), 8.09 (s, 1H), 8.25 (s, 1H), 8.94 (s, 1H).
    • EXAMPLE 294 tert-Butyl 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-ylcarbamate
  • Example 293 was converted to the corresponding carboxylic acid in a similar manner as described in Example 18. Diphenyl phosphorylazide (25 μL, 0.10 mmol) was added to a mixture of the carboxylic acid (40 mg, 0.10 mmol), tert-butanol (10 mL), and triethyl amine (20 μL, 0.10 mmol), and the solution was heated at 80° C. After 18 hours, the solution was cooled and concentrated. The yellow residue was dissolved in CH[2371] 2Cl2 (30 mL), washed sequentially with 0.5 N aqueous HCl (40 mL) and saturated aqueous NaHCO3 (25 mL), and brine (25 mL). The combined aqueous washes were back-extracted with CH2Cl2 (2×25 mL). The organic layers were combined, dried (MgSO4), filtered, and concentrated to a yellow residue. Flash silica gel flash column chromatography (15% acetone in hexane) provided the title compound (13 mg, 28% yield) as a bright yellow solid.
  • MS (APCI) m/e: 460 ([2372] 35Cl)/462 (37C);
  • [2373] 1H NMR (300 MHz, CDCl3) δ8.91 (s, 1H), 8.11 (s, 1H), 7.71 (s, 1H), 7.35 (d, J=8.9 Hz, 2H), 7.03 (d, J=8.9 Hz, 2H), 3.97 (d, J=11.4 Hz, 2H), 1.54 (s, 9H).
    • EXAMPLE 295 2-[4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-amine
  • Trifluoroacetic acid (0.5 mL) was added to Example 294 (9.0 mg, 20 μmol) in CH[2374] 2Cl2 (1.5 mL) at 0° C. After 1 h, the volatiles were removed, and the orange residue was dissolved in 0.5 N aqueous HCl (35 mL). The aqueous phase was washed once with Et2O (10 mL); the ether wash was extracted with 1 N HCl (2×20 mL). The acidic layers were combined, and saturated aqueous potassium carbonate was added until the solution was basic (pH>12). The alkaline phase was extracted with EtOAc (3×40 mL); the organic extracts were combined, dried (MgSO4), filtered, and concentrated to a dark brown solid (9 mg). Purification by flash silica gel column chromatography (20% acetone in hexane) provided the title compound as a bright yellow solid (6.8 mg, 97% yield).
  • mp 168-170° C. (decomposes); [2375]
  • MS (APCI) m/e: 3.60 ([2376] 35Cl)/362 (37Cl);
  • [2377] 1H NMR (300 MHz, CDCl3) δ8.90 (s, 1H), 8.11 (s, 1H), 7.68 (s, 1H), 7.35 (d, J=9.2 Hz, 2H), 7.02 (d, J=8.9 Hz, 2H), 6.07 (s, 1H), 3.89 (br s, 2H).
    • EXAMPLE 296 4-(4-Chlorophenoxy)-2-(4,5-dihydro-1,3-oxazol-2-yl)thieno[2,3-c]pyridine
  • To a solution of Example 150 (0.14 g, 0.38 mmol) in anhydrous dichloromethane (4 mL) was added 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.09 mL, 0.57 mmol). The reaction was stirred 24 hours and an excess of morpholine (0.2 mL) was added to react with any remaining starting material. The reaction was stirred 4 hours then partitioned between EtOAc (100 mL) and H[2378] 2O (100 mL). The organic layer was washed with dilute NaH2PO4 (100 mL), sat. NaHCO3 (100 mL), brine (100 mL), partially dried (Na2SO4), and concentrated to a solid. The crude product was purified by flash chromatography on silica gel using EtOAc/hexane as eluant to yield the title compound as a solid (0.07 g, 55%).
  • mp 158-160° C. (dec); [2379]
  • MS (APCI) m/e: 331 (M+H)[2380] +;
  • [2381] 1H NMR (300 MHz, DMSO-d6) δ4.01 (t, J=9.6 Hz, 2 H), 4.48 (t, J=9.6 Hz, 2 H), 7.14 (m, 2 H), 7.47 (m, 2 H), 7.62 (s, 1 H), 8.24 (s, 1 H), 9.19 (s, 1 H);
  • Anal. calcd for C[2382] 16H11ClN2O2S: C, 58.09;H, 3.35; N, 8.47. Found: C, 58.16; H, 3.31;N, 8.27.
    • EXAMPLE 297 4-(4-Chlorophenoxy)-2-(1,3-oxazol-2-yl)thieno[2,3-c]pyridine
  • The title compound may be produced from Example 296 according to the procedure of Ishibashi, Y., et al. (Tetrahedron Lett. 1996, 37(17), 2997-3000). [2383]
    • EXAMPLE 298 4-(4-Chlorophenoxy)-2-(4,5-dihydro-1H-imidazol-2-yl)thieno[2,3-c]pyridine
  • A suspension of Example 154 (0.15 g, 0.43 mmol) and calcium oxide (0.12 g, 2.15 mmol) in phenyl ether (10 mL) was heated to 220-250° C. The reaction was stirred 45 minutes over which reaction volume decreased due to evaporation of solvent. The reaction was cooled to room temperature and diluted with 10% MeOH/dichloromethane (25 mL) then filtered. The filtrate was concentrated and residue was purified by preparative HPLC using a gradient of 30%-90% acetonitrile/water+0.1% TFA over 40 minutes. The product containing fractions were combined and neutralized with sat NaHCO[2384] 3. The product crystalized upon standing for 3 days and was collected by filtration, and dried in a desiccator to yield the title compound as a tan needles (23 mg, 16%).
  • mp 154-155° C.; [2385]
  • MS (APCI) m/e: 330 (M+H)[2386] +;
  • [2387] 1H NMR (300 MHz, DMSO-d6) δ3.46 (td, J=9.9, 1.7 Hz, 2H), 3.83 (t, J=9.9 Hz, H), 7.12 (m, 2H), 7.34 (br s, 1H), 7.46 (m, 2H), 7.81 (s, 1H), 8.17 (s, 1H), 9.11 (s, 1H);
  • Anal. calcd for C[2388] 16H12ClN3OS: C, 58.27; H, 3.67; N, 12.74. Found: C, 58.15; H, 3.50; N, 12.73.
    • EXAMPLE 299 4-(4-chlorophenoxy)-2-(1H-imidazol-2-yl)thieno[2,3-c]pyridine
  • The title compound may be produced from Example 298 according to the procedure of Zimmerman, S. C., et al. (J. Org. Chem. 1989, 54(6), 1256-1264). [2389]
    • EXAMPLE 300 4-Chloro-3-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 300 was prepared as in Example 125 from the corresponding 4-chloro methyl ester which was isolated as a by-product from example 125A. [2390]
  • MS (DCI/NH[2391] 3) m/e: 227 (M+H)+;
  • [2392] 1H NMR (300 MHz, DMSO-d6) δ2.55 (s, 3H), 6.95 (d, 2H), 7.57 (d, 2H), 7.90 (b, 1H), 8.00.(b, 1H), 8.27 (s, 1H), 9.15 (s, 1H).
    • EXAMPLE 301 3-Amino-4-chlorothieno[2,3-c]pyridine-2-carboxamide
  • Methyl 3-amino-4-chlorothieno[2,3-c]pyridine-2-carboxylate was isolated from the crude product mixture of Example 131B. The mixture was hydrolyzed as described in Example 18, and the resultant acid was coupled with ammonium chloride using the procedure for Example 92. The product was isolated by filtration and washed with water after precipitating the reaction mixture by pouring it into 5% sodium bicarbonate solution. [2393]
  • MS (DCI/NH3) m/e: 228 (M+H)[2394] +;
  • [2395] 1H NMR (300 MHz, DMSO-d6) δ7.01 (br s, 2H), 7.49 (br s, 2H), 8.42 (s, 1H), 9.11 (s, 1H).
    • EXAMPLE 302 9-(4-Chlorophenoxy)pyrido[4′,3′:4,5]thieno[3,2-d]pyrimidine-2,4(1H, 3H)-dione
  • To a suspension of Example 131D (70 mg, 0.22 mmol) in anhydrous tetrahydrofuran (5 mL) under nitrogen atmosphere was added 1,1-carbonyldiimidazole (71 mg, 0.44 mmol) and triethylamine (60 μL, 0.44 mmol). The reaction mixture was stirred at reflux for 48 hours and then ambient temperature for an additional 24 hours. The reaction mixture was poured into a 1:1 solution of water: saturated NH[2396] 4Cl and the resulting solid collected by filtration. This material was purified by flash chromatography on silica gel eluting with 20% acetone-hexane. The desired fractions were combined, evaporated and slurried in hot EtOAC to obtain title compound (39 mg) in 51% yield.
  • MS (APCI) m/e: (M−H)[2397] −344;
  • [2398] 1H NMR (300 MHz, DMSO-d6) δ7.32 (m, 2H), 7.55 (m, 2H), 7.92 (s, 1H), 9.09 (s, 1H), 11.22 (br s, 1H), 11.72 (br s, 1H);
  • HPLC: Supelco C-18 column, water:acetonitrile 0:90-90:0, 30 minute elution, flow rate 0.8 mL/min, rt 20.33 min. [2399]
    • EXAMPLE 303 4-(4-Chlorophenoxy)-N,3-dimethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 125A was prepared as in Example 218 to provide the title compound. [2400]
  • MS (DCI/NH[2401] 3) m/e: 333 (M+H)+;
  • [2402] 1H NMR (300 MHz, DMSO-d6) δ2.55 (s, 3H), 2.80 (d, 3H), 7.05 (d, 2H), 7.45 (d, 2H), 8.20 (s, 1H), 8.55 (b, 1H), 9.18 (s, 1H);
    • EXAMPLE 304 4-(4-Bromophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-bromophenol were processed as in Example 125 to provide the title compound. [2403]
  • mp 177-178° C.; [2404]
  • MS (DCI/NH[2405] 3) m/e: 364 (M+H)+;
  • [2406] 1H NMR (300 MHz, DMSO-d6) δ2.55 (s, 3H), 6.95 (d, 2H), 7.57 (d, 2H), 7.90 (m, 1H), 8.00 (m, 1H), 8.27 (s, 1H), 9.15 (s, 1H);
  • Anal. Calcd for C[2407] 15H11BrN2O2S: C, 49.60; H, 3.05; N, 7.71. Found: C, 49.36; H, 3.24; N, 7.61.
    • EXAMPLE 305 7-Chloro-4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 305A Methyl 4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylate, N-oxide
  • Example 125A was prepared according to the procedure of Example 123A to provide the title compound. [2408]
  • MS (DCI/NH[2409] 3) m/e: 350 (M+H)+;
  • [2410] 1H NMR (300 MHz, DMSO-d6) δ2.78 (s, 3H), 3.88 (s, 3H), 7.28 (m, 2H), 7.51 (m, 2H) 7.68 (br s, 1H), 8.92 (br s, 1H).
    • EXAMPLE 305B Methyl 7-Chloro-4-(4-chlorophenoxy)-3-methylthienol2,3-c]pyridine-2-carboxamide
  • Example 305A was prepared according to the procedure of Example 1C to provide the title compound. [2411]
  • HPLC: Supelco C-18 column, gradient elution 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 31.64 minutes; [2412]
  • MS (DCI/NH[2413] 3) m/e: 368 (M+H)+;
  • [2414] 1H NMR (300 MHz, DMSO-d6) δ2.78 (s, 3H), 3.92 (s, 3H), 7.18 (m, 2H), 7.48 (m, 2H) 8.01 (s, 1H).
    • EXAMPLE 305C 7-Chloro-4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylic acid
  • Example 305B was prepared according to the procedure of Example 18 substituting tetrahydrofuran for isopropanol to provide the title compound. [2415]
  • HPLC: Supelco C-18 column, gradient elution 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 27.25 minutes; [2416]
  • MS (APCI) m/e: 354 (M+H)[2417] +;
  • [2418] 1H NMR (300 MHz, DMSO-d6) δ2.72 (s, 3H), 7.16 (m, 2H), 7.49 (m, 2H), 8.01 (s, 1H).
    • EXAMPLE 305D 7-Chloro-4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 305C was prepared according to Example 92 to provide the title compound. [2419]
  • HPLC: Supelco C-18 column, gradient elution 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 24.75 minutes; [2420]
  • MS (DCI/NH[2421] 3) m/e: 353 (M+H)+;
  • [2422] 1H NMR (300 MHz, DMSO-d6) δ2.58 (s, 3H), 7.10 (m, 2H), 7.47 (m, 2H), 8.0 (br s, 1H), 8.02 (s, 1H), 8.03 (br s, 1H).
    • EXAMPLE 306 tert-Butyl 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate EXAMPLE 306A tert-Butyl 3,5-Dichloropyridine-4-oxalate
  • Example 17A was followed except for replacing the methyl formate with t-Butyl chlorooxalate to provide the titled compound. [2423]
  • MS (DCI/NH[2424] 3) m/e: 241 (M+H)+;
  • [2425] 1H NMR (300 MHz, DMSO-d6) δ1.5 (s, 9H), 8.85 (s, 2H).
    • EXAMPLE 306B tert-Butyl 2-(Methoxycarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate
  • Example 306A and 4-chlorophenol were processed as in Example 61 to provide the title compound. [2426]
  • MS (DCI/NH[2427] 3) m/e: 420 (M+H)+;
  • [2428] 1H NMR (300 MHz, DMSO-d6) δ1.42 (s, 9H), 3.95 (s, 3H), 7.18 (d, 2H), 7.50 (d, 2H) 8.05 (s, 1H), 9.20 (s, 1H).
    • EXAMPLE 306C tert-Butyl 2-(Aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate
  • Example 306B was prepared as in Example 217 to provide the title compound. [2429]
  • MS (DCI/NH3) m/e: 405 (M+H)[2430] +;
  • [2431] 1H NMR (300 MHz, DMSO-d6) δ1.35 (s, 9H), 7.10 (d, 2H), 7.45 (d, 2H), 7.95 (m, 1H) 8.08 (s, 1H), 8.14 (m, 1H), 9.18 (s 1H).
    • EXAMPLE 306D 2-(Aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylic acid
  • Example 306C (0.08 g, 0.2mmol) was placed in a cold solution of trifluoroacetic acid (0.5 mL) and methylene chloride (0.5 mL) and stirred for 1 hour. The solution was evaporated and treated slowly with a cold solution of sodium bicarbonate (20 mL), and then the mixture was extracted with ethyl acetate (3×20 mL). The ethyl acetate extract was dried and evaporated to provide the title compound. [2432]
  • MS (DCI/NH[2433] 3) m/e: 349 (M+H)+;
  • [2434] 1H NMR (300 MHz, DMSO-d6) δ7.05 (d, 2H), 7.45 (d, 2H), 7.95 (b, 1H), 8.05 (m, 1H), 8.15 (s, 1H), 9.20 (s, 1H).
    • EXAMPLE 307 Methyl 4-(4-toluidino)thieno[2,3-c]pyridine-2-carboxamide
  • A mixture of Example 93C (271 mg, 1 mmol), 4-methyl-aniline (150 mg, 1.4 mmol), sodium t-butoxide (134.5 mg, 1.4 mmol), 18-crown-6 (370 mg, 1.4 mmol), Pd[2435] 2(dba)3 (46 mg, 5 mol %) and BINAP (31 mg, 5 mol %) were combined in a three necked round bottom flask equipped with a condenser, internal temperature probe and a N2 inlet. This was evacuated under nitrogen and anhydrous tetrahydrofuran (5 mL) was added. The reaction mixture was warmed at 45° C. for three days, solid materials were filtered through celite and washed with a mixture of ethyl acetate and acetone. The filtrate was diluted with ethyl acetate (100 mL), washed with brine (2×50 mL), dried:(MgSO4) and evaporated to dryness under reduced pressure. The title compound was obtained in 29% yield (86 mg), by flash chromatography on silica gel eluting with 30% acetone-hexane.
  • MS (DCI/NH[2436] 3) m/e: 298 (M+H)+;
  • [2437] 1H NMR (300 MHz, DMSO-d6) δ2.25 (s, 3H), 2.80 (d, J=6 Hz, 3H), 7.02 (d, J=9 Hz, 2H), 7.10 (d, J=9 Hz, 2H), 8.13 (s, 1H), 8.26 (s, 1H), 8.36 (m, 1H), 8.76 (br s, 1H); 13C NMR (75 MHz, DMSO-d;6) δ20.4 (CH3), 26.4 (CH2), 118.2 (CH), 118.2 (CH), 122.1 (CH), 129.8 (CH), 130.0 (C), 130.6 (CH), 130.7 (C), 135.9 (C), 136.5 (CH), 137.1 (C), 140.3 (C), 142.3 (C), 161.6 (CO).
    • EXAMPLE 308 4-(4-Chloroanilino)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • The title compound (500 mg, 84%) was prepared as in Example 307 except substituting 4-chloroaniline (510 mg, 4 mmol) for 4-methylaniline and reaction was warmed at 60° C. for 20 hours. [2438]
  • MS (APCI) m/e: 318 (M+H)[2439] +, 352 (M+Cl)−;
  • [2440] 1H NMR (400 MHz, DMSO-d6) d: 2.83 (d, J=4 Hz, 3H), 7.07 (d, J=9 Hz, 2H), 7.32 (d, J=9 Hz, 2H), 8.11 (s, 1H), 8.38 (s, 1H), 8.67 (s, 1H), 8.85 (d, J=4 Hz, 1H), 8.91 (s, 1H);
  • [2441] 13C NMR (100 MHz, DMSO-d6) δ26.3 (CH3), 118.1 (2×CH), 121.7 (CH), 123.6 (C), 129.1 (2×CH), 133.0 (CH), 134.4 (C), 137.1 (C), 137.2 (C), 138.2 (CH), 142.6 (C), 143.2 (C), 161.4(C).
    • EXAMPLE 309 Methyl 4-(4-morpholinyl)thieno[2,3 -c]pyridine-2-carboxamide
  • The title compound (105 mg, 38%) was prepared as in Example 308 except substituting morpholine (0.175 mL, 2 mmol) for 4-chloroaniline. [2442]
  • MS (APCI) m/e: 278 (M+H)[2443] +; 312 (M+Cl)−;
  • [2444] 1H NMR (400 MHz, DMSO-d6) δ2.91 (d, J=4 Hz, 3H), 3.23 (m, 4H), 3.91 (m, 4H), 8.14 (s, 1H), 8.18 (s, 1H), 8.96 (s, 1H), 8.99 (d, J=4 Hz, 1H);
  • [2445] 13C NMR (100 MHz, DMSO-d6) δ26.1 (CH3), 51.6 (2×CH2), 66.3 (CH2), 121.2 (CH), 131.6 (CH), 137.1 (C), 137.9 (C), 139.0 (C), 143.3 (C), 143.9 (C), 161.3 (CO).
    • EXAMPLE 311 7-Chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 311A Methyl 7-chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • Example 61A was prepared as in Example 1C to provide the title compound. [2446]
  • HPLC: Supelco C-18 column, gradient elution of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/minutes RT 30.35 minutes; [2447]
  • MS (DCI/NH[2448] 3) m/e: 354 (M+H)+;
  • [2449] 1H NMR (300 MHz; DMSO-d6) δ3.91 (s, 3H), 7.14 (m, 2H), 7.45 (m, 2H), 7.91 (s, 1H); 8.24 (s, 1H); 9.21 (s, 1H).
    • EXAMPLE 311B 7-Chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 311A was prepared according to the procedure of Example 44 to provide the title compound. [2450]
  • MS (DCI/NH[2451] 3) m/e: 339 (M+H)+;
  • [2452] 1H NMR (300 MHz, DMSO-d6) δ7.20 (m, 2H), 748 (m, 2H), 7.94 (br s, 1H), 8.04 (s, 1H) 8.22 (s, 1H), 8.49 (br s, 1H);
  • Anal. calcd for C[2453] 14H8Cl2N2O2S: C, 56.42; H, 3.28; N, 10.12. Found: C, 56.31; H, 3.22; N, 10.01;
    • EXAMPLE 312 7-Chloro-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 311A was prepared as described in Example 171 to provide the title compound. [2454]
  • MS (DCI/NH3) m/e: 353 (M+H)[2455] +;
  • [2456] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H); 7.16 (m, 2H), 7.49 (m, 2H), 8.05 (s, 1H), 8.17 (s, 1H), 9.04 (br s, 2H).
    • EXAMPLE 313 7-Chloro-4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 311A was prepared according to the procedure of Example 114 to provide the title compound. [2457]
  • HPLC: Supelco C-18 column, gradient elution of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/minutes RT 23.49 minutes; [2458]
  • mp 129-132° C.; [2459]
  • MS ((DCI/NH[2460] 3) m/e: 382 (M+H)+;
  • [2461] 1H NMR (300 MHz, DMSO-d6) δ3.33 (m, 2H), 3.51 (m, 2H), 4.82 (t, 1H), 7.19 (m, 2H), 7.48 (m, 2H), 8.08 (s, 1H), 8.27 (s, 1H), 9.12 (br t, 1H), 9.18 (s, 1H), 12.81 (br s, 1H).
    • EXAMPLE 314 7-Bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 314A Methyl 7-Bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • Example 123A was prepared as in Example 1C substituting phosphorous oxybromide for phosphorous oxychloride to provide the title compound. [2462]
  • MS (ESI) m/e: 400 (M+H)[2463] +;.
  • [2464] 1H NMR (300 MHz, DMSO-d6) δ3.91 (s, 3H), 7.22 (m, 2H), 7.48 (m, 2H), 8.19 (s, 1H) 8.20 (s, 1H).
    • EXAMPLE 314B 7-Bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide
  • Example 314A was prepared according to Example 44 to provide the title compound. [2465]
  • HPLC: Supelco C-18 column, gradient elution of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 24.95 minutes; [2466]
  • MS (DCI/NH[2467] 3) m/e: 385 (M+H)+;
  • [2468] 1H NMR (300 MHz, DMSO-d6) δ7.22 (m, 2H), 7.44 (m, 2H), 7.95 (s, 1H), 8.02 (s, 1H), 8.29 (s, 1H); 8.51 (br s, 1H).
    • EXAMPLE 315 7-Bromo-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 314A was prepared according to the procedure of Example 171 to provide the title compound. [2469]
  • HPLC: Supelco C-18 column, gradient elution of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 25.40 minutes; [2470]
  • MS (DCI/NH[2471] 3) m/e: 397 (M+H)+;
  • [2472] 1H NMR (300 MHz, DMSO-d6) δ2.81 (d, 3H), 3.97 (s, 3H), 7.19 (m, 2H), 7.48 (m, 2H) 8.04 (s, 1H), 8.21 (s, 1H), 9.05 (br s, 1H).
    • EXAMPLE 316 4-(4-Bromophenoxy)-7-chlorothieno[2,3-c]pyridine-2-carboxamide
  • Example 316 was prepared as in Example 311 but substituting 4-bromophenol for 4-chlorophenol to provide the title compound. [2473]
  • MS (DCI/NH[2474] 3) m/e: 383, 385 (M+H)+; p0 1H NMR (300 MHz, DMSO-d6) δ7.14 (d, 2H, J=8.9 Hz), 7.61 (d, 2H, J=8.8 Hz), 7.98 (br s, 1H), 8.05 (s, 1H), 8.22 (s, 1H), 8.52 (br s, 1H);
  • Anal. calcd for C[2475] 14H8N2O2SBrCl.0.5 H2O: C, 42.82; H, 2.31; N, 7.10. Found: C, 42.62; H, 2.26; N, 6.82.
    • EXAMPLE 317 4-(4-Bromophenoxy)-7-chloro-N-methylthieno[2,3-c]pyridine-2-carboxamide
  • Example 317 was prepared as in Example 312 but substituting 4-bromophenol for 4-chlorophenol to provide the title compound. [2476]
  • MS (DCI/NH[2477] 3) m/e: 397, 399 (M+H)+;
  • [2478] 1H NMR (300 MHz, DMSO-d6) δ2.80 (d, 3H, J=4.7 Hz), 7.13 (d, 2H, J=9.2 Hz), 7.60 (d, 2H, J=9.2 Hz), 8.07 (s, 1H), 8.13 (s, 1H), 9.03 (q, 1H, J=4.7 Hz);
  • Anal. calcd for C[2479] 15H10N2O2SBrCl: C, 45.30; H, 2.53; N, 7.04. Found: C, 45.25; H, 2.31; N, 6.86.
    • EXAMPLE 318 7-Chloro-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-trifluoromethylphenol were processed as in Example 311 to provide the title compound. [2480]
  • mp 175-176° C.; [2481]
  • MS (DCI/NH[2482] 3) m/e: 373 (M+H)+;
  • [2483] 1H NMR (300 MHz, DMSO-d6) δ7.30 (d, 2H), 7.80 (d, 2H), 8.00 (s, 1H), 8.20 (s, 1H), 8.25 (s, 1H), 8.55 (s, 1H);
  • Anal. Calcd for C[2484] 16H10ClF3N2O2S: C, 48.33; H, 2.16; N, 7.52. Found: C, 48.26; H, 2.25; N, 7.40.
    • EXAMPLE 319 7-Chloro-N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 17A and 4-trifluoromethylphenol were processed as in Example 312 to provide the title compound. [2485]
  • mp 178-179° C; [2486]
  • MS (DCI/NH[2487] 3) m/e: 387 (M+H)+;
  • [2488] 1H NMR (300 MHz, DMSO-d6) δ2.80 (s, 3H), 7.30 (d, 2H), 7.80 (d, 2H), 8.00 (s, 1H) 8.25 (s, 1H), 8.55 (m, 1H);
  • Anal. Calcd for C[2489] 16H10ClF3N2O2S: C, 49.68; H, 2.61; N, 7.24. Found: C, 49.58; H, 2.54; N, 6.94.
    • EXAMPLE 320 7-Chloro-N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide
  • Example 320 was prepared according to the procedure of Example 319, with the substitution of aminoethanol for methylamine. [2490]
  • mp 96-97° C.; [2491]
  • MS (ESI/NH[2492] 3) m/e: 415 (M+H)+;
  • [2493] 1H NMR (300 MHz, CDCl3) δ3.66 (t, 2H, J=4.8 Hz), 3.87 (t, 2H, J=4.8 Hz), 6.63 (m, 1H), 7.11 (d, 2H, J=8.5 Hz), 7.64 (d, 2H, J=8.5 Hz), 7.72 (s, 1H), 8.02 (s, 1H).
    • EXAMPLE 321 4-(4-Chlorophenoxy)-N, 7-dimethylthieno[2,3-c]pyridine-2-carboxamide EXAMPLE 321A Methyl 4-(4-Chlorophenoxy)-N, 7-dimethylthieno[2,3-c]pyridine-2-carboxylate
  • Example 311A was prepared as Example 95A but substituting methyl boronic acid for 4-(triflouoromethyl)phenyl boronic acd and substituting dichlorobis(tricyclo-hexylphosphine) palladium for tetrakis(triphenylphosphine)palladium and substituting NMP for DME to provide the title compound. [2494]
  • MS (DCI/NH[2495] 3) m/e: 334 (M+H)+;
  • [2496] 1H NMR (300 MHz, DMSO-d6) δ2.74 (d, 3H), 3.91 (s, 3H), 7.14, (m, 2H), 7.44 (m, 2H), 7.91 (s, 1H), 8.22 (s, 1H).
    • EXAMPLE 321B 4-(4-Chlorophenoxy)-N, 7-dimethylthieno[2,3-c]pyridine-2-carboxamide
  • Example 321A was prepared according to the procedure of Example 171 to provide the title compound. [2497]
  • HPLC Supelco C-18 column, gradient elution of 0.1% aqueous TFA:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/minutes RT 20.70 minutes; [2498]
  • MS (DCI/NH[2499] 3) m/e: 334 (M+H)+;
  • [2500] 1H NMR (300 MHz, DMSO-d6) δ2.82 (d, 3H), 7.04 (m, 2H), 7.41 (m, 2H), 8.04, (s, 1H), 8.11 (s, 1H), 8.92 (br s, 1H).
    • EXAMPLE 322 4-(4-Chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxamide EXAMPLE 322A 4-(4-Chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxylic acid
  • Example 311A (100 mg, 0.28 mmol) was dissolved in 25% sodium methoxide in methanol (10 mL) and was warmed to 60° C. in a pressure tube for 3 days. The solvent was removed under reduced pressure and the residue was redissolved in methylene chloride and acidified with formic acid. The organic layer was washed with H[2501] 2O and brine, dried (Na2SO4) and the solvent removed under reduced pressure to afford the title compound (50 mg, 54%) as an off-white solid.
  • MS (DCI) m/e 336 (M+H)[2502] +;
  • [2503] 1H NMR (300 MHz, DMSO-d6) δ4.18 (s, 3H), 6.92 (m, 2H), 7.31 (m, 2H), 7.54 (s, 1H), 7.69 (s, 1H).
    • EXAMPLE 322B 4-(4-Chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxamide
  • Example 322A (40 mg, 0.12 mmol) was treated according to the procedure of Example 92 to provide the title compound (23 mg, 0.58 mmol) as a white solid. [2504]
  • mp >250° C.; [2505]
  • MS (DCI/NH[2506] 3) m/e: 335 (M+H)+;
  • [2507] 1H NMR (300 MHz, DMSO-d6) δ4.08 (s, 3H), 7.01 (m, 2H), 7.38 (m, 2H), 7.82 (br s, 1H), 7.90 (s, 1H), 8.04 (s, 1H), 8.43 (s, 1H).
    • EXAMPLE 323 4-(4-Chlorophenoxy)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxamide EXAMPLE 323A Methyl 4-(4-Chlorophenoxy)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxylate
  • A solution of Example 311A (200 mg, 0.597 mmol) in acetic anhydride (20 mL) was heated at reflux for 18 hours. The reaction was cooled and poured over ice. The mixture was allowed to stir 1 hour before CH[2508] 2Cl2 (100 mL) was added. The organic extracts were washed with 1 N NaOH (100 mL), H2O (50 mL) brine (50 mL), dried (Na2SO4), filtered and rotoevaporated to afford a crude brown residue. This residue was directly dissolved in DMF (20 mL) and H2O (3 mL), treated with K2CO3 and warmed to 60° C. for 2 hours. The reaction was allowed to cool to room temperature and then was rotoevaporated. The crude residue was purified by column chromatography on silica gel eluting with 10% ethyl acetate/hexane with a gradient to 50% ethyl acetate/hexane to provide the title compound.
  • MS (DCI/NH[2509] 3) m/e: 336 (M+H)+;
  • [2510] 1H NMR (300 MHz, DMSO-d6) δ3.82 (s, 3H), 7.09 (m, 2H), 7.38 (m, 2H), 7.42 (s, 1H), 7.52 (s, 1H), 11.84 (br s, 1H).
    • EXAMPLE 323B 4-(4-Chlorophenoxy)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxamide
  • Example 323A was prepared according to Example 44 to provide the title compound. [2511]
  • HPLC: Supelco, C-18 column, eluent gradient of water:acetonitrile 0:90-90:0 over 30 minutes, detection at 254 nm, flow rate of 0.8 mL/min, RT 18.61 minutes; [2512]
  • mp>250° C.; [2513]
  • MS (APCI) m/e: 321(M+H)[2514] +;
  • [2515] 1H NMR (300 MHz, DMSO-d6) δ7.04 (m, 2H), 7.38 (m, 2H), 7.40 (s, 1H), 7.75 (s, 1H), 8.32 (br s, 1H).
    • EXAMPLE 324 4-(4-Chlorophenoxy)-N-methyl-7-(methylamino)thieno[2,3-c]pyridine-2-carboxamide
  • Example 311A (27 mg, 76 mmol) was treated according to the procedure of Barraclough, et. al (J. Med. Chem. 1990, 33, 2231) to afford the title compound (12 mg, 45% yield). [2516]
  • MS (DCI/NH[2517] 3) m/e: 348 (35Cl)/350(37Cl);
  • [2518] 1H NMR (CDCl3, 300 MHz) δ2.98 (d, 3H), 3.16 (d, 3H), 4.65 (d, 1H), 6.56 (d, 1H), 6.83 (d, 2H), 7.27 (d, 2H), 7.47 (s, 1H), 7.86 (s, 1H).
    • EXAMPLE 325 N-Methyl-7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide
  • Example 142D (10 mg, 33 mmol) was treated according to the procedure of Example 96 to give the title compound (1.5 mg, 75%) as a white solid. [2519]
  • MS (DCI/NH[2520] 3) m/e: 300 (M+H)+, 317 (M+NH3)+;
  • [2521] 1H NMR (CDCl3, 300 MHz) δ2.39 (s, 3H), 3.07 (d, J=5.1 Hz, 3H), 7.06 (d, J=8.8 Hz, 2H), 7.23 (d, J=8.5 Hz, 2H), 7.52 (d, J=5.5 Hz, 1H), 8.18 (s, 1H), 9.02 (s, 1H).
    • EXAMPLE 327 4-(4-Chlorophenoxy)furo[2,3-c]pyridine-2-carboxamide EXAMPLE 327A Ethyl 4-(4-Chlorophenoxy)furo[2,3-c]pyridine-2-carboxylate
  • To a solution of 4-chlorophenol (1.08 g, 8.7 mmol) in anhydrous tetrahydrofuran (25 mL) under nitrogen atmosphere at 0° C. was added dropwise a solution of potassium tert-butoxide (1.0 M solution in THF, 8.7 mL, 8.7 mmol). The reaction mixture was then stirred and heated at 65° C. for 2 hours, cooled to 0° C., then treated with Example 17A (1.0 g, 5.7 mmol) in anhydrous tetrahydrofuran (10 mL) and warmed at 65° C. for 2 hours. The reaction was cooled to 0° C., ethyl glycolate (1.07 mL, 11.4 mmol) and cesium carbonate (3.0 g, 9.2 mmol) were added, and the mixture was heated at 65° C. for 3 hours. The reaction was cooled and concentrated, and the residue was then diluted with ethyl acetate (50 mL) and washed with brine (3×50 mL), then dried (MgSO[2522] 4). The ethyl acetate was then evaporated to give an oil. Purification by flash chromatography on silica gel eluting with 10% ethyl acetate-hexane yielded 0.110 g (6.1%) of the title compound as a glassy residue.
  • MS (DCI/NH[2523] 3) m/e: 318 (M+H)+;
  • [2524] 1H NMR (300 MHz, DMSO-d6) δ1.35 (t, 2H, CH2), 4.4 (q, 3H, CH3), 7.2 (d, J=9 Hz, 2H), 7.5 (d, J=9 Hz, 2H), 8.09 (s, 1H), 8.23 (s, 1H), 9.25 (s, 1H).
    • EXAMPLE 327B 4-(4-Chlorophenoxy)furo[2,3-c]pyridine-2-carboxylic acid
  • To a solution of lithium hydroxide monohydrate (0.0113 g, 0.5 mmol), in tetrahydrofuran (5 mL) and water (1 mL) was added Example 327A (0.1 g, 0.3 mmol), and the mixture was heated at 50° C. for 2 hours. The mixture was cooled, and then formic acid was added until it was acidic (pH?). The mixture was then extracted with ethyl acetate (50 mL), and the extract was washed with brine (2×20 mL), dried (MgSO[2525] 4), and evaporated. Purification by flask chromatography on silica gel eluting with 20% acetone-hexane yielded 0.710 g (81.6%) of the title compound as a glassy residue.
  • MS (DCI/NH[2526] 3) m/e: 290 (M+H)+;
  • [2527] 1H NMR (300 MHz, DMSO-d6) δ3.4 (br s, 1H), 7.2 (d, J=9 Hz, 2H), 7.5 (d, J=9 Hz, 2H), 8.09 (s, 1H), 8.23 (s, 1H), 9.25 (s, 1H).
    • EXAMPLE 327C 4-(4-Chlorophenoxy)furo[2,3-c]pyridine-2-carboxamide
  • A solution of Example 327B (0.15 g, 0.5 mmol) in DMF (10 mL) was treated with 1-hydroxybenzotriazole hydrate (0.104 g, 0.66 mmol), NH[2528] 4Cl (0.0948 g, 0.017 mmol), and 4-methylmorpholine (0.141 g, 0.14mmol). The solution was cooled to 0° C. and treated with 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.115 g, 0.6 mmol), warmed to room temperature, stirred overnight, poured into saturated NaHCO3, filtered, washed with brine (3×20 mL), dried (MgSO4), and evaporated. Purification by flask chromatography on silica gel eluting with 20% acetone-hexane yielded 0.030 g (21%) of the title compound as a glassy residue.
  • MS (DCI/NH[2529] 3) m/e: 289 (M+H)+;
  • [2530] 1H NMR (300 MHz, DMSO-d6) δ7.18 (d, 2H), 7.29 (s, 1H), 7.5 (d, 2H), 7.82 (br s, 1H), 8.25 (s, 1H), 8.35 (br s, 1H), 8.95 (s, 1H);
    • EXAMPLE 328 4-(4-Chlorophenoxy)furo[2,3-c]pyridine-2-carbothioamide
  • To a solution of Example 327 (0.06 g, 0.2 mmol) in toluene (5 mL) was added Lawesson's reagent (0.1 g, 0.2 mmol). The reaction was then refluxed for 1 hour, then cooled, evaporated and dissolved in ethyl acetate. The ethyl acetate solution was washed with brine (3×15 mL), dried (MgSO[2531] 4), and evaporated. Purification by flask chromatography on silica gel eluting with 20% acetone-hexane yielded 0.022 g (37%) of the title compound as a light yellow solid.
  • MS (DCI/NH[2532] 3) m/e: 305 (M+H)+;
  • [2533] 1H NMR (300 MHz, DMSO-d6) δ7.20 (d, 2H), 7.29 (s, 1H), 7.5 (d, 2H), 8.25 (s, 1H), 8.82 (s, 1H), 9.95 (b, 2H).
    • EXAMPLE 329 4-(2-Phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 329A tert-Butyl E- and Z-4-(2-phenylethenyl)thieno[2,3-c]pyridine-2-carboxylate
  • To a stirred solution of diethyl benzylphosphonate (0.08 mL, 0.38 mmol) in dichloromethane (2 mL) at −78° C., a 0.5 M solution of potassium bis(trimethylsilyl)amide in toluene (0.84 mL, 0.42 mmol) was added dropwise. After 45 min, a solution of Example 237E (0.10 g, 0.38 mmol) in dichloromethane (3 mL) was slowly added and reaction stirred 1 hour. Bath was removed and reaction stirred 20 minutes. Reaction was quenched into a dilute aqueous solution of NaHCO[2534] 3. Aqueous was extracted with dichloromethane (2×25 mL), ethyl acetate (2×25 mL). All organic phases were combined, dried (Na2SO4), and concentrated to yield a colored oil. The residue was purified by flash chromatography on silica gel using EtOAc/hexane as eluent. The mixture of stereoisomers was dried in a desiccator to yield a solid (0.07 g; 55%): MS (APCI) m/e: 338 (M+H)+.
    • EXAMPLE 329B E-4-(2-Phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 329A (0.07 g, 0.21 mmol) was dissolved in a solution of 10% H[2535] 2SO4/MeOH (10 mL). Solution was heated to reflux for 6 hours then stirred at room temperature for 16 hours. The reaction was concentrated under reduced pressure, then basified with sat. NaHCO3 (50 mL); The aqueous phase was extracted with dichloromethane (2×50 mL) and the organic extracts were combined. The organic layer was washed with a dilute brine solution (100 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure to a colored residue. The residue was dissolved in methanol (8 mL) and chloroform (1 mL). A balloon of ammonia gas was applied and reaction heated to 35° C. for 24 hours. The reaction was concentrated and the residue was purified by HPLC using a gradient of 25%-65% acetonitrile/water+0.1% TFA over 40 minutes. Products were neutralized with Sat. NaHCO3 to yield the title compound (27 mg, 46%), and additionally the corresponding Z-isomer (14 mg, 24%).
  • mp 257-258° C.; [2536]
  • MS (DCI/NH[2537] 3) m/e: 281 (M+H)+;
  • [2538] 1H NMR (300 MHz, DMSO-d6) δ7.34 (dd, J=7.6, 7.2 Hz, 1H), 7.46 (dd, J=7.6, 7.2 Hz, 2H), 7.55 (d, J=16.5 Hz, 1H), 7.64 (d, J=16.5 Hz, 1H), 7.73 (d, J=7.2 Hz, 2H), 7.88 (br s, 1H), 8.37 (br s, 1H), 8.62.(s, 1H), 8.85 (br s, 1H), 9.18 (s, 1H);
  • Anal calcd for (C[2539] 16H12N2OS 0.2 H2O): C, 67.68; H, 4.40; N, 9.87. Found: C, 67.47; H, 4.18; N, 9.84.
    • EXAMPLE 330 4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 330A 4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (160 mg, 53%) was prepared as in Example 95A but substituting 4-cholorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2540]
  • MS (APCI) m/e: 304 (M+H)[2541] +;
  • [2542] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 7.69 (m, 4H), 8.30 (s, 1H), 8.60 (s, 1H), 9.42 (s, 1H).
    • EXAMPLE 330B 4-(4-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 330A was prepared as in Example 44 to provide the title compound (60 mg, 60%). [2543]
  • MS (APCI) m/e: 289 (M+H)[2544] +;
  • [2545] 1H NMR (400 MHz, DMSO-d6) δ7.63 (d, J=8 Hz, 2H), 7.69 (d, J=8 Hz, 2H), 7.77 (s, 1H), 8.19 (s, 1H), 8.41 (s, 1H), 8.51 (s, 1H), 9.30 (s, 1H).
    • EXAMPLE 331 4-[3-(Trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxalamide EXAMPLE 331A 4-[3-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (100 mg, 30%) was prepared as in Example 95A but substituting 4-(trifluoromethyl)phenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2546]
  • MS (APCI) m/e: 338 (M+H)[2547] +;
  • [2548] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 7.81-7.93 (m, 4H), 8.01 (s, 1H), 8.67 (s, 1H), 9.46 (s, 1H).
    • EXAMPLE 331B 4-[3-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxalamide
  • Example 331A was prepared as in Example 44 to provide the title compound (90 mg, 94%). [2549]
  • MS (APCI) m/e: 323(M+H)[2550] +;
  • [2551] 1H NMR (400 MHz, DMSO-d6) δ7.85 (s, 1H), 7.90-7.97 (m, 4H), 8.25 (s, 1H), 8.46 (s, 1H), 8.69 (s, 1H), 9.38 (s, 1H).
    • EXAMPLE 332 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 332A 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (130 mg, 43%) was prepared as in Example 95A but substituting 3-chlorophenyl boronic acid for 4-chlorophenyl boronic acid. [2552]
  • MS (APCI) m/e: 304 (M+H)[2553] +;
  • [2554] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 7.59-7.68 (m, 3H), 7.75 (s, 1H), 8.02 (s, 1H), 8.62 (s, 1H), 9.43 (s, 1H).
    • EXAMPLE 332B 4-(3-Chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 332A was prepared as in Example 44 to provide the title compound (82mg, 86%). [2555]
  • MS (APCI) m/e: 288 (M+H)[2556] +;
  • [2557] 1H NMR (400 MHz, DMSO-d6) δ7.58-7.62 (m, 3H), 7.62 (s, 1H), 7.69 (s, 1H), 8.19 (s, 1H), 8.49 (s, 1H), 8.51 (s, 1H), 9.31 (s, 1H).
    • EXAMPLE 333 4-(4-Bromophenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 333A 4-(4-Bromophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (148mg, 42%) was prepared as in Example 95A but substituting 4-bromophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2558]
  • MS (APCI) m/e 305 (M+H)[2559] +;
  • [2560] 1H NMR (300 MHz, DMSO-d6) δ3.91 (s, 3H), 7.61 (d, J=7.5 Hz, 2H), 7.77 (d, J=7.5 Hz, 2H), 8.02 (s, 1H), 8.57 (s, 1H), 9.40 (s, 1H).
    • EXAMPLE 333B 4-(4-bromophenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 333A was prepared as in Example 44 to provide the title compound (118 mg, 88%). [2561]
  • MS (APCI) m/e: 333, 335 (1:1) (M+H)[2562] +;
  • [2563] 1H NMR (300 MHz, DMSO-d6) δ7.63 (d, J=7.5 Hz, 2H), 7.79 (d, J=7.5 Hz, 2H), 7.84 (s, 1H), 8.22 (s, 1H), 8.46 (s, 1H), 9.33 (s, 1H).
    • EXAMPLE 334 4-(3-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 334A 4-(3-Aminophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (90 mg, 32%) was prepared as in Example 95A but substituting 3-aminophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2564]
  • MS (APCI) m/e: 285 (M+H)[2565] +;
  • [2566] 1H NMR (300 MHz, DMSO-d6) δ3.92 (s, 3H), 5.34 (s, 2H), 6.67-6.76 (m, 2H), 6.81 (m, 1H), 7.22 (t, J=7.5 Hz, 1H), 8.07 (s, 1H), 8.53 (s, 1H), 9.36 (s, 1H).
    • EXAMPLE 334B 4-(3-Aminophenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 334A was prepared as in Example 44 to provide the title compound (83 mg, 98%). [2567]
  • MS (APCI) m/e 270 (M+H)[2568] +;
  • [2569] 1H NMR (300 MHz, DMSO-d6) δ5.30 (s, 2H), 6.67-6.82 (m, 3H), 7.22 (t, J=7.5 Hz, 1H), 7.79 (s, 1H), 8.23 (s, 1H), 8.43 (s, 1H), 8.51 (s, 1H), 9.25 (s, 1H).
    • EXAMPLE 335 4-(3,5-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 335A 4-(3,5-Dichlorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (90 mg, 27%) was prepared as in Example 95A but substituting 3,5-dichlorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2570]
  • MS (APCI) m/e: 338 (M+H)[2571] +.
    • EXAMPLE 335B 4-(3,5-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 335A was prepared as in Example 44 to provide the title compound (21 mg, 24%). [2572]
  • MS (APCI) m/e: 323 (M+H)[2573] +;
  • [2574] 1H NMR (300 MHz, DMSO-d6) δ7.73 (d, J=2.25 Hz, 2H), 7.80 (m, 1H), 7.88 (s, 1H), 8.20 (s, 1H), 8.5 3 (s, 1H), 8.5 6 (s, 1H), 9.3 6 (s, 1H).
    • EXAMPLE 336 4-(2,4-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 336A 4-(214-Dichlorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (100 mg, 30%) was prepared as in Example 95A but substituting 2,4-dichlorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2575]
  • MS (APCI) m/e: 338 (M+H)[2576] +;
  • [2577] 1H NMR (300 MHz, DMSO-d6) δ3.38 (s, 3H), 7.59 (s, 1H), 7.61 (d, J=2.25 Hz, 1H), 7.70 (s, 1H), 7.86 (d, J=2.25 Hz, 1H), 8.49 (s, 1H), 9.45 (s, 1H).
    • EXAMPLE 336B 4-(2,4-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 336A was prepared as in Example 44 to provide the title compound. [2578]
  • [2579] 1H NMR (300 MHz, DMSO-d6) δ7.60 (s, 1H), 7.64 (m, 1H), 7.81 (br.s, 1H), 7.87 (s, 1H), 7.91 (m, 1H), 8.37 (br.s, 1H), 8.45 (s, 1H), 9.37(s, 1H).
    • EXAMPLE 337 4-(3,4-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 337A 4-(3,4-Dichlorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (130 mg, 39%) was prepared as in Example 95A but substituting 3,4-dichlorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2580]
  • MS (APCI) m/e: 338 (M+H)[2581] +;
  • [2582] 1H NMR (300 MHz, DMSO-d6) δ3.94 (s, 3H), 7.67-7.76 (m, 1H), 7.85 (m, 1H), 7.79 (d, J=2.25 Hz, 1H), 8.06 (s, 1H), 8.63 (s, 1H), 9.44 (s, 1H).
    • EXAMPLE 337B 4-(3,4-Dichlorohenyl)thieno[2,3-c]pyridine-2-carboxamide
  • Example 337A was prepared as in Example 44 to provide the title compound (44 mg, 46%). [2583]
  • MS (APCI) m/e: 323(M+H)[2584] +;
  • [2585] 1H NMR (300 MHz, DMSO-d6) δ7.65-7.68 (m, 1H), 7.84-7.87 (m, 2H), 8.96 (d, J=2.25 Hz, 1H), 8.21 (s,1H), 8.47 (s, 1H), 8.56 (s, 1H), 9.35 (s, 1H).
    • EXAMPLE 338 4-[2,4-Difluorophenyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 338A 4-[2,4-Difluorophenyl]thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (130 mg, 42%) was prepared as in Example 95A but substituting 2,4-difluorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2586]
  • MS (APCI) m/e: 306 (M+H)[2587] +;
  • [2588] 1H NMR (300 MHz, DMSO-d6) δ3.90 (s, 3H), 7.26 (m, 1H), 7.45 (m, 1H), 7.63 (m, 1H) 7.81 (d, J=3 Hz, 1H), 8.55 (s, 1H), 9.44(s, 1H).
    • EXAMPLE 338B 4-[2,4-Difluorophenyl]thieno[2,3-c]pyridine-2-carboxamide
  • Example 338A was processeded as in Example 44 to provide the title compound. [2589]
  • MS (APCI) m/e: 291 (M+H)[2590] +;
  • [2591] 1H NMR (300 MHz, DMSO-d6) δ7.30 (m, 1H), 7.49 (m,1H), 7.66 (m, 1H), 7.77 (s, 1H), 7.99 (s, 1H), 8.39 (s, 1H), 8.47 (s, 1H), 9.34 (s, 1H).
    • EXAMPLE 339 4-[4-Fluorphenyl]thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 339A 4-(4-Fluorophenyl)thieno[2,3-c]pyridine-2-carboxalate
  • The title compound (100 mg, 35%) was prepared as in Example 95A but substituting 4-fluorophenyl boronic acid for 4-(trifluoromethyl)phenyl boronic acid. [2592]
  • MS (APCI) m/e: 288 (M+H)[2593] +;
  • [2594] 1H NMR (300 MHz, DMSO-d6) δ3.89 (s, 3H), 7.38-7.48 (m, 2H), 7.55-7.64 (m, 1H), 7.78 (d, J=3 Hz, 1H), 8.57 (s, 1H), 9.44 (s, 1H).
    • EXAMPLE 339B 4-[4-Fluorophenyl]thieno[2,3-c]pyridine-2carboxamide
  • Example 339A was processed as in Example 44 to provide the title compound. [2595]
  • MS (APCI) m/e: 273 (M+H)[2596] +;
  • [2597] 1H NMR (300 MHz, DMSO-d6) δ7.40-7.50 (m, 2H), 7.57-7.65 (m, 2H), 7.81 (s, 1H), 8.01 (s, 1H), 8.47 (s, 1H), 8.51 (s, 1H), 9.36 (s, 1H).
    • EXAMPLE 340 5-Chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide EXAMPLE 340A 2,3,5-Trichloro-4-formylpyridine
  • A solution of lithium diisopropylamide (7.3 mL, 1.5 M in cyclohexane, 11 mmol) in 10 mL of dry THF under nitrogen at −78° C. was treated with 2,3,5-trichloropyridine (2 g, 11 mmol) in 20 mL THF over a 30 minute period, stirred an additional 30 minutes, then methyl formate (1.4 mL, 1.3 g, 22 mmol) in 14 mL THF was added slowly to the brown solution over 15 minutes, allowed to slowly warm to room temperature and stirred overnight. The resultant dark brown solution was poured onto ice and saturated NaHCO[2598] 3, extracted with ethyl acetate, washed with brine, dried (Na2SO4) and concentrated. The brown oil was flash chromatographed on silica gel with 20-33% ethyl acetate/hexane to provide the title compound (1.7 g, 74%).
  • MS (APCI—NH[2599] 3) m/e: 211 (M+H)+, 229 (M+NH4)+;
  • [2600] 1H NMR (300 MHz, DMSO-d6) δ10.26 (s, 1H), 8.70 (s, 1H).
    • EXAMPLE 340B 2-Chloro-3,5-bis(4-bromophenoxy)-4-pyridinecarboxaldehyde
  • A solution of 4-bromophenol (1.04 g, 6 mmol) in 4 mL THF at 0° C. was treated with potassium t-butoxide (4 mL, 1 M in THF, 4 mmol) via syringe, allowed to warm to room temperature and stirred one hour, cooled to 0° C., Example 340A (390 mg, 2 mmol) in 2 mL THF was added, the reaction heated to 60° C. for two hours, and then allowed to cool to room temperature. The reaction mixture was diluted with ethyl acetate, washed with 1 N NaOH, brine, dried (Na[2601] 2SO4) and concentrated. The brown residue was flash chromatographed on silica gel twice with 1-2% methanol/dichloromethane and then 5-20% ethyl acetate/hexane to provide the title compound (235 mg, 24%).
  • MS (APCI—NH[2602] 3) m/e: 483 (M−H)−, 517 (M+Cl)−;
  • [2603] 1H NMR (300 MHz, DMSO-d6) δ10.20 (s, 1H), 8.24 (s, 1H), 7.63 (m, 2H), 7.53 (m, 2H), 7.24 (m, 2H), 6.99 (m, 2H).
    • EXAMPLE 340C Methyl 5-Chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate
  • A solution of 340B (227 mg, 0.47 mmol) in 2 mL THF was treated with methyl thioglycolate (50 μL, 0.52 mmol) followed by powdered Cs[2604] 2CO3 (179 mg, 0.55 mmol), stirred at room temperature for 21 hours, heated to 60° C. for 15 minutes, then allowed to cool to room temperature. The reaction was diluted with ethyl acetate and distilled water, washed with 1 M K2CO3, brine, dried (MgSO4) and concentrated. The residue was flash chromatographed on silica gel with 5-20% ethyl acetate/hexane followed by HPLC purification (C-18), gradient eluent of 30-90% CH3CN/H2O with 0.1% TFA to provide the title compound (6 mg, 3%).
  • MS (APCI—NH[2605] 3) m/e: 400 (M+H)+;
  • [2606] 1H NMR (300 MHz, DMSO-d6) δ9.20 (s, 1H), 7.78 (s, 1H), 7.51 (d, 2H), 6.93 (d, 2H), 3.90 (s, 3H).
    • EXAMPLE 340D 5-Chloro-4-(4-chlorophenoxy)thieno[2,3 -c]pyridine-2-carboxamide
  • A solution of 340C (5 mg, 0.013 mmol) in 1 mL methanol and 1 mL dichloromethane was treated with 2M ammonia in methanol (3 mL, 6 mmol) in a pressure tube and heated to 60° C. for 4 hours, allowed to cool to room temperature, and concentrated. The residue was filtered through a plug of silica with 95/5 dichloromethane/methanol, concentrated, then purified by reverse phase HPLC (C-18) 20-75% CH[2607] 3CN/H2O with 0.1% TFA to provide the title compound (4.2 mg, 84%).
  • HPLC (C-18, 4.6×250 mm), 0.8 mL/min, λ=254 nm, CH[2608] 3CN:H2O with 0.1% TFA 0-90%, RT 23.3 min (98.52% area);
  • MS (APCI—NH[2609] 3) m/e: 385 (M+H)+;
  • [2610] 1H NMR (300 MHz, MeOH-d4) δ8.98 (s, 1H), 7.9 (s, 1H), 7.49 (d, 2H), 6.83 (d, 2H).
  • The foregoing is merely illustrative and is not intended to limit the invention to the disclosed compounds. Variations and changes which are obvious to one skilled in the art are to be within the scope and nature of the invention which are defined in the appended claims. [2611]

Claims (23)

What is claimed is:
1. A compound having Formula I
Figure US20030220365A1-20031127-C00099
or a pharmaceutically acceptable salt or prodrug thereof, where the symbol z,900 represents a single bond or a double bond, provided that when one bond is a double bond, the adjacent bond is a single bond;
E, F, and G are independently selected from.
(1) carbon,:
(2) nitrogen, and
(3) N+—O−,
provided that at least one of E, F or G is nitrogen or N+—O−, and further provided that at least one of E, F or G is carbon;
Y and Z are independently selected from
(b 1) carbon,
(2) nitrogen,
(3) oxygen, and
(4) S(O)t where t is an integer 0-2,
provided that at least one of Y or Z is other than carbon;
LA is selected from
(1) a covalent bond,
(2) —O—,
(3) —S(O)t—,
(4) —NR6— where R6 is selected from
(a) hydrogen,
(b) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from,
(i) aryl and
(ii) cycloalkyl of three to ten carbons,
(c) alkanoyl where the alkyl part is of one to ten carbons, and
(d) cycloalkyl of three to ten carbons,
(5) —C(W)— where W is selected from
(a) O and
(b) S, and
(6) alkenylene;
XA is selected from
(1) halo,
(2) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from
(a) oxo,
(b) cycloalkyl of three to ten carbons,
(c) —CO2R7 where R7 is selected from
(i) hydrogen and
(ii) alkyl of one to ten carbons optionally substituted with 1, or 2 substituents independently selected from
aryl and
cycloalkyl of three to ten carbons,
(d) —NR8R9 where R8 and R9 are independently selected from
(i) hydrogen,
(ii) alkyl of one to six carbons optionally substituted with 1 or 2 substituents independently selected from
—OH,
aryl,
heterocycle,
cycloalkyl of three to ten carbons, and
—NRARB where RA and RB are independently selected from:
 hydrogen and
 alkyl of one to six carbons optionally substituted with 1 or 2 substituents selected from —OH,
(iii) alkanoyl where the alkyl part is of one to to ten carbons,
(iv) cycloalkyl of three to ten carbons,
(v) alkoxy,
(vi) heterocycle, and
(vii) aryl,
where (vi) and (vii) are substituted with 1 or 2 substituents independently selected from
alkyl of one to six carbons and
halo,
(e) —C(W)R10 where W is previously defined and R10 is selected from
(i) hydrogen,
(ii) alkyl of one to ten carbons optionally substituted with 1, or 2 substituents independently selected from
aryl and
cycloalkyl of three to ten carbons,
(iii) —NR8R9, and
(iv) —OR7,
(f) —OH,
(g) aryl, and
(h) heterocycle,
where (g) and (h) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
(i) alkyl of one to twenty carbons,
(ii) —NR8R9,
(iii) alkoxy of one to ten carbons,
(iv) thioalkoxy of one to ten carbons,
(v) halo,
(vi) perfluoroalkyl of one to three carbons,
(vii) alkenyl of two to ten carbons,
(viii) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from
alkoxy of one to ten carbons and
—OH,
(ix) —CO2R7,
(x) aryl, and
(xi) —CHO,
(3) cycloalkyl of three to ten carbons,,
(4) aryl,
(5) heterocycle
where (4) and (5) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
(a) alkyl of one to twenty carbons,
(b) alkyl of one to ten carbons substituted with 1, 2, or 3 substituents independently selected from
(i) —OR11 where R11 is selected from hydrogen,
—C(W)R12 where R12 is selected from
alkyl of one to ten carbons,
cycloalkyl of three to ten carbons,
aryl, and
heterocycle, and
heterocycle optionally substituted with 1, 2, 3, or 4 substituents independently selected from
—OH and
alkyl of one to six carbons optionally substituted with 1 or 2 substituents selected from —OH,
(ii) alkoxy of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from
alkoxy and
alkoxyalkoxy,
(iii) spiroalkyl of three to ten carbons, and
(iv) halo,
(c) alkoxy of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from;
(i) alkoxy and
(ii) alkoxyalkoxy,:
(d) thioalkoxy of one to ten carbons,
(e) halo,
(f) perfluoroalkyl of one to three carbons,
(g) alkenyl of two to ten carbons optionally substituted with 1 or 2 substituents independently selected from
(i) —C(W)R10 and
(ii) —C(W)R12,
(h) —CO2R7,
(i) —NR8R9,
(j) aryl,
(k) —C(W)R12,
(l) —CHO,
(m) —C(O)NR8R9,
(n) —CN,
(o) heterocycle optionally substituted with 1 or 2 substituents independently selected from
(i) alkyl of one to ten carbons and
(ii) perfluoroalkyl of one to three carbons,
(p) —C(W)R10,
(q) ethylenedioxy, and
(r) —OCF3,
(6): —OR7,
(7) hydrogen, and
(8) —NR8R9;
LB is selected from
(1) a covalent bond,
(2) —O—,
(3) —S(O)t—,
(4) —NR6—,
(5) —C(W)—; and
(6) —C(═NR13)— where R13 is selected from
(a) hydrogen,
(b) —NO2,
(c) —CN, and
(d) —OR14 where R14 is selected from
(i) hydrogen,
(ii) aryl, and
(iii) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents independently selected from
aryl and
—C(O)R15 where R15 is selected from:
hydrogen,
—OH,
alkoxy, and
NRARB;
XB is selected from
(1) hydrogen,
(2) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from
(a) —CO2R7,
(b) —NR8R9,
(c) —C(W)NR8R9,
(d) heterocycle,
(e) aryl optionally substituted with 1 or 2 substituents independently selected from
(i) alkyl of one to ten carbons,
(ii) —NO2, and
(iii) —NRARB,
(f) —OR16 where R16 is selected from
(i) hydrogen and
(ii) —C(W)NRARB, and
(g) —NRAC(W)NR8R9,
(3) alkenyl of two to six carbons optionally substituted with 1 or 2 substituents independently selected from
(a) —C(W)NRARB,
(b) —CO2R7, and
(c) heterocycle,
(4) —NR17R18 where R17 and R18 are independently selected from
(a) hydrogen,
(b) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from
(i) —OH,
(ii) —C(W)R10,
(iii) —NRAC(═NR13)NRBR19 where RA, RB, and R13 are previously defined and R19 is selected from
hydrogen,
alkyl of one to ten carbons, and
—NO2,
(iv) heterocycle,
(v) aryl,
(vi) halo, and
(vii) —NRARB,
(c) alkoxy,
(d): aryl optionally substituted with 1, 2, or 3 substituents independently selected from
(i) halo,
(ii) alkyl of one to ten carbons,
(iii) alkoxy of one to ten carbons, and
(iv) perfluoroalkyl of one to three carbons,
(e) heterocycle,
(f) —NRARB,
(g) —C(O)R20 where R20 is selected from
(i) hydrogen,
(ii) alkyl of one to ten carbons,
(iii) —OR12, and
(iv) —NRARB,
(h) cycloalkyl of three to ten carbons, and
(i) —OH,
(5) alkoxy,
(6) —OH,
(7) —NRAC(═NR13)NRBR19,
(8) —C(W)NR8R9,
(9) aryl,
(10) heterocycle,
where (9) and (10) can be optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from
(a) halo,
(b) alkyl of one to ten carbons optionally substituted with 1, 2, or 3 substituents independently selected from
(i) halo,
(ii) alkoxy of one to ten carbons,
(iii) —NRARB,
(iv) —OH,
(v) —CO2R7,
(vi) —C(W)NRARB, and
(vii) aryl,
(c) —NRARB,
(d) alkoxy of one to ten carbons,
(e) thioalkoxy of one to ten carbons,
(f) perfluoroalkyl of one to three carbons,
(g) —OH,
(h) —C(W)NR8R9,
(i) —CO2R7,
(j) —NRAC(W)OR21 where RA is previously defined and R21 is selected from
(i) alkyl of one to ten carbons optionally substituted with 1 or 2 substituents selected from
aryl and
cycloalkyl of three to ten carbons,
(ii) aryl, and
(iii) cycloalkyl of three to ten carbons,
(k) alkenyl of two to ten carbons,
(l) heterocycle,
(m) aryl, and
(n) —NO2,
(11) —CN,
(12) —CHO,
(13) halo, and
(14) —B(ORA)(ORB);
provided that when R1, R2, R3, R4, and R5 are hydrogen or absent, -LA- is a covalent bond, and -LB- is a covalent bond, then one of XA or XB is other than hydrogen; and
R1, R2, R3, R4, and R5 are absent or independently selected from
(1) hydrogen,
(2) alkyl of one to six carbons optionally substituted with 1 or 2 substituents independently selected from
(a) —OC(O)R22, where R22 is selected from
(i) alkyl,
(ii) alkoxy, and
(iii) NRARB,
(b) alkoxy,
(c) —OH,
(d) —NRARB,
(e) heterocycle, and.
(f) aryl,
(3) —CO2R7,
(4) —C(O)NRARB,
(5) —SR23 where R23 is selected from
(a) hydrogen,
(b) alkyl of one to six carbons,
(c) aryl optionally substituted with 1 or 2 substituents selected from
(i) alkyl of one to six carbons and
(ii) halo,
(6) —NRARB,
(7) halo,
(8) alkoxy,
(9) perfluoroalkyl of one to three carbons,
(10) —OH, and
(11) heterocycle,
provided that when E, F, and Y are carbon, G is nitrogen, Z is sulfur, -LA- is a covalent bond, and XA is halo, R1 is other than —CO2R7.
2. A compound according to claim 1 where F and Y are carbon, E and G are independently nitrogen or N+—O−, and Z is S(O)t.
3. A compound according to claim 2 selected from the group consisting of methyl 2-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)thio]acetate,
6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-(2-pyridinylthio)thieno[2,3-d]pyrimidine,
6-ethyl-4-[(2-methylethyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-[(phenylmethyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-[(5 -methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-d]pyrimidine, ethyl 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine-6-carboxylate,
6-ethyl-N-(phenylmethyl)thieno[2,3-d]pyrimidin-4-amine,
6-ethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine,
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine,
4-chloro-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine, and
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine.
4. A compound according to claim 1 where F and Z are carbon, E and G are independently nitrogen or N+—O−, and Y is S(O)t.
5. A compound according to claim 4 selected from the group consisting of
7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine,
7-methyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[3,2-d]pyrimidine,
7-methyl-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]thieno[3,2-d]pyrimidine,
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-7-methylthieno[3,2-d]pyrimidine,
7-methyl-N-[(4-(methylthio)phenyl]thieno[3,2-d]pyrimidin-7-amine, and
7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-6-carboxamide.
6. A compound according to claim 1 where E, G and Y are carbon, F is nitrogen or N+—O−, and Z is S(O)t.
7. A compound according to claim 6 selected from the group consisting of
methyl 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylate,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(2-pyridinylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-chlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, N-methoxy-N-methyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
N-methoxy-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide, N-(4-chlorophenyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde,
4-[(4-methylphenyl)thio]thieno[2,3 -c]pyridine-2-carboxaldehyde, O-methyloxime,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-(phenylmethyl)oxime,
2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-ylmethylene]amino]oxy]acetic acid,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-phenyloxime,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, oxime
2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-ylmethylene]amino]oxy]acetamide,
(E)-3-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]-2-propenamide,
1-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone,
2-benzoyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine,
2-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine,
1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone, oxime, N-(2,3-dihydroxypropyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid, hydrazide, N2-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]carbonyl]-N6-[(nitroamino)iminomethyl]-L-lysine, methyl ester, N-(aminoiminomethyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carbothioamide, 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine, methyl 4-[(2-methoxy-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxylate,
4-[(2-amino-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-bromophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(phenylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-[[4-(trifluoromethyl)phenyl]thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(2-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3,5-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(2,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(2-methyl-3-furanyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[[(4-chlorophenyl)methyl]thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3,4-dichlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methoxyphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(cyclohexylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-Methylphenyl)thio]-N-[3-(4-morpholinyl)propyl]thieno[2,3-c]pyridine-2-carboxamide,trifluoromethylacetate salt,
4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxamide,; methyl 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxylate,
4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide, methyl 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxylate,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, methyl 4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate,
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-octylphenoxy)thieno[2,3 -c]pyridine-2-carboxamide,
4-[4-(1-methylethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(2-bromo-4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1,2-dihydroxyethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[2-(2-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[2-(2,3-dihydroxypropyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, 1-oxide,
4-[3-(pentadecyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3 -chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-t-butylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-2-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-methoxyphenoxy)thieno[2,3-c]pyridine-2-carboxamide, ethyl 3-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate,
4-Phenoxythieno[2,3-c]pyridine-2-carboxamide,
4-(3-Bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-Fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,5-Dimethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3—Chloro-4-methylphenoxy)thieno[2,3-c]pyridine 2-carboxamide,
4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-(Methoxymethyl)phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridinium, iodide,
4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-(4-(4-Chlorophenoxy)thieno[2,3-c]pyridin-2-yl)-O-(3-tetrahydrofuranyl)carbamate,
4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-methanol, (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoic acid,
4-(4-Chlorophenoxy)thieno[2,3-c]pyridine-2-carboxaldehyde, (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide,
4-bromothieno[2,3-c]pyridine-2-carboxamide, methyl 4-bromothieno[2,3-c]pyridine-2-carboxylate, 4-chlorothieno[2,3-c]pyridine-2-carboxamide, 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide, methyl 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxylate, N-methyl-4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide,
4-phenylthieno[2,3-c]pyridine-2-carboxamide, methyl 4-phenylthieno[2,3-c]pyridine-2-carboxylate,
4-([1,1′-biphenyl]-4-ylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-(5-formyl-2-furanyl)thieno[2,3-c]pyridine-2-carboxamide, ethyl 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate,
4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid,
4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide, methyl 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxalate,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-methanol,
4-(4-Chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,N-diethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-cyclopropylthieno[2,3-c]pyridine-2-carboxamide,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]pyrrolidine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]piperidine,
4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]morpholine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-methylpiperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-phenyllpiperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(phenylmethyl)piperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(2-pyridinyl)piperazine,
4-(4-chlorophenoxy)-N-(2-hydroxyethyl)lthieno[2,3-c]pyridine-2-carboxamide,
4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-N-(1-methylethyl)-1-piperazineacetamide, trifluoroacetate salt,
4-(4-chlorophenoxy)-N-[1-(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[1,1-bis(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide,
(D,L)-4-(4-chlorophenoxy)-N-(2-hydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[2-(4-morpholinyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide,
4-(4-morpholinyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3 -c]pyridine-2-carboxamide, N-oxide, methyl (4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-oxide,
4-(4-chlorophenoxy)-2-(2-methoxyphenyl)thieno[2,3-c]pyridine,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine,
4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, Methyl 4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylate,
3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, methyl 3-amino-4-(4-chlorophenoxy)thieno[2,3 -c]pyridine-2-carboxylate,
3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbothioamide,
4-(4-chlorophenoxy)-N-ethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-chloroethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, 4-(4-bromophenoxy)-N-(2-hydroxyethyl)thieno[2,3-d]pyridine-2-carboxamide,
4-(2-bromo-4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-(2-aminoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide,
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carbohydrazide,
4-(4-chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide,
2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid,
N-(2-amino-2-oxoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-amino-2oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
(2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid,
N-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
(2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid,
(2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid,
4-(4-chlorophenoxy)-N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
(2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid,
4-(4-chlorophenoxy)-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[(1R)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(3-pyridinyloxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide,
N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-fluorophenoxy)thieno[2,3 -c]pyridine-2-carboxamide,
4-(4-chloro-3-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3-difluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3-difluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno [2 3-c]pyridine-2carboxamide,
4-[3-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N,N-dimethyl-4-(4-vinylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-cyanophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-cyanophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(acetylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(4-morpholinyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(hydroxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(2-methoxyethyl) phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(2-methoxyethoxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(2-methoxyethoxy)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-{[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy}benzyl 2-furoate,
4-[4-({[(2R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-acetylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(4-morpholinylcarbonyl)phenoxy]thieno [2,3-c]pyridine-2-carboxamide, N-methyl-4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-230 carboxamide,
4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-[(E)-3-(4-morpholinyl)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-{(E)-3-[(2,3-dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-{(E)-3-[(2,3 -dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-((E)-3-{[2-(1H-imidazol-4-yl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy3-N-methylthieno [2,3-c]pyridine-2-carboxamide,
4-14-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1H-imidazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(1H-pyrazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(1H-1,2,4-triazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(2-thienyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-([1,1′-biphenyl]-4-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(1-methyl-1H-imidazol-5-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-{4-[1-(hydroxymethyl)cyclopropyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(trifluoromethoxy)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
5-{4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine,
4-[4-(1,1-difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-{2-[2-(2-ethoxyethoxy)ethoxy]-1,1-difluoroethyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium,
4-(4-bromophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium,
2-(aminocarbonyl)-4-(4-chlorophenoxy)-6-{[(isopropoxycarbonyl)oxy]methyl}thieno[2,3-c]pyridin-6-ium,
4-(benzyloxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-chlorophenyl)(hydroxy)methyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N4-(4-chlorophenyl)thieno[2,3-c]pyridine-2,4-dicarboxamide,
[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]methanol,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde oxime;
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone oxime,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methoxy-N-methyl-2-oxoacetamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbonitrile,
4-(4-chlorophenoxy)-N′-hydroxythieno[2,3-c]pyridine-2-carboximidamide,
4-(4-chlorophenoxy)-N′-cyanothieno[2,3-c]pyridine-2-carboximidamide,
[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](2-nitrophenyl)methanol,
[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](2-nitrophenyl)methanone,
(2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone,
(2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol,
[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](3-nitrophenyl)methanol,
(3-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone,
(3-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol,
4-(4-bromophenoxy)-2-vinylthieno[2,3-c]pyridine,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol,
1-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol,
[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanamine,
[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl carbamate,
N-{[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl}urea,
(E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide,
(E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-N-ethyl-2-propenamide,
3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2yl]-2,3-dihydroxy-N-methylpropanamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylamine,
4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylformamide,
N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]urea,
N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N′-methylthiourea,
4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-sulfonamide,
4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-sulfonamide,.
4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-sulfonamide,
4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]phenol,
3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline,
4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline,
4-(4-chlorophenoxy)-2-(5-nitro-2-pyridinyl)thieno[2,3-c]pyridine,
6-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-pyridinamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-pyridinamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-amine,
5-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-ylamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-]-4H-1,2,4-triazol-3-amine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-thiadiazol-2-amine,
4-(4-chlorophenoxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine,
5-{4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine,
4-(4-chlorophenoxy)-2-[5-(methylsulfanyl)-1,3 ,4-oxadiazol-2-yl]thieno[2,3-c]pyridine,
4-(4-chlorophenoxy)-2-(2-methyl-2H-1,2,3,4-tetraazol-5-yl)thieno[2,3-c]pyridine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4-methyl-4H-1,2,4-triazol-3-amine,
4-(4-chlorophenoxy)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]thieno[2,3-c]pyridine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-3-amine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-1,3,4-thiadiazol-2-amine,
4-(4-chlorophenoxy)-2-(1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine,
2-(1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine,
3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl}-1,2,4-oxadiazol-5-amine,
2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine,
methyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-l 3-thiazole-4-carboxylate,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxamide,
tert-butyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-ylcarbamate,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-amine,
4-chloro-3-methylthieno[2,3-c]pyridine-2-carboxamide,
3-amino-4-chlorothieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,3-dimethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-3-methylthieno [2,3-c]pyridine-2-carboxamide,
tert-butyl 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate,
N-methyl-4-(4-toluidino)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloroanilino)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-(4morpholinyl)thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide,
7-bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
7-bromo-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-7-chlorothieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-7-chloro-N-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,7-dimethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-methyl-7-(methylamino)thieno[2,3-c]pyridine-2-carboxamide,
4-[(E)-2-phenylethenyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-[3-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,5-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,4-difluorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-fluorophenyl)thieno[2,3-c]pyridine-2-carboxamide, and
4-(4-bromophenoxy)-5-chlorothieno[2,3-c]pyridine-2-carboxamide.
8. A compound according to claim 1 where E, F and Y are carbon, G is nitrogen or N+—O−, and Z is S(O)t.
9. A compound according to claim 8 selected from the group consisting of
4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine,
4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide,
4-chloro-N-(4-chlorophenyl)thieno[2,3-b]pyridine-5-carboxamide,
ethyl 4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-b]pyridine-5-carboxylate,
methyl 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxylate, and methyl 3-amino-6-chlorothieno[2,3-b]pyridine-2-carboxylate.
10. A compound according to claim 1 where E, F, and Z are carbon, G is nitrogen or N+—O−, and Y is S(O)t.
11. A compound according to claim 10 which is
7-[(4-methylphenyl)thio]thieno[3,2-b]pyridine-2-carboxamide.
12. A compound according to claim 1 where F, G, and Y are carbon, E is nitrogen or N+—O−, and Z is S(O)t.
13. A compound according to claim 12 selected from the group consisting of
2-bromo-4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine,
4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carbonitrile,
4-(4-Methylphenoxy)thieno[3,2-c]pyridine-2-carboxamide, and
4-(4-Methylphenoxy)thieno[3,2-c]pyridine-2-carbonitrile.
14. A compound according to claim 1 where E and G are carbon, F and Y are independently nitrogen or N+—O−, and Z is S(O)t.
15. A compound according to claim 14 selected from the group consisting of
methyl 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxylate, 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide, and N-methyl-7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide.
16. A compound according to claim 1 where E and G are carbon, F is nitrogen or N+—O−, and Y and Z are nitrogen.
17. A compound according to claim 1 where G and Y are carbon, E and F are independently nitrogen or N+—O−, and Z is S(O)t.
18. A compound according to claim 1 where E, G and Z are carbon, F is nitrogen or N+—O−, and Y is S(O)t.
19. A compound according to claim 1 where E and G are carbon, F is nitrogen or N+—O−, Y is nitrogen, and Z is oxygen.
20. A compound according to claim 1 where E, G and Y are carbon, F is nitrogen or N+—O−, and Z is O.
21. A compound according to claim 20 selected from the group consisting of
4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carboxamide and
4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carbothioamide.
22. A compound selected from the group consisting of
methyl 2-[(6-ethylthieno[2,3-d]pyrimidin-4-yl)thio]acetate,
6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-(2-pyridinylthio)thieno[2,3-d]pyrimidine,
6-ethyl-4-[(2-methylethyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-[(phenylmethyl)thio]thieno[2,3-d]pyrimidine,
6-ethyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-d]pyrimidine,
ethyl 6-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-d]pyrimidine-6-carboxylate,
6-ethyl-N-(phenylmethyl)thieno[2,3-d]pyrimidin-4-amine,
6-ethyl-N-(5-methyl-1,3,4-thiadiazol-2-yl)thieno[2,3-d]pyrimidin-4-amine,
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine,
4-chloro-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine,
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-6-ethyl-2-(phenylmethyl)thieno[2,3-d]pyrimidine,
7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine,
7-methyl-4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[3,2-d]pyrimidine,
7-methyl-4-[[5-(methylthio)-1,3,4-thiadiazol-2-yl]thio]thieno[3,2-d]pyrimidine,
4-[(5-amino-1,3,4-thiadiazol-2-yl)thio]-7-methylthieno[3,2-d]pyrimidine,
7-methyl-N-[(4-(methylthio)phenyl]thieno[3,2-d]pyrimidin-7-amine,
7-methyl-4-[(4-methylphenyl)thio]thieno[3,2-d]pyrimidine-6-carboxamide,
methyl 4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylate,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxylic acid,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(2-pyridinylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-chlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
N-methoxy-N-methyl-4-(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
N-methoxy-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
N-(4-chlorophenyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-methyloxime,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-(phenylmethyl)oxime,
2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-ylmethylene]amino]oxy]acetic acid,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, O-phenyloxime,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxaldehyde, oxime,
2-[[[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-ylmethylene]-amino]oxy]acetamide,
(E)-3-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]-2-propenamide,
1-[4-[(4-methylphenyl)thio]thieno[2,3-c]pyridin-2-yl]ethanone,
2-benzoyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine,
2-ethyl-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine,
1-[4-[(4-methylphenyl)thio]thieno[2,3 -c]pyridin-2-yl]ethanone, oxime,
N-(2,3-dihydroxypropyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno [2,3-c]pyridine-2-carboxylic acid, hydrazide,
N2N-4-[(4-methylphenyl)thio]thieno[2.3-c]pyridin-2-yl]carbonyl]-N6-[(nitroamino)iminomethyl]-L-lysine, methyl ester,
N-(aminoiminomethyl)-4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-carbothioamide,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine,
methyl 4-[(2-methoxy-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxylate,
4-[(2-amino-2-oxoethyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-bromophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(phenylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-[[4-(trifluoromethyl)phenyl]thio]thieno [2,3-c]pyridine-2-carboxamide,
4-[(2-methylphenyl)thio]thieno[2,3c]pyridine-2-carboxamide,
4-[(3-methylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3,4-methylphenyl)thio]thieno[2,3-]pyridine-2-carboxamide,
4-[(3,5-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(2,4-dimethylphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(2-methyl-3-furanyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[[(4-chlorophenyl)methyl]thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(3,4-dichlorophenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-methoxyphenyl)thio]thieno[2,3-c]pyridine-2-carboxamide,
4-(cyclohexylthio)thieno[2,3 -c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]-N-[3-(4-morpholinyl)propyl]thieno[2,3-c]pyridine-2-carboxamide,trifluoromethylacetate salt,
4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxamide, methyl 4-[(4-methylphenyl)sulfinyl]thieno[2,3-c]pyridine-2-carboxylate,
4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
methyl 4-(4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxylate,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, methyl 4-(4-chlorophenoxy)thieno [2,3-c]pyridine-2-carboxylate,
4-[4-(trifluoromethyl)phenoxy]thieno[2 3-c]pyridine-2-carboxamide,
4-(4-octylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1-methylethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(2-bromo-4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-ethenylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1,2-dihydroxyethyl)phenoxy]thieno [2,3-c]pyridine-2-carboxamide,
4-[2-(2-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[2-(2,3-dihydroxypropyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, 1-oxide,
4-[3-(pentadecyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-t-butylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-2-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-methoxyphenoxy)thieno[2,3-c]pyridine-2-carboxamide, ethyl 3-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate,
4-phenoxythieno[2,3-c]pyridine-2-carboxamide,
4-(3-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,5-dimethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-chloro-4-methylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-iodophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-(methoxymethyl)phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridinium, iodide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-(4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl)-O-(3-tetrahydrofuranyl)carbamate,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-methanol, (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenoic acid,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxaldehyde, (E)-3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide,
4-bromothieno[2,3-c]pyridine-2-carboxamide, methyl 4-bromothieno[2,3-c]pyridine-2-carboxylate,
4-chlorothieno[2,3-c]pyridine-2-carboxamide,
4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide, methyl 4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxylate, N-methyl-4-[4-(trifluoromethyl)phenyl]thieno[2,3-c]pyridine-2-carboxamide,
4-phenylthieno[2,3-c]pyridine-2-carboxamide, methyl 4-phenylthieno[2,3-c]pyridine-2-carboxylate,
4-([1,1′-biphenyl]-4-ylthio)thieno[2,3-c]pyridine-2-carboxamide,
4-(5-formyl-2-furanyl)thieno[2,3-c]pyridine-2-carboxamide, ethyl 4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoate,
4-[[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy]benzoic acid,
4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxamide, methyl 4-(1-phenylethenyl)thieno[2,3-c]pyridine-2-carboxalate,
4-[(4-methylphenyl)thio]thieno[2,3-c]pyridine-2-methanol,
4-(4-Chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,N-diethylthieno[2,3 -c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-cyclopropylthieno[2,3-c]pyridine-2-carboxamide,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]pyrrolidine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]piperidine,
4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]morpholine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-methylpiperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-phenyllpiperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(phenylmethyl)-piperazine,
1-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-4-(2-pyridinyl)-piperazine,
4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide,
4-[[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]-N-(1-methylethyl)-1-piperazineacetamide, trifluoroacetate salt,
4-(4-chlorophenoxy)-N-[1-(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[1,1-bis(hydroxymethyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide, (D,L)-4-(4-chlorophenoxy)-N-(2-hydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[2-(4-morpholinyl)ethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-sulfonamide,
4-(4-morpholinyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, N-oxide, methyl (4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid, N-oxide,
4-(4-chlorophenoxy)-2-(2-methoxyphenyl)thieno[2,3-c]pyridine,
4-(4-Chlorophenoxy)thieno[2,3-c]pyridine,
4-(4-Chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, Methyl 4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxylate,
3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, methyl 3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylate,
3-amino-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxylic acid,
4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine,
4-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxamide,
4-chloro-N-(4-chlorophenyl)thieno[2,3-b]pyridine-5-carboxamide, ethyl 4-[(5-methyl-1,3,4-thiadiazol-2-yl)thio]thieno[2,3-b]pyridine-5-carboxylate,
7-[(4-methylphenyl)thio]thieno[3,2-b]pyridine-2-carboxamide, methyl 6-[(4-methylphenyl)thio]thieno[2,3-b]pyridine-2-carboxylate, methyl 3-amino-6-chlorothieno[2,3-b]pyridine-2-carboxylate,
2-bromo-4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine,
4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carboxamide,
4-[(4-methylphenyl)thio]thieno[3,2-c]pyridine-2-carbonitrile,
4-(4-Methylphenoxy)thieno[3,2-c]pyridine-2-carboxamide,
4-(4-Methylphenoxy)thieno[3,2-c]pyridine 2-carbonitrile,
7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide, methyl 7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxylate,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbothioamide,
4-(4-chlorophenoxy)-N-ethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-chloroethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N-(2-hydroxyethyl)thieno[2,3 -c]pyridine-2-carboxamide,
4-(2-bromo-4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-(2-aminoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-hydroxy thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)thieno[2,3c]pyridine-2-carbohydrazide,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbohydrazide,
4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carbohydrazide,
4-(4-chlorophenoxy)-N-hydroxythieno[2,3-c]pyridine-2-carboxamide,
2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)acetic acid, N-(2-amino-2-oxoethyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
N-(2-amino-2-oxoethyl)-4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
(2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl]amino)-3-hydroxypropanoic acid,
N-[(1S)-2-amino-1-(hydroxymethyl)-2-oxoethyl]-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
(2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)-3-hydroxypropanoic acid,
(2R)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid,
4-(4-chlorophenoxy)-N-[(1R)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
(2S)-2-({[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]carbonyl}amino)propanoic acid,
4-(4-chlorophenoxy)-N-[(1S)-1-methyl-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[(1R)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N-[(1S)-1-(hydroxymethyl)-2-(methylamino)-2-oxoethyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(3-pyridinyloxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-N,N-dimethylthieno[2,3-c]pyridine-2-carboxamide, N,N-dimethyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloro-3-ethylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-fluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3-difluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3-difluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(3-fluorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,3,4-trifluorophenoxy)thieno[2,3-c]pyridine-2-carboxamide, N-ethyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[3-(trifluoromethyl)phenoxy]thieno[2,3 c]pyridine-2-carboxamide, N,N-dimethyl-4-(4-vinylphenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-cyanophenoxy)-N-methylthieno[2,3 -c]pyridine-2-carboxamide,
4-(4-cyanophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-aminophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(acetylamino)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-[4-(4-morpholinyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(hydroxymethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(hydroxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(methoxymethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(2-methoxyethoxy)methyl]phenoxy}thieno [2,3 -c]pyridine-2-carboxamide,
4-{4-[(2-methoxyethoxy)methyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-{[2-(2-methoxyethoxy)ethoxy]methyl}phenoxy)-N-methylthieno[2,3 -c]pyridine-2-carboxamide,
4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-{4-[(tetrahydro-2H-pyran-2-yloxy)methyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-{[2-(aminocarbonyl)thieno[2,3-c]pyridin-4-yl]oxy}benzyl 2-furoate,
4-[4-({[(2R,4R,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy}methyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-acetylphenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-[4-(4-morpholinylcarbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-({[2-(4-morpholinyl)ethyl]amino}carbonyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(E)-3 -(4-morpholinyl)-3 -oxo-1 -propenyl]phenoxy}thieno[2,3 -c]pyridine-2-carboxamide,
4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-((E)-3-{[2-(4-morpholinyl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]thieno[2,3 -c]pyridine-2-carboxamide,
4-(4-{(E)-3-[(2,3-dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-{(E)-3-[(2,3-dihydroxypropyl)amino]-3-oxo-1-propenyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-((E)-3-{[2-(1H-imidazol-4-yl)ethyl]amino}-3-oxo-1-propenyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-{4-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-14-[(E)-3-({2-[bis(2-hydroxyethyl)amino]ethyl}amino)-3-oxo-1-propenyl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1H-imidazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-[4-(1H-pyrazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-[4-(1H-1,2,4-triazol-1-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-{4-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]phenoxy}thieno[2,3-c]pyridine-2-carboxamide,
4-[4-(4,5-dihydro-1H-imidazol-2-yl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(2-thienyl)phenoxy]thieno[2,3 -c]pyridine-2-carboxamide, 4-([1,1′-biphenyl]-4-yloxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide, N-methyl4-[4-(1-methyl-1H-imidazol-5-yl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-[1-(hydroxymethyl)cyclopropyl]phenoxy}-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
N-methyl-4-[4-(trifluoromethoxy)phenoxy]thieno[2,3-c]pyridin -2-carboxamide, 5-{4-[4-(1-{[2-(2-ethoxyethoxy)ethoxy]methyl}cyclopropyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine,
4-[4-(1,1-difluoro-2-hydroxyethyl)phenoxy]-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-{2-[2-(2-ethoxyethoxy)ethoxy]-1,1-difluoroethyl}phenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium,
4-(4-bromophenoxy)-6-{[(2,2-dimethylpropanoyl)oxy]methyl}-2-[(methylamino)carbonyl]thieno[2,3-c]pyridin-6-ium,
2-(aminocarbonyl)-4-(4-chlorophenoxy)-6-{[(isopropoxycarbonyl)oxy]methyl}thieno[2,3-c]pyridin-6-ium,
4-(benzyloxy)thieno[2,3-c]pyridine-2-carboxamide,
4-[(4-chlorophenyl)(hydroxy)methyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorobenzoyl)-N-methylthieno[2,3-c]pyridine-2-carboxamide, N4-(4-chlorophenyl)thieno[2,3-c]pyridine-2,4-dicarboxamide, [4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]methanol,
4-(4-bromophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde oxime,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbaldehyde O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone O-methyloxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-ethanone oxime,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1-propanone oxime,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methoxy-N-methyl-2-oxoacetamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carbonitrile,
4-(4-chlorophenoxy)-N′-hydroxythieno[2,3-c]pyridine-2-carboximidamide,
4-(4-chlorophenoxy)-N′-cyanothieno[2,3-c]pyridine-2-carboximidamide [4-(4-chlorophenoxy)thieno[2,3 -c]pyridin-2-yl](2-nitrophenyl)methanol, [4-(4-chlorophenoxy)thieno[2,3 -c]pyridin-2-yl](2-nitrophenyl)methanone, (2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone, (2-aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol, [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl](3 -nitrophenyl)methanol, (3 -aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanone, (3 -aminophenyl)[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanol,
4-(4-bromophenoxy)-2-vinylthieno[2,3-c]pyridine,
1-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol,
1-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2-ethanediol, [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methanamine, [4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl carbamate, N-{[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]methyl}urea, (E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2-propenamide, (E)-3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-2-propenamide,
3-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-2,3-dihydroxy-N-methylpropanamide,
4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylamine,
4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-ylformamide, N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]urea, N-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N′-methylthiourea,
4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-sulfonamide,
4-(4-chlorophenoxy)-N-(2,3-dihydroxypropyl)thieno[2,3-c]pyridine-2-sulfonamide,
4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-sulfonamide,
4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]phenol,
3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline,
4-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]aniline,
4-(4-chlorophenoxy)-2-(5-nitro-2-pyridinyl)thieno[2,3-c]pyridine,
6-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-3-pyridinamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-2-pyridinamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-amine,
5-[4-(4-bromophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-oxadiazol-2-ylamine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4H-1,2,4-triazol-3-amine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3,4-thiadiazol-2-amine,
4-(4-chlorophenoxy)-2-(5-methyl-1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine,
5-{4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridin-2-yl}-1,3,4-oxadiazol-2-amine,
4-(4-chlorophenoxy)-2-[5-(methylsulfanyl)-1,3,4-oxadiazol-2-yl]thieno[2,3-c]pyridine,
4-(4-chlorophenoxy)-2-(2-methyl-2H-1,2,3,4-tetraazol-5-yl)thieno[2,3-c]pyridine, 5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-4-methyl-4H-1,2,4-triazol-3-amine,
4-(4-chlorophenoxy)-2-[5-(trifluoromethyl)-1,2,4-oxadiazol-3-yl]thieno[2,3-c]pyridine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-3-amine,
5-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-N-methyl-1,3,4-thiadiazol-2-amine,
4-(4-chlorophenoxy)-2-(1,2,4-oxadiazol-3-yl)thieno[2,3-c]pyridine,
2-(1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine,
3-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,2,4-oxadiazol-5-amine,
2-(5-methyl-1,3,4-oxadiazol-2-yl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine,
methyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxylate,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazole-4-carboxamide, tert-butyl 2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-ylcarbamate,
2-[4-(4-chlorophenoxy)thieno[2,3-c]pyridin-2-yl]-1,3-thiazol-4-amine,
4-chloro-3-methylthieno[2,3-c]pyridine-2-carboxamide,
3-amino-4-chlorothieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,3-dimethylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-3-methylthieno[2,3-c]pyridine-2-carboxamide, tert-butyl 2-(aminocarbonyl)-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-3-carboxylate,
N-methyl-4-(4-toluidino)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chloroanilino)-N-methylthieno[2,3-c]pyridine-2-carboxamide, N-methyl-4-(4-morpholinyl)thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-(4-chlorophenoxy)-N-(2-hydroxyethyl)thieno[2,3-c]pyridine-2-carboxamide,
7-bromo-4-(4-chlorophenoxy)thieno[2,3-c]pyridine-2-carboxamide,
7-bromo-4-(4-chlorophenoxy)-N-methylthieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-7-chlorothieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenoxy)-7-chloro-N-methylthieno[2,3-c]pyridine-2-carboxamide,
7-chloro-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-N-methyl-4-[4-(trifluoromethyl)phenoxy]thieno[2,3-c]pyridine-2-carboxamide,
7-chloro-N-(2-hydroxyethyl)-4-[4-(trifluoromethyl)phenoxy]thieno[2,3 -c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)-N,7-dimethylthieno[2,3-c]pyridine-2-carboxamide, 4-(4-chlorophenoxy)-7-methoxythieno[2,3-c]pyridine-2-carboxamide, 4-(4-chlorophenoxy)-7-oxo-6,7-dihydrothieno[2,3-c]pyridine-2-carboxamide, 4-(4-chlorophenoxy)-N-methyl-7-(methylamino)thieno[2 3-c]pyridine-2-carboxamide,
N-methyl-7-(4-methylphenoxy)[1,3]thiazolo[5,4-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenoxy)furo[2,3-c]pyridine-2-carbothioamide,
4-[(E)-2-phenylethenyl]thieno[2,3-c]pyridine-2-carboxamide,
4-(4-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-[3-(trifluoromethyl)phenyl]thieno[2;3-c]pyridine-2-carboxamide,
4-(3-chlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4-bromophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3-aminophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,5-dichlorophenyl)thieno[2 3-c]pyridine-2-carboxamide,
4-(2,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(3,4-dichlorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(2,4-difluorophenyl)thieno[2,3-c]pyridine-2-carboxamide,
4-(4(4-fluorophenyl)thieno[2,3-c]pyridine-2-carboxamide, and
4-(4-bromophenoxy)-5-chlorothieno[2,3-c]pyridine-2-carboxamide.
23. A method for treating reperfusion injuries and inflammatory diseases comprising administering an effective amount of a compound of claim 1.
US10/387,317 1998-06-04 2003-03-12 Cell adhesion-inhibiting antiinflammatory compounds Abandoned US20030220365A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/387,317 US20030220365A1 (en) 1998-06-04 2003-03-12 Cell adhesion-inhibiting antiinflammatory compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US8790798P 1998-06-04 1998-06-04
US09/325,336 US6232320B1 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antiinflammatory compounds
US09/799,729 US6579882B2 (en) 1998-06-04 2001-03-06 Cell adhesion-inhibiting antiinflammatory compounds
US10/387,317 US20030220365A1 (en) 1998-06-04 2003-03-12 Cell adhesion-inhibiting antiinflammatory compounds

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/799,729 Division US6579882B2 (en) 1998-06-04 2001-03-06 Cell adhesion-inhibiting antiinflammatory compounds

Publications (1)

Publication Number Publication Date
US20030220365A1 true US20030220365A1 (en) 2003-11-27

Family

ID=26777511

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/325,336 Expired - Lifetime US6232320B1 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antiinflammatory compounds
US09/799,729 Expired - Fee Related US6579882B2 (en) 1998-06-04 2001-03-06 Cell adhesion-inhibiting antiinflammatory compounds
US10/387,317 Abandoned US20030220365A1 (en) 1998-06-04 2003-03-12 Cell adhesion-inhibiting antiinflammatory compounds

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/325,336 Expired - Lifetime US6232320B1 (en) 1998-06-04 1999-06-03 Cell adhesion-inhibiting antiinflammatory compounds
US09/799,729 Expired - Fee Related US6579882B2 (en) 1998-06-04 2001-03-06 Cell adhesion-inhibiting antiinflammatory compounds

Country Status (1)

Country Link
US (3) US6232320B1 (en)

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050282820A1 (en) * 2004-06-17 2005-12-22 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
US20060058341A1 (en) * 2004-09-15 2006-03-16 Connolly Peter J Thiazolopyridine kinase inhibitors
WO2006046040A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US20060111355A1 (en) * 2004-11-23 2006-05-25 Wyeth Gonadotropin releasing hormone receptor antagonists
US20060189618A1 (en) * 2005-02-18 2006-08-24 Wyeth 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189617A1 (en) * 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US20060189616A1 (en) * 2005-02-18 2006-08-24 Wyeth 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060264631A1 (en) * 2005-05-18 2006-11-23 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US20060270848A1 (en) * 2005-05-26 2006-11-30 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor
WO2007088345A1 (en) 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2007122410A1 (en) 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
WO2007127175A3 (en) * 2006-04-26 2007-12-27 Piramed Ltd Pharmaceutical compounds
US20080221097A1 (en) * 2005-08-09 2008-09-11 Glaxo Group Limited Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
US20080242695A1 (en) * 2007-03-30 2008-10-02 Morgan Bradley P Certain Chemical Entities, Compositions, and Methods
US20080255143A1 (en) * 2003-07-29 2008-10-16 Smithkline Beecham Corporation Inhibitors of Akt Activity
WO2009013462A1 (en) * 2007-07-23 2009-01-29 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US20090029345A1 (en) * 2006-08-01 2009-01-29 Alan Russell Modulating skeletal muscle
WO2009042607A1 (en) 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US20090209607A1 (en) * 2007-02-07 2009-08-20 Seefeld Mark A Inhibitors of akt activity
US7589206B2 (en) 2004-06-09 2009-09-15 Glaxo Group Limited Pyrrolopyridine derivatives
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US7696210B2 (en) 2004-06-17 2010-04-13 Wyeth Gonadotropin releasing hormone receptor antagonists
US20100093741A1 (en) * 2006-08-02 2010-04-15 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20100197754A1 (en) * 2009-01-30 2010-08-05 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
US7795245B2 (en) 2005-05-20 2010-09-14 Atlantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
WO2010138589A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
US20110014212A1 (en) * 2006-08-02 2011-01-20 Aaron Hinken Certain Chemical Entities, Compositions and Methods
US20110021558A1 (en) * 2008-01-21 2011-01-27 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US20110021496A1 (en) * 2007-10-26 2011-01-27 F. Hoffmann-La Roche Ag Thienopyrimidine derivatives as p13k inhibitors
US20110172191A1 (en) * 2008-06-19 2011-07-14 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2011130654A1 (en) 2010-04-16 2011-10-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
WO2012088254A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
EP2518074A1 (en) 2006-12-07 2012-10-31 F. Hoffmann-La Roche AG Phosphoinositide 3-kinase inhibitor compounds and methods of use
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2014130923A2 (en) 2013-02-25 2014-08-28 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
US9290496B2 (en) 2013-11-21 2016-03-22 Pfizer Inc. Purine derivatives
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
US9540383B2 (en) 2012-11-20 2017-01-10 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9555036B2 (en) 2012-08-24 2017-01-31 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9877968B2 (en) 2008-08-11 2018-01-30 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US10112946B2 (en) 2011-07-22 2018-10-30 Glaxosmithkline Llc Composition
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
US10709714B2 (en) 2013-11-22 2020-07-14 Clifton Life Sciences LLC Gastrin antagonists for treatment and prevention of osteoporosis

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
CA2395593C (en) 1999-12-24 2011-08-02 Aventis Pharma Limited Azaindoles
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
GB0115109D0 (en) * 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0117583D0 (en) * 2001-07-19 2001-09-12 Astrazeneca Ab Novel compounds
EP2335700A1 (en) * 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
GB0118479D0 (en) * 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
WO2003059874A2 (en) 2001-12-21 2003-07-24 Pharmacia Corporation Aromatic thioether liver x-receptor modulators
ES2314224T3 (en) * 2002-03-07 2009-03-16 F. Hoffmann-La Roche Ag BIRCINAL PYRIMIDINE AND PYRIDINE INHIBITORS OF P38 QUINASA.
MXPA04011048A (en) * 2002-05-06 2005-02-17 Vertex Pharmaceutivals Inc Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase.
WO2003099775A1 (en) * 2002-05-24 2003-12-04 Pharmacia Corporation Sulfone liver x-receptor modulators
EP1509495A1 (en) * 2002-05-24 2005-03-02 Pharmacia Corporation Anilino liver x-receptor modulators
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
EP2008654A1 (en) * 2002-06-06 2008-12-31 Boehringer Ingelheim Pharmaceuticals, Inc. 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amides
AU2003272552A1 (en) * 2002-09-17 2004-04-08 Pharmacia Corporation Aromatic liver x-receptor modulators
WO2004065395A1 (en) 2003-01-17 2004-08-05 Astrazeneca Ab Thienopyridazinones and their use in modulation of autoimmune disease
SE0300120D0 (en) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
SE0300119D0 (en) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7098231B2 (en) * 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
GB0315950D0 (en) * 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
JP5189765B2 (en) * 2003-08-01 2013-04-24 バイオコン・リミテッド Aryl carbamate oligomers for hydrolyzable prodrugs and prodrugs containing the same
KR20060108666A (en) * 2003-11-10 2006-10-18 와이어쓰 Methods and compositions for selectin inhibition
RU2006120489A (en) * 2003-11-10 2007-12-20 Уайт (Us) METHODS AND COMPOSITIONS INTENDED FOR INHIBITING SELECTIN
BRPI0417369A (en) * 2003-12-05 2007-04-10 Boehringer Ingelheim Pharma Substituted 3-amino-thieno [2,3-b] pyridine-2-carboxylic acid amide compounds as ikk inhibitors
DE10357510A1 (en) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroaryl-substituted benzenes
ES2431314T3 (en) * 2004-02-20 2013-11-26 Boehringer Ingelheim International Gmbh Viral Polymerase Inhibitors
DE102004017438A1 (en) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituted phenylaminopyrimidines
US7459562B2 (en) * 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) * 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
AU2005238180A1 (en) * 2004-05-04 2005-11-10 F. Hoffmann-La Roche Ag Thienopyridines as IKK inhibitors
EP1745051A1 (en) * 2004-05-04 2007-01-24 F.Hoffmann-La Roche Ag Thienopyridazines as ikk inhibitors
US20050256154A1 (en) * 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
EP1753428A4 (en) * 2004-05-14 2010-09-15 Abbott Lab Kinase inhibitors as therapeutic agents
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
US7598259B2 (en) * 2004-06-15 2009-10-06 Schering Corporation mGluR1 antagonists as therapeutic agents
PE20060526A1 (en) * 2004-06-15 2006-07-13 Schering Corp TRICYCLE COMPOUNDS AS ANTAGONISTS OF MGLUR1
US7432373B2 (en) * 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR101257343B1 (en) * 2004-07-30 2013-04-23 메틸진 인코포레이티드 Inhibitors of vegf receptor and hgf receptor signaling
JP2008508358A (en) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Aryl-amino substituted pyrrolopyrimidine multikinase inhibitor compounds
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
WO2006047397A1 (en) * 2004-10-21 2006-05-04 Dow Agrosciences Llc Thieno-pyrimidine compounds having fungicidal activity
US7674822B2 (en) * 2004-11-24 2010-03-09 Wyeth PTP1b inhibitors
AR054416A1 (en) 2004-12-22 2007-06-27 Incyte Corp PIRROLO [2,3-B] PIRIDIN-4-IL-AMINAS AND PIRROLO [2,3-B] PIRIMIDIN-4-IL-AMINAS AS INHIBITORS OF THE JANUS KINASES. PHARMACEUTICAL COMPOSITIONS.
CA2608726C (en) * 2005-05-20 2013-07-09 Methylgene Inc. Inhibitors of vegf receptor and hgf receptor signaling
CA2611370C (en) 2005-05-20 2014-11-25 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling
CN101238127A (en) * 2005-05-20 2008-08-06 艾伦托斯制药控股公司 Pyrimidine or triazine fused bicyclic metalloprotease inhibitors
EP1910358A2 (en) * 2005-07-14 2008-04-16 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
CN102127078A (en) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Heterocyclic janus kinase 3 inhibitors
JP5015154B2 (en) * 2005-08-12 2012-08-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Viral polymerase inhibitor
JP2009504692A (en) * 2005-08-16 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー Novel 4-amino-thieno [3,2-c] pyridine-7-carboxylic acid amide
KR20080052630A (en) * 2005-09-01 2008-06-11 어레이 바이오파마 인크. Raf inhibitor compounds and methods of use thereof
EP2270014A1 (en) 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
EP1963320A1 (en) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Pyrrolopyridine kinase inhibiting compounds
TW201434835A (en) * 2005-12-13 2014-09-16 Incyte Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
US20080108611A1 (en) * 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
KR100846988B1 (en) * 2006-03-06 2008-07-16 제일약품주식회사 Novel thienopyrimidine derivatives or pharmaceutically acceptable salts thereof, process for the preparation thereof and pharmaceutical composition comprising the same
US7723330B2 (en) 2006-03-07 2010-05-25 Array Biopharma Inc. Heterobicyclic pyrazole compounds and methods of use
PE20080145A1 (en) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv TETRAHYDRO-PYRIMIDOAZEPINE AS MODULATORS OF TRPV1
WO2007107005A1 (en) * 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
UA93548C2 (en) * 2006-05-05 2011-02-25 Айерем Елелсі Compounds and compositions as hedgehog pathway modulators
US7592353B2 (en) * 2006-06-06 2009-09-22 Boehringer Ingelheim International Gmbh Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US7932390B2 (en) * 2006-06-29 2011-04-26 Hoffman-La Roche Inc. Substituted thieno[3,2-C]pyridine carboxylic acid derivatives
US20080004253A1 (en) * 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
US20080125454A1 (en) * 2006-10-05 2008-05-29 Wyeth Methods and Compositions for Treatment of Scleritis and Related Disorders
ES2415863T3 (en) 2006-12-22 2013-07-29 Incyte Corporation Substituted heterocycles as Janus Kinase inhibitors
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
PT2125792E (en) * 2007-02-19 2011-03-01 Glaxosmithkline Llc Purine derivatives as immunomodulators
LT3070090T (en) 2007-06-13 2019-06-25 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CL2008001709A1 (en) 2007-06-13 2008-11-03 Incyte Corp Compounds derived from pyrrolo [2,3-b] pyrimidine, jak kinase modulators; pharmaceutical composition; and use in the treatment of diseases such as cancer, psoriasis, rheumatoid arthritis, among others.
DE102007027799A1 (en) * 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted furopyrimidines and their use
DE102007027800A1 (en) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituted bicyclic heteroaryl compounds and their use
MX2010001636A (en) * 2007-08-14 2010-03-15 Hoffmann La Roche Diazo bicyclic smac mimetics and the uses thereof.
EP2070929A1 (en) 2007-12-11 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Alkynylaryl compounds and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP2224929B1 (en) 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
SG182146A1 (en) * 2008-03-05 2012-07-30 Methylgene Inc Inhibitors of protein tyrosine kinase activity
PT2288610T (en) 2008-03-11 2016-10-17 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
LT2320905T (en) * 2008-08-11 2017-09-11 Glaxosmithkline Llc Novel adenine derivatives
US8802684B2 (en) 2008-08-11 2014-08-12 Glaxosmithkline Llc Adenine derivatives
WO2010018130A1 (en) * 2008-08-11 2010-02-18 Smithkline Beecham Corporation Purine derivatives for use in the treatment of allergic, inflammatory and infectious diseases
BRPI0917458A2 (en) * 2008-08-11 2015-12-01 Glaxosmithkline Llc compound, method of treating disease and conditions, pharmaceutical composition, method for treating or preventing disease, and use of a compound
CL2009001884A1 (en) * 2008-10-02 2010-05-14 Incyte Holdings Corp Use of 3-cyclopentyl-3- [4- (7h-pyrrolo [2,3-d] pyrimidin-4-yl) -1h-pyrazol-1-yl) propanonitrile, janus kinase inhibitor, and use of a composition that understands it for the treatment of dry eye.
PE20100362A1 (en) * 2008-10-30 2010-05-27 Irm Llc PURINE DERIVATIVES THAT EXPAND HEMATOPOYETIC STEM CELLS
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
KR101771401B1 (en) * 2009-05-22 2017-08-25 인사이트 홀딩스 코포레이션 N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS
PT2432472T (en) 2009-05-22 2019-12-09 Incyte Holdings Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
WO2010151318A1 (en) * 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2010151317A1 (en) 2009-06-22 2010-12-29 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
EP2451796B1 (en) 2009-07-08 2013-04-17 Dermira (Canada), Inc. Tofa analogs useful in treating dermatological disorders or conditions
WO2011028685A1 (en) * 2009-09-01 2011-03-10 Incyte Corporation Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
JP5946768B2 (en) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ Hydroxyl, keto and glucuronide derivatives of 3- (4- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile
US8575340B2 (en) 2010-02-10 2013-11-05 Glaxosmithkline Llc Purine derivatives and their pharmaceutical uses
CN102844317B (en) * 2010-02-18 2015-06-03 因西特公司 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
EP2545045B1 (en) 2010-03-10 2016-01-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EA035981B1 (en) 2010-05-21 2020-09-09 Инсайт Холдингс Корпорейшн Jak inhibitor formulation for topical application
TW201219401A (en) 2010-09-14 2012-05-16 Lexicon Pharmaceuticals Inc Bicyclic inhibitors of Notum Pectinacetylesterase and methods of their use
TW201249845A (en) 2010-11-19 2012-12-16 Incyte Corp Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
WO2012088015A2 (en) 2010-12-22 2012-06-28 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
ES2547916T3 (en) 2011-02-18 2015-10-09 Novartis Pharma Ag MTOR / JAK inhibitor combination therapy
ES2560611T3 (en) 2011-06-20 2016-02-22 Incyte Holdings Corporation Phenyl azetidinyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
US9358229B2 (en) 2011-08-10 2016-06-07 Novartis Pharma Ag JAK PI3K/mTOR combination therapy
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
ES2790358T3 (en) 2011-12-28 2020-10-27 Global Blood Therapeutics Inc Substituted Heteroaryl Aldehyde Compounds and Methods for Their Use in Increasing Tissue Oxygenation
LT3141542T (en) 2011-12-28 2020-09-25 Global Blood Therapeutics, Inc. Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN102702223A (en) * 2012-05-28 2012-10-03 盛世泰科生物医药技术(苏州)有限公司 Method for preparing 2-bromo-4-chlorothieno[3, 2-C]pyridine
GEP201606598B (en) 2012-11-08 2017-01-10 Pfizer Heteroaromatic compounds as dopamine d1 ligands
JP5857168B2 (en) 2012-11-08 2016-02-10 ファイザー・インク Heteroaromatic compounds as dopamine D1 ligands and their use
CN105007901A (en) 2012-11-15 2015-10-28 因赛特公司 Sustained-release dosage forms of ruxolitinib
MA38347A1 (en) 2013-02-22 2017-10-31 Pfizer Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of janus kinases (jak)
TWI634121B (en) 2013-03-06 2018-09-01 英塞特控股公司 Processes and intermediates for making a jak inhibitor
AU2014249050B2 (en) 2013-03-12 2017-10-05 Celgene Quanticel Research, Inc. Histone dementhylase inhibitors
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR20150132146A (en) 2013-03-15 2015-11-25 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
KR102293060B1 (en) 2013-03-15 2021-08-23 글로벌 블러드 테라퓨틱스, 인크. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
AP2015008721A0 (en) 2013-03-15 2015-09-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US10100043B2 (en) 2013-03-15 2018-10-16 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
TWI822248B (en) 2013-08-07 2023-11-11 美商英塞特控股公司 Sustained release dosage forms for a jak1 inhibitor
EA201992707A1 (en) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. COMPOUNDS AND THEIR APPLICATIONS FOR HEMOGLOBIN MODULATION
CN114181194A (en) 2014-02-07 2022-03-15 全球血液疗法股份有限公司 Crystalline polymorph of a compound
AP2016009464A0 (en) 2014-04-25 2016-09-30 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
US9868744B2 (en) 2014-04-25 2018-01-16 Pfizer Inc. Heteroaromatic compounds and their use as dopamine D1 ligands
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
US10131669B2 (en) 2014-07-24 2018-11-20 Pfizer Inc. Pyrazolopyrimidine compounds
DK3177624T3 (en) 2014-08-06 2019-07-01 Pfizer IMIDAZOPYRIDAZINE COMPOUNDS
ES2750655T3 (en) 2014-08-12 2020-03-26 Pfizer Pyrrolo [2,3-d] pyrimidine derivatives useful to inhibit Janus kinase
SG11201702119PA (en) 2014-09-17 2017-04-27 Quanticel Pharmaceuticals Inc Histone demethylase inhibitors
NZ729078A (en) 2014-12-11 2021-07-30 Natco Pharma Ltd 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
MA41841A (en) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc ALDEHYDE COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, HYPOXIA, AND AUTOIMMUNE AND CONNECTIVE TISSUE DISEASES
US9994586B2 (en) * 2015-08-17 2018-06-12 Duquesne University Of The Holy Spirit Monocyclic, thieno, pyrido, and pyrrolo pyrimidine compounds and methods of use and manufacture of the same
EP3383392A1 (en) 2015-12-04 2018-10-10 Global Blood Therapeutics, Inc. Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
TWI752307B (en) 2016-05-12 2022-01-11 美商全球血液治療公司 Novel compound and method of preparing compound
US10154992B2 (en) * 2016-07-12 2018-12-18 The Regents Of The University Of California Compounds and methods for treating HIV infection
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
TW202332423A (en) 2016-10-12 2023-08-16 美商全球血液治療公司 Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
US10596161B2 (en) 2017-12-08 2020-03-24 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MD3746429T2 (en) 2018-01-30 2022-08-31 Incyte Corp Processes for preparing (1-(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
WO2019165374A1 (en) 2018-02-26 2019-08-29 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
CN113768927A (en) 2018-03-30 2021-12-10 因赛特公司 Treatment of hidradenitis suppurativa with JAK inhibitors
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms

Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318883A (en) * 1962-07-04 1967-05-09 Boehringer Sohn Ingelheim Novel dihydrothieno[3, 2-d]pyrimidines
US3401030A (en) * 1964-09-09 1968-09-10 Union Carbide Corp Method of defoliating cotton plants
US3459759A (en) * 1965-11-24 1969-08-05 Shell Oil Co Certain substituted imidazo-(4,5-b or c)pyridines
US3470183A (en) * 1966-06-09 1969-09-30 Burroughs Wellcome Co Thienopyrimidines
US3845065A (en) * 1972-02-18 1974-10-29 Merck & Co Inc 4-oxo-4,5-dihydrothieno(3,2-c)pyridines
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US3903095A (en) * 1972-02-18 1975-09-02 Merck & Co Inc Certain substituted-thieno{8 3,2-c{9 -pyridines
US3998835A (en) * 1975-04-08 1976-12-21 Sandoz Ltd. 1-Substituted amino-3-thieno-[3,2-c]pyridinyloxy-2-propanols
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
US4375544A (en) * 1978-01-28 1983-03-01 Croda Synthetic Chemicals Limited Fused pyridines
US4496568A (en) * 1977-12-19 1985-01-29 Pacor Antiinflammatory thieno [2,3-c]pyridine derivatives
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
US4876067A (en) * 1986-09-12 1989-10-24 Boehringer Mannheim Gmbh Multilayer test strip device with a dissolvable reagent layer
US4935431A (en) * 1988-02-25 1990-06-19 Smithkline Beckman Intercredit B.V. Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors
US4988707A (en) * 1989-09-13 1991-01-29 G. D. Searle & Co. Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines
US5006532A (en) * 1987-01-30 1991-04-09 Merck & Co. Inc., Inc. Derivatives of 3-hydroxyazabenzo(beta)thiophene useful as 5-lipoxygenase inhibitors
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
US5079255A (en) * 1989-06-29 1992-01-07 Meiji Seika Kabushiki Kaisha Thiazolo [4,5-6] pyridine derivatives and anti-ulcerative composition containing same
US5227384A (en) * 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
US5280026A (en) * 1989-05-30 1994-01-18 Smithkline Beecham Intercredit B.V. Thienopyrimidines
US5324727A (en) * 1991-09-26 1994-06-28 Mitsubishi Chem Ind 3,6-disubstituted pyridazine derivatives
US5506238A (en) * 1989-09-29 1996-04-09 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5714495A (en) * 1995-04-14 1998-02-03 Adir Et Compagnie Pyridine compounds as melatonergic agents
US5747486A (en) * 1994-11-08 1998-05-05 Takeda Chemical Industries Thienopyridine or thienopyrimidine derivatives and their use
US5801057A (en) * 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE257830C (en)
FR1453897A (en) 1965-06-16 1966-07-22 Thiophene and thienopyridazine derivatives
AR208500A1 (en) 1972-06-14 1977-02-15 Merck & Co Inc PROCEDURE FOR THE PREPARATION OF OXAZOLE (4,5-B) -PYRIDINES DERIVATIVES
FR2334356A1 (en) 1975-12-10 1977-07-08 Parcor Thieno pyridines and salts - having sedative, antiinflammatory, analgesic and platelet aggregation-inhibiting activity
FR2336132A1 (en) 1975-12-23 1977-07-22 Parcor Antiinflammatory thieno-indolizines - also with blood platelet aggregation inhibitory activity
FR2452490A1 (en) 1979-03-30 1980-10-24 Sanofi Sa 2-Hydroxy-3-aminopropoxy thieno-pyridine derivs. - useful as antiinflammatories, beta blockers and antiarrhythmics for human and veterinary medicine
CA1261256A (en) 1984-06-13 1989-09-26 Ian A. Shanks Devices for use in chemical test procedures
DE3533331A1 (en) 1985-09-18 1987-03-26 Heumann Ludwig & Co Gmbh Pyridothiazole derivatives, process for their preparation, and medicaments containing these compounds
US4804658A (en) 1986-09-15 1989-02-14 G. D. Searle & Co. Imidazopyridine derivatives and pharmaceutical compositions
DD257830A1 (en) 1987-03-02 1988-06-29 Univ Leipzig PROCESS FOR PREPARATION OF 3- (FUNCTIONALIZED) ALKYL-PYRIDO- / 3 ', 2': 4,5 / THIENO / 3,2-D / PYRIMIDIN-4 (3H) -ONEE
GB8712747D0 (en) 1987-05-30 1987-07-01 Pfizer Ltd Therapeutic agents
MY104933A (en) 1987-09-30 1994-07-30 Pfizer Ltd Platelet activating factor antagonists
ATE118006T1 (en) 1988-03-15 1995-02-15 Searle & Co 1H/3H-(4-(N,N-CYCLOALKYL AND/OR BRANCHED ALKYLCARBOXAMIDO)-BENZYL>IMDAZO(4,5-C>PYRIDINES AS PAF ANTAGONISTS.
CA2012716A1 (en) 1989-03-22 1990-09-22 Akito Tanaka Thiazole compounds, processes for the preparation thereof and pharmaceutical composition comprising the same
DE4008726A1 (en) * 1990-03-19 1991-09-26 Basf Ag Thieno-(2,3-D)pyrimidine derivs. - are plant growth regulators, herbicides and pesticides, esp. insecticides
US5585492A (en) 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
DE19629657A1 (en) 1996-07-23 1998-01-29 Boehringer Mannheim Gmbh Volume-independent diagnostic test carrier and method for determining analyte with its aid
AU711587B2 (en) 1996-11-06 1999-10-14 Darwin Discovery Limited Quinolines and their therapeutic use
DE69809391T2 (en) 1997-02-06 2003-07-10 Therasense Inc SMALL VOLUME SENSOR FOR IN-VITRO DETERMINATION
SK18542000A3 (en) 1998-06-04 2001-12-03 Abbott Laboratories Cell adhesion-inhibiting anti-inflammatory compounds

Patent Citations (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3318883A (en) * 1962-07-04 1967-05-09 Boehringer Sohn Ingelheim Novel dihydrothieno[3, 2-d]pyrimidines
US3401030A (en) * 1964-09-09 1968-09-10 Union Carbide Corp Method of defoliating cotton plants
US3459759A (en) * 1965-11-24 1969-08-05 Shell Oil Co Certain substituted imidazo-(4,5-b or c)pyridines
US3470183A (en) * 1966-06-09 1969-09-30 Burroughs Wellcome Co Thienopyrimidines
US3845065A (en) * 1972-02-18 1974-10-29 Merck & Co Inc 4-oxo-4,5-dihydrothieno(3,2-c)pyridines
US3903095A (en) * 1972-02-18 1975-09-02 Merck & Co Inc Certain substituted-thieno{8 3,2-c{9 -pyridines
US3891660A (en) * 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US4038396A (en) * 1975-02-24 1977-07-26 Merck & Co., Inc. Anti-inflammatory oxazole[4,5-b]pyridines
US3998835A (en) * 1975-04-08 1976-12-21 Sandoz Ltd. 1-Substituted amino-3-thieno-[3,2-c]pyridinyloxy-2-propanols
US4496568A (en) * 1977-12-19 1985-01-29 Pacor Antiinflammatory thieno [2,3-c]pyridine derivatives
US4375544A (en) * 1978-01-28 1983-03-01 Croda Synthetic Chemicals Limited Fused pyridines
US4876067A (en) * 1986-09-12 1989-10-24 Boehringer Mannheim Gmbh Multilayer test strip device with a dissolvable reagent layer
US4808595A (en) * 1986-12-24 1989-02-28 Merck & Co., Inc. Furopyridine sulfonamides and their opthalmological compositions
US5006532A (en) * 1987-01-30 1991-04-09 Merck & Co. Inc., Inc. Derivatives of 3-hydroxyazabenzo(beta)thiophene useful as 5-lipoxygenase inhibitors
US4935431A (en) * 1988-02-25 1990-06-19 Smithkline Beckman Intercredit B.V. Substituted 7-amino-thienopyridine derivatives as gastric acid secretion inhibitors
US5227384A (en) * 1988-03-14 1993-07-13 G. D. Searle & Co. 5-substituted [4,5-c] imidazopyridines and pharmaceutical use thereof
US5026698A (en) * 1988-11-02 1991-06-25 Nissan Chemical Industries, Ltd. Thienopyridine type mevalonolactones
US5280026A (en) * 1989-05-30 1994-01-18 Smithkline Beecham Intercredit B.V. Thienopyrimidines
US5079255A (en) * 1989-06-29 1992-01-07 Meiji Seika Kabushiki Kaisha Thiazolo [4,5-6] pyridine derivatives and anti-ulcerative composition containing same
US4988707A (en) * 1989-09-13 1991-01-29 G. D. Searle & Co. Pharmacologically active phenylalkanoyl substituted imidazo (4,5-C) pyridines
US5506238A (en) * 1989-09-29 1996-04-09 Eisai Co., Ltd. Biphenylmethane derivative and pharmacological use
US5324727A (en) * 1991-09-26 1994-06-28 Mitsubishi Chem Ind 3,6-disubstituted pyridazine derivatives
US5747486A (en) * 1994-11-08 1998-05-05 Takeda Chemical Industries Thienopyridine or thienopyrimidine derivatives and their use
US5597823A (en) * 1995-01-27 1997-01-28 Abbott Laboratories Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
US5869486A (en) * 1995-02-24 1999-02-09 Ono Pharmaceutical Co., Ltd. Fused pyrimidines and pyriazines as pharmaceutical compounds
US5714495A (en) * 1995-04-14 1998-02-03 Adir Et Compagnie Pyridine compounds as melatonergic agents
US5801057A (en) * 1996-03-22 1998-09-01 Smart; Wilson H. Microsampling device and method of construction

Cited By (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080255143A1 (en) * 2003-07-29 2008-10-16 Smithkline Beecham Corporation Inhibitors of Akt Activity
US7589206B2 (en) 2004-06-09 2009-09-15 Glaxo Group Limited Pyrrolopyridine derivatives
US7696210B2 (en) 2004-06-17 2010-04-13 Wyeth Gonadotropin releasing hormone receptor antagonists
US20050282820A1 (en) * 2004-06-17 2005-12-22 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
US7714130B2 (en) 2004-06-17 2010-05-11 Wyeth Processes for preparing gonadotropin releasing hormone receptor antagonists
US20060058341A1 (en) * 2004-09-15 2006-03-16 Connolly Peter J Thiazolopyridine kinase inhibitors
US7659284B2 (en) 2004-09-15 2010-02-09 Janssen Pharmaceutica Nv Thiazolopyridine kinase inhibitors
US8153629B2 (en) 2004-10-25 2012-04-10 F. Hoffmann-La Roche Ag Pharmaceutical compounds
JP2008517894A (en) * 2004-10-25 2008-05-29 パイレームド リミテッド Pharmaceutical compounds
US7750002B2 (en) 2004-10-25 2010-07-06 Piramed Limited Pharmaceutical compounds
US20100280027A1 (en) * 2004-10-25 2010-11-04 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2006046031A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US8101607B2 (en) 2004-10-25 2012-01-24 F. Hoffman-La Roche Ag Pharmaceutical compounds
CN101087794B (en) * 2004-10-25 2011-05-18 霍夫曼-拉罗奇有限公司 Pharmaceutical compounds
US20090131429A1 (en) * 2004-10-25 2009-05-21 Stephen Shutteleworth Pharmaceutical compounds
WO2006046035A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
JP2008517892A (en) * 2004-10-25 2008-05-29 パイレームド リミテッド Pharmaceutical compounds
JP2008517893A (en) * 2004-10-25 2008-05-29 パイレームド リミテッド Pharmaceutical compounds
US7776856B2 (en) 2004-10-25 2010-08-17 F. Hoffman-La Roche Ag Pharmaceutical compounds
US20080207611A1 (en) * 2004-10-25 2008-08-28 Plramed Limited Pharmaceutical compounds
US20080207609A1 (en) * 2004-10-25 2008-08-28 Plramed Limited Pharmaceutical compounds
AU2005298404B2 (en) * 2004-10-25 2012-08-23 F. Hoffman-La Roche Ag Pharmaceutical compounds
US7872003B2 (en) 2004-10-25 2011-01-18 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2006046040A1 (en) * 2004-10-25 2006-05-04 Piramed Limited Pharmaceutical compounds
US8946217B2 (en) 2004-10-25 2015-02-03 F. Hoffmann-La Roche Ag Pharmaceutical compounds
AU2005298408B2 (en) * 2004-10-25 2012-08-23 F. Hoffman-La Roche Ag Pharmaceutical compounds
KR101466529B1 (en) 2004-10-25 2014-11-27 에프. 호프만-라 로슈 아게 Pharmaceutical compounds
US20060111355A1 (en) * 2004-11-23 2006-05-25 Wyeth Gonadotropin releasing hormone receptor antagonists
US7538113B2 (en) 2005-02-18 2009-05-26 Wyeth 4-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189618A1 (en) * 2005-02-18 2006-08-24 Wyeth 4-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US7534796B2 (en) 2005-02-18 2009-05-19 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US7582634B2 (en) 2005-02-18 2009-09-01 Wyeth 7-substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189617A1 (en) * 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189616A1 (en) * 2005-02-18 2006-08-24 Wyeth 7-Substituted imidazo[4,5-c]pyridine antagonists of gonadotropin releasing hormone receptor
US20060189619A1 (en) * 2005-02-24 2006-08-24 Wyeth 3-({4-[2-(4-Tert-butylphenyl)-1h-benzimidazol-4-yl]piperazin-1-yl}methyl)pyrido[2,3-b]]pyrazi ne compounds
US20060264631A1 (en) * 2005-05-18 2006-11-23 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US7531542B2 (en) 2005-05-18 2009-05-12 Wyeth Benzooxazole and benzothiazole antagonists of gonadotropin releasing hormone receptor
US8835441B2 (en) 2005-05-20 2014-09-16 Amgen Inc. Heterobicyclic metalloprotease inhibitors
US7795245B2 (en) 2005-05-20 2010-09-14 Atlantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
US20060270848A1 (en) * 2005-05-26 2006-11-30 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor
US7582636B2 (en) 2005-05-26 2009-09-01 Wyeth Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor
US20080221097A1 (en) * 2005-08-09 2008-09-11 Glaxo Group Limited Imidazopyridine Derivatives as Cannabinoid Receptor Ligands
US7625890B2 (en) 2005-11-10 2009-12-01 Smithkline Beecham Corp. Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors
US8604051B2 (en) 2006-01-31 2013-12-10 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US20090149437A1 (en) * 2006-01-31 2009-06-11 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US8394822B2 (en) 2006-01-31 2013-03-12 Ucb Pharma, S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2007088345A1 (en) 2006-01-31 2007-08-09 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US8283359B2 (en) 2006-01-31 2012-10-09 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2007127175A3 (en) * 2006-04-26 2007-12-27 Piramed Ltd Pharmaceutical compounds
US8252792B2 (en) 2006-04-26 2012-08-28 F. Hoffman-La Roche Ag Pyrimidine derivatives as PI3K inhibitors
US20100016306A1 (en) * 2006-04-26 2010-01-21 F. Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
US8802670B2 (en) 2006-04-26 2014-08-12 F. Hoffmann-La Roche Ag Pharmaceutical compounds
US9943519B2 (en) 2006-04-26 2018-04-17 Genentech, Inc. Pharmaceutical compounds
US20080076758A1 (en) * 2006-04-26 2008-03-27 Piramed Limited Pharmaceutical compounds
EP2402347A1 (en) * 2006-04-26 2012-01-04 F. Hoffmann-La Roche AG Pharmaceutical compounds
AU2007243457B2 (en) * 2006-04-26 2012-02-23 F. Hoffmann-La Roche Ag Pharmaceutical compounds
WO2007122410A1 (en) 2006-04-26 2007-11-01 F.Hoffmann-La Roche Ag Pyrimidine derivatives as pi3k inhibitors
US8697693B2 (en) 2006-04-26 2014-04-15 F. Hoffmann LaRoche AG Pharmaceutical compounds
US20090029345A1 (en) * 2006-08-01 2009-01-29 Alan Russell Modulating skeletal muscle
US8227603B2 (en) 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
US20110014212A1 (en) * 2006-08-02 2011-01-20 Aaron Hinken Certain Chemical Entities, Compositions and Methods
US20100210645A1 (en) * 2006-08-02 2010-08-19 Cytokinetics, Inc. Certain Chemical Entities, Compositions and Methods
US7956056B2 (en) 2006-08-02 2011-06-07 Cytokinetics, Inc. Certain 1H-imidazo[4,5-B]pyrazin-2(3H)-ones and 1H-imidazo[4,5-B]pyrazin-2-ols, compositions thereof, and methods for their use
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US8716291B2 (en) 2006-08-02 2014-05-06 Cytokinetics, Inc. Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
US10766899B2 (en) 2006-08-02 2020-09-08 Cytokinetics, Incorporated Methods for preparing substituted imidazo[4,5-b]pyrazines
US20100093741A1 (en) * 2006-08-02 2010-04-15 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US8293761B2 (en) 2006-08-02 2012-10-23 Cytokinetics, Inc. Certain chemical entities, compositions and methods
EP2518074A1 (en) 2006-12-07 2012-10-31 F. Hoffmann-La Roche AG Phosphoinositide 3-kinase inhibitor compounds and methods of use
US20110071182A1 (en) * 2007-02-07 2011-03-24 Smithkline Beecham Corporation Inhibitors of AKT Activity
US8410158B2 (en) 2007-02-07 2013-04-02 Glaxosmithkline Llc Inhibitors of Akt activity
US8273782B2 (en) 2007-02-07 2012-09-25 Glaxosmithkline Llc Inhibitors of Akt activity
US8946278B2 (en) 2007-02-07 2015-02-03 Glaxosmithkline Llc Inhibitors of AkT activity
US20090209607A1 (en) * 2007-02-07 2009-08-20 Seefeld Mark A Inhibitors of akt activity
US20100041726A1 (en) * 2007-02-07 2010-02-18 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US20080242695A1 (en) * 2007-03-30 2008-10-02 Morgan Bradley P Certain Chemical Entities, Compositions, and Methods
US20100179124A1 (en) * 2007-07-23 2010-07-15 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US8350037B2 (en) 2007-07-23 2013-01-08 Ucb Pharma, S.A. Thieno-pyridine derivatives as MEK inhibitors
WO2009013462A1 (en) * 2007-07-23 2009-01-29 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
WO2009042607A1 (en) 2007-09-24 2009-04-02 Genentech, Inc. Thiazolopyrimidine p13k inhibitor compounds and methods of use
US8293735B2 (en) 2007-10-26 2012-10-23 F. Hoffmann-La Roche Ag Thienopyrimidine derivatives as P13K inhibitors
US20110021496A1 (en) * 2007-10-26 2011-01-27 F. Hoffmann-La Roche Ag Thienopyrimidine derivatives as p13k inhibitors
US8487101B2 (en) 2008-01-21 2013-07-16 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US20110021558A1 (en) * 2008-01-21 2011-01-27 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US8637491B2 (en) 2008-06-19 2014-01-28 Ucb Pharma S.A. Thieno-pyridine derivatives as MEK inhibitors
US20110172191A1 (en) * 2008-06-19 2011-07-14 Ucb Pharma S.A. Thieno-pyridine derivatives as mek inhibitors
US9877968B2 (en) 2008-08-11 2018-01-30 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US10117873B2 (en) 2008-08-11 2018-11-06 Glaxosmithkline Llc 6-amino-purin-8-one compounds
US8609711B2 (en) 2009-01-30 2013-12-17 Glaxosmithkline Llc Crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamic hydrochloride
US20100197754A1 (en) * 2009-01-30 2010-08-05 Chen Pingyun Y CRYSTALLINE N--5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
WO2010105008A2 (en) 2009-03-12 2010-09-16 Genentech, Inc. Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
WO2010138589A1 (en) 2009-05-27 2010-12-02 Genentech, Inc. Bicyclic pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
WO2011130654A1 (en) 2010-04-16 2011-10-20 Genentech, Inc. Fox03a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2012088254A1 (en) 2010-12-22 2012-06-28 Genentech, Inc. Autophagy inducer and inhibitor combination therapy for the treatment of neoplasms
US10272082B2 (en) 2011-07-13 2019-04-30 Cytokinetics, Inc. Combination ALS therapy
US10112946B2 (en) 2011-07-22 2018-10-30 Glaxosmithkline Llc Composition
US10022442B2 (en) 2012-08-24 2018-07-17 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9662336B2 (en) 2012-08-24 2017-05-30 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9555036B2 (en) 2012-08-24 2017-01-31 Glaxosmithkline Llc Pyrazolopyrimidine compounds
US9907847B2 (en) 2012-11-20 2018-03-06 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9550785B2 (en) 2012-11-20 2017-01-24 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9540383B2 (en) 2012-11-20 2017-01-10 Glaxosmithkline Llc Pyrrolopyrimidines as therapeutic agents for the treatment of diseases
US9428512B2 (en) 2012-11-20 2016-08-30 Glaxosmithkline Llc Compounds
WO2014130923A2 (en) 2013-02-25 2014-08-28 Genentech, Inc. Methods and compositions for detecting and treating drug resistant akt mutant
US9290496B2 (en) 2013-11-21 2016-03-22 Pfizer Inc. Purine derivatives
US10709714B2 (en) 2013-11-22 2020-07-14 Clifton Life Sciences LLC Gastrin antagonists for treatment and prevention of osteoporosis

Also Published As

Publication number Publication date
US20010020030A1 (en) 2001-09-06
US6579882B2 (en) 2003-06-17
US6232320B1 (en) 2001-05-15

Similar Documents

Publication Publication Date Title
US6232320B1 (en) Cell adhesion-inhibiting antiinflammatory compounds
EP1090009A2 (en) Cell adhesion-inhibiting antinflammatory compounds
EP1181296A1 (en) Cell adhesion-inhibiting antiinflammatory compounds
CA2390948A1 (en) Cell adhesion-inhibiting antiinflammatory compounds
CA2647208C (en) Glucokinase activators
ES2378704T3 (en) Glucokinase activators
US7902203B2 (en) Anti-infective agents
AU2006330924B2 (en) Anti-viral compounds
EP1971611B1 (en) Anti-viral compounds
AU2003270701B2 (en) Antiinflammation agents
ES2357230T3 (en) ANTI-INFECTIVE AGENTS.
US20050075331A1 (en) Anti-infective agents
KR20090077051A (en) 3-aza-bicyclo[3.1.0]hexane derivatives
AU2003291670A1 (en) Anti-infective agents
JP6469693B2 (en) Imidazopyridine derivatives as modulators of TNF activity
CA2681695A1 (en) 2-aminopyridine analogs as glucokinase activators
EP3080133B1 (en) Imidazothiazole derivatives as modulators of tnf activity
RU2684635C1 (en) Tetrahydroimidazopyridine derivatives as tnf activity modulators
JP5250649B2 (en) Antiinfectives
WO2009015897A1 (en) Novel heterocyclic compounds as mglu5 antagonists
MXPA00011994A (en) Cell adhesion-inhibiting antinflammatory compounds
CZ20004500A3 (en) Antiphlogistic compounds inhibiting cell adhesion
MXPA01012443A (en) Cell adhesion-inhibiting antiinflammatory compounds.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION